WO2023028603A2 - Engineered compositions - Google Patents

Abstract

Provided herein are engineered coronavirus polypeptides, polynucleotides that encode the polypeptides, vectors and host cells that comprise the polynucleotides and/or express the polypeptides, and related compositions. Disclosed embodiments include, for example, engineered spike ectodomains, monomeric receptor binding domains (RBDs), engineered RBDs, and fusion proteins that comprise any one or more of the foregoing.

Description

ENGINEERED COMPOSITIONS

REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

The contents of the electronic sequence listing (930585_424WO_SEQUENCE_LISTING.xml; Size: 1,351,654 bytes; and Date of Creation: August 26, 2022) is herein incorporated by reference in its entirety.

BACKGROUND

A novel betacoronavirus emerged in Wuhan, China, in late 2019. As of August 21, 2022, approximately 596 million cases of infection by this virus (termed, among other names, SARS- CoV-2), were confirmed worldwide, and had resulted in approximately 6.45 million deaths. Other coronaviruses, such as SARS-CoV, MERS, OC43, and HKU1 have also posed health risks to humans and other species. Modalities for preventing or treating coronavirus infections are needed.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Figures 1A-1C show certain embodiments of coronavirus spike ectodomain fusions of the present disclosure. (1A) Spike ectodomain fusions associate to form a trimer; each fusion monomer of the trimer comprises a foldon C-terminal to the spike ectodomain. (IB) C-terminal to the foldon is a Townsend linker followed by a SpyTag peptide (for example, comprising the amino acid sequence AHIVMVDAYKPTK (SEQ ID NO.:700). (1C) C-terminal to the foldon is a linker (e.g., GSG or GPP) followed by a stem-helix polypeptide (e.g., comprising the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701), engineered from the SARS-CoV-2 epitope region recognized by the antibody S2P6 as described herein). In some embodiments, one to three copies of [linker-stem-helix polypeptide] are arranged in a series, wherein each linker can be the same or different (e.g., each can independently be a GS linker, a GSG linker, a GPP linker, a (Gly_xSer_y)n linker, a Townsend linker, or the like).

In certain of the present Figures, Receptor Binding Domains (RBDs) are shown containing a lighter portion and a shaded or darker portion, and the darker portion may be indicated as "epitope" or "RBD epitope". This is for illustrative purposes only, and does not restrict any embodiment of the present disclosure to necessarily comprise a particular epitope. Certain constructs are described in further detail herein.

Figures 2A-2C show certain embodiments of RBD monomer constructs of the present disclosure. (2A) RBD polypeptide isolated from the SARS-CoV-2 South African variant S ectodomain. (2B) A SpyTag peptide is linked to the RBD polypeptide (N-terminal to and/or C- terminal to the RBD polypeptide) via a Townsend linker (GSGGSGGSGGTG; SEQ ID NO.:702). (2C) A SpyTag peptide is fused N-terminal to the RBD polyeptide and a stem-helix polypeptide ("S2P6") is fused C-terminal of the RBD polypeptide.

Figures 3A and 3B show certain embodiments of spike ectodomain:foldon:RBD fusion constructs of the present disclosure. A spike protein ectodomain trimer can comprise, C-terminal to each spike ectodomain of the trimer, a foldon. Each of the three foldons can be linked to an RBD polypeptide (two RBD polypeptides are shown linked in a series, though one, two, three, or more RBD polypeptides in a chain extending from a foldon may be present). In Figure 3A, a linker (comprised of a non-stem-helix polypeptide; e.g., a Townsend, GSG, GS, or GPP linker) is disposed between each foldon and a corresponding first RBD polypeptide, and between each first RBD polypeptide and a corresponding second RBD polypeptide. A further linker is disposed each second RBD polypeptide and a stem-helix polypeptide ("C-ter S2P6"). Another embodiment is shown in Figure 3B, with a stem-helix polypeptide disposed between each foldon and a corresponding first RBD polypeptide, and between each first RBD polypeptide and a corresponding second RBD polypeptide. A stem-helix polypeptide is also linked (via a non- stem-helix polypeptide, such as, for example, a Townsend, GS, GSG, or GPP linker) to each second RBD polypeptide.

Figures 4A and 4B show certain embodiments of RBD concatemers of the present disclosure. Concatemers can comprise, for example, three (4A) or five (4B) RBD polypeptides. The RBD polypeptides shown in Figures 4A and 4B are heterotypic (each being sourced from a different coronavirus or coronavirus strain), but one or more of the RBD polypeptides of a concatemer can also, or alternatively, be homotypic. In the upper concatemer in each of Figures 4 A and 4B, non-stem -helix polypeptide linkers (such as, for example, a Townsend, GS, GSG, or GPP linker) link successive RBD polypeptides to form a single chain fusion protein. In the lower construct shown in each of Figures 4A and 4B, stem-helix polypeptides function as linkers to connect successive RBD polypeptides to form a single chain fusion protein. In further embodiments (not shown), contamers comprise a tag, such as a SpyTag, and optionally a tag for purification, such as a His-tag.

Figures 5A-5G summarize mutations that were made in the RBD of a SARS-CoV-2 S protein backbone (South African variant) to generate certain protein constructs of the present disclosure ("251 "-"382" under the header marked "Construct" in each Figure), as described in Example 4. Amino acid numbering (top row in each Figure) is in reference to Wuhan-1 S protein sequence. The corresponding wild-type amino acid sequence for each region is shown in Figures 5A, 5C, and 5E. A dash ("-") indicates that the wild-type residue at the indicated position is preserved.

Figure 6 shows certain embodiments of (left) a sequence-engineered RBD: SpyTag fusion protein and (right) an S-ectodomain:foldon: SpyTag fusion comprising a sequence- engineered RBD of the present disclosure. In some embodiments, an engineered RBD is selected from among those summarized in Figures 5A-5G; see also Examples 4 and 8, and Tables 1 and 2. In the figure, a Townsend linker links the RBD or foldon to the SpyTag.

Figure 7 shows another embodiment of a spike ectodomaimfoldon: SpyTag fusion of the present disclosure. Shown is a spike ectodomain fusion (assembled into a trimer) based on the SARS-CoV-2 South African variant backbone, in fusion with a foldon and a SpyTag. Two RBDs of the trimer are in an "up" conformation. Fusion of the foldon to the SpyTag is via a linker. Figures 8A and 8B show certain embodiments of additional spike ectodomain:foldon:RBD fusion constructs of the present disclosure. A spike protein ectodomain trimer is shown; one or more monomer can comprise an RBD in an "up" or "open" conformation. A foldon is fused to each spike ectodomain monomer. Each of the three foldons is linked to one (8A) or two successive (8B) RBD monomer polypeptides (also referred-to as "isolated" RBD polypeptides). In some embodiments, all of the RBD monomer polypeptides are different than one or more of, and can be different than all three of, the three RBDs comprised in the spike protein ectodomain trimer. In other words, the RBD in a spike ectodomain portion of a fusion can be different than one or more of the isolated RBDs disposed C-terminal to the foldon. For example, each spike protein ectodomain of the trimer can be derived from SARS-CoV-2 South African variant, while each RBD monomer polypeptide can be from, or derived from, another coronavirus or another coronavirus variant. In each of the two constructs shown in Figure 8 A, all three of the RBD monomer polypeptides are the same as one another, and are different from one or more of the RBDs comprised in the spike protein ectodomain trimer. In Figure 8B, all three of the (first) RBD monomer polypeptides that are directly linked to a foldon are the same as one another, and all three of the (second) RBD monomer polypeptides that are linked to the (first) RBD monomer polypeptides are the same as one another. The RBD monomer polypeptides are all different to one or more RBDs of the S ectodomain trimer.

Figures 9A-11 show general organizational schemes of certain constructs of the present disclosure, as described in Example 8.

Figure 12 shows binding of monoclonal antibody S2P6 (recombinantly expressed as human IgGl), which comprises a VH of SEQ ID NO.:26 (CDRH1, CDRH2, and CDRH3 of SEQ ID NOs.:27-29, respectively) and a VL of SEQ ID NO.:30 (CDRL1, CDRL2, and CDRL3 of SEQ ID NOs.:31-33, respectively) to the spike (S) protein of different human betacoronaviruses as measured by enzyme-linked immunoabsorbant assay (ELISA). Pre-fusion stabilized S proteins from SARS-CoV (Urbani strain, AAP13441), SARS-CoV-2 (BetaCoV/Wuhan-Hu-1/2019), MERS (London 1/2012), OC43, and HKU1 were coated at 1 pg/ml. PBS-only was used as a negative control. Half maximal effective concentration (EC50) is reported in ng/ml.

Figure 13 shows an alignment of partial S2 segments from human beta-coronavirus spike proteins. The linker region in the C-terminal portion of the prefusion ectodomain is indicated with a square.

Figures 14A-14C illustrate a partially conserved linker region in the C-terminal portion of the pre-fusion ectodomain of human betacoronavirus spike proteins. Figure 14A shows an alignment of partial spike protein amino acid sequences from different human betacoronaviruses. Figure 14B shows SARS-CoV-2 spike protein and identifies the linker region (region inside square, containing N1158 glycan). Figure 14C shows a detailed view of the linker region shown in Figure 14B, and indicates certain amino acid residues (numbering is in accordance with pre-fusion conformation). Figures 15A-15C show structure of the SARS-CoV-2 S protein (Figure 15 A), and a detailed view (Figure 15B) of the conserved linker region and certain amino acid residues and N1158 glycan. In Figure 15C, residues in the pre-fusion (bottom) and post-fusion (top) conformations is shown. Numbering of the residues in post-fusion images does not account for the signal peptide.

Figure 16 shows binding of S2P6 to pre-fusion spike protein of betacoronaviruses MERS, HKU1, OC43, SARS-CoV, and SARS-CoV-2. Calculated EC50 values are shown to the right of the graph.

Figure 17 shows results of peptide scanning to identify coronavirus spike protein motifs bound by antibody S2P6 (expressed as recombinant IgGl with M428L and N434S Fc mutations) within each of seven coronavirus spike proteins using a PEPperCHIP® Pan-Corona Spike Protein Microarray. The microarray includes spike protein of SARS-CoV-2 (UniProt ID P0DTC2), SARS-CoV (UniProt ID P59594), MERS-CoV (UniProt ID A0A140AYZ5), HCoV-OC43 (UniProt ID P36334), HCoV-HKUl (UniProt ID U3NAI2), HCoV-NL63 (UniProt ID Q6Q1S2), and HCoV-229E (UniProt ID Pl 5423). Each spike protein sequence is converted into 15-amino acid peptides with a peptide-peptide overlap of 13 amino acids. The array contains 4,564 different peptides printed in duplicate. Antibody S2P6, expressed as recombinant IgGl with M428L and N434S ("MLNS") Fc mutations, was incubated with the array at a concentration of 10 pg/ml. A response was observed for adjacent peptides with the consensus motif FKEELDKYF (found in SARS-CoV-2 and SARS-CoV; SEQ ID NO:57) and with similar motifs GIDFQDELDEFFK (found in MERS-CoV; SEQ ID NO: 58) and DFKEELDQWFK (found in HCoV-OC43; SEQ ID NO:59). These motifs are located in the surface-exposed linker region at the tail of the pre-fusion ectodomain.

Figure 18 shows the results of prophylactic administration of antibody S2P6 (expressed as hamster IgG2a) to Syrian hamsters before intranasal challenge with SARS-CoV-2 Wuhan Hu- 1. Viral RNA in the lung (left panel) and viral titer (right panel) following infection were measured.

Figure 19 shows a cladogram of representative a- and P-coronavirus S glycoprotein amino acid sequences inferred via maximum likelihood analysis.

Figure 20 shows results of flow cytometry analysis of antibody S2P6 binding (from 10 to 0.22 pg/ml) to a panel of 26 S glycoproteins representative of all sarbecovirus clades (left) and 8 SARS-CoV-2 variants (right) displayed as a heat map of log geo-MFI (geometric mean fluorescent intensity).

Figure 21 shows binding of antibody S2P6 to linear peptides (15-mer peptides overlapping by 13 residues) spanning the SARS-CoV/SARS-CoV-2 S, OC43 S and MERS-CoV S sequences.

Figure 22 shows an alignment of the P-coronavirus stem helix region for multiple P- coronaviruses with the antibody S2P6 epitope region boxed. Residue numbering is shown according to SARS-CoV-2 S. N-linked glycosylation sequons are surrounded by dashed lines. Figure 23 shows an analysis of memory B-cell binding to P-coronavirus stem helix peptides from 21 COVID-19 convalescent individuals. Each dot represents an individual culture containing oligo-clonal B cells screened against stem helix peptides in ELISA (left panel). The cut-off value (0.4) is indicated by a dotted line. Pairwise reactivity comparison is shown for SARS-CoV/-2 and OC43 (middle panel) and SARS-CoV/-2 and HKU1 (right panel).

Figure 24 shows an analysis of memory B-cell binding to P-coronavirus stem helix peptides from 16 vaccinees. Each dot represents an individual culture containing oligo-clonal B cells screened against stem helix peptides in ELISA (left panel). The cut-off value (0.4) is indicated by a dotted line. Pairwise reactivity comparison is shown for SARS-CoV/-2 and OC43 (middle panel) and SARS-CoV/-2 and HKU1 (right panel).

Figure 25 shows a longitudinal analysis of vaccinees' plasma antibody binding to P- coronavirus stem helix peptides.

Figure 26 shows test results in Syrian hamsters administered the indicated amount of antibody S2P6 harboring either a hamster (Hm) or a human (Hu) constant region before intranasal challenge with prototypic SARS-CoV-2 (Wuhan- 1 related). Viral RNA loads are shown in the left graph and replicating virus titers are show in the right graph. * P<0.05, Mann- Whitney test.

Figure 27 shows results in Syrian hamsters after prophylactic administration of 20 mg/kg of human antibody S2P6. Hamsters were challenged after antibody administration with SARS- CoV-2 B.1.351 VOC. Viral RNA loads are shown in the left graph and replicating virus titers are show in the right graph.

Figure 28 shows binding of antibody S2P6 (left graph) and antibody S2S43 (right graph) to prefusion P-coronavirus S ectodomain trimers by ELISA.

Figures 29A-29C show the geo-mean fluorescence intensity as measured in flow cytometry for antibody S2P6 binding to a panel of 26 S glycoproteins representative of all sarbecovirus clades and 8 SARS-CoV-2 variants.

Figure 30 shows a phylogenetic tree of sarbecoviruses as inferred via maximum likelihood analysis of spike amino acid sequences.

Figure 31 shows a heat map of binding (fluorescence intensity) of antibody S2P6 to stem helix peptides (amino acid sequence at bottom of heat map) harboring each possible amino acid substitution (along left-hand side of heat map) at the indicated stem helix peptide amino acid position. The white to dark gradient indicates the degree of loss of binding as compared to the native residue (defining the white) shown as a crossed square. Squares surrounded by dashed lines indicate substitutions enhancing binding as compared to the native residue. Asterisks highlight substitutions found in antibody S2P6 viral escapes.

Figure 32 shows epitope conservation among P-coronavirus sequences with human and animal hosts as retrieved from GISAID. The consensus sequence for SARS-CoV-2 is reported on the x axis and predominant substitutions are indicated by a bold letter. Figures 33A-33F show binding to P-coronavirus stem helix peptides of IgG memory B- cells from convalescent individuals for each individual tested. Cut-off (OD=0.4) is indicated by a dotted line and frequencies of scoring positive cultures are reported for each antigen.

Figures 34A-34D show binding to P-coronavirus stem helix peptides of IgG memory B- cells from vaccinees for each tested individual. Cut-off (OD=0.4) is indicated by a dotted line and frequencies of scoring positive cultures are reported for each antigen.

Figure 35 shows binding to P-coronavirus stem helix peptide of IgG memory B-cells from an immune individual after first vaccine dose showing high response to SARS-CoV2 (top left graph) and of two pre-pandemic individuals (top right and lower graphs).

Figure 36 illustrates the design of five coronavirus constructs of the present disclosure that were tested in an in vivo mouse model, as described in Example 13.

Figure 37 shows in vitro neutralizing antibody titers in mouse sera against the indicated coronaviruses following immunization of the mice with the indicated construct (CoV0199, CoV0064, CoV0200, CoV0211, CoV0208), as described in Example 13.

Figure 38 shows comparative radar representations of measured coronavirus neutralizing antibody ED50 GMTs from sera of mice immunized with the indicated construct, as described in Example 13.

Figures 39A-39B show comparative radar representations of measured coronavirus binding antibodies (reported in ECL geometric mean) from sera of mice immunized with the indicated construct, as described in Example 13.

Figure 40 illustrates the design of six coronavirus constructs and combinations of coronavirus constructs of the present disclosure (Groups 1-6 in the Figure) that were tested in an in vivo mouse model, as described in Example 14.

Figures 41A-41B show in vitro neutralizing antibody titers in mouse sera against the indicated coronaviruses following immunization of the mice with the indicated construct or combination of constructs, as described in Example 14.

Figures 42A-42C show comparative radar representations of measured coronavirus neutralizing antibody responses from sera of mice immunized with the indicated construct or combinations of constructs, as described in Example 14.

Figures 43A-45B show results from biolayer interferometry (BLI) assays assessing binding by certain anti-SARS-CoV-2 antibodies and the indicated constructs of the present disclosure, as described in Example 15.

Figure 46 shows (top) neutralizing antibody titers against the indicated coronaviruses in sera of mice that received two immunizations with a mRNA SARS-CoV2 spike protein vaccine, followed by boost with either Cov0064 or the mRNA spike protein vaccine (PBS included as control), and (bottom) fold-change in neutralizing antibody titers against each coronavirus, as compared to the titer achieved with the mRNA spike protein vaccine boost (1.0), as described in Example 16.

Figure 47 shows breadth of sarbecovirus binding by antibodies elicited by the immunization of mice as described in Example 16. ELISA data show fold-change in binding antibody titers against the indicated antigens (engineered S2P6 peptide; RBDs from Clade 1 viruses SARS-CoV-1 and Wivl; RBDs from Clade 2 viruses YN2013 and S2X2011; and RBDs from Clade 3 viruses BTKY72 and BGR2008).

Figure 48 shows breadth of anti-sarbecovirus neutralizing antibodies elicited by the immunization of mice as described in Example 16. Each data point represents sera from an an individual mouse in a VSV-based pseudovirus neutralization assay.

Figures 49A-49D show breadth of sarbecovirus binding by antibodies elicited by the immunization of mice as described in Example 16. ELISA data show antibody binding EC50s against the indicated antigens (engineered S2P6 peptide; RBDs from S ARS-Cov2 -Wuhan-Hu- 1 (Wu), -B.1.351 (Beta), SARS-Covl, Wiv-1, RatG13, PangGD, PangGx, Anlogl l2, YN2013, SX2001, SC2018, ZC45, BTK72, and BGR2008.

Figures 50A-50B show partial sequence alignments of the constructs Cov0204-Cov0233.

Figures 51A-51B show percentages of Thl CD4+ T cells (51A) and Th2 CD4+ T cells in mice following administration of the indicated construct, (51B) as described in Example 13.

Figures 52A-52B show percentages of Thl CD8+ T cells (52A) and Th2 CD8+ T cells in mice following administration of the indicated construct, (52B) as described in Example 13.

Figures 53A-55B show comparative radar representations of measured SARS-Cov2- and SARS-CoV-binding antibody responses from sera of mice immunized with the indicated construct or combinations of constructs, as described in Example 14.

Figures 56-58 show comparative radar representations of measured CD4+ T cell responses from sera of mice immunized with the indicated construct or combinations of constructs, as described in Example 14.

Figures 59-61 show comparative radar representations of measured CD8+ T cell responses from sera of mice immunized with the indicated construct or combinations of constructs, as described in Example 14.

DETAILED DESCRIPTION

Provided herein are engineered coronavirus polypeptides, polynucleotides that encode the polypeptides, vectors and host cells that comprise the polynucleotides and/or express the polypeptides, and related compositions. Disclosed embodiments include, for example, engineered spike ectodomains, monomeric receptor binding domains (RBDs), engineered RBDs, and fusion proteins that comprise one or more RBD polypeptides, one or more spike ectodomains, or both. The engineered polypeptides have advantageous antigenic and protective properties against coronavirus infections, such as, for example, SARS-CoV-2 and variants thereof, and other coronaviruses. In some embodiments, an engineered polypeptide comprises an element e.g., a peptide tag) that enables conjugation to a substrate of interest, such as a nanoparticle comprising a cognate binding partner for the element (e.g. for the peptide tag). In some embodiments, an engineered polypeptide comprises amino acid sequences from two or more (e.g. two, three, four, five, or more) coronaviruses or coronavirus strains. In some embodiments, an engineered polypeptide comprises one or more copies of a polypeptide comprising a stem-helix antigenic region or motif that is highly conserved across betacoronaviruses, or comprising an engineered variant of such a region or motif.

Disclosed embodiments included fusion proteins comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second RBD polypeptide by a peptide linker. In certain embodiments, a fusion protein further comprises a third RBD polypeptide. In certain embodiments, a fusion protein further comprises a fourth RBD polypeptide. In certain embodiments, the fusion protein further comprises a fifth RBD polypeptide. In certain further embodiments, the fusion protein comprises one or more additional RBD polypeptide. Each of the two, three, or five (or more) RBD polypeptides can be different from one another; e.g., may be derived from different coronaviruses or different strains of a coronavirus. Each of the two, three, four, or five RBD polypeptides can be linked to one or two of the other RBD polypeptides in the fusion, such as by a peptide linker. In some embodiments, a peptide linker comprises a stem-helix polypeptide. In other embodiments, a non-stem-helix polypeptide is used as a linker.

Also provided is an isolated polypeptide comprising or consisting of: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.:218 without SEQ ID NO.:706; (iii) SEQ ID NO.:712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:715 without SEQ ID NO.:706; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) SEQ ID NO.:717 without SEQ ID NO.:706; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

Also provided is a fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii): (i) one or more peptide tag; (ii) one or more stem-helix polypeptide, wherein, optionally, the one or more stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Also provided is an isolated polypeptide comprising a structure:

RBD1 - LI - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 wherein RBD1, RBD2, RBD3, RBD4, and RBD5 are each a different RBD polypeptide selected from the group consisting of: SARS-CoV-2 Beta variant; SARS-CoV-2 Omicron variant; SARS- CoV-2 Delta variant; PANG/GX; MP789; RaTG13; and RsSHC014, wherein RBD1 is the N- terminal RBD polypeptide of the fusion protein and/or RBD5 is the C-terminal RBD polypeptide of the fusion protein, and wherein LI, L2, L3, and L4 are each a linker.

Also provided is an isolated polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59.

Also rovided is an isolated polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO.:701, the amino acid sequence of SEQ ID NO.: 14, the amino acid sequence of SEQ ID N0.: 15, the amino acid sequence of SEQ ID N0.: 16, or the amino acid sequence of SEQ ID NO.: 17. Also provided are fusion proteins that comprise (i) a coronavirus spike protein ectodomain ("S ectodomain"), and (ii) C-terminal to the S ectodomain, an oligomerization domain, wherein, optionally, the oligomerization domain is fused directly to a C-terminus of the S ectodomain. In some embodiments, the oligomerization domain comprises a trimerization domain such as, for example, a foldon. In certain further embodiments, the fusion protein comprises, disposed C-terminal to the oligomerization domain: (1) a peptide tag; (2) a stem-helix polypeptide as provided herein; (3) one or more coronavirus receptor binding domain (RBD) polypeptide, or any combination of ( 1 )-(3). In some embodiments, the peptide tag comprises a SpyCatcher tag. In some embodiments, the stem-helix peptide comprises an antigenic portion or epitope, and/or can function as a linker. In some embodiments, the one or more (e.g., one, two, three, or more) RBD polypeptides can be identical to one another, or one or more of the RBD polypeptides can be different from one or more of the others. For example, an RBD polypeptide have an amino acid sequence that is different from, or that is the same as, the amino acid sequence of (1) the RBD comprised in the S ectodomain and/or of (2) another RBD polypeptide that is comprised in the fusion. A S ectodomain or RBD (RBD polypeptide or RBD comprised in a S ectodomain) of a fusion may comprise a wild-type amino acid sequence, or may comprise one or more mutations (substitutions, insertions, and/or deletions) as described herein.

Also provided are protein trimers comprising three polypeptides, wherein each of the three polypeptides comprises: (i) a coronavirus S ectodomain; and (ii) C-terminal to the S ectodomain, a trimerization domain, wherein the three trimerization domains associate with one another to form a trimer. In some embodiments, each of the three trimerization domains comprises a foldon. In certain embodiments, one, two, or three of the polypeptides in the trimer comprises a fusion protein selected from the fusion proteins disclosed herein.

Also provided are an isolated coronavirus receptor binding domain (RBD) polypeptides, wherein an RBD polypeptide is not comprised in a spike protein ectodomain. Also provided are fusion proteins that comprise an RBD polypeptide and one or both of: (i) one or more peptide tag; and (ii) one or more stem-helix polypeptide.

Also provided are engineered variants of a coronavirus receptor binding domain (RBD) and engineered variants of a sarbecovirus spike ectodomain, wherein one or more modifications is present in RBD relative to a wild-type or parental RBD or spike (S) ectodomain, respectively. In some embodiments, a variant RBD or S ectodomain comprises one or more amino acid substitutions, insertions, and/or deletions in the RBD as compared to a wild-type or parental RBD or S ectodomain, respectively. Disclosed embodiments include RBD amino acid sequences that are engineered to, for example, include a non-native glycosylation motif, to delete two or three amino acids at certain positions, and/or to include a substitution and/or an insertion of one or more amino acids at certain positions.

In certain embodiments, an isolated and/or engineered polypeptide is provided that comprises a conserved antigenic region or motif from a sarbecovirus stem-helix region (e.g., of a SARS-CoV-2 S2 subunit), or an antigenic or epitope-containing portion thereof. In some embodiments, the polypeptide contains modifications to, for example, increase stability of the wild-type stem-helix polypeptide, contain two or more copies of antigenic region or motif, or the like.

In certain embodiments, an isolated polypeptide is provided that comprises, consists essentially of, or consists of the amino acid sequence set forth in any one of SEQ ID NOs.: 107- 249, 255-565, and 576-699.

In certain embodiments, an isolated polypeptide is provided that comprises the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699 with the signal peptide, and optionally a linker sequence adjacent the signal peptide, removed.

In certain embodiments, an isolated polypeptide is provided that comprises the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the His-tag is replaced with a different peptide tag.

In certain embodiments, an isolated polypeptide is provided that comprises the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the His-tag is not HHHHHHHH (i.e., is a His-tag of a longer or a shorter length than HHHHHHHH).

Also provided are polynucleotides that encode a disclosed polypeptide, as well as vectors and host cells that comprise the same. In some embodiments, disclosed compositions are capable of eliciting a protective immune response in a mammal against one or more betacoronavirus. In some embodiments, disclosed compositions are capable of eliciting a protective immune response in a mammal against plurality of coronaviruses, such as betacoronaviruses, such as, for example, a sarbecovirus, a merbecovirus, an embecovirus, a SARS-CoV-2 variant, a SARS-CoV, or the like.

Also provided are methods of using a disclosed polypeptide, RBD polypeptide, fusion protein, polynucleotide, vector, host cell, composition, combination, or cocktail to treat or to induce an immune response against a coronavirus infection in a subject.

Prior to setting forth this disclosure in more detail, it may be helpful to an understanding thereof to provide definitions of certain terms to be used herein. Additional definitions are set forth throughout this disclosure.

A "coronavirus" refers to a group of related RNA viruses that are known to cause diseases in mammals and birds. Coronaviruses can cause respiratory tract infections in humans. Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a characteristic spike protein projecting from their surface. The spike protein includes a receptor binding domain (RBD), which can interact with receptors on a host cell surface (e.g., with human ACE2).

Coronaviruses include, for example, genus alphacoronavirus (species including Alphacoronavirus 1 (TGEV, Feline coronavirus, Canine coronavirus), Human coronavirus 229E, Human coronavirus NL63, Miniopterus bat coronavirus 1, Miniopterus bat coronavirus HKU8, Porcine epidemic diarrhea virus, Rhinolophus bat coronavirus HKU2, Scotophilus bat coronavirus 512), genus betacoronavirus (species including Betacoronavirus 1 (Bovine Coronavirus, Human coronavirus OC43), Hedgehog coronavirus 1, Human coronavirus HKU1, Middle East respiratory syndrome-related coronavirus, Murine coronavirus, Pipistrellus bat coronavirus HKU5, Rousettus bat coronavirus HKU9, Severe acute respiratory syndrome- related coronavirus (SARS-CoV, SARS-CoV-2), Tylonycteris bat coronavirus HKU4), genus gammacoronavirus (species include Avian coronavirus, Beluga whale coronavirus SW1) and genus deltracoronavirus (species include Bulbul coronavirus HKU11, Porcine coronavirus HKU15). Coronaviruses and coronavirus strains are known in the art and discussed further herein.

As used herein, "SARS-CoV-2", also referred to herein as "Wuhan seafood market phenomia virus", or “Wuhan coronavirus” or "Wuhan CoV", or "novel CoV", or "nCoV", or "2019 nCoV", or "Wuhan nCoV" is a betacoronavirus believed to be of lineage B (sarbecovirus). SARS-CoV-2 was first identified in Wuhan, Hubei province, China, in late 2019 and spread within China and to other parts of the world by early 2020. Symptoms of SARS-CoV-2 infection include fever, dry cough, and dyspnea.

The genomic sequence of SARS-CoV-2 isolate Wuhan-Hu-1 is provided in GenBank MN908947.3 (January 23, 2020), and the amino acid translation of the genome is provided in GenBank QHD43416.1 (January 23, 2020). Like other coronaviruses (e.g., SARS- CoV-1), SARS-CoV-2 comprises a "spike" or surface ("S") type I transmembrane glycoprotein containing a receptor binding domain (RBD). RBD is believed to mediate entry of the lineage B SARS coronavirus to respiratory epithelial cells by binding to the cell surface receptor angiotensinconverting enzyme 2 (ACE2). In particular, a receptor binding motif (RBM) in the RBD interacts with ACE2.

The amino acid sequence of the Wuhan-Hu-1 surface glycoprotein is provided in SEQ ID NO.: 1. A Wuhan-Hu-1 RBD amino acid sequence is provided in SEQ ID NO.:2; additional nonlimiting examples of Wuhan-Hu- 1 RBD polypeptide sequences of the present disclosure are provided SEQ ID NOs.:722 and 723. Wuhan-Hu- 1 S protein has approximately 73% amino acid sequence identity with SARS-CoV S protein. The amino acid sequence of Wuhan-Hu-1 RBM is provided in SEQ ID NO.:744. Wuhan-Hu-1 RBD has approximately 75% to 77% amino acid sequence similarity to SARS-CoV RBD, and SARS-CoV-2 RBM has approximately 50% amino acid sequence similarity to SARS-CoV RBM. Unless otherwise indicated herein, Wuhan-Hu- 1 refers to a virus comprising the amino acid sequence set forth in SEQ ID NO.: 1, optionally with the genomic sequence set forth in GenBank MN908947.3 (January 23, 2020).

A number of SARS-CoV-2 variants have been identified. Some SARS-CoV-2 variants contain an N439K mutation, which has enhanced binding affinity to the human ACE2 receptor (Thomson, E.C., et al., The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity. bioRxiv, 2020). Some SARS-CoV-2 variants contain an N501 Y mutation, which is associated with increased transmissibility, including the lineages B. l.1.7 (also known as the "alpha" variant, 20I/501Y.V1, and VOC 202012/01; (del69-70, dell44, N501 Y, A570D, D614G, P681H, T716I, S982A, and DI 118H mutations)), discovered in the United Kingdom, and B.1.351 (also known as the "beta" variant and 20H/501Y.V2; L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, and A701V mutations), discovered in South Africa (Tegally, H., et al., Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv, 2020: p. 2020.12.21.20248640; Leung, K., et al., Early empirical assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. medRxiv, 2020: p. 2020.12.20.20248581). B.1.351 includes the RBD mutations K417N and E484K (Legally, H., et al., Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv, 2020: p. 2020.12.21.20248640). SARS-CoV-2 B.1.617.2 (also referred to as the "delta" or Indian variant, and as 21A/S:478K; containing T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, and D950N mutations. B.1.617.2 includes two mutations in the RBD of SARS-CoV2 spike protein: L452R and T478K. SARS-CoV-2 B.1.1.529 (also referred to as the "omicron") was first identified in South Africa and includes the following mutations in the RBD of SARS-CoV2 spike protein: G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, and Y505H. Subvariants of B.1.1.529 may also include R346K or Q493K; variants in the omicron lineage include BA.1, BA.1.1, BA.2, BA.2, BA.4, and BA.5 lineages. Other SARS-CoV-2 variants include the Lineage B.1.1.28, which was first reported in Brazil; the Variant P.l, lineage B.1.1.28 (also known as 20J/501Y.V3 and as the "gamma" variant), which was first reported in Japan; Variant L452R, which was first reported in California in the United States (Pan American Health Organization, Epidemiological update: Occurrence of variants of SARS-CoV-2 in the Americas, January 20, 2021, available at reliefweb.int/sites/reliefweb.int/files/resources/2021-jan-20-phe-epi-update-SARS-CoV-2.pdf); a SARS CoV-2 of clade 19A; SARS CoV-2 of clade 19B; a SARS CoV-2 of clade 20A; a SARS CoV-2 of clade 20B; a SARS CoV-2 of clade 20C; a SARS CoV-2 of clade 20D; a SARS CoV-2 of clade 20E (EU1); a SARS CoV-2 of clade 20F; a SARS CoV-2 of clade 20G; and SARS CoV-2 BL 1.207; and other SARS CoV-2 lineages described in Rambaut, A., et al., A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 5, 1403-1407 (2020). The foregoing SARS-CoV-2 variants, and the amino acid and nucleotide sequences thereof, are incorporated herein by reference. Accordingly, it will be understood that SARS-CoV-2 includes Wuhan Hu-1 and variants thereof, including presently disclosed variants.

SARS-CoV (also called SARS-CoV-1) is another betacoronavirus that causes respiratory symptoms in infected individuals. The amino acid sequence of SARS-CoV Urbani strain has GenBank accession number AAP13441.1, and a spike protein amino acid sequence of SARS- CoV Urbani strain is provided in SEQ ID NO.:22.

Coronavirus spike ectodomains have been observed in an "open" or "up" conformation, wherein the RBD (or at least two RBDs, in the context of a spike protein trimer) points away from the C-terminal end of the spike protein. Conformational dynamics of SARS-CoV-2 RBD and SARS-CoV RBD, for example, are discussed in Yuan et al., Science 365:630-633 (2020) and Joyce et al., doi: 10.1101/2020.03.15.992883 (2020). Spike protein mutations that have been shown to promote an open conformation of the RBD include D614G, and K986P with V987P. In some embodiments, a fusion protein or polypeptide of the present disclosure comprises a spike protein ectodomain comprising an RBD in an open conformation. In some embodiments, a polypeptide trimer comprises three RBDs (e.g., each comprised in a coronavirus spike protein ectodomain of the trimer, wherein one or more of the spike protein ectodomains are each comprised in a fusion protein as described herein), and one or more of the RBDs is in an open conformation. In certain embodiments, one RBD is in an open conformation. In certain embodiments, two RBDs are in an open conformation. In certain embodiments, three RBDs are in an open conformation.

Human coronavirus OC43 is also a betacoronavirus. Genomic and amino acid sequences of the OC43 surface glycoprotein (“S protein”) are provided in GenBank AY585229.1. See also SEQ ID No.:23 herein.

MERS-CoV is yet another betacoronavirus. Genomic and amino acid sequences of MERS-CoV strain London 1/2012 surface glycoprotein (“S protein”) are provided in SEQ ID NO.:24 (see also GenBank KC164505).

Human coronavirus HKU1 is another betacoronavirus. The amino acid sequence of HKU1 surface glycoprotein (“S protein”) is provided in SEQ ID NO:25 (see also GenBank YP_173238). While SARS-CoV and SARS-CoV-2 bind ACE2, certain other betacoronaviruses are believed to enter cells by binding to other receptors. For example, MERS-CoV is believed to bind dipeptidyl peptidase-4 (DPP4), and OC43 and HKU1 are believed to bind 9-O-acetylated sialic acid (9-O-Ac-Sia) receptor.

In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. Also, any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness, are to be understood to include any integer within the recited range, unless otherwise indicated. As used herein, the term "about" means ± 20% of the indicated range, value, or structure, unless otherwise indicated. "About" includes, e.g., ± 15%, ± 10%, and ± 5%. It should be understood that the terms "a" and "an" as used herein refer to "one or more" of the enumerated components. The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the terms "include," "have," and "comprise" are used synonymously, which terms and variants thereof are intended to be construed as non-limiting.

"Optional" or "optionally" means that the subsequently described element, component, event, or circumstance may or may not occur, and that the description includes instances in which the element, component, event, or circumstance occurs and instances in which they do not.

In addition, it should be understood that the individual constructs, or groups of constructs, derived from the various combinations of the structures and subunits described herein, are disclosed by the present application to the same extent as if each construct or group of constructs was set forth individually. Thus, selection of particular structures or particular subunits is within the scope of the present disclosure. The term "consisting essentially of is not equivalent to "comprising" and refers to the specified materials or steps of a recited subject-matter, or to those that do not materially affect the basic characteristics of a recited subjectmatter. For example, a protein domain, region, or module (e.g., a binding domain; a coronavirus RBD) or a protein "consists essentially of a particular amino acid sequence when the amino acid sequence of a domain, region, module, or protein includes extensions, deletions, mutations, or a combination thereof (e.g., amino acids at the amino- or carboxy -terminus or between domains) that, in combination, contribute to at most 20% (e.g., at most 15%, 10%, 8%, 6%, 5%, 4%, 3%, 2% or 1%) of the length of a domain, region, module, or protein and do not substantially affect (i.e., do not reduce the activity by more than 50%, such as no more than 40%, 30%, 25%, 20%, 15%, 10%, 5%, or 1%) the activity of the domain(s), region(s), module(s), or protein (e.g., the target binding affinity of a binding protein, or the ability of the protein to elicit an immune response in a mammalian subject).

As used herein, "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y- carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a-carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

As used herein, "mutation" refers to a change in the sequence of a nucleic acid molecule or polypeptide molecule as compared to a reference or wild-type nucleic acid molecule or polypeptide molecule, respectively. A mutation can result in several different types of change in sequence, including substitution, insertion or deletion of nucleotide(s) or amino acid(s).

A "conservative substitution" refers to amino acid substitutions that do not significantly affect or alter binding characteristics of a particular protein. Generally, conservative substitutions are ones in which a substituted amino acid residue is replaced with an amino acid residue having a similar side chain. Conservative substitutions include a substitution found in one of the following groups: Group 1 : Alanine (Ala or A), Glycine (Gly or G); Group 2: Aspartic acid (Asp or D), Glutamic acid (Glu or Z); Group 3 : Asparagine (Asn or N), Glutamine (Gin or Q), Serine (Ser or S), Threonine (Thr or T); Group 4: Arginine (Arg or R), Lysine (Lys or K), Histidine (His or H); Group 5: Isoleucine (He or I), Leucine (Leu or L), Methionine (Met or M), Valine (Vai or V); and Group 6: Phenylalanine (Phe or F), Tyrosine (Tyr or Y), Tryptophan (Trp or W). Additionally or alternatively, amino acids can be grouped into conservative substitution groups by similar function, chemical structure, or composition (e.g., acidic, basic, aliphatic, aromatic, or sulfur-containing). For example, an aliphatic grouping may include, for purposes of substitution, Gly, Met, Ala, Vai, Leu, and He. Other conservative substitutions groups include: sulfur-containing: Met and Cysteine (Cys or C); acidic: Asp, Glu; small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, and Gly; polar, negatively charged residues and their amides: Asp, Asn, Glu, and Gin; polar, positively charged residues: His, Arg, and Lys; large aliphatic, nonpolar residues: Met, Leu, He, Vai, and Cys; and large aromatic residues: Phe, Tyr, and Trp. Additional information can be found in Creighton (1984) Proteins, W.H. Freeman and Company.

As used herein, "protein" or "polypeptide" refers to a polymer of amino acid residues. Proteins apply to naturally occurring amino acid polymers, as well as to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, and non-naturally occurring amino acid polymers. Variants of proteins, peptides, and polypeptides of this disclosure are also contemplated. In certain embodiments, variant proteins, peptides, and polypeptides comprise or consist of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9% identical to an amino acid sequence of a defined or reference amino acid sequence as described herein.

As used herein, "fusion protein" refers to a protein that, in a single chain, has at least two distinct domains and/or motifs, wherein the domains or motifs are not naturally found together (e.g., in the given arrangement, order, or number, or at all) in a protein. In certain embodiments, a fusion protein comprises at least two distinct domains and/or motifs that are not found together in a single naturally occurring peptide or polypeptide. For example, in some embodiments, a fusion protein comprises a spike ectodomain polypeptide fused (directly or via a linking amino acid sequence) to one or more of: a foldon; a linker; a heterologous RBD (e.g., an isolated RBD monomer); a peptide tag (e.g., a SpyTag); and a stem-helix polypeptide. In some embodiments, a fusion protein comprises a single (monomeric) isolated RBD fused to one or more of: a linker; a peptide tag (e.g., a SpyTag); and a stem-helix polypeptide. In some embodiments, a fusion protein comprises two or more isolated RBD polypeptides fused via linkers to form a single chain polypeptide (also referred-to herein as an RBD concatemer). In certain further embodiments, a fusion protein comprising an RBD concatemer further comprises a peptide tag (e.g., a SpyTag, a His Tag, or another type of tag); a spike ectodomain polypeptide with an optional foldon; or any combination thereof.

In certain embodiments, a fusion protein comprises one or more additional copies of an amino acid sequence that normally occurs in a reference protein that is otherwise the same as, or is substantially the same as, the fusion protein. For example, in some embodiments, a fusion protein of the present disclosure comprises (i) a spike protein ectodomain that naturally comprises therein an RBD, and (ii) one or more further copies of the RBD amino acid sequence. As another non-limiting example, in some embodiments, a fusion protein of the present disclosure comprises (i) a spike protein ectodomain that naturally comprises therein any one of SEQ ID NOs.:4-14, and (ii) one or more further copies any one or more of SEQ ID NOs.:4-14, and/or can comprise an engineered sequence that comprises any one or more of SEQ ID NOS.:4- 14. As yet another example, in some embodiments, an isolated RBD polypeptide is fused to a stem-helix polypeptide, and neither the RBD polypeptide nor the stem-helix polypeptide is comprised within a spike polypeptide.

"RBD polypeptide" refers to a Receptor Binding Domain (RBD) from a coronavirus spike protein, or a fragment or portion of an RBD. An RBD polypeptide can be engineered, including having engineered features such as described herein. For example, an RBD may be engineered to replace native amino acids with amino acids at corresponding positions in a different RBD; e.g. using a SARS-CoV-2 Wuhan-Hu- 1 RBD polypeptide as a starting point, one or more point mutations from one or more SARS-CoV-2 variants may be introduced into the RBD polypeptide. An RBD polypeptide can be a full-length RBD from a source protein (e.g. from a spike protein of a naturally occurring coronavirus), or can be less than the full-length RBD and comprise a length as described herein, or can comprise the full-length RBD along with flanking sequence from the source protein. An RBD polypeptide will typically have a length of from about 190 to about 230 amino acids, or from about 190 to about 220 amino acids, or a length in a range (the following ranges are inclusive of the specified numbers): from 190 amino acids to 230 amino acids; from 190 amino acids to 220 amino acids; from 190 amino acids to 215 amino acids; from 190 amino acids to 210 amino acids; from 190 amino acids to 205 amino acids; from 195 amino acids to 220 amino acids; from 195 amino acids to 215 amino acids; from 195 amino acids to 210 amino acids; from 195 amino acids to 205 amino acids; from 200 amino acids to 220 amino acids; from 200 amino acids to 215 amino acids; from 200 amino acids to 210 amino acids; or from 200 amino acids to 205 amino acids. An RBD polypeptide may have a length of between 190 amino acids and 230 amino acids, or of between 190 amino acids and 225 amino acids, or of between 190 amino acids and 220 amino acids, or of between 190 amino acids and 215 amino acids, or of between 190 amino acids and 210 amino acids, or of between 190 amino acids and 205 amino acids, or of between 200 amino acids and 230 amino acids, or of between 200 amino acids and 225 amino acids, or of between 200 amino acids and 220 amino acids, or of between 200 amino acids and 215 amino acids, or of between 200 amino acids and 210 amino acids, or of between 200 amino acids and 205 amino acids, or of 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, or 230 amino acids.

An RBD polypeptide may be from, or engineered from, a coronavirus spike protein. Examples of coronavirus spike proteins include those from strains that infect human, pangolin, palm civet, bat, or any combination thereof. The spike protein may be from, e.g. SARS-CoV-2 Wuhan-Hu- 1; SARS-CoV-2 Alpha variant (aka B.1.1.7) and Q lineages; SARS-CoV-2 Beta variant (aka B.1.351) and descendant lineages); SARS-CoV-2 Omicron variant (aka B.1.1.529) and BA.1, BA.1.1, BA.2, BA.3, BA.4 and BA.5 lineages; SARS-CoV-2 Delta variant (aka B.1.617.2); SARS-CoV-2 Gamma variant (aka P.l and descendant lineages thereof); SARS- CoV-2 Epsilon variant (aka B.1.427 and B.1.429); SARS-CoV-2 Eta variant (aka B.1.525); SARS-CoV-2 Iota variant (aka B.1.526); SARS-CoV-2 Kappa variant (aka B.1.617.1); SARS- CoV-2 1.617.3 variant; SARS-CoV-2 Mu variant (aka B.1.621, B.1.621.1); SARS-CoV-2 Zeta (aka P.2); SARS-CoV-2 A.27 (Mayotte); SARS-CoV (aka SARS-CoV-1); PANG GX (aka PCoV_GX-P4L or PCoV_GX-P5L); PANG GD (aka MP789); RaTG13; RsSHC014; BtKY72; BatCoV/BB9904/BGR/2008; BM48-31/BGR/2008; BtRs-B etaCo V/YN20 I 8B; PC4-241; RmYN02; BtRs-BetaCoV/YN2013; Rp/Shaanxi2011; Longquan-140; Rfl/2004; HKU3-12; BtRf-BetaCoV/JL2012; Rs4231; and ZC45. An RBD polypeptide may be isolated from or derived from a Clade la sarbecovirus, a Clade lb sarbecovirus, a Clade 2 sarbecovirus, or a Clade 3 sarbecovirus. A fusion protein comprising a plurality of RBD polypeptides can comprise RBD polypeptides from two or more of: a Clade la sarbecovirus; a Clade lb sarbecovirus; a Clade 2 sarbecovirus; and a Clade 3 sarbecovirus.

Non-limiting examples of spike proteins (from which RBD polypeptides can be sourced), as well as accession (e.g., NCBI GenBank) and SEQ ID NOs. are provided in Table A.

Table A. Non-limiting Examples of Spike Proteins

By way of non-limiting illustration, the spike protein amino acid sequence of SARS- CoV-2 Wuhan-Hu- 1 is shown below with 232 continuous amino acids shown in bold font; in some embodiments, an RBD polypeptide has any length as described herein, provided the RBD polypeptide sequence is encompassed within the 232 continuous amino acids shown below. mjvflvllpl vssqcvnltt rtqlppaytn sftrgvyypd kvfrssvlhs tqdlflpffs nvtwjhaihv sgtngtkrfd npvlpfndgv yfasteksni irgwifgttl dsktqslliv nnatnvvikv cefqfcndpf Igvyyhknnk swmesefrvy ssannctfey vsqpflmdle gkqgnfknlr ejvfknidgy fkiyskhtpi nlvrdlpqgf saleplvdlp iginitrfqt llalhrsylt pgdsssgwta gaaayyvgyl qprtfllkyn engtitdavd caldplsetk ctlksftvek giyqtsnfrv qptesivrfp nitnlcpfge vfnatrfasv yawnrkrisn cvadysvlyn sasfstfkcy gvsptklndl cftnvyadsf virgdevrqi apgqtgkiad ynyklpddft gcviawnsnn Idskvggnyn ylyrlfrksn Ikpferdist eiyqagstpc ngvegfncyf plqsygfqpt ngvgyqpyrv vvlsfellha patvcgpkks tnlvknkcvn fnfngltgtg vltesnkkfl pfqqfgrdia dttdavrdpq tleilditpc sfggvsvitp gtntsnqvav lyqdvnctev pvaihadqlt ptwrvystgs nvfqtragcl igaehvnnsy ecdipigagi casyqtqtns prrarsvasq siiaytmslg aensvaysnn siaiptnfti svtteilpvs mtktsvdctm yicgdstecs nlllqygsfc tqlnraltgi aveqdkntqe vfaqvkqiyk tppikdfggf nfsqilpdps kpskrsfied llfnkvtlad agftkqygdc Igdiaardli caqkfngltv Ipplltdemi aqytsallag titsgwtfga gaalqipfam qmayrfngig vtqnvlyenq klianqfnsa igkiqdslss tasalgklqd vvnqnaqaln tlvkqlssnf gaissvlndi Isrldkveae vqidrlitgr Iqslqtyvtq qliraaeira sanlaatkms ecvlgqskrv dfcgkgyhlm sfpqsaphgv vflhvtyvpa qeknfttapa ichdgkahfp regyfvsngt hwjvtqrnjy epqiittdnt jvsgncdvvi givnntvydp Iqpeldsfke eldkyfknht spdvdlgdis ginasvvniq keidrlneva knlneslidl qelgkyeqyi kwpwyiwlgf iagliaivmv timlccmtsc csclkgccsc gscckfdedd sepvlkgvkl hyt

(SEQ ID NO. : 1)

In other embodiments, an RBD polypeptide is from any coronavirus (e.g. any strain as set forth in Table A) and has any length as described herein, provided the RBD polypeptide sequence is encompassed within a sequence of about 230 continuous amino acids of the coronavirus spike protein; the about 230 continuous amino acids of the coronavirus spike protein will preferably correspond, or will substantially correspond, to the positions of the amino acids shown in bold in SEQ ID NO.: 1, above, when the sequences are optimally aligned. Non-limiting examples of RBD polypeptide sequences are provided in SEQ ID NOs.:2 and 722-737.

As used herein, the term "stem-helix polypeptide" refers to a polypeptide that comprises, consists essentially of, or consists of a portion of a betacoronavirus stem-helix region (located in S2) that comprises a sequence according to the consensus sequence in SEQ ID NO.:4, or a fragment or sequence variant of SEQ ID NO.:4 that optionally retains antigenicity and/or binding by an antibody, such as antibody S2P6, antibody S2S343, antibody B6 (Sauer et al., Nature Structural & Molecular Biology 25:478-486 (2021), and/or antibody 28D9 (Wang et al., Nature Communications 72:1715 (2021) doi.org/10.1038/s41467-021-21968-w); B6 and 28D9 are incorporated herein by reference. A stem-helix polypeptide is typically less than 100, less than 90, less than 80, less than 70, less than 60, less than 50, less than 40, less than 30, less than 25, less than 20, or less than 10 amino acids in length (though it may be comprised within a larger polypeptide, such as a fusion protein as described herein). In some embodiments, a fusion protein comprises two, three, four, five, or more stem-helix polypeptides linked in a single chain fusion. In some embodiments, a fusion protein comprises one, two, three, four, five, six, seven, eight, nine, ten, or more stem-helix polypeptides.

In some embodiments, a stem-helix polypeptide comprises, consists essentially of, or consists of an amino acid sequence according to any one of SEQ ID NOs.:4-19 or 57-59. In some embodiments, a stem-helix polypeptide comprises, consists essentially of, or consists of any one of SEQ ID NOs.:5-12 (or a variant thereof comprising one, two, or three amino acid substitutions) and one to five, or one to ten, or one to twenty amino acids that flank SEQ ID NO.:5, 6,7, 8, 9, 10, 11, or 12 in the N-terminal and/or C-terminal direction in the betacoronavirus spike ectodomain, optionally wherein the one to five, one to ten, or one to twenty flanking amino acids comprise one or more amino acid substitutions as compared to the betacoronavirus spike ectodomain sequence. In some embodiments, a stem-helix polypeptide comprises, consists essentially of, or consists of any one of SEQ ID NOs.:5-12 and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more N-terminal and/or C-terminal flanking amino acids from, or derived from, the betacoronavirus spike ectodomain to which the stem-helix polypeptide is native. Additionally or alternatively, a stem-helix polypeptide can comprise linker amino acids (e.g., PG, GP, PGP, GPP, a glycine-serine linker (e.g. GS or GSG or the like), a Townsend linker, a Whitlow linker, or the like)) flanking, on one end or both, the amino acid sequence from, or engineered from, the betacoronavirus spike ectodomain sequence. In certain embodiments, a stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). In some embodiments, a stem-helix polypeptide functions as a linker between two polypeptides (e.g., between a foldon and a RBD polypeptide, between a first RBD polypeptide and a second RBD polypeptide, between an RBD polypeptide and a peptide tag, between a spike ectodomain and a peptide tag, or the like). Stem-helix polypeptides are described further herein.

As used herein, "oligomerization domain" refers to a polypeptide that mediates, or that functions with one or more other like oligomerization domains to mediate, assembly of polypeptide subunits into a polypeptide oligomer. Oligomerization domains may exist, for example, as dimers, trimers, tetramers, or pentamers. Non-limiting examples of oligomerization domains include fibritin trimerization domains, collagen helices, coiled-coil structures, and chloramphenicol acetyl transferase (CAT).

A preferred fibritin trimerization domain is a foldon, found in the C-terminal domain of T4 fibritin (see, e.g., Meier et al. J. Mol. Bio. 344(4): 1051-69 (2004)). An example of a foldon sequence is the C-terminal 27-residues from T4 fibritin (GYIPEAPRDGQAYVRKDGEWVLLSTFL; SEQ ID NO.:703), which forms a p-propeller-like structure. Collagen triple helices are the primary secondary structure of various types of fibrous collagen, including type I collagen. Contemplated embodiments include natural collagen helices, as well triple helices derived from synthetic peptides (see, e.g. Kotch and Raines, PNAS 703(9):3028-3033 (2006), which synthetic helices are incorporated by reference herein). Coiled- coils comprise two or more (usually, from two to seven) alpha-helices coiled or wound together like strands of a rope (see, e.g. Truebestein and Leonard, Bioessays 35(9): 903 -916 (2016), which coiled-coils described therein, and methods of using the same, are incorporated by reference). If will be appreciated that in certain embodiments, a trimerization domain, such as a foldon, will be linked to another domain or portion of a fusion protein by a linker, such as, for example, a GS linker, a GSG linker, a GPP linker, a Townsend linker (GSGGSGGSGGTG (SEQ ID NO.:702)), a (Gly_xSer_y)n linker, or the like.

Certain embodiments include a fusion protein that comprises one or more peptide tag. A peptide tag can specifically bind to a cognate receptor or binding partner, preferably with high affinity and/or avidity, and will typically have a length of about five to about twenty amino acids. A peptide tag will typically be fused N-terminal and/or C-terminal to a polypeptide of interest, and in some cases will be fused to the N-terminus and/or to the C-terminus of the polypeptide of interest, optionally with an intervening linker. A peptide tag can additionally or alternatively be comprised within the polypeptide of interest. Peptide tag:cognate binding partner combinations can be used for, e.g., coupling a protein of interest to another protein or a substrate, such as for assembly of a protein delivery vehicle (e.g. a nanoparticle), or for purification.

Examples of tag:binding partner pairs include the Spy Tag: Spy Catcher system (Zakeri et al., PNAS 709(12):E690-697)) and derivatives thereof, including SpyTag002/SpyCatcher002 (Keeble et al., Angew Chem Int Ed Engl. 56(52): 16521 - 16525) and SpyTag003/SpyCatcher003 (Keeble et al., PNAS 776(52):26523-26533 (2019). Spy Tag: Spy Catcher systems are engineered from Streptococcus pyogenes fibronectin-binding protein FbaB and permit irreversible conjugation of recombinant proteins via formation of an isopeptide bond between the SpyTag- bearing protein and a SpyCatcher-bearing protein or structure of interest (e.g., a nanoparticle, a virus-like particle). Conjugation of an antigen to a substrate using a Spy Tag: Spy Catcher system has been described (e.g. Cohen et al., PLoS One (2021), https://doi.org/10.1371/journal.pone.0247963). An example of a SpyTag peptide is a peptide that comprises or consists of the amino acid sequence AHIVMVDAYKPTK (SEQ ID NO.:700). A "SpyCatcher" peptide includes any of the foregoing SpyCatcher peptides. Other exemplary tag cassettes include Strep tag® (which refers the original Strep tag®, Strep tag® II, or any variant thereof; see, e.g., U.S. Patent No. 7,981,632, which Strep tags are incorporated herein by reference), His tag (e.g., HHHHHHHH (SEQ ID NO.:704)), Flag® tag, Xpress tag, Avitag™, Calmodulin tag, Polyglutamate tag, HA tag, Myc tag, Nus tag, S tag, SBP tag, Softag® 1, Softag® 3, V5 tag, CREB-binding protein (CBP), glutathione S-transf erase (GST), maltose binding protein (MBP), green fluorescent protein (GFP), and Thioredoxin tag.

It will be understood that while certain exemplified embodiments of fusion proteins and polypeptides disclosed herein comprise a peptide tag such as a SpyTag, a His Tag, or both, alternatively no peptide tag may be present, or as different peptide tag or tags may be used.Disclosed polypeptides (e.g., RBD monomers, fusion proteins) can comprise a signal peptide (also known as a leader sequence, leader peptide, or transit peptide). Signal peptides target newly synthesized polypeptides to their appropriate location inside or outside the cell. Signal peptides may be located at the N-terminal or the C-terminal end of a polypeptide, and will gernally be located at the N-terminal end of a polypeptide. A signal peptide may be removed from the polypeptide during or once localization or secretion is completed. Polypeptides that have a signal peptide are referred to herein as a "pre-protein" and polypeptides having their signal peptide removed are referred to herein as "mature" proteins or polypeptides. Accordingly, contemplated are any of the presently disclosed fusion proteins or polypeptides provided as a pre-protein, and also as a mature protein.

Non-limiting examples of signal peptides include: the signal peptide MNTQILVFALIAIIPTNADKI (SEQ ID NO.:705; from influenza H7 HA (A/HongKong/125/2017)); the signal peptide MAPLLLLLPLLWAGALA (SEQ ID NO.:706; modified from CD33); and the signal peptide sequence MFVFLVLLPLVS (SEQ ID NO.:707) or MFVFLVLLPLVSS (SEQ ID NO.:708) from SARS-CoV-2. It will be appreciated that any suitable naturally occurring or engineered signal peptide can be employed. Certain signal peptides and characteristics of these are decribed in Owji et al., European Journal of Cell Biology 97(6):422-441 (2018); the signal peptides of which are incorporated herein by reference. In certain embodiments, a signal peptide is, or is derived from, a signal peptide of a viral protein.

It will be appreciated that any of the presently disclosed polypeptides can comprise a signal peptide, a peptide tag, both of these, or neither of these. Certain disclosed amino acid sequences comprise a signal peptide; such a signal peptide will be recognized by those of ordinary skill in the art, and the amino acid sequence resulting from removal of the signal peptide will also be recognized. For example, the construct Cov0251 comprises the amino acid sequence of SEQ ID NO.:302. It will be appreciated that SEQ ID NO.:302 comprises the signal peptide MNTQILVFALIAIIPTNADKI (SEQ ID NO.:705), and that this sequence may be removed (or absent), or may be replaced with a different signal peptide. It will further be appreciated that in some embodiments, a signal peptide is linked to a further sequence (e.g., a SpyTag sequence, an RBD or the like) by a linker, and that if the signal peptide is removed, so too can all or a portion of the linker be removed. In the case of SEQ ID NO.: 302, a GSG linker separates the signal peptide from a SpyTag sequence. It will also be appreciated that a linker sequence may be longer, shorter, or present in more or fewer copies than is shown in an exemplified protein construct herein.

A polynucleotide encoding a polypeptide, for example a fusion protein, may be constructed using PCR, recombinantly engineered, or the like, or such polypeptides can be synthesized.

"Nucleic acid molecule" or "polynucleotide" or "polynucleic acid" refers to a polymeric compound including covalently linked nucleotides, which can be made up of natural subunits (e.g., purine or pyrimidine bases) or non-natural subunits (e.g., morpholine ring). Purine bases include adenine, guanine, hypoxanthine, and xanthine, and pyrimidine bases include uracil, thymine, and cytosine. Nucleic acid molecules include polyribonucleic acid (RNA), which includes mRNA, microRNA, siRNA, viral genomic RNA, and synthetic RNA, and polydeoxyribonucleic acid (DNA), which includes cDNA, genomic DNA, and synthetic DNA, either of which may be single or double stranded. If single-stranded, the nucleic acid molecule may be the coding strand or non-coding (anti-sense) strand. A nucleic acid molecule encoding an amino acid sequence includes all nucleotide sequences that encode the same amino acid sequence. Some versions of the nucleotide sequences may also include intron(s) to the extent that the intron(s) would be removed through co- or post-transcriptional mechanisms. In other words, different nucleotide sequences may encode the same amino acid sequence as the result of the redundancy or degeneracy of the genetic code, or by splicing.

Variants of nucleic acid molecules of this disclosure are also contemplated. Variant nucleic acid molecules are at least 70%, 75%, 80%, 85%, 90%, and are preferably 95%, 96%, 97%, 98%, 99%, or 99.9% identical a nucleic acid molecule of a defined or reference polynucleotide as described herein, or that hybridize to a polynucleotide under stringent hybridization conditions of 0.015M sodium chloride, 0.0015M sodium citrate at about 65-68°C or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide at about 42°C. Nucleic acid molecule variants retain the capacity to encode a binding domain thereof having a functionality described herein, such as binding a target molecule.

"Percent sequence identity" refers to a relationship between two or more sequences, as determined by comparing the sequences. Preferred methods to determine sequence identity are designed to give the best match between the sequences being compared. For example, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment). Further, non-homologous sequences may be disregarded for comparison purposes. The percent sequence identity referenced herein is calculated over the length of the reference sequence, unless indicated otherwise. Methods to determine sequence identity and similarity can be found in publicly available computer programs. Sequence alignments and percent identity calculations may be performed using a BLAST program (e.g., BLAST 2.0, BLASTP, BLASTN, or BLASTX). The mathematical algorithm used in the BLAST programs can be found in Altschul et al., Nucleic Acids Res. 25:3389-3402, 1997. Within the context of this disclosure, it will be understood that where sequence analysis software is used for analysis, the results of the analysis are based on the "default values" of the program referenced. "Default values" mean any set of values or parameters which originally load with the software when first initialized.

The term "isolated" means that the material is removed from its original environment (e.g, the natural environment if it is naturally occurring). For example, a naturally occurring nucleic acid or polypeptide present in a living animal in which it naturally occurs is not isolated, but the same nucleic acid or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated. Such nucleic acid could be part of a vector and/or such nucleic acid or polypeptide could be part of a composition (e.g., a cell lysate), and still be isolated in that such vector or composition is not part of the natural environment for the nucleic acid or polypeptide. As another illustration, an RBD polypeptide or a stem-helix polypeptide is "isolated" when not present as part of a spike protein or spike protein ectodomain; e.g., the RBD or stem-helix polypeptide can be present in an isolated fragment or portion of a spike protein or spike protein ectodomain.

Additionally, in some embodiments, a composition of the present disclosure is "isolated" in the sense that it is physically separated from and not comprised within a subject to whom the composition can be, was, or is to be administered.

Any of the presently disclosed polypeptides, fusion proteins, polynucleotides, vectors, and host cells may be provided in isolated form.

The term "gene" means the segment of DNA or RNA involved in producing a polypeptide chain; in certain contexts, it includes regions preceding and following the coding region (e.g., 5’ untranslated region (UTR) and 3’ UTR) as well as intervening sequences (introns) between individual coding segments (exons).

A "functional variant" refers to a polypeptide or polynucleotide that is structurally similar or substantially structurally similar to a parent or reference compound of this disclosure, but differs slightly in composition (e.g., one base, atom or functional group is different, added, or removed), such that the polypeptide or encoded polypeptide is capable of performing at least one function of the parent polypeptide with at least 50% efficiency, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% level of activity of the parent polypeptide. In other words, a functional variant of a polypeptide or encoded polypeptide of this disclosure has "similar binding," "similar affinity" or "similar activity" when the functional variant displays no more than a 50% reduction in performance in a selected assay as compared to the parent or reference polypeptide, such as an assay for measuring binding affinity (e.g., Biacore® or tetramer staining measuring an association (Ka) or a dissociation (KD) constant).

As used herein, a "functional portion" or "functional fragment" refers to a polypeptide or polynucleotide that comprises only a domain, portion or fragment of a parent or reference compound, and the polypeptide or encoded polypeptide retains at least 50% activity associated with the domain, portion or fragment of the parent or reference compound, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% level of activity of the parent polypeptide, or provides a biological benefit (e.g., effector function). A "functional portion" or "functional fragment" of a polypeptide or encoded polypeptide of this disclosure has "similar binding" or "similar activity" when the functional portion or fragment displays no more than a 50% reduction in performance in a selected assay as compared to the parent or reference polypeptide (preferably no more than 20% or 10%, or no more than a log difference as compared to the parent or reference with regard to affinity).

As used herein, the term "engineered," "recombinant," or "non-natural" refers to an organism, microorganism, cell, nucleic acid molecule, or vector that includes at least one genetic alteration or has been modified by introduction of an exogenous or heterologous nucleic acid molecule, wherein such alterations or modifications are introduced by genetic engineering (i.e., human intervention). Genetic alterations include, for example, modifications introducing expressible nucleic acid molecules encoding functional RNA, proteins, fusion proteins or enzymes, or other nucleic acid molecule additions, deletions, substitutions, or other functional disruption of a cell’s genetic material. Additional modifications include, for example, noncoding regulatory regions in which the modifications alter expression of a polynucleotide, gene, or operon. An engineered protein includes a protein that arises as a result of genetic engineering, e.g. by substitution, deletion, insertion, rearrangement, fusion, use of non-natural amino acids, or the like.

As used herein, "heterologous" or "non-endogenous" or "exogenous" refers to any gene, protein, compound, nucleic acid molecule, or activity that is not native to a host cell or a subject, or any gene, protein, compound, nucleic acid molecule, or activity native to a host cell or a subject that has been altered. Heterologous, non-endogenous, or exogenous includes genes, proteins, compounds, or nucleic acid molecules that have been mutated or otherwise altered such that the structure, activity, or both is different as between the native and altered genes, proteins, compounds, or nucleic acid molecules. In certain embodiments, heterologous, non-endogenous, or exogenous genes, proteins, or nucleic acid molecules (e.g., receptors, ligands, etc.) may not be endogenous to a host cell or a subject, but instead nucleic acids encoding such genes, proteins, or nucleic acid molecules may have been added to a host cell by conjugation, transformation, transfection, electroporation, or the like, wherein the added nucleic acid molecule may integrate into a host cell genome or can exist as extra-chromosomal genetic material (e.g., as a plasmid or other self-replicating vector). The term "homologous" or "homolog" refers to a gene, protein, compound, nucleic acid molecule, or activity found in or derived from a host cell, species, or strain. For example, a heterologous or exogenous polynucleotide or gene encoding a polypeptide may be homologous to a native polynucleotide or gene and encode a homologous polypeptide or activity, but the polynucleotide or polypeptide may have an altered structure, sequence, expression level, or any combination thereof. A non-endogenous polynucleotide or gene, as well as the encoded polypeptide or activity, may be from the same species, a different species, or a combination thereof.

In certain embodiments, a nucleic acid molecule or portion thereof native to a host cell will be considered heterologous to the host cell if it has been altered or mutated, or a nucleic acid molecule native to a host cell may be considered heterologous if it has been altered with a heterologous expression control sequence or has been altered with an endogenous expression control sequence not normally associated with the nucleic acid molecule native to a host cell. In addition, the term "heterologous" can refer to a biological activity that is different, altered, or not endogenous to a host cell. As described herein, more than one heterologous nucleic acid molecule can be introduced into a host cell as separate nucleic acid molecules, as a plurality of individually controlled genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a fusion protein, or any combination thereof. When

As used herein, the term "endogenous" or "native" refers to a polynucleotide, gene, protein, compound, molecule, or activity that is normally present in a host cell or a subject.

The term "expression", as used herein, refers to the process by which a polypeptide is produced based on the encoding sequence of a nucleic acid molecule, such as a gene. The process may include transcription, post-transcriptional control, post-transcriptional modification, translation, post-translational control, post-translational modification, or any combination thereof. An expressed nucleic acid molecule is typically operably linked to an expression control sequence (e.g., a promoter).

The term "operably linked" refers to the association of two or more nucleic acid molecules on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). "Unlinked" means that the associated genetic elements are not closely associated with one another and the function of one does not affect the other.

As described herein, more than one heterologous nucleic acid molecule can be introduced into a host cell as separate nucleic acid molecules, as a plurality of individually controlled genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a polypeptide, or any combination thereof. When two or more heterologous nucleic acid molecules are introduced into a host cell, it is understood that the two or more heterologous nucleic acid molecules can be introduced as a single nucleic acid molecule (e.g., on a single vector), on separate vectors, integrated into the host chromosome at a single site or multiple sites, or any combination thereof. The number of referenced heterologous nucleic acid molecules or protein activities refers to the number of encoding nucleic acid molecules or the number of protein activities, not the number of separate nucleic acid molecules introduced into a host cell.

The term "construct" refers to any polynucleotide that contains a recombinant nucleic acid molecule (or, when the context clearly indicates, a fusion protein of the present disclosure). A (polynucleotide) construct may be present in a vector (e.g., a bacterial vector, a viral vector) or may be integrated into a genome. A "vector" is a nucleic acid molecule that is capable of transporting another nucleic acid molecule. Vectors may be, for example, plasmids, cosmids, viruses, a RNA vector or a linear or circular DNA or RNA molecule that may include chromosomal, non-chromosomal, semi -synthetic or synthetic nucleic acid molecules. Vectors of the present disclosure also include transposon systems (e.g., Sleeping Beauty, see, e.g., Geurts et al., Mol. Ther. 5:108, 2003: Mates et al., Nat. Genet. 41.753, 2009). Exemplary vectors are those capable of autonomous replication (episomal vector), capable of delivering a polynucleotide to a cell genome (e.g., viral vector), or capable of expressing nucleic acid molecules to which they are linked (expression vectors).

As used herein, "expression vector" or "vector" refers to a DNA construct containing a nucleic acid molecule that is operably linked to a suitable control sequence capable of effecting the expression of the nucleic acid molecule in a suitable host. Vectors may also be RNA-based, and may comprise viral sequence, non-viral sequence, or both (see e.g. Schott et al. Mol Ther. 24(9): 1513-1527 (2016)). Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation. The vector may be a plasmid, a phage particle, a virus, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself or deliver the polynucleotide contained in the vector into the genome without the vector sequence. In the present specification, "plasmid," "expression plasmid," "virus," and "vector" are often used interchangeably.

The term "introduced" in the context of inserting a nucleic acid molecule into a cell, means "transfection", "transformation," or "transduction" and includes reference to the incorporation of a nucleic acid molecule into a eukaryotic or prokaryotic cell wherein the nucleic acid molecule may be incorporated into the genome of a cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).

In certain embodiments, polynucleotides of the present disclosure may be operatively linked to certain elements of a vector. For example, polynucleotide sequences that are needed to effect the expression and processing of coding sequences to which they are ligated may be operatively linked. Expression control sequences may include appropriate transcription initiation, termination, promoter, and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequences); sequences that enhance protein stability; and possibly sequences that enhance protein secretion. Expression control sequences may be operatively linked if they are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.

In certain embodiments, the vector comprises a plasmid vector or a viral vector (e.g., a lentiviral vector or a y-retroviral vector). Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g., measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox, and canarypox). Other viruses include, for example, Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus. Examples of retroviruses include avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).

"Retroviruses" are viruses having an RNA genome, which is reverse-transcribed into DNA using a reverse transcriptase enzyme, the reverse-transcribed DNA is then incorporated into the host cell genome. "Gammaretrovirus" refers to a genus of the retroviridae family. Examples of gammaretroviruses include mouse stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis viruses.

"Lentiviral vectors" include HIV-based lentiviral vectors for gene delivery, which can be integrative or non-integrative, have relatively large packaging capacity, and can transduce a range of different cell types. Lentiviral vectors are usually generated following transient transfection of three (packaging, envelope, and transfer) or more plasmids into producer cells. Like HIV, lentiviral vectors enter the target cell through the interaction of viral surface glycoproteins with receptors on the cell surface. On entry, the viral RNA undergoes reverse transcription, which is mediated by the viral reverse transcriptase complex. The product of reverse transcription is a double-stranded linear viral DNA, which is the substrate for viral integration into the DNA of infected cells.

In certain embodiments, the viral vector can be a gammaretrovirus, e.g., Moloney murine leukemia virus (MLV)-derived vectors. In other embodiments, the viral vector can be a more complex retrovirus-derived vector, e.g., a lentivirus-derived vector. HIV-l-derived vectors belong to this category. Other examples include lentivirus vectors derived from HIV-2, FIV, equine infectious anemia virus, SIV, and Maedi-Visna virus (ovine lentivirus). Methods of using retroviral and lentiviral viral vectors and packaging cells for transducing mammalian host cells with viral particles containing transgenes are known in the art and have been previous described, for example, in: U.S. Patent 8,119,772; Walchli et al., PLoS One 6 327939, 2011; Zhao et al., J. Immunol. 174'AM5, 2005; Engels et al., Hum. Gene Ther. 14'.1155, 2003; Frecha et al., Mol. Ther. 18A74 , 2010; and Verhoeyen et al., Methods Mol. Biol. 506:97, 2009. Retroviral and lentiviral vector constructs and expression systems are also commercially available. Other viral vectors also can be used for polynucleotide delivery including DNA viral vectors, including, for example adenovirus-based vectors and adeno-associated virus (AAV)-based vectors; vectors derived from herpes simplex viruses (HSVs), including amplicon vectors, replication-defective HSV and attenuated HSV (Krisky et al., Gene Ther. 5: 1517, 1998).

Other vectors that can be used with the compositions and methods of this disclosure include those derived from baculoviruses and a-viruses. (Jolly, D J. 1999. Emerging Viral Vectors, pp 209-40 in Friedmann T. ed. The Development of Human Gene Therapy. New York: Cold Spring Harbor Lab), or plasmid vectors (such as sleeping beauty or other transposon vectors). When a viral vector genome comprises a plurality of polynucleotides to be expressed in a host cell as separate transcripts or polypeptides, the viral vector may also comprise additional sequences between the two (or more) transcripts allowing for bicistronic or multi ci stronic expression. Examples of such sequences used in viral vectors include internal ribosome entry sites (IRES), furin cleavage sites, viral 2A peptide, or any combination thereof.

Plasmid vectors, including DNA-based polypeptide-encoding plasmid vectors for direct administration to a subject, are described further herein.

As used herein, the term "host" refers to a cell or microorganism targeted for genetic modification with a heterologous nucleic acid molecule to produce a polypeptide of interest. A host cell can also be a cell or microorganism targeted for genetic modification with a heterologous nucleic acid molecule to produce a polynucleotide of interest.

A host cell may include any individual cell or cell culture which may receive a vector or the incorporation of nucleic acids or express proteins. The term also encompasses progeny of the host cell, whether genetically or phenotypically the same or different. Suitable host cells may depend on the vector and may include mammalian cells, animal cells, human cells, simian cells, insect cells, yeast cells, and bacterial cells. These cells may be induced to incorporate the vector or other material by use of a viral vector, transformation via calcium phosphate precipitation, DEAE-dextran, electroporation, microinjection, or other methods. See, for example, Sambrook el al., Molecular Cloning: A Laboratory Manual 2d ed. (Cold Spring Harbor Laboratory, 1989).

In the context of a coronavirus infection, a "host" refers to a cell or a subject infected with a coronavirus.

"Antigen" or "Ag", as used herein, refers to an immunogenic molecule that provokes an immune response. This immune response may involve antibody production, activation of specific immunologically-competent cells, activation of complement, antibody dependent cytotoxicity, or any combination thereof. An antigen (immunogenic molecule) may be, for example, a peptide, glycopeptide, polypeptide, glycopolypeptide, polynucleotide, polysaccharide, lipid, or the like. It is readily apparent that an antigen can be synthesized, produced recombinantly, or derived from a biological sample. Exemplary biological samples that can contain one or more antigens include tissue samples, stool samples, cells, biological fluids, or combinations thereof. Antigens can be produced by cells that have been modified or genetically engineered to express an antigen. Antigens can also be present in a betacoronavirus (e.g., a surface glycoprotein or portion thereof), such as present in a virion, or expressed or presented on the surface of a cell infected by a betacoronavirus.

The term "epitope" or "antigenic epitope" includes any molecule, structure, amino acid sequence, or protein determinant that is recognized and specifically bound by a cognate binding molecule, such as an immunoglobulin, or other binding molecule, domain, or protein. Epitopic determinants generally contain chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three-dimensional structural characteristics, as well as specific charge characteristics. Where an antigen is or comprises a peptide or protein, the epitope can be comprised of consecutive amino acids (e.g., a linear epitope), or can be comprised of amino acids from different parts or regions of the amino acid sequence that are brought into proximity by protein folding (e.g., a discontinuous or conformational epitope), or non-contiguous amino acids that are in close proximity irrespective of protein folding.

Terms understood by those in the art of antibody technology are each given the meaning acquired in the art, unless expressly defined differently herein. For example, the term "antibody" refers to an intact antibody comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as any antigen-binding portion or fragment of an intact antibody that has or retains the ability to bind to the antigen target molecule recognized by the intact antibody, such as an scFv, Fab, or Fab'2 fragment. Thus, the term "antibody" herein is used in the broadest sense and includes polyclonal and monoclonal antibodies, including intact antibodies and functional (antigen-binding) antibody fragments thereof, including fragment antigen binding (Fab) fragments, F(ab')2 fragments, Fab' fragments, Fv fragments, recombinant IgG (rlgG) fragments, single chain antibody fragments, including single chain variable fragments (scFv), and single domain antibodies (e.g., sdAb, sdFv, nanobody) fragments. The term encompasses genetically engineered and/or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multispecific, e.g., bispecific antibodies, diabodies, triabodies, tetrabodies, tandem di-scFv, and tandem tri-scFv. Unless otherwise stated, the term "antibody" should be understood to encompass functional antibody fragments thereof. The term also encompasses intact or full-length antibodies, including antibodies of any class or sub-class, including IgG and sub-classes thereof (IgGl, IgG2, IgG3, IgG4), IgM, IgE, IgA, and IgD.

The terms "VL" or "VL" and " VH" or "VH" refer to the variable binding region from an antibody light chain and an antibody heavy chain, respectively. In certain embodiments, a VL is a kappa (K) class (also "VK" herein). In certain embodiments, a VL is a lambda (X) class. The variable binding regions comprise discrete, well-defined sub-regions known as "complementarity determining regions" (CDRs) and "framework regions" (FRs). The terms "complementarity determining region," and "CDR," are synonymous with "hypervariable region" or "HVR," and refer to sequences of amino acids within antibody variable regions, which, in general, together confer the antigen specificity and/or binding affinity of the antibody, wherein consecutive CDRs (i.e., CDR1 and CDR2, CDR2 and CDR3) are separated from one another in primary structure by a framework region. There are three CDRs in each variable region (HCDR1, HCDR2, HCDR3; LCDR1, LCDR2, LCDR3; also referred to as CDRHs and CDRLs, respectively). In certain embodiments, an antibody VH comprises four FRs and three CDRs as follows: FR1- HCDR1-FR2-HCDR2-FR3-HCDR3-FR4; and an antibody VL comprises four FRs and three CDRs as follows: FR1-LCDR1-FR2-LCDR2-FR3-LCDR3-FR4. In general, the VH and the VL together form the antigen-binding site through their respective CDRs.

VH and VL amino acid sequences of certain antibodies are provided herein. Engineered Polypeptides

The present disclosure provides, in part, recombinant polypeptides derived and/or engineered from a coronavirus spike protein ectodomain (or an RBD thereof), and compositions (e.g., immunogenic compositions) comprising the same.

In some embodiments, a polypeptide is provided that is from, or that is an engineered variant of, a stem helix portion of a SARS-CoV-2 spike polypeptide. In some contexts, the polypeptide is from, or is engineered from, an antigenic portion of a connection domain or linker domain disposed between a HR2 region and a central helix (CH) region of the S protein. Briefly, as taught in the present Examples, an antigenic portion of this domain is conserved across multiple P-coronavirus glycoproteins. An antigenic sequence or motif (e.g., a naturally occurring amino acid sequence or an engineered variant thereof), can be present in an immunogenic composition, in a fusion protein, or the like, including in multiple copies. Presently disclosed antigenic sequences from SARS-CoV-2 stem helix and engineered variants thereof can, in various embodiments, be used as linkers to link two or more polypeptides of interest; for example, two receptor binding domain (RBD) polypeptides, forming a fusion protein. Herein, polypeptides that comprise, consist of, or consist essentially of a disclosed antigenic sequence or motif from SARS-CoV-2 S protein stem helix (and/or an engineered variant of a SARS-CoV-2 S protein stem helix polypeptide) may be referred-to as stem-helix polypeptides. However, a full- length SARS-CoV-2 S protein that naturally contains a stem helix portion is distinct from a "stem-helix polypeptide"; a stem-helix polypeptide will generally be shorter than, isolated from, and/or engineered relative to the S protein.

In certain embodiments, a stem-helix polypeptide is comprised in, or comprises one or more of the S protein amino acids of, the S protein amino acid sequence FX1X2ELX3X4 X5FKNX6X7X8X9X10X11X12X13X14 (SEQ ID NO.:46), wherein: Xi is K, E, or Q; X2 is E, S, or D; X₃ is D or S; X₄ is K, Q, H, or E; X₅ is Y, W, or F; X₆ is H, Q, or V; X7 is T or S; Xs is S, L, or T; X9 is P, V, L, or S; X10 is D, A, P, or I; Xu is V or P; X12 is D or N; X13 is L or F; and X14 is G, S, or T. In particular embodiments, the N at position 11 of SEQ ID NO.:46 is glycosylated.

It will be understood that a stem-helix polypeptide can be present in a recombinant (e.g., fusion or otherwise engineered) protein, and/or as a fragment separated or isolated from a spike polypeptide. For example, in some embodiments, an isolated polypeptide is provided that has or comprises a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than 11 amino acids, and comprises an amino acid sequence according to SEQ ID NO.:4. In certain further embodiments, the polypeptide comprises the amino acid sequence set forth in SEQ ID NO.:5. In certain embodiments, a stemhelix polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO.:701.

In some embodiments, an isolated polypeptide is provided that has or comprises a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than about 10 amino acids, or no more than 6 amino acids, and comprises the amino acid sequence set forth in any one of SEQ ID NOs.:4-12 and 14.

In certain embodiments, an isolated polypeptide is provided that comprises or consists of any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 continuous amino acid residues of SEQ ID NO.: 13, provided that the isolated peptide comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 continuous amino acids of SEQ ID NO.:5.

In particular embodiments, an isolated polypeptide is provided that comprises the amino acid sequence set forth in any one of SEQ ID NOs.: 14 -19. In some embodiments, a polypeptide is provided that comprises: (i) the amino acid sequence according to any one of SEQ ID NOs.:4- 14; and (ii) the amino acid sequence set forth in SEQ ID NO.: 15. In some embodiments, a polypeptide is provided that comprises: (i) a plurality of any one or more of SEQ ID NOs.:4-14, wherein the plurality is homogenous, homotypic, heterogeneous, or heterotypic; and, disposed between and connecting a two of the plurality, (ii) a linker sequence. Also provided is a polypeptide that comprises: (i) two, three, four, five, or more copies of SEQ ID NO.: 16; (ii) two three, four, five, or more copies of SEQ ID NO. : 17; and/or (iii) one or more copy of SEQ ID NO.: 16 and one or more copy of SEQ ID NO.: 17. Also provided is a polypeptide that comprises SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein X is 2 or more, 3 or more, 4 or more, or 5 or more.

As described herein, a stem-helix polypeptide can be comprised in a fusion protein. In some embodiments, a fusion protein is provided that comprises (i) a SARS-CoV-2 spike polypeptide or a portion thereof and (ii) a stem-helix polypeptide as disclosed herein. In certain further embodiments, the SARS-CoV-2 spike polypeptide comprises (i) one or more modification that promotes an open conformation of a receptor binding domain (RBD) of the spike polypeptide (e.g., D614G, K986P with V987P) and/or (ii) one or more modification that promotes stabilization of a SARS-CoV-2 spike polypeptide trimer.

A fusion protein can comprise a plurality of polypeptides each independently selected from a polypeptide according to the present disclosure. In some embodiments, the polypeptide or polypeptides of are disposed in a S2 subunit of the SARS-CoV-2 spike protein.

In some embodiments, a fusion protein comprises comprising SEQ ID NO.: 18 or SEQ ID NO. : 19, wherein X is 2 or more, 3 or more, 4 or more, or 5 or more. In some embodiments, a fusion protein comprises (i) an (e.g. SARS-CoV-2) spike polypeptide receptor binding domain (RBD) polypeptide and (ii) a stem-helix polypeptide as provided herein. In certain embodiments, the RBD is not comprised in a native (e.g. SARS-CoV-2) spike polypeptide. In certain embodiments, the fusion protein comprises a plurality of RBD polypeptides of (i) and/or a plurality of polypeptides of (ii). In certain further embodiments, the fusion protein comprises a linker sequence disposed between and connecting a two of the plurality of RBD polypeptides.

A fusion protein can comprise any suitable number of linkers, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more. Where two or more linkers are present, two or more of the linkers may have the same amino acid sequences as one another, or may have different amino acid sequences as compared to one another. A linker present in a fusion protein of the present disclosure can, for example, comprise or consist of a stem-helix polypeptide. Alternative linkers may be chosen, for example, based on: (1) their ability to adopt a flexible extended conformation; (2) their inability or lack of ability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides and/or on a target molecule; and/or (3) the lack or relative lack of hydrophobic or charged residues that might react with the polypeptides and/or target molecule. In certain embodiments, peptide linker sequences contain, for example, Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala, may also be included in a linker sequence. Other amino acid sequences which may be usefully employed as linker include those disclosed in Maratea et al., Gene 40:39 46 (1985); Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258 8262 (1986); U.S. Pat. No. 4,935,233, and U.S. Pat. No. 4,751,180. Other illustrative and non-limiting examples of linkers may include, for example, Glu-Gly-Lys-Ser-Ser-Gly-Ser-Gly-Ser-Glu-Ser-Lys-Val-Asp (SEQ ID NO: 19) (Chaudhary et al., Proc. Natl. Acad. Sci. USA 87: 1066-1070 (1990)) and Lys-Glu-Ser-Gly-Ser- Val-Ser-Ser-Glu-Gln-Leu-Ala-Gln-Phe-Arg-Ser-Leu-Asp (SEQ ID NO: 20) (Bird et al., Science 242:423-426 (1988)) and the pentamer Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 21) when present in a single iteration or repeated 1 to 5 or more times, or more. Any suitable linker may be used, and in general can be about 2 (e.g., GS, GP, PG, or the like), 3 (e.g., GSG, PGP, GPP, or the like), 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 15 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100 amino acids in length, or less than about 200 amino acids in length, and will preferably comprise a flexible structure (can provide flexibility and room for conformational movement between two regions, domains, motifs, fragments, or modules connected by the linker), and will preferably be biologically inert and/or have a low risk of immunogenicity in a human. Non-limiting examples of linkers include those comprising or consisting of the amino acid sequence set forth in any one or more of SEQ ID NOs: 20-21, 97- 106, and 702. In certain embodiments, the linker comprises or consists of an amino acid sequence having at least 75% (i.e., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence set forth in any one of SEQ ID NOs: 20-21, 97-106, or 702.

A plurality of RBD polypeptides present in a fusion protein or composition of the present disclosure can be homotypic, heterotypic, homogenous, and/or heterogenous.

In some embodiments, a fusion protein is provided that comprises: ([RBD]-Px-[RBD]) , wherein each RBD is an RBD polypeptide and the RBD polypeptides may be the same as, or different to, one another, P is a stem-helix polypeptide as provided herein, x is 1 or more, and j' is one or more. In certain embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.: 16 or SEQ ID NO.: 17. In certain embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein, optionally, X is 2, 3, 4, 5, 6, 7, 8, 9, 10, or more. In certain embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.:701.

In any of the presently disclosed embodiments, a spike polypeptide can comprise an RBD polypeptide having, or an RBD polypeptide can have, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 9%, or 100% identity to SEQ ID

NO.:2. In some embodiments, the fusion protein does not comprise SEQ ID NO.:2 or a naturally occurring variant thereof.

Also provided are engineered RBD polypeptides and Spike polypeptides that comprise the same. In any of the presently disclosed embodiments, a spike protein and/or an RBD can comprise any one or more of (i)-(iv) : (i) one or more amino acid substitution relative to a native RBD; (ii) one or more amino acid deletion relative to a native RBD; (iii) one or more amino acid insertion relative to a native RBD; (iv) one or more non-native carbohydrate attachment site relative to a native RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof.

In some embodiments, an engineered variant of a SARS-CoV-2 receptor binding domain (RBD) polypeptide is provided that comprises any one or more of (i)-(iv) : (i) one or more amino acid substitution relative to a native RBD; (ii) one or more amino acid deletion relative to a native RBD; (iii) one or more amino acid insertion relative to a native RBD; (iv) one or more non-native carbohydrate attachment site relative to a native RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof.

In other embodimients, an engineered variant SARS-CoV-2 spike polypeptide is provided that comprises, in a receptor binding domain (RBD), any one or more of (i)-(iv): (i) one or more amino acid substitution relative to a native RBD; (ii) one or more amino acid deletion relative to a native RBD; (iii) one or more amino acid insertion relative to a native RBD; (iv) one or more non-native carbohydrate attachment site relative to a native RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof, wherein, optionally, the engineered variant SARS-CoV-2 spike polypeptide comprises (i) one or more modification that promotes an open conformation of a receptor binding domain (RBD) of the spike polypeptide (e.g., D614G, K986P with V987P) and/or (ii) one or more modification that promotes stabilization of a SARS-CoV-2 spike polypeptide trimer.

It will be understood that an engineered variant RBD or spike polypeptide can, for example, be comprised in a fusion protein, and/or in a composition, with a presently disclosed stem-helix polypeptide.

Certain embodiments of variant RBDs or spike polypeptides provided herein are derived from a "backbone" spike polypeptide of SEQ ID NO.: 1. For ease of reference, amino acid numbering according to SEQ ID NO. : 1 can be used, though it will be understood that the present disclosure includes variant RBDs that may be isolated or otherwise separated from a spike polypeptide. Accordingly, reference to amino acid numbering according to SEQ ID NO.: 1 does not necessarily mean that the subject RBD or RBD-containing polypeptide is comprised in a spike polypeptide of SEQ ID NO. : 1, or is comprised in a spike polypeptide at all. In other words, amino acid numbering according to SEQ ID NO.: 1 or any other spike polypeptide amino acid sequence can simply provide a frame of reference for identifying amino acids.

Moreover, certain embodiments provide variant RBDs or spike polypeptides that are missing one or more (e.g., one, two, three, or more) amino acids that are present in a reference sequence (e.g. a reference sequence of SEQ ID NO.: 1), and/or that comprise one or more additional amino acids not present the reference sequence. For example, certain embodiments provide variant RBDs or spike polypeptides that comprise one or more deleted and/or inserted amino acids as compared to SEQ ID NO.: 1. However, for reference in these embodiments, amino acid numbering in accordance with SEQ ID NO. : 1 will be preserved. By way of illustration, if a variant RBD comprises a deletion of amino acids 444-447 as compared to SEQ ID NO.: 1, the numbering of amino acids downstream of the deletion does not change with respect to SEQ ID NO.: 1; e.g., amino acid 450 in the variant RBD, in accordance with SEQ ID NO.: 1 numbering, will be amino acid 450 whether amino acids 444-447 are present or absent.

It will be understood that amino acids which are "replaced by" an amino acid or amino acids can refer to amino acid substitution, and can also refer, in some contexts, to an amino acid deletion and/or insertion. By way of example, the amino acid sequence N-G-V can be "replaced by" a single G amino acid by deleting the N and V amino acids. In other words, "replaced by" can refer to a difference in the amino acids of a reference sequence (e.g., SEQ ID NO.: 1) versus a subject variant sequence at a corresponding position or region.

In some embodiments, a fusion protein is provided that comprises: (i) a coronavirus spike protein ectodomain (S ectodomain); and (ii) C-terminal to the S ectodomain, an oligomerization domain, wherein, optionally, the oligomerization domain is fused or linked to a C-terminus of the S ectodomain, and wherein, optionally, the coronavirus comprises a betacoronavirus. In some embodiments, the S ectodomain comprises a receptor binding domain (RBD) in an open conformation.

In certain embodiments, the oligomerization domain comprises a trimerization domain. In some embodiments, the trimerization domain comprises a foldon, wherein the foldon optionally comprises or consists of the amino acid sequence GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO.:703).

In certain further embodiments, the fusion protein further comprises, C-terminal to the oligomerization domain: (i) a peptide tag; (ii) one or more stem-helix polypeptide, optionally comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701); or (iii) both (i) and (ii). In certain further embodiments, the peptide tag comprises a SpyTag, wherein, optionally, the SpyTag comprises the amino acid sequence AHIVMVDAYKPTK (SEQ ID NO.:700). In certain still further embodiments, the fusion protein further comprises a linker disposed between and connecting (i) the oligomerization domain and the peptide tag or (ii) the oligomerization domain with (iii) the stem-helix polypeptide of the one or more stem-helix polypeptide. In certain further embodiments, the linker comprises or consists of the amino acid sequence GS, GSG, GPP, GSGGSGGSGGTG (SEQ ID NO.:702), GPPSPPG (SEQ ID NO.:709), GSGSGS (SEQ ID NO.:710), GSGSGSGSG (SEQ ID NO.:711), PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701), or the amino acid sequence set forth in any one of SEQ ID NOs.:97-106.

In some embodiments, the fusion protein further compries, C-terminal to the oligomerization domain, a first RBD polypeptide. In some embodiments, the fusion protein further comprises, C-terminal to the first RBD polypeptide, a second RBD polypeptide. In certain further embodiments, the fusion protein further comprises, C-terminal to the second RBD polypeptide, a third RBD polypeptide.

In some embodiments, the fusion protein further comprises: (a) a linker disposed between and linking the oligomerization domain and the first RBD polypeptide; and/or (b) a linker disposed between and linking the first RBD polypeptide and the second RBD polypeptide; and/or (c) a linker disposed between and linking the second RBD polypeptide and the third RBD polypeptide. In certain further embodiments: (i) the linker of (a) comprises, consists essentially of, or consists of the same amino acid sequence as the linker of (b); (ii) the linker of (a) comprises, consists essentially of, or consists of the same amino acid sequence as the linker of (c); (iii) the linker of (a) comprises, consists essentially of, or consists of a different amino acid sequence than the linker of (b); (iv) the linker of (a) comprises, consists essentially of, or consists of a different amino acid sequence than the linker of (c); (v) the linker of (b) comprises, consists essentially of, or consists of the same amino acid sequence as the linker of (c); (vi) the linker of (b) comprises, consists essentially of, or consists of of a different amino acid sequence than the linker of (c); or (vii) the linker of (a), the linker of (b), and the linker of (c) comprise, consist essentially of, or consist of of the same amino acid sequence. In certain further embodiments, the linker of (a), the linker of (b), and/or the linker of (c) comprises or consists of the amino acid sequence GS, GSG, GPP, GSGGSGGSGGTG (SEQ ID NO.:702), GPPSPPG (SEQ ID NO.:709), GSGSGS (SEQ ID NO.:710), GSGSGSGSG (SEQ ID NO.:711), or PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701), or the amino acid sequence set forth in any one of SEQ ID NOs.:97-106.

In some embodiments, a fusion protein comprises the S ectodomain and the first RBD polypeptide, wherein the first RBD polypeptide comprises, consists essentially of, or consists of an amino acid sequence that is the same as the amino acid sequence of the RBD comprised in the S ectodomain. In certain embodiments, the fusion protein comprises the second RBD polypeptide and optionally the third RBD polypeptide, wherein the second RBD polypeptide and the optional third RBD polypeptide each comprise, consist essentially of, or consist of an amino acid sequence that is the same as the amino acid sequence of the RBD comprised in the S ectodomain. In some embodiments, the first RBD polypeptide comprises, consists essentially of, or consists of an amino acid sequence that is different than the amino acid sequence of the RBD comprised in the S ectodomain. In some embodiments, the fusion protein comprises the second RBD polypeptide and optionally the third RBD polypeptide, wherein the second RBD polypeptide and the optional third RBD polypeptide each independently comprise, consist essentially of, or consist of an amino acid sequence that is the same as or is different to the amino acid sequence of the RBD comprised in the S ectodomain. In certain further embodiments, the fusion protein comprises, C-terminal to: the first RBD polypeptide; the optional second RBD polypeptide; and/or the optional third RBD polypeptide, a stem-helix polypeptide, optionally comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the fusion protein does not comprise, C-terminal to: the first RBD polypeptide; the optional second RBD polypeptide; and/or the optional third RBD polypeptide, a stem-helix polypeptide, optionally comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Also provided is a polypeptide trimer, wherein each of the three polypeptides of the trimer comprises: (i) a coronavirus spike protein ectodomain (S ectodomain; i.e. native or engineered); and (ii) C-terminal to the S ectodomain, a trimerization domain, wherein the three trimerization domains associate with one another to form a trimer, and wherein, optionally, each of the three trimerization domains comprises a foldon and/or the coronavirus comprises a betacoronavirus.

In certain embodiments, one, two, or three of the polypeptides comprises a fusion protein as disclosed herein, wherein the two or three fusion proteins, if present, optionally comprise, consist essentially of, or consist of the same amino acid sequence as one another.

Also provided is an isolated coronavirus receptor binding domain (RBD) polypeptide, wherein, optionally, the coronavirus comprises a betacoronavirus.

In some embodiments, the RBD polypeptide is comprised in a fusion protein, wherein the fusion protein further comprises one or both of (i) and (ii): (i) one or more peptide tag; (ii) one or more stem-helix polypeptide, wherein, optionally, the one or more stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). In certain embodiments, the fusion protein comprises: (a) a peptide tag linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises a N- terminus of the RBD polypeptide; (b) a peptide tag linked or fused to a second end of the RBD polypeptide, wherein the second end optionally comprises a C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide; (d) a stem-helix polypeptide linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide; or (e) any combination of (a)-(d). In some embodiments, the one or more peptide tag comprises a SpyTag. In some embodiments, the fusion protein comprises a linker disposed between and linking (1) the RBD polypeptide and (2) a peptide tag of the one or more peptide tag. In some embodiments, the fusion protein further comprises two or more linkers that comprise the same amino acid sequence as one another, and/or the linker, or one or more of the two or more linkers, comprises or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.:702). In certain embodiments, the fusion protein comprises a linker disposed between and connecting (1) the RBD polypeptide and (2) a one of the one or more stem -helix polypeptide.

In some embodiments, the fusion protein comprises: (i) a peptide tag fused or linked to the N-terminus of the RBD polypeptide; and (ii) a stem-helix polypeptide fused or linked to the C -terminus of the RBD polypeptide. In cetain further embodiments, the fusion protein comrpises, in N-terminal to C-terminal direction, an optional signal peptide, an optional linker, a Spy Tag (optionally AHIVMVDAYKPTK (SEQ ID NO.:700)), a linker (optionally GSGGSGGSGGTG; SEQ ID NO.:702), an RBD, a linker (optionally GSGGSGGSGGTG; SEQ ID NO.:702), and a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Also provided is a fusion protein comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second coronavirus RBD polypeptide, wherein, optionally, the coronavirus comprises a betacoronavirus. In some embodiments, the fusion protein comprises the first RBD polypeptide, the second RBD polypeptide, and a third RBD polypeptide, the first RBD polypeptide being linked to the second RBD polypeptide by a linker (1), and the second RBD polypeptide being linked to the third RBD polypeptide by a linker (2). In certain further embodiments, the linker (1) and the linker (2) comprise, consist essentially of, or consist of the same amino acid sequence. In other embodiments, the linker (1) and the linker (2) have different amino acid sequences from one another. In some embodiments, the linker of a fusion protein comprises a stem-helix polypeptide. In some embodiments of fusion protein, the linker (1) and the linker (2) each comprise a stem-helix polypeptide.

In some embodiments, the fusion protein comprises an RBD polypeptide from any one or more of the following: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 A.27; SARS-like coronavirus ZC45. In some embodiments, the fusion protein comprises an RBD polypeptide from any one or more of the following: SARS-CoV-2 Beta variant; SARS-CoV-2 A.2.7 + S494P; SARS-like coronavirus isolate Rs4231. In some embodiments, the fusion protein comprises an RBD polypeptide from any one or more of the following: SARS-CoV-2 Delta variant; GX-Pangolin; SARS-like coronavirus isolate Rs4231. In some embodiments, the fusion protein comprises an RBD polypeptide from any one or more of the following: SARS-CoV-2 Wuhan-Hu- 1; SARS- CoV-2 Beta variant (also called B.1.351); SARS-CoV-2 Delta variant (also called B.1.617.2); and SARS-CoV-2 Omicron variant (also called B.1.1.529). In some embodiments, the fusion protein comprises an RBD polypeptide that comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:2 and 722-729. In some embodiments, the fusion protein comprises an RBD polypeptide from any one or more of the following: PANG/GX; MP789; RaTG13; and RsSHC014. In some embodiments, the fusion protein comprises an RBD polypeptide that comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:730-737.

In some embodiments, the fusion protein comprises three RBD polypeptides, wherein wherein the three RBD polypeptides are from: MP789; RaTG13; and RsSHC014. In some embodiments, the fusion protein comprises three RBD polypeptides, wherein the three RBD polypeptides comprise the amino acid sequence set forth in: (i) SEQ ID NO.:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731, respectively. In some embodiments, the fusion protein comprises three RBD polypeptides, wherein the three RBD polypeptides consist of the amino acid sequence set forth in: (i) SEQ ID NO.:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731, respectively. In certain embodiments, a stem-helix polypeptide comprises or consists of the amino acid sequence according to any one of SEQ ID NOs.:701, 4-19, 46, and 57-59. In some embodiments, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the fusion protein comprises three RBD polypeptides, wherein the three RBD polypeptides are from: (i) SARS-CoV-2 Wuhan-Hu-1, SARS-CoV-2A.27, and SARS-like coronavirus ZC45, respectively; (ii) SARS-CoV-2 Beta variant, SARS-CoV-2 A.2.7 + S494P, and SARS-like coronavirus isolate Rs4231, respectively; or (iii) SARS-CoV-2 Delta variant, GX-Pangolin, and SARS-like coronavirus isolate Rs4231, respectively.

In some embodiments, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the fusion protein further comprises a fourth RBD polypeptide and a fifth RBD polypeptide, wherein the fourth RBD polypeptide is linked to the third RBD polypeptide by a linker (3) and the fifth RBD polypeptide is linked to the fourth RBD polypeptide by a linker (4). In certain embodiments, two, three, or all four of the linkers (l)-(4) comprise, consist essentially of, or consist of the same amino acid sequence. In further embodiments, the two or more of the linkers have different amino acid sequences from one another. In some embodiments, one or more of the linkers (l)-(4) comprises or consists of a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). In some embodiments, each of the peptide linkers (l)-(4) comprises or consists of a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the fusion protein comprises an RBD polypeptide from each of: (i) SARS-CoV-2 Beta variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (ii) SARS-CoV-2 Beta variant; SARS-CoV-2 Omi cron variant; MP789; RaTG13; and RsSHC014; or (iii) SARS- CoV-2 Omicron variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (iv) SARS-CoV-2 Delta variant; SARS-CoV-2 Omicron variant; MP789; RaTG13; and RsSHC014.

In some embedments, the fusion protein comprises five RBD polypeptides, wherein the five RBD polypeptides comprise the amino acid sequence set forth in SEQ ID NO.: (i) 725, 731, 733, 735, and 737, respectively; or (ii) 725, 731, 729, 735, and 737, respectively; or (iii) 729, 731, 733, 735, and 737, respectively; or (iv) 727, 731, 729, 735, and 737, respectively. In certain further embodiments: (1) the RBD polypeptide comprising SEQ ID NO.:725 comprises or consists of SEQ ID NO.:724; (2) the RBD polypeptide comprising SEQ ID NO.:727 comprises or consists of SEQ ID NO.:726; (3) the RBD polypeptide comprising SEQ ID NO.:729 comprises or consists of SEQ ID NO.:728; (4) the RBD polypeptide comprising SEQ ID NO.:731 comprises or consists of SEQ ID NO.:730; (5) the RBD polypeptide comprising SEQ ID NO.:733 comprises or consists of SEQ ID NO.:732; (6) the RBD polypeptide comprising SEQ ID NO.:735 comprises or consists of SEQ ID NO.:734; and/or (7) the RBD polypeptide comprising SEQ ID NO.:737 comprises or consists of SEQ ID NO.:736.

In some embodiments, the fusion protein comprises five RBD polypeptides, wherein the five RBD polypeptides comprise or consist of the amino acid sequence set forth in SEQ ID NO.: (i) 724, 732, 734, 736, and 730, respectively; or (ii) 724, 728, 734, 736, and 730, respectively; or (iii) 728, 732, 734, 736, and 730, respectively; or (iv) 726, 728, 735, 736, and 730, respectively.

In certain embodiments, the fusion protein comprises, comprising, in N-terminal to C- terminal direction of the fusion protein: (i) an RBD polypeptide from SARS-CoV-2 Beta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (ii) an RBD polypeptide from SARS-CoV-2 Beta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from SARS-CoV-2 Omicron variant; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (iii) an RBD polypeptide from SARS-CoV-2 Omicron variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (iv) an RBD polypeptide from SARS- CoV-2 Delta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from SARS- CoV-2 Omicron variant; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13.

In certain embodiments, the fusion protein comprses, in N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide comprising SEQ ID NO.:725; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:733; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or (ii) an RBD polypeptide comprising SEQ ID NO.:725; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or (iii) an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:733; an RBD polypeptide from comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or (iv) an RBD polypeptide comprising SEQ ID NO.:727; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737.

In some embodiments, the fusion protein comprises, in N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide comprising or consisting of SEQ ID NO.:724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (ii) an RBD polypeptide comprising or consisting of SEQ ID NO.:724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (iii) an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (iv) an RBD polypeptide comprising or consisting of SEQ ID NO.:726; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736.

In certain embodiments, the fusion protein comprises the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) disposed between the first and second RBD polypeptides, between the second and third RBD polypeptides, between the third and fourth RBD polypeptides, and between the fourth and fifth RBD polypeptides, wherein the first RBD polypeptide is the N-terminal RBD polypeptide of the fusion protein and the fifth RBD polypeptide is the C-terminal RBD polypeptide of the fusion protein.

In some embodiments, the fusion protein further comprises a peptide tag, wherein, optionally, the peptide tag is disposed at a C-terminus of the fusion protein, preferably fused to a C-terminus of a C-terminal RBD polypeptide of the fusion protein. In some embodiments, the peptide tag is disposed at the C-terminus of the fusion protein. The peptide can comprise a SpyTag and/or a His tag. In some embodiments, the fusion protein does not comprise a peptide tag disposed at a C-terminus of the fusion protein, optionally at the C-terminus of the C-terminal RBD polypeptide.

In certain embodiments, the fusion protein does not comprise a His tag disposed at a C- terminus of the fusion protein.

In some embodiments, the fusion protein of any one of claims 1-34, comprising a signal peptide, wherein, optionally, the signal peptide is disposed at a N-terminus of the fusion protein, and is preferably fused to the N-terminus of the N-terminal RBD polypeptide. The signal peptide can comprise or consist of the amino acid sequence MAPLLLLLPLL WAGALA (SEQ ID NO.:706), the amino acid sequence MNTQILVFALIAIIPTNADKI (SEQ ID NO.:705), the amino acid sequence MFVFLVLLPLVS (SEQ ID NO.:707) or the amino acid sequence MFVFLVLLPLVSS (SEQ ID NO.:708), and preferably consists of SEQ ID NO.:706.

In certain embodiments, the fusion protein, when administered to a mammal (e.g. a mouse, such as a female BALB/c mouse, optionally twice via intramuscular injection, wherein the two administrations are 20 or 21 days apart), elicits neutralizing antibodies against any one or more of, and optionally all of: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 B.1.351; SARS-CoV-2 B.1.617.2; SARS-CoV-2 B.1.1.529; and SARS-CoV-1, wherein, optionally, neutralizing antibodies are assessed using sera collected from the mammal 14 days post-second immunization, in a Vesicular Stomatitis Virus/Coronavirus Pseudovirus system, optionally using Vero-E6 TMPRSS cells. In certain embodiments, a fusion protein, when administered to a mammal that had previously received a mRNA SARS-CoV-2 spike protein vaccine, elicits:

(i) neutralizing antibodies against any one or more of, and optionally all of: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 BAI; SARS-CoV-2 BA2; SARS-CoV-2 BA5; and SARS-CoV-1, optionally to a degree that is greater than is elicited by a third administration of the mRNA SARS-CoV-2 spike protein vaccine, wherein, optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered once via intramuscular injection and/or at Day 60 and the mammal had received the mRNA spike protein vaccine at Day 0 and again at Day 14; and/or neutralizing antibodies are assessed using sera collected from the mammal at Day 67 in a Vesicular Stomatitis Virus/Coronavirus Pseudovirus system; and/or

(ii) antibodies that bind to an RBD from any one or more of: S ARS-Cov2 -Wuhan-Hu- 1 (Wu); - B.1.351 (Beta); SARS-Covl; Wiv-1; RatG13; PangGD; PANG/GX; Anlogl l2; YN2013; SX2001; SC2018; ZC45; BTK72; and BGR2008, optionally to a degree that is greater than is elicited by a third administration of the mRNA SARS-CoV-2 spike protein vaccine, wherein, optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered once via intramuscular injection and/or at Day 60 and the mammal had received the mRNA spike protein vaccine at Day 0 and again at Day 14; and/or binding antibodies are assessed by ELISA using sera collected from the mammal at Day 67.

In certain embodiments the fusion protein is capable of being bound by any one or more of the following antibodies: S2P6; S2E12; S2K146; S2X259; S309; and S2H97, or an antigenbinding fragment thereof, wherein, optionally, the antigen-binding fragment comprises a Fab that comprises the VH and VL of the antibody and further comprises an IgGl CHI and either an IgG kappa CL or an IgG lambda CL.

Also provided is an isolated polypeptide comprising or consisting of: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.:218 without SEQ ID NO.:706; (iii) SEQ ID NO.:712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:715 without SEQ ID NO.:706; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) SEQ ID NO.:717 without SEQ ID NO.:706; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

Also provided is a fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii): (i) one or more peptide tag;

(ii) one or more stem-helix polypeptide, wherein, optionally, the one or more stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the fusion protein comprises: (a) a peptide tag linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises a N-terminus of the RBD polypeptide; (b) a peptide tag linked or fused to a second end of the RBD polypeptide, wherein the second end optionally comprises a C-terminus of the RBD polypeptide;

(c) a stem-helix polypeptide linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide; (d) a stem-helix polypeptide linked or fused to a second end of the RBD polypeptide, wherein the first end optionally comprises the C-terminus of the RBD polypeptide; or (e) any combination of (a)-(d). In some embodiments, the peptide tag comprises a His tag, wherein, optionally, the His tag comprises or consists of the amino acid sequence HHHHHHHH (SEQ ID NO.:704). In some embodiments, the peptide tag comprises a SpyTag. In certain embodiments, the fusion protein comprises a linker disposed between and linking (1) the RBD polypeptide and (2) a peptide tag of the one or more peptide tag. In some embodiments, the fusion protein comprises two or more linkers that comprise the same amino acid sequence as one another. In some embodiments, the linker, or one or more of the two or more linkers, comprises or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.:702). In some embodiments, the fusion protein comprises a linker disposed between and connecting (1) the RBD polypeptide and (2) a one of the one or more stem-helix polypeptide.

In certain embodiments, the fusion protein comprises a structure

PT1 — LI — RBD — L2 — SHP — PT2, wherein: PT1 and PT2 are each an optional peptide tag; LI and L2 are each an optional linker; RBD is an RBD polypeptide; and SHP is a stem-helix polypeptide.

In some embodiments: PT1, if present, has the amino acid sequence of SEQ ID NO.:700; LI, if present, has the amino acid sequence of SEQ ID NO.:702; L2 is absent or, if present, has the amino acid sequence GSG, GPP, GS, or PGP; SHP has the amino acid sequence of SEQ ID NO.:701; and PT2, if present, has the amino acid sequence of SEQ ID NO.:704. In some embodiments: (i) PT1, LI, SHP, L2, and PT2 are present; (ii) PT1, LI, SHP, and PT2 are present; (iii) L2, SHP, and PT2 are present; (iv) SHP and PT2 are present; (v) SHP and optionally L2 are present or (vi) L2, SHP, and and PT2 are present.

In certain embodiments, the fusion protein comprises: (i) a signal peptide fused or linked to a N-terminus of the RBD polypeptide; and (ii) a stem-helix polypeptide fused or linked to a C- terminus of the RBD polypeptide. In some embodiments, the fusion protein comprises, in N- terminal to C-terminal direction, a signal peptide (optionally MAPLLLLLPLL WAGALA (SEQ ID NO.:706)), an optional linker, an RBD, an optional linker, and a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the RBD polypeptide is from any one of: SARS-CoV-2-Wuhan- Hu-1; SARS-CoV-2 Beta variant; SARS-CoV-2 Omi cron variant; SARS-CoV-2 Delta variant; PANG GX; MP789; RatG13; RsSCH014; RmYN02; BM48-31/BGR/2008; PC4-241; Rfl/2004; and Rp/Shaanxi 2011.

In some embodiments, the RBD polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:724-737. Also provided is an isolated polypeptide comprising a structure:

RBD1 - LI - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 wherein RBD1, RBD2, RBD3, RBD4, and RBD5 are each a different RBD polypeptide selected from the group consisting of: SARS-CoV-2 Beta variant; SARS-CoV-2 Omicron variant; SARS-CoV-2 Delta variant; PANG/GX; MP789; RaTG13; and RsSHC014, wherein RBD1 is the N-terminal RBD polypeptide of the fusion protein and/or RBD5 is the C- terminal RBD polypeptide of the fusion protein, and wherein LI, L2, L3, and L4 are each a linker. In some embodiments, one or more of LI, L2, L3, and L4 comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59, and wherein, optionally, LI, L2, L3, and L4 each independently comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59. In certain embodiments, LI, L2, L3, and L4 are identical, and LI, L2, L3, and L4 are preferably SEQ ID NO.:701. In some embodiments, RBD1, RBD2, RBD3, RBD4, and RBD5 are independently selected from the group consisting of: (i) SEQ ID NO.: 724 or 725; (ii) SEQ ID NO.: 726 or 727; (iii) SEQ ID NO.: 728 or 729; (iv) SEQ ID NO.: 730 or 731; (v) SEQ ID NO.: 732 or 733; (vi) SEQ ID NO.: 734 or 735; and (vii) SEQ ID NO.: 736 or 737, preferably wherein five of (i)-(vii) are present.

In certain embodiments, RBD1, RBD2, RBD3, RBD4, and RBD5 are from:

(i) SARS-CoV-2 Beta variant; RsSHC014; PANG/GX; MP789; and RaTG13, respectively; or

(ii) SARS-CoV-2 Beta variant; RsSHC014; SARS-CoV-2 Omicron variant; MP789; and RaTG13, respectively; or (iii) SARS-CoV-2 Omicron variant; RsSHC014; PANG/GX; MP789; and RaTG13, respectively; or (iv) SARS-CoV-2 Delta variant; RsSHC014; SARS-CoV-2 Omicron variant; MP789; RaTG13, respectively.

In some embodiments, RBD1, RBD2, RBD3, RBD4, and RBD5 comprise the amino acid sequence set forth in SEQ ID NO.: (i) 725, 731, 733, 735, and 737, respectively; or (ii) 725, 731, 729, 735, and 737, respectively; or (iii) 729, 731, 733, 735, and 737, respectively; or (iv) 727,

731, 729, 735, and 737, respectively, wherein, optionally, RBD1, RBD2, RBD3, RBD4, and RBD5 comprise or consists of the amino acid sequence set forth in SEQ ID NO.: (1)724, 730,

732, 734, and 736, respectively; or (2) 724, 730, 728, 734, and 736, respectively; or (3) 728, 730, 732, 734, and 736, respectively; or (4) 726, 730, 728, 734, and 736, respectively.

Also provided is an isolated polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59. Also provided is an isolated polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO.:701, the amino acid sequence of SEQ ID NO.: 14, the amino acid sequence of SEQ ID NO.: 15, the amino acid sequence of SEQ ID NO. : 16, or the amino acid sequence of SEQ ID NO. : 17.

In some embodiments, a fusion protein comprises an RBD polypeptide from each of: (i) SARS-CoV-2 Wuhan-Hu- 1, SARS-CoV-2 A.27, SARS-CoV-2 Alpha variant + E484K + S494P, SARS-like coronavirus ZC45, and SARS-CoV-1; or (ii) SARS-CoV-2 Delta variant, SARS- CoV-2 Beta variant, SARS-CoV-2 A.27 + S494P, GX-Pangolin, and SARS-like coronavirus isolate Rs4231. In some embodiments, the fusion protein further comprises a peptide tag, wherein, optionally, the peptide tag is disposed at a C-terminus of the fusion protein.

In certain further embodiments, the peptide tag comprises a SpyTag and/or a His tag.

In any of the presently disclosed embodiments, the coronavirus can comprise a betacoronavirus, wherein the betacoronavirus comprises a sarbeovirus. In some embodiments, the sarbecovirus comprises a SARS-CoV-2, a SARS coronavirus, a SARS-like coronavirus, or an engineered variant thereof. In certain further embodiments, the sarbecovirus comprises a SARS-CoV-2, a Wuhan-Hu- 1, an A.27 (Mayotte), an A.27 with a S494P substitution mutation, an AAV49723.1, an ATO98157.1, an AVP78031.1, a B.1.315, a B.167.2, a Wuhan-Hu-1 with the substitution mutations E484K, S494P, and N501Y, a QHD43416.1, an ADE34812, an AIA6227, a QIA48632.1, or any combination thereof. In particular embodiments, the sarbecovirus comprises a SARS-CoV-2.

Also provided is a polypeptide comprising a variant of a SARS-CoV-2 Receptor Binding Domain (RBD), wherein the variant RBD comprises any one or more of the following changes (i)-(xiii) relative to an RBD comprising amino acids 328-531 of SEQ ID NO.: 1, wherein the numbering of amino acids is according to SEQ ID NO.:1: (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, by a single G amino acid, or by a single S amino acid; (ii) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, by the two amino acids G-G, or by the two amino acids G-S; (iii) a Y449G substitution; (iv) a Q498A substitution, a Q498G substitution, or a Q498N substitution, optionally further comprising a P499A substitution or a P499G substitution; (v) a P499A substitution or a P499G substitution; (vi) a T500A substitution; (vii) aN450G substitution; (viii) a L452A substitution; (ix) a T470N substitution and a I472T substitution; (x) a V483A substitution; (xi) amino acids 481-483 (N-G-V) replaced by a single G amino acid; (xii) a E484A substitution; (xiii) a Q493 A substitution.

Also provided is a isolated polypeptide comprising a variant of a SARS-CoV-2 Receptor Binding Domain (RBD), wherein the variant RBD comprises any one or more of the following changes (i)-(vi) relative to an RBD comprising amino acids 328-531 of SEQ ID NO.:1, wherein the numbering of amino acids is according to SEQ ID NO.:1: (i) amino acids 444-447 (K-V-G- G) replaced by a single P amino acid, by a single G amino acid, or by a single S amino acid; (ii) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, by the two amino acids G-G, or by the two amino acids G-S; (iii) a Y449G substitution; (iv) a Q498A substitution, a Q498G substitution, or a Q498N substitution, optionally further comprising a P499A substitution or a P499G substitution; (v) a P499A substitution or a P499G substitution; (vi) a T500A substitution.

Also provided is an isolated polypeptide comprising a variant of a SARS-CoV-2 Receptor Binding Domain (RBD), wherein the variant RBD comprises any one or more of the following changes (i)-(viii) relative to an RBD comprising amino acids 328-531 of SEQ ID NO.:1, wherein the numbering of amino acids is according to SEQ ID NO.:1: (i) a N450G substitution; (ii) a L452A substitution; (iii) a T470N substitution* (iv) a I472T substitution* (v) a V483A substitution; (vi) amino acids 481-483 (N-G-V) replaced with a single G amino acid; (vii) a K484A substitution; (viii) a Q493 A substitution.

Also provided is an isolated polypeptide comprising a variant of a SARS-CoV-2 Receptor Binding Domain (RBD), wherein the variant RBD comprises the following change(s) relative to an RBD comprising amino acids 328-531 of SEQ ID NO.: 1, wherein the numbering of amino acids is according to SEQ ID NO. : 1 : (1) a Y449G substitution; or (2) a Q498A substitution; or (3) a Q498G substitution; or (4) a T500A substitution; or (5) Y449G and Q498A substitutions; or (6) Y449G and Q498G substitutions; or (7) Y449G and T500A substitutions; or (8) Q498A and T500A substitutions; or (9) Q498G and T500A substitutions; or

(10) Y449G, Q498A, and T500A substitutions; or (11) Y449G, Q498G, and T500A substitutions; or (12) a Q498N substitution; or (13) Q498N and P499A substitutions; or (14) Y449G, Q498N, and P499A substitutions; or (15) Q498N and P499G substitutions; or (16) Y449G, Q498N, and P499G substitutions; or (17) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid; or (18) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid; or (19) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid; or (20) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G; or (21) amino acids 444-447 (K-V-G- G) replaced by the two amino acids G-G; or (22) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S; or (23) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a Q498N substitution, and (iii) a P499A substitution; or (24) (i) amino acids 444- 447 (K-V-G-G) replaced by a single P amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (25) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a Q498N substitution, and (iii) a P499G substitution; or (26) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (27) (i) amino acids 444-447 (K-V- G-G) replaced by a single G amino acid, (ii) a Q498N substitution, and (iii) a P499A substitution; or (28) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (29) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a Q498N substitution, and (iii) a P499G substitution; or (30) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (31) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Q498N substitution, and (iii) a P499A substitution; or (32) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (33) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Q498N substitution, and (iii) a P499G substitution; or (34) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (35) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G,

(11) a Q498N substitution, and (iii) a P499A substitution; or (36) (i) amino acids 444-447 (K-V- G-G) replaced by the two amino acids P-G, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (37) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a Q498N substitution, and (iii) a P499G substitution; or (38) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (39) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Q498N substitution, and (iii) a P499A substitution; or (40) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (41) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Q498N substitution, and (iii) a P499G substitution; or (42) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (43) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Q498N substitution, and (iii) a P499A substitution; or (44) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (45) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Q498N substitution, and (iii) a P499G substitution; or (46) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (47) aN450G substitution; or (48) a L452A substitution; or (49) a V483 A substitution; or (50) a K484A substitution; or (51) a Q493 A substitution; or (52) N450G and Q493 A substitutions; or (53) L452A and Q493 A substitutions; or (54) N450G, V483 A, and Q493 A substitutions; or (55) N450G, K484A, and Q493 A substitutions; or (56) L452A, V483 A, and Q493 A substitutions; or (57) L452A, K484A, and Q493 A substitutions; or (58) T470N and I472T substitutions; or (59) N450G, T470N, and I472T substitutions; or (60) L452A, T470N, and I472T substitutions; or (61) T470N, I472T, and V483 A substitutions; or (62) N450G, T470N, I472T, and V483 A substitutions; or (63) L452A, T470N, I472T, and V483 A substitutions; or (64) T470N, I472T, V483 A, and Q493 A substitutions; or (65) N450G, T470N, I472T, V483 A, and Q493 A substitutions; or (66) L452A, T470N, I472T, V483A, and Q493A substitutions; or (67) amino acids 481-483 (N-G-V) replaced with a single G amino acid; or (68) (i) amino acids 481-483 (N-G-V) replaced with a single G amino acid, and (ii) a K484A substitution; or (69) (i) amino acids 481-483 (N-G-V) replaced with a single G amino acid, (ii) a K484A substitution, and (iii) a Q493 A substitution; or (70) (i) a L452A substitution, (ii) amino acids 481-483 (N-G-V) replaced with a single G amino acid, and (iii) a K484A substitution; or (71) (i) a L452A substitution, (ii) amino acids 481-483 (N-G-V) replaced with a single G amino acid, (iii) a K484A substitution, and (iv) a Q493 A substitution; or (72) (i) a T470N substitution, (ii) a I472T substitution, and (iii) amino acids 481-483 (N-G-V) replaced with a single G amino acid; or (73) (i) a T470N substitution, (ii) a I472T substitution, (iii) amino acids 481-483 (N-G-V) replaced with a single G amino acid, and (iv) a K484A substitution; or (74) (i) a T470N substitution, (ii) a I472T substitution, (iii) amino acids 481-483 (N-G-V) replaced with a single G amino acid, (iv) a K484A substitution, and (v) a Q493 A substitution; or (75) (i) a L452A substitution, (ii) a T470N substitution, (iii) a I472T substitution, and (iv) amino acids 481-483 (N-G-V) replaced with a single G amino acid; or (76) (i) a L452A substitution, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G- V) replaced with a single G amino acid, (v) a K484A substitution, and (vi) a Q493 A substitution; or (77) K484A, Q493 A, and Q498A substitutions; or (78) K484A, Q493 A, and Q498G substitutions; or (79) Y449G, K484A, Q493A, Q498A, P499A, and T500A substitutions; or (80) Y449G, K484A, Q493 A, Q498G, P499A, and T500A substitutions; or (81) Y449G, L452A, V483 A, K484A, Q493 A, Q498A, P499A, and T500A substitutions; or (82) Y449G, L452A, V483 A, K484A, Q493 A, Q498G, P499A, and T500A substitutions; or (83) T470N, I472T, Q498N, and P499A substitutions; or (84) Y449G, T470N, I472T, Q498N, and P499A substitutions; or (85) T470N, I472T, Q493 A, Q498N, and P499A substitutions; or (86) T470N, I472T, K484A, Q498N, and P499A substitutions; or (87) L452A, T470N, I472T, Q498N, and P499A substitutions; or (88) Y449G, T470N, I472T, Q493 A, Q498N, and P499A substitutions; or (89) Y449G, T470N, I472T, K484A, Q498N, and P499A substitutions; or (90) Y449G, L452A, T470N, I472T, Q493 A, Q498N, and P499A substitutions; or (91) Y449G, L452A, T470N, I472T, K484A, Q498N, and P499A substitutions; or (92) Y449G, L452A, T470N, I472T, K484A, Q493 A, Q498N, and P499A substitutions; or (93) T470N, I472T, Q498N, and P499G substitutions; or (94) Y449G, T470N, I472T, Q498N, and P499G substitutions; or (95) T470N, I472T, Q493 A, Q498N, and P499G substitutions; or (96) T470N, I472T, K484A, Q198N, and P499G substitutions; or (97) L452A, T470N, I472T, Q498N, and P499G substitutions; or (98) Y449G, T470N, I472T, Q493 A, Q498N, and P499G substitutions; or (99) Y449G, T470N, I472T, K484A, Q498N, and P499G substitutions; or (100) Y449G, L452A, T470N, I472T, Q493 A, Q498N, and P499G substitutions; or (101) Y449G, L452A, T470N, I472T, K484A, Q498N, and P499G substitutions; or (102) Y449G, L452A, T470N, I472T, K484A, Q493 A, Q498N, and P499G substitutions; or (103) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (104) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (105) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (106) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (107) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (108) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (109) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (110) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (111) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (112) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G,

(ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (113) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (114) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S,

(ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (115) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481- 483 (N-G-V) replaced by a single G amino acid, (vi) a Q493 A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (116) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a Q493A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (117) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a L452A substitution,

(iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a Q493 A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (118) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a Q493A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (119) (i) amino acids 444-447 (K-V-G- G) replaced by the two amino acids G-G, (ii) a L452A substitution, (iii) a T470N substitution,

(iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a Q493A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (120) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G- V) replaced by a single G amino acid, (vi) a Q493A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (121) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (122) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (123) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (124) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (125) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (126) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (127) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (128) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (129) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (130) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (131) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (132) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution.

In certain embodiments, the polypeptide comprises no further changes relative to amino acids 444-500 of SEQ ID NO. : 1 and/or relative to amino acids 328-531 of SEQ ID NO. : 1.

In certain embodiments, the polypeptide comprises at most 15, at most 14, at most 13, at most 12, at most 11, at most 10, at most 9, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2, or at most 1 further change(s) relative to amino acids 444-500 of SEQ ID NO.: 1 and/or relative to amino acids 328-531 of SEQ ID NO.: 1, wherein each further change independently comprises: (i) a deletion of one, two, or three amino acids; (ii) an insertion of one, two, or three amino acids; (iii) a conservative substitution; or (iv) a non-conservative substitution.

In certain embodiments, the polypeptide comprises an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to amino acids 444-500 of SEQ ID NO. : 1.

In certain embodiments, the polypeptide comprises an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to amino acids 328-531 of SEQ ID NO. : 1.

In certain embodiments, the polypeptide comprises: (i) amino acids 453-469 of SEQ ID NO.: 1, or a variant sequence thereof having one, two, or three amino acid substitutions; and/or (ii) amino acids 473-480 of SEQ ID NO.: 1, or a variant sequence thereof having one, two, or three amino acid substitutions; and/or (iii) amino acids 485-492 of SEQ ID NO.: 1, or a variant sequence thereof having one, two, or three amino acid substitutions; and/or (iv) amino acids 501- 531 of SEQ ID NO. : 1, or a variant sequence thereof having one, two, or three amino acid substitutions; and/or (v) amino acids 328-443 of SEQ ID NO.: 1, or a variant sequence thereof having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acids 328-443 of SEQ ID NO. : 1. In certain embodiments, the polypeptide comprises any one or more of the following amino acids, wherein the numbering of amino acids is according to SEQ ID NO.: 1 : S443; N448; Y451; E471; Y501. In certain embodiments of a polypeptide: (i) amino acids 498-500 (numbering according to SEQ ID NO.: 1) comprise N-A-T, N-P-T, or N-G-T, respectively; and/or (ii) amino acids 470-472 (numbering according to SEQ ID NO.: 1) comprise N-X-T, wherein X is any amino acid, and is preferably E.

In certain embodiments, the polypeptide further comprises: a signal peptide; a SpyTag; a linker; a stem-helix polypeptide; or any combination thereof.

In certain embodiments, the polypeptide consists essentially, or consists of, a variant RBD as disclosed herein. In certain embodiments, the polypeptide comprises an amino acid sequence having at least 80%, at least 85%, or at least 90% identity to the amino acid sequence set forth in SEQ ID NO. : 1.

In certain embodiments, the polypeptide is or comprises a variant SARS-CoV-2 spike polypeptide. In certain further embodiments, the polypeptide further comprises: a signal peptide; a SpyTag; a linker; a stem-helix polypeptide; or any combination thereof. In certain embodiments, the polypeptide comprises: a SpyTag; a linker; a stem-helix polypeptide; or any combination thereof.

Also provided is an isolated polypeptide having a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than 11 amino acids, and comprising an amino acid sequence according to SEQ ID NO.:4. In some embodiments, the polypeptide comprises the amino acid sequence set forth in SEQ ID NO.:5.

Also provided is an isolated polypeptide having a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than about 10 amino acids, or no more than 6 amino acids, and comprising the amino acid sequence set forth in any one of SEQ ID NOs.:4-12 and 14. Also provided is an isolated polypeptide comprising or consisting of any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 continuous amino acid residues of SEQ ID NO. : 13, provided that the isolated peptide comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 continuous amino acids of SEQ ID NO.:5. Also provided is an isolated isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO.: 14 or 701. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO.: 15. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs. : 16-19. Also provided is an isolated polypeptide comprising: (i) the amino acid sequence according to any one of SEQ ID NOs.:4-14; and (ii) the amino acid sequence set forth in SEQ ID NO.: 15. Also provided is an isolated polypeptide comprising: (i) a plurality of any one or more of SEQ ID NOs.:4-14, wherein the plurality is homogenous, homotypic, heterogeneous, or heterotypic; and, disposed between and connecting a two of the plurality; (ii) a linker sequence. Also provided is an isolated polypeptide comprising: (i) two, three, four, five, or more copies of SEQ ID NO.: 16; (ii) two three, four, five, or more copies of SEQ ID NO.: 17; and/or (iii) one or more copy of SEQ ID NO.: 16 and one or more copy of SEQ ID NO.: 17. Also provided is an isolated polypeptide comprising SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein X is 2 or more, 3 or more, 4 or more, or 5 or more.

Also provided is a fusion protein comprising (i) a SARS-CoV-2 spike polypeptide or a portion thereof and (ii) a stem-helix polypeptide as disclosed herein, wherein, optionally, the SARS-CoV-2 spike polypeptide comprises (i) one or more modification that promotes an open conformation of a receptor binding domain (RBD) of the spike polypeptide (e.g., D614G, K986P with V987P) and/or (ii) one or more modification that promotes stabilization of a SARS-CoV-2 spike polypeptide trimer. In certain further embodiments, the fusion protein comprises a plurality of stem-helix polypeptides as disclosed herein. In certain embodiments, the stem-helix polypeptide or stem-helix polypeptides are disposed in a S2 subunit of the SARS-CoV-2 spike polypeptide. In certain embodiments, the fusion protein comprise SEQ ID NO.: 18 or SEQ ID NO. : 19, wherein X is 2 or more, 3 or more, 4 or more, or 5 or more.

Also provided is a fusion protein comprising (i) a SARS-CoV-2 receptor binding domain (RBD) and (ii) a stem-helix polypeptide as disclosed herein. In certain embodiments, the RBD is not comprised in a betacoronavirus spike polypeptide. In certain embodiments, the fusion protein comprises a plurality of RBDs of (i) and/or a plurality of polypeptides of (ii). In certain embodiments, the fusion protein further comprises a linker disposed between and linking a two of the plurality of RBDs. In certain embodiments, the linker comprises or consists of a stemhelix polypeptide as disclosed herein.

In certain embodiments, the plurality of RBDs is homotypic. In other embodiments, the plurality of RBDs is heterotypic.

In certain embodiments, the fusion protein comprises: ([RBD]-Px-[RBD]) , wherein each RBD is a RBD polypeptide and the RBD polypeptides can be the same or different as one another, P is a stem-helix polypeptide as disclosed herein, x is 1 or more, and j' is one or more. In certain further embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.: 16 or SEQ ID NO.: 17 or SEQ ID NO.:701. In certain further embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein, optionally, X is 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.

In certain emodiments, the spike polypeptide or a portion thereof of a fusion protein comprises an RBD having, or wherein the RBD has, or wherein an RBD of the plurality has, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 9%, or 100% identity to SEQ ID NO.:2.

In some embodiments, the fusion protein does not comprise SEQ ID NO.:2 or a naturally occurring variant thereof.

In certain embodiments of a fusion protein, the spike polypeptide or a portion thereof comprises in an RBD, or the RBD comprises, or an RBD of the plurality comprise, any one or more of (i)-(iv): (i) one or more amino acid substitution relative to a native RBD; (ii) one or more amino acid deletion relative to a native RBD; (iii) one or more amino acid insertion relative to a native RBD; (iv) one or more non-native carbohydrate attachment site relative to a native RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof.

Also provided is a polypeptide comprising a variant of a SARS-CoV-2 receptor binding domain (RBD), comprising any one or more of (i)-(iv): (i) one or more amino acid substitution relative to a native RBD; (ii) one or more amino acid deletion relative to a native RBD; (iii) one or more amino acid insertion relative to a native RBD; (iv) one or more non-native carbohydrate attachment site relative to a native RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof.

Also provided is a polypeptide comprising a variant of a SARS-CoV-2 receptor binding domain (RBD), comprising any one or more of (i)-(iv) : (i) one or more amino acid substitution relative to a native RBD; (ii) one or more amino acid deletion relative to a native RBD; (iii) one or more amino acid insertion relative to a native RBD; (iv) one or more non-native carbohydrate attachment site relative to a native RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof, wherein, optionally, the engineered variant SARS-CoV-2 spike polypeptide comprises (i) one or more modification that promotes an open conformation of a receptor binding domain (RBD) of the spike polypeptide (e.g., D614G, K986P with V987P) and/or (ii) one or more modification that promotes stabilization of a SARS-CoV-2 spike polypeptide trimer. In certain embodiments, the polypeptide comprises: (i) a SARS-CoV-2 spike polypeptide; (ii) a linker, wherein, optionally, the linker comprises a stem-helix polypeptide; (iii) a peptide tag, where, optionally, the peptide tag comprises a SpyTag; (iv) a further RBD; (v) a stem -helix polypeptide; or (vi) any combination of (i)-(v).

Also provided is an isolated polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699 with the signal peptide removed, wherein, optionally, a linker sequence adjacent the signal peptide is also removed. Also provided is an isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the variation consists of a His-tag being replaced with a different peptide tag. Also provided is an isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the variation consists of the His-tag not being HHHHHHHH (/.< ., is a His-tag of a longer or a shorter length than HHHHHHHH). Also provided is an isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the variation consists of no His-tag being present. Also provided is an isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the variation consists of no peptide tag being present.

Also provided is an an isolated polypeptide, wherein the polypeptide is any one of: Cov0001-Cov0070, Cov0091-Cov0098, CovOlOl, Cov0102, Cov0121-Cov0128, Cov0130, Cov0132, Cov0151-Cov0514, Cov0556-Cov0629, Cov0631, Cov0633, Cov0662-Cov0690, Cov0693, Cov0722-Cov0739.

Exemplary polypeptides of the present disclosure include: CovOOOl, Cov0002, Cov0003, Cov0004, Cov0005, Cov0006, Cov0007, Cov0008, Cov0009, CovOOlO, CovOOl l, Cov0012,

Cov0314, Cov0315, Cov0316, Cov0317, Cov0318, Cov0319, Cov0320, Cov0321, Cov0322, Cov0323, Cov0324, Cov0325, Cov0326, Cov0327, Cov0328, Cov0329, Cov0330, Cov0331, Cov0332, Cov0333, Cov0334, Cov0335, Cov0336, Cov0337, Cov0338, Cov0339, Cov0340, Cov0341, Cov0342, Cov0343, Cov0344, Cov0345, Cov0346, Cov0347, Cov0348, Cov0349, Cov0350, Cov0351, Cov0352, Cov0353, Cov0354, Cov0355, Cov0356, Cov0357, Cov0358, Cov0359, Cov0360, Cov0361, Cov0362, Cov0363, Cov0364, Cov0365, Cov0366, Cov0367, Cov0368, Cov0369, Cov0370, Cov0371, Cov0372, Cov0373, Cov0374, Cov0375, Cov0376, Cov0377, Cov0378, Cov0379, Cov0380, Cov0381, Cov0382, Cov0383, Cov0384, Cov0385, Cov0386, Cov0387, Cov0388, Cov0389, Cov0390, Cov0391, Cov0392, Cov0393, Cov0394, Cov0395, Cov0396, Cov0397, Cov0398, Cov0399, Cov0400, Cov0401, Cov0402, Cov0403, Cov0404, Cov0405, Cov0406, Cov0407, Cov0408, Cov0409, Cov0410, Cov0411, Cov0412, Cov0413, Cov0414, Cov0415, Cov0416, Cov0417, Cov0418, Cov0419, Cov0420, Cov0421, Cov0422, Cov0423, Cov0424, Cov0425, Cov0426, Cov0427, Cov0428, Cov0429, Cov0430, Cov0431, Cov0432, Cov0433, Cov0434, Cov0435, Cov0436, Cov0437, Cov0438, Cov0439, Cov0440, Cov0441, Cov0442, Cov0443, Cov0444, Cov0445, Cov0446, Cov0447, Cov0448, Cov0449, Cov0450, Cov0451, Cov0452, Cov0453, Cov0454, Cov0455, Cov0456, Cov0457, Cov0458, Cov0459, Cov0460, Cov0461, Cov0462, Cov0463, Cov0464, Cov0625, Cov0466, Cov0467, Cov0468, Cov0469, Cov0470, Cov0471, Cov0472, Cov0473, Cov0474, Cov0475, Cov0476, Cov0477, Cov0478, Cov0479, Cov0480, Cov0481, Cov0482, Cov0483, Cov0484, Cov0485, Cov0486, Cov0487, Cov0488, Cov0489, Cov0490, Cov0491, Cov0492, Cov0493, Cov0494, Cov0495, Cov0496, Cov0497, Cov0498, Cov0499, Cov0500, Cov0501, Cov0502, Cov0503, Cov0504, Cov0505, Cov0506, Cov0507, Cov0508, Cov0509, Cov0510, Cov0511, Cov0512, Cov0513, Cov0514, Cov0746, Cov0747, Cov0748, Cov0749, Cov0750, Cov0751, Cov0758, Cov0759, Cov0761, and Cov0762. The amino acid sequences of these exemplary polypeptides are provided herein. Variants of these polypeptides wherein a different signal peptide is present, a different peptide tag is present, a signal peptide is absent, and/or a peptide tag is absent, are also provided.

Polynucleotides, Vectors, and Host cells

In another aspect, the present disclosure provides isolated polynucleotides that encode any of the presently disclosed fusion proteins, RBD polypeptides, stem-helix polypeptides, spike polypeptides, polypeptides, or the like. In certain embodiments, the polynucleotide is codon- optimized for expression in a host cell. A known or identified coding sequence can be codon optimized using known techniques and tools, e.g., using the GenScript® OptimiumGene™ tool; see also Scholten et al., Clin. Immunol. 119 : 135, 2006). Codon-optimized sequences include sequences that are partially codon-optimized (i.e., one or more codon is optimized for expression in the host cell) and those that are fully codon-optimized.

It will also be appreciated that polynucleotides encoding polypeptides of the present disclosure may possess different nucleotide sequences while still encoding a polypeptide due to, for example, the degeneracy of the genetic code, splicing, and the like. In any of the presently disclosed embodiments, the polynucleotide can comprise deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). In some embodiments, the RNA comprises messenger RNA (mRNA). In some embodiments, the RNA consists of messenger RNA (mRNA).

In some embodiments, the polynucleotide (e.g. mRNA) comprises a modified nucleoside, a cap-1 structure, a cap-2 structure, or any combination thereof. In certain embodiments, the polynucleotide comprises a pseudouridine, a N6-methyladenonsine, a 5-methylcytidine, a 2- thiouridine, or any combination thereof. In some embodiments, the pseudouridine comprises N1 -methylpseudouridine. These features are known in the art and are discussed in, for example, Zhang et al. Front. Immunol., DOI=10.3389/fimmu.2019.00594 (2019); Eyler et al. PNAS 116(46): 23068-23071; DOI: 10.1073/pnas.1821754116 (2019); Nance and Meier, ACS Cent. Sci. 2021, 7, 5, 748-756; doi.org/10.1021/acscentsci.lc00197 (2021), and van Hoecke and Roose, J. Translational Med 17:54 (2019); https://doi.org/10.1186/sl2967-019-1804-8, which modified nucleosides and mRNA features are incorporated herein by reference.

Vectors are also provided, wherein the vectors comprise or contain a polynucleotide as disclosed herein. A vector can comprise any one or more of the vectors disclosed herein. In certain embodiments, a DNA plasmid construct comprises a single open reading frame encoding two polypeptides or sequences of interest, wherein the sequence encoding the first polypeptide and the sequence encoding the second polypeptide are optionally separated by polynucleotide encoding a protease cleavage site and/or by a polynucleotide encoding a self-cleaving peptide. In some embodiments, substituent components of a polypeptide or polypeptide complex (e.g., spike protein ectodomain trimer) are encoded by a polynucleotide comprised in a single plasmid. In other embodiments, substituent components of the polypeptide or polypeptide complex are encoded by a polynucleotide comprised in two or more plasmids. An exemplary expression vector is pVaxl, available from Invitrogen®. A DNA plasmid of the present disclosure can be delivered to a subject by, for example, electroporation (e.g., intramuscular electroporation), or with an appropriate formulation (e.g., hyaluronidase).

In a further aspect, the present disclosure also provides a host cell expressing a polypeptide according to the present disclosure; or comprising or containing a vector or polynucleotide according the present disclosure.

Examples of such cells include but are not limited to, eukaryotic cells, e.g., yeast cells, animal cells, insect cells, plant cells; and prokaryotic cells, including E. coli. In some embodiments, the cells are mammalian cells. In certain such embodiments, the cells are a mammalian cell line such as CHO cells (e.g., DHFR- CHO cells (Urlaub et al., PNAS 77:4216 (1980)), human embryonic kidney cells (e.g., HEK293T cells), PER.C6 cells, Y0 cells, Sp2/0 cells. NS0 cells, human liver cells, e.g. Hepa RG cells, myeloma cells or hybridoma cells. Other examples of mammalian host cell lines include mouse sertoli cells (e.g., TM4 cells); monkey kidney CV1 line transformed by SV40 (COS-7); baby hamster kidney cells (BHK); African green monkey kidney cells (VERO-76); monkey kidney cells (CV1); human cervical carcinoma cells (HELA); human lung cells (W138); human liver cells (Hep G2); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3 A); mouse mammary tumor (MMT 060562); TRI cells; MRC 5 cells; and FS4 cells. Mammalian host cell lines suitable for protein production also include those described in, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).

In certain embodiments, a host cell is a prokaryotic cell, such as an E. coli. The expression of peptides in prokaryotic cells such as E. coli is well established (see, e.g., Pluckthun, A. Bio/Technology 9:545-551 (1991). For example, polypeptides may be produced in bacteria, in particular when glycosylation is not needed. For expression of polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237; 5,789,199; and 5,840,523.

In particular embodiments, the cell may be transfected with a vector according to the present description with an expression vector. The term "transfection" refers to the introduction of nucleic acid molecules, such as DNA or RNA (e.g. mRNA) molecules, into cells, such as into eukaryotic cells. In the context of the present description, the term "transfection" encompasses any method known to the skilled person for introducing nucleic acid molecules into cells, such as into eukaryotic cells, including into mammalian cells. Such methods encompass, for example, electroporation, lipofection, e.g., based on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or transfection based on cationic polymers, such as DEAE-dextran or polyethylenimine, etc. In certain embodiments, the introduction is non-viral.

Moreover, host cells of the present disclosure may be transfected stably or transiently with a vector according to the present disclosure, e.g. for expressing a polypeptide according to the present disclosure. In such embodiments, the cells may be stably transfected with the vector as described herein. Alternatively, cells may be transiently transfected with a vector according to the present disclosure encoding a polypeptide as disclosed herein. In any of the presently disclosed embodiments, a polynucleotide may be heterologous to the host cell.

Accordingly, the present disclosure also provides recombinant host cells that heterologously express a polypeptide of the present disclosure. For example, the cell may be of a species or cell line that is different to the species or cell line from which a polypeptide was fully or partially obtained or engineered (e.g., CHO cells expressing a a stem-helix polypeptide). In some embodiments, the cell type of the host cell does not express the polypeptide in nature. Moreover, the host cell may impart a post-translational modification (PTM; e.g., glycosylation or fucosylation) on the polypeptide that is not present in a native state of the polypeptide (or in a native state of a parent or reference polypeptide from which the polypeptide was engineered or derived). Such a PTM may result in a functional difference (e.g., reduced immunogenicity). Accordingly, a polypeptide of the present disclosure that is produced by a host cell as disclosed herein may include one or more post-translational modification that is distinct from the the polypeptide (or parent or reference polypeptide) in a native state.

Insect cells useful expressing a polypeptide are known in the art and include, for example, Spodoptera frugipera Sf9 cells, Trichoplusia ni BTI-TN5B1-4 cells, and Spodoptera frugipera SfSWTOl “Mimic™” cells. See, e.g., Palmberger et al., J. Biotechnol. 753(3-4): 160- 166 (2011). Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

Eukaryotic microbes such as filamentous fungi or yeast are also suitable hosts for cloning or expressing protein-encoding vectors, and include fungi and yeast strains with "humanized" glycosylation pathways, resulting in the production of for example an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22: 1409-1414 (2004); Li et al., Nat. Biotech. 24:210-215 (2006).

Plant cells can also be utilized as hosts for expressing a polypeptide. For example, PLANTIBODIES™ technology (described in, for example, U.S. Pat. Nos. 5,959,177; 6,040,498; 6,420,548; 7,125,978; and 6,417,429) employs transgenic plants to produce antibodies.

In certain embodiments, the host cell comprises a mammalian cell. In particular embodiments, the host cell is a CHO cell, a HEK293 cell, a PER.C6 cell, a Y0 cell, a Sp2/0 cell, a NS0 cell, a human liver cell, a myeloma cell, or a hybridoma cell.

In a related aspect, the present disclosure provides methods for producing a polypeptide, wherein the methods comprise culturing a host cell of the present disclosure under conditions and for a time sufficient to produce the polypeptide. Methods useful for isolating and purifying recombinantly produced polypeptides, by way of example, may include obtaining supernatants from suitable host cell/vector systems that secrete the recombinant polypeptide into culture media and then concentrating the media using a commercially available filter. Following concentration, the concentrate may be applied to a single suitable purification matrix or to a series of suitable matrices, such as an affinity matrix or an ion exchange resin. One or more reverse phase HPLC steps may be employed to further purify a recombinant polypeptide. These purification methods may also be employed when isolating an immunogen from its natural environment. Methods for large scale production of one or more of the isolated/recombinant polypeptide described herein include batch cell culture, which is monitored and controlled to maintain appropriate culture conditions. Purification of soluble polypeptides may be performed according to methods described herein and known in the art and that comport with laws and guidelines of domestic and foreign regulatory agencies.

Other Compositions

Also provided herein are compositions that comprise any one or more of the presently disclosed polypeptides, polynucleotides, vectors, or host cells, e.g. singly or in any combination, and can further comprise a pharmaceutically acceptable carrier, excipient, or diluent. Carriers, excipients, and diluents are discussed in further detail herein.

In certain embodiments, a composition comprises a polynucleotide (e.g., mRNA) coupled to a suitable delivery vehicle or carrier. Exemplary vehicles or carriers for administration to a human subject include a lipid or lipid-derived delivery vehicle, such as a liposome, solid lipid nanoparticle, oily suspension, submicron lipid emulsion, lipid microbubble, inverse lipid micelle, cochlear liposome, lipid microtubule, lipid microcylinder, or lipid nanoparticle (LNP) or a nanoscale platform (see, e.g., Li et al. Wilery Interdiscip Rev. Nanomed Nanobiotechnol. 77(2):el530 (2019)). Principles, reagents, and techniques for designing appropriate mRNA and and formulating mRNA-LNP and delivering the same are described in, for example, Pardi et al. (J Control Release 277345-351 (2015)); Thess et al. (Mol Ther 23: 1456-1464 (2015)); Thran et al. (EMBO Mol Med 9(10): 1434-1448 (2017); Kose et al. (Set. Immunol. 4 eaaw6647 (2019); and Sabnis et al. (Mol. Ther. 26: 1509-1519 (2018)), which techniques, include capping, codon optimization, nucleoside modification, purification of mRNA, incorporation of the mRNA into stable lipid nanoparticles (e.g., ionizable cationic lipid/phosphatidylcholine/cholesterol/PEG- lipid; ionizable lipid:distearoyl PC:cholesterol:polyethylene glycol lipid), and subcutaneous, intramuscular, intradermal, intravenous, intraperitoneal, and intratracheal administration of the same, are incorporated herein by reference.

Methods and Uses

Also provided herein are methods of treating a subject, or inducing an immune response in a subject, using a fusion protein, RBD polypeptide, polypeptide, polynucleotide, vector, host cell, composition, combination, or cocktail of the present disclosure. In some contexts, the subject has, is believed to have, or is at risk for having an infection by a coronavirus, such as a sarbecovirus e.g. a SARS-CoV-2. "Treat," "treatment," or "ameliorate" refers to medical management of a disease, disorder, or condition of a subject (e.g., a human or non-human mammal, such as a primate, horse, cat, dog, goat, mouse, or rat). In general, an appropriate dose or treatment regimen comprising a composition (fusion protein, polypeptide, RBD polypeptide, polynucleotide, composition, host cell, vector, combination, cocktail, or the like) of the present disclosure is administered in an amount sufficient to elicit a therapeutic or prophylactic benefit. Therapeutic or prophylactic/preventive benefit includes improved clinical outcome; lessening or alleviation of symptoms associated with a disease; decreased occurrence of symptoms; improved quality of life; longer disease-free status; diminishment of extent of disease, stabilization of disease state; delay or prevention of disease progression; remission; survival; prolonged survival; or any combination thereof. In certain embodiments, therapeutic or prophylactic/preventive benefit includes reduction in the frequency, rate and/or severity of coronavirus infection (i.e., in a statistically significant manner), reduction or prevention of hospitalization for treatment of a sarbecovirus infection, such as a SARS-CoV-2 infection (i.e., in a statistically significant manner). In certain embodiments, therapeutic or prophylactic/preventive benefit includes a reduced duration of hospitalization for treatment of a sarbecovirus infection, such as a SARS- CoV-2 infection (i.e., in a statistically significant manner). In certain embodiments, therapeutic or prophylactic/preventive benefit includes a reduced or abrogated need for respiratory intervention, such as intubation and/or the use of a respirator device. In certain embodiments, therapeutic or prophylactic/preventive benefit includes reversing a late-stage disease pathology and/or reducing mortality. In certain embodiments, treatment is administered as pre-exposure prophylaxis, as peri-exposure prophylaxis, or as post-exposure prophylaxis.

A "therapeutically effective amount" or "effective amount" of a polypeptide, fusion protein, polynucleotide, vector, host cell, composition, combination, or cocktail of this disclosure refers to an amount thereof sufficient to result in a therapeutic effect, including prevention of disease, improved clinical outcome; lessening or alleviation of symptoms associated with a disease; decreased occurrence of symptoms; improved quality of life; longer disease-free status; diminishment of extent of disease, stabilization of disease state; delay of disease progression; remission; survival; or prolonged survival in a statistically significant manner. When referring to an individual active ingredient, administered alone, a therapeutically effective amount refers to the effects of that ingredient or cell expressing that ingredient alone. When referring to a combination, a therapeutically effective amount refers to the combined amounts of active ingredients or combined adjunctive active ingredient with a cell expressing an active ingredient that results in a therapeutic effect, whether administered serially, sequentially, or simultaneously. A combination may comprise, for example, two different constructs that can comprise the same or different epitopes.

Methods of treatment may include inducing an immune response directed against and/or specific a coronavirus infection in a subject by administering to the subject an effective amount of a fusion protein, polypeptide, RBD polypeptide, polynucleotide, vector, host cell, composition, combination, or cocktail of the present disclosure. The immune response may involve antibody production (e.g. production of coronavirus-binding and optionally coronavirusneutralizing antibodies), activation of specific immunologically competent cells, fixation of complement, antibody-dependent cell-mediated cytotoxicicity (also called antibody-dependent cellular cytotoxicity), antibody-dependent cellular phagocytosis, production of cytokines, or any combination thereof.

An immune response can comprise, e.g., activation of dendritic cells (e.g. as assessed by increased expression of CD80, CD86, CD83, HLA-DR, IL- 12, CD40L, CD40, BAFF, April, or any combination thereof), activation of host T cells (e.g. CD4+ T cells and/or CD8+ T cells, e.g. as assessed by increased expression of CD25, CD137, ICOS, CD4, CD3, CD28, ICOS, CD8, CD69, or any combination thereof, and/or by increased proliferation), proliferation of coronavirus-antigen-specific T cells, activation and/or proliferation of host B cells, polyclonal humoral immune response (e.g., production of IgM and/or IgG antibodies), production of one or more cytokine, fever, or the like. In some embodiments, an immune response attenuates an intensity of infection or protects against an infection.

Accordingly, in certain embodiments, methods are provided for treating a coronavirus (e.g. sarbecovirus) infection, such as a SARS-CoV-2 infection, in a subject, wherein the methods comprise administering to the subject an effective amount of fusion protein, polypeptide, RBD polypeptide, polynucleotide, vector, host cell, composition, combination, or cocktail as disclosed herein.

Subjects that can be treated by the present disclosure are, in general, human and other primate subjects, such as monkeys and apes for veterinary medicine purposes. Other model organisms, such as mice and rats, may also be treated according to the present disclosure. In any of the aforementioned embodiments, the subject may be a human subject. The subjects can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects.

A number of criteria are believed to contribute to high risk for severe symptoms or death associated with a coronavirus (e.g. sarbecovirus) infection. These include, but are not limited to, age, occupation, general health, pre-existing health conditions, and lifestyle habits. In some embodiments, a subject treated according to the present disclosure comprises one or more risk factors.

In certain embodiments, a human subject treated according to the present disclosure is an infant, a child, a young adult, an adult of middle age, or an elderly person. In certain embodiments, a human subject treated according to the present disclosure is less than 1 year old, or is 1 to 5 years old, or is between 5 and 125 years old (e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or 125 years old, including any and all ages therein or therebetween). In certain embodiments, a human subject treated according to the present disclosure is 0-19 years old, 20-44 years old, 45-54 years old, 55-64 years old, 65-74 years old, 75-84 years old, or 85 years old, or older. Persons of middle, and especially of elderly age are believed to be at particular risk. In particular embodiments, the human subject is 45-54 years old, 55-64 years old, 65-74 years old, 75-84 years old, or 85 years old, or older. In some embodiments, the human subject is male. In some embodiments, the human subject is female.

In certain embodiments, a human subject treated according to the present disclosure is a resident of a nursing home or a long-term care facility, is a hospice care worker, is a healthcare provider or healthcare worker, is a first responder, is overweight or clinically obese, is or has been a smoker, has or had chronic obstructive pulmonary disease (COPD), is asthmatic (e.g., having moderate to severe asthma), has an autoimmune disease or condition (e.g., diabetes), and/or has a compromised or depleted immune system (e.g., due to AIDS/HIV infection, a cancer such as a blood cancer, a lymphodepleting therapy such as a chemotherapy, a bone marrow or organ transplantation, or a genetic immune condition), has chronic liver disease, has cardiovascular disease, has a pulmonary or heart defect, works or otherwise spends time in close proximity with others, such as in a factory, shipping center, hospital setting, or the like. In certain embodiments, a human subject treated according to the present disclosure is a family member or other close contact of any one or more of the above.

In certain embodiments, a subject treated according to the present disclosure has received a vaccine for a coronavirus, such as a sarbecovirus e.g. SARS-CoV-2. In certain embodiments, the subject has previously received one or more, two or more, three or more, four or more, or five or more doses of a vaccine composition. In certain embodiments, the subject has received two or more different coronavirus vaccine compositions. In certain embodiments, the subject has received a coronavirus vaccine composition including at least a portion of a SARS-CoV-2 spike protein (e.g., a RBD polypeptide or a full spike protein), a polynucleotide (e.g. mRNA) encoding at least a portion of a SARS-CoV-2 spike protein (e.g. encoding an RBD polypeptide, or encoding a full spike proteins), or a live, attenuated, or inactivated (e.g. heat-killed or inactivated with p -propiolactone) virus. In certain embodiments, the subject has received a coronavirus vaccine composition including Comirnaty (Pfizer-BioNTech), Spikevax (Modema), Janssen coronavirus vaccine (Johnson & Johnson), Nuvoxovid/Covavax (Novavax), Vaxzevria (Oxford- AstraZeneca), Coronavac aka BBIBP-CorV aka BBIBP (Sinovac), Covaxin aka BBV152 (Bharat Biotech), Convidecia aka AD5-nCOV (CanSino Biologies), Sputnik V aka Gam-COVID-Vac, Sinopharm WIBP aka WIBP-CorV (Sinovac), Abdala, Soberana 2, Soberana Plus, ZF2001 aka Anhui Zhifei Longcom ZifiVax ZF2001 aka ZF-UZ- VAC -2001 aka Zifivax (Anhui Zhifei Longcom Biopharmaceutical), Corbevax (Texas Children’s Hospital/Baylor College of Medicine/Dynavax), COVIran Barekat (Sifa Pharmed Industrial Group), VAT00002 or VAT00008 (Sanofi-GSK), SCB-2019 (Clover Biopharmaceuticals), VLA2001 (Valneva), HIPRA SARS-CoV-2 aka PHH-1 V (HIPRA), mRNA- 1273.214 (Moderna), Sputnik V bivalent (L452R; Gamal eya National Research Center of Epidemiology and Microbiology), or any combination thereof.

Typical routes of administering the presently disclosed compositions thus include, without limitation, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. The term "parenteral", as used herein, includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In certain embodiments, administering comprises administering by a route that is selected from oral, intravenous, parenteral, intragastric, intrapleural, intrapulmonary, intrarectal, intradermal, intraperitoneal, intratumoral, subcutaneous, topical, transdermal, intracisternal, intrathecal, intranasal, and intramuscular. In particular embodiments, a method comprises orally administering the peptide, polynucleotide, vector, host cell, or composition to the subject.

Pharmaceutical compositions according to certain embodiments of the present invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a subject or patient may take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container may hold a plurality of dosage units. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition to be administered will, in any event, contain an effective amount of a polypeptide, fusion protein, RBD polypeptide, polynucleotide, vector, host cell, composition, cocktail, or combination of the present disclosure, for treatment of a disease or condition of interest in accordance with teachings herein.

A composition may be in the form of a solid or liquid. In some embodiments, the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form. The carrier(s) may be liquid, with the compositions being, for example, an oral oil, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration. When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi solid, semi liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid. As a solid composition for oral administration, the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like. Such a solid composition will typically contain one or more inert diluents or edible carriers. In addition, one or more of the following may be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, com starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent. When the composition is in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.

The composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, preferred compositions contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included. Liquid pharmaceutical compositions, whether they be solutions, suspensions or other like form, may include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer’s solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.

In certain embodiments, the composition may include a pharmaceutically effective amount of an adjuvant to enhance the prophylactic or therapeutic effects of the treatment. Any suitable adjuvant known to those skilled in the art may be used. Non-limiting examples of suitable adjuvants include: amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (Alum), AS04 (monophosphoryl lipid A (MPL) with an aluminum salt), MF59 (oil in water emulsion composed of squalene), AF03 (oil in water emulsion composed of squalene), AS01B (MPL and QS-21), CpG 1018 (cytosine phosphoguanine), alhydroxiquim-II, and AS03 (tocopherol and squalene).

The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. An injectable pharmaceutical composition is preferably sterile.

A liquid composition intended for either parenteral or oral administration should contain an amount of a construct as herein disclosed such that a suitable dosage will be obtained. Typically, this amount is at least 0.01% of the construct in the composition. When intended for oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition. Certain oral pharmaceutical compositions contain between about 4% and about 75% of the construct. In certain embodiments, pharmaceutical compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 10% by weight of construct prior to dilution.

The composition may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in a composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device. The pharmaceutical composition may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug. The composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.

A composition may include various materials which modify the physical form of a solid or liquid dosage unit. For example, the composition may include materials that form a coating shell around the active ingredients. The materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients may be encased in a gelatin capsule. The composition may consist essentially of dosage units that can be administered as an aerosol. The term aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols may be delivered in single phase, bi phasic, or tri phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. One of ordinary skill in the art, without undue experimentation, may determine preferred aerosols.

It will be understood that compositions of the present disclosure also encompass carrier molecules for polynucleotides, as described herein (e.g., lipid nanoparticles, nanoscale delivery platforms, and the like).

The pharmaceutical compositions may be prepared by methodology well known in the pharmaceutical art. For example, a composition intended to be administered by injection can be prepared by combining a composition that comprises a construct as described herein and optionally, one or more of salts, buffers and/or stabilizers, with sterile, distilled water so as to form a solution. A surfactant may be added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the peptide composition so as to facilitate dissolution or homogeneous suspension of the construct in the aqueous delivery system. In general, an appropriate dose and treatment regimen provide the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (such as described herein, including an improved clinical outcome (e.g., a decrease in frequency, duration, or severity of diarrhea or associated dehydration, or inflammation, or longer disease-free and/or overall survival, or a lessening of symptom severity). For prophylactic use, a dose should be sufficient to prevent, delay the onset of, or diminish the severity of a disease associated with disease or disorder. Prophylactic benefit of the compositions administered according to the methods described herein can be determined by performing pre-clinical (including in vitro and in vivo animal studies) and clinical studies and analyzing data obtained therefrom by appropriate statistical, biological, and clinical methods and techniques, all of which can readily be practiced by a person skilled in the art.

Compositions are administered in an effective amount (e.g., to treat a coronavirus infection such as a SARS-CoV-2 infection), which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the subject; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy. In certain embodiments, following administration of therapies according to the formulations and methods of this disclosure, test subjects will exhibit about a 10% up to about a 99% reduction in one or more symptoms associated with the disease or disorder being treated as compared to placebo-treated or other suitable control subjects.

Generally, a therapeutically effective daily dose of a construct as disclosed herein may be (for a 70 kg mammal) from about 0.001 mg/kg (i.e., 0.07 mg) to about 100 mg/kg (i.e., 7.0 g); preferably a therapeutically effective dose is (for a 70 kg mammal) from about 0.01 mg/kg (i.e., 0.7 mg) to about 50 mg/kg (i.e., 3.5 g); more preferably a therapeutically effective dose is (for a 70 kg mammal) from about 1 mg/kg (i.e., 70 mg) to about 25 mg/kg (i.e., 1.75 g). For polynucleotides, vectors, host cells, and related compositions of the present disclosure, a therapeutically effective dose may be different than for a polypeptide.

In certain embodiments, a method comprises administering the polypeptide, fusion protein, RBD polypeptide, polynucleotide, vector, host cell, composition, combination, or cocktail as one or more, two or more, three or more, four or more, or five or more doses. The interval between the administration of two doses can vary from 1, 2, 3, 4, 5, 6 or 7 days, to 1, 2, 3, 4, 5, 6, 7 or 8 weeks, to 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18 or 24 months. The intervals between single doses may be constant or vary over the course of treatment. In some embodiments, treatment is administered once yearly, or twice yearly, or about every six months, or about every 12 months, or about every three months. In some embodiments, treatment is administered in advance of a winter season.

In certain embodiments, a method comprises administering the polypeptide, fusion protein, polynucleotide, vector, host cell, combination, cocktail, or composition at least one time prior to the subject being exposed to and optionally infected by a sarbecovirus, such as SARS- CoV-2.

Compositions comprising a polypeptide, fusion protein, polynucleotide, vector, host cell, composition, cocktail, or combination of the present disclosure may also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents. Such combination therapy may include administration of a single pharmaceutical dosage formulation which contains a compound of the invention and one or more additional active agents, as well as administration of compositions comprising a construct of the disclosure and each active agent in its own separate dosage formulation. For example, a composition as described herein and the other active agent can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations. Similarly, a composition as described herein and the other active agent can be administered to the subject together in a single parenteral dosage composition such as in a saline solution or other physiologically acceptable solution, or each agent administered in separate parenteral dosage formulations. Where separate dosage formulations are used, the compositions comprising a composition and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially and in any order; combination therapy is understood to include all these regimens.

In certain embodiments, a combination therapy is provided that comprises a composition as provided here and one or more of anti-coronavirus antibody, one or more anti-inflammatory agent, and/or one or more anti-viral agent. In some embodiments, the anti-coronavirus antibody comprises an anti-sarbecovirus antibody such as bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, or bebtelovimab. In some embodiments, the one or more antiinflammatory agent comprises a corticosteroid such as, for example, dexamethasone, prednisone, or the like. In some embodiments, the one or more anti-inflammatory agents comprise a cytokine antagonist such as, for example, an antibody that binds to IL6 (such as siltuximab), or to IL-6R (such as tocilizumab), or to IL-lp, IL-7, IL-8, IL-9, IL-10, FGF, G-CSF, GM-CSF, IFN-y, IP- 10, MCP-1, MIP-1 A, MIP1-B, PDGR, TNF-a, or VEGF. In some embodiments, antiinflammatory agents such as leronlimab, ruxolitinib and/or anakinra are used. In some embodiments, the one or more anti-viral agents comprise nucleotide analogs or nucelotide analog prodrugs such as, for example, remdesivir, sofosbuvir, acyclovir, and zidovudine. In particular embodiments, an anti-viral agent comprises lopinavir, ritonavir, favipiravir, nirmatrelvir, molnupiravir, or any combination thereof. Other anti-inflammatory agents for use in a combination therapy of the present disclosure include non-steroidal anti-inflammatory drugs (NSAIDS). It will be appreciated that in such a combination therapy, the composition of the present disclosure and the one or more anti-coronavirus antibody, the one or more antiinflammatory agent, and/or one or the more antiviral agent can be administered in any order and any sequence, or together.

In some embodiments, a composition of the present disclosure is administered to a subject who has previously received one or more anti-coronavirus antibody, one or more anti- inflammatory agent, and/or one or more antiviral agent. In some embodiments, one or more anticoronavirus antibody, one or more anti-inflammatory agent, and/or one or more antiviral agent is administered to a subject who has previously received a peptide, polynucleotide, vector, host cell, or composition of the present disclosure.

In certain embodiments, a combination therapy is provided that comprises two or more compositions of the present disclosure. A method can comprise administering a first composition to a subject who has received a second composition, or can comprise administering two or more compositions together. For example, in particular embodiments, a method is provided that comprises administering to the subject (a) a first composition, when the subject has received a second composition; (b) the second composition, when the subject has received the composition; or (c) the first composition, and the second composition.

In a related aspect, uses of the presently disclosed fusion proteins, polypeptides, RBD polypeptides, polynucleotides, vectors, host cells, combinations, cocktails, and compositions are provided.

In certain embodiments, a polypeptide, fusion protein, RBD polypeptide, polynucleotide, vector, host cell, combination, cocktail, or composition is provided for use in a method of treating a coronavirus infection, such as a sarbecovirus or a SARS-CoV-2 infection, in a subject.

In certain embodiments, a polypeptide, fusion protein, RBD polypeptide, polynucleotide, vector, host cell, combination, cocktail, or composition is provided for use in a method of manufacturing or preparing a medicament for treating a coronavirus infection, such as a sarbecovirus or a SARS-CoV-2 infection, in a subject.

The following non-limiting Embodiments are also provided:

Embodiment 1. A fusion protein comprising:

(i) a coronavirus spike protein ectodomain (S ectodomain); and

(ii) C-terminal to the S ectodomain, an oligomerization domain, wherein, optionally, the oligomerization domain is fused or linked to a C-terminus of the S ectodomain, and wherein, optionally, the coronavirus comprises a betacoronavirus.

Embodiment 2. The fusion protein of Embodiment 1, wherein the S ectodomain comprises a receptor binding domain (RBD) in an open conformation.

Embodiment 3. The fusion protein of Embodiment 1 or 2, wherein the oligomerization domain comprises a trimerization domain.

Embodiment 4. The fusion protein of Embodiment 3, wherein the trimerization domain comprises a foldon, wherein the foldon optionally comprises or consists of the amino acid sequence GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO.:703).

Embodiment 5. The fusion protein of any one of Embodiments 1-4, further comprising, C-terminal to the oligomerization domain: (i) a peptide tag; (ii) one or more stem-helix polypeptide, optionally comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701); or (iii) both (i) and (ii). Embodiment 6. The fusion protein of Embodiment 5, wherein the peptide tag comprises a SpyTag, wherein, optionally, the SpyTag comprises the amino acid sequence AHIVMVDAYKPTK (SEQ ID NO.:700).

Embodiment 7. The fusion protein of Embodiment 5 or 6, further comprising a linker disposed between and connecting (i) the oligomerization domain and the peptide tag or (ii) the oligomerization domain with (iii) the stem-helix polypeptide of the one or more stem-helix polypeptide.

Embodiment 8. The fusion protein of Embodiment 7, wherein the linker comprises or consists of the amino acid sequence GS, GSG, GPP, GSGGSGGSGGTG (SEQ ID NO.:702), GPPSPPG (SEQ ID NO.:709), GSGSGS (SEQ ID NO.:710), GSGSGSGSG (SEQ ID NO.:711), PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701), or the amino acid sequence set forth in any one of SEQ ID NOs.:97-106.

Embodiment 9. The fusion protein of any one of Embodiments 1-8, further comprising, C -terminal to the oligomerization domain, a first RBD polypeptide.

Embodiment 10. The fusion protein of Embodiment 9, further comprising, C-terminal to the first RBD polypeptide, a second RBD polypeptide.

Embodiment 11. The fusion protein of Embodiment 10, further comprising, C-terminal to the second RBD polypeptide, a third RBD polypeptide.

Embodiment 12. The fusion protein of any one of Embodiments 9-11, comprising:

(a) a linker disposed between and linking the oligomerization domain and the first RBD polypeptide; and/or

(b) a linker disposed between and linking the first RBD polypeptide and the second RBD polypeptide; and/or

(c) a linker disposed between and linking the second RBD polypeptide and the third RBD polypeptide.

Embodiment 13. The fusion protein of Embodiment 12, wherein: (i) the linker of (a) comprises, consists essentially of, or consists of the same amino acid sequence as the linker of (b); (ii) the linker of (a) comprises, consists essentially of, or consists of the same amino acid sequence as the linker of (c); (iii) the linker of (a) comprises, consists essentially of, or consists of a different amino acid sequence than the linker of (b); (iv) the linker of (a) comprises, consists essentially of, or consists of a different amino acid sequence than the linker of (c); (v) the linker of (b) comprises, consists essentially of, or consists of the same amino acid sequence as the linker of (c); (vi) the linker of (b) comprises, consists essentially of, or consists of of a different amino acid sequence than the linker of (c); or (vii) the linker of (a), the linker of (b), and the linker of (c) comprise, consist essentially of, or consist of of the same amino acid sequence.

Embodiment 14. The fusion protein of Embodiment 12 or 13, wherein the linker of (a), the linker of (b), and/or the linker of (c) comprises or consists of the amino acid sequence GS, GSG, GPP, GSGGSGGSGGTG (SEQ ID NO.:702), GPPSPPG (SEQ ID NO.:709), GSGSGS (SEQ ID NO.:710), GSGSGSGSG (SEQ ID NO. :711), or PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701), or the amino acid sequence set forth in any one of SEQ ID NOs.:97-106.

Embodiment 15. The fusion protein of any one of Embodiments 9-14, wherein the first RBD polypeptide comprises, consists essentially of, or consists of an amino acid sequence that is the same as the amino acid sequence of the RBD comprised in the S ectodomain.

Embodiment 16. The fusion protein of any one of Embodiments 10-15, comprising the second RBD polypeptide and optionally the third RBD polypeptide, wherein the second RBD polypeptide and the optional third RBD polypeptide each comprise, consist essentially of, or consist of an amino acid sequence that is the same as the amino acid sequence of the RBD comprised in the S ectodomain.

Embodiment 17. The fusion protein of any one of Embodiments 9-14 and 16, wherein the first RBD polypeptide comprises, consists essentially of, or consists of an amino acid sequence that is different than the amino acid sequence of the RBD comprised in the S ectodomain.

Embodiment 18. The fusion protein of any one of Embodiments 10-17, comprising the second RBD polypeptide and optionally the third RBD polypeptide, wherein the second RBD polypeptide and the optional third RBD polypeptide each independently comprise, consist essentially of, or consist of an amino acid sequence that is the same as or is different to the amino acid sequence of the RBD comprised in the S ectodomain.

Embodiment 19. The fusion protein of any one of Embodiments 9-18, comprising, C- terminal to: the first RBD polypeptide; the optional second RBD polypeptide; and/or the optional third RBD polypeptide, a stem-helix polypeptide, optionally comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 20. The fusion protein of any one of Embodiments 9-19, which does not comprise, C-terminal to: the first RBD polypeptide; the optional second RBD polypeptide; and/or the optional third RBD polypeptide, a stem-helix polypeptide, optionally comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 21. A polypeptide trimer, wherein each of the three polypeptides of the trimer comprises: (i) a coronavirus spike protein ectodomain (S ectodomain); and (ii) C- terminal to the S ectodomain, a trimerization domain, wherein the three trimerization domains associate with one another to form a trimer, and wherein, optionally, each of the three trimerization domains comprises a foldon, and wherein, optionally, the coronavirus comprises a betacoronavirus.

Embodiment 22. The polypeptide trimer of Embodiment 21, wherein one, two, or three of the polypeptides comprises a fusion protein of any one of Embodiments 1-20, wherein the two or three fusion proteins, if present, optionally comprise, consist essentially of, or consist of the same amino acid sequence as one another.

Embodiment 23. An isolated coronavirus receptor binding domain (RBD) polypeptide, wherein, optionally, the coronavirus comprises a betacoronavirus. Embodiment 24. A fusion protein comprising the RBD polypeptide of Embodiment 23 and one or both of (i) and (ii): (i) one or more peptide tag; (ii) one or more stem -helix polypeptide, wherein, optionally, the one or more stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 25. The fusion protein of Embodiment 24, comprising: (a) a peptide tag linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises a N-terminus of the RBD polypeptide; (b) a peptide tag linked or fused to a second end of the RBD polypeptide, wherein the second end optionally comprises a C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide;

(d) a stem-helix polypeptide linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide; or (e) any combination of (a)-(d).

Embodiment 26. The fusion protein of Embodiment 24 or 25, wherein the one or more peptide tag comprises a SpyTag.

Embodiment 27. The fusion protein of any one of Embodiments 24-26, comprising a linker disposed between and linking (1) the RBD polypeptide and (2) a peptide tag of the one or more peptide tag.

Embodiment 28. The fusion protein of Embodiment 27, comprising two or more linkers that comprise the same amino acid sequence as one another.

Embodiment 29. The fusion protein of Embodiment 27 or 28, wherein the linker, or one or more of the two or more linkers, comprises or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.:702).

Embodiment 30. The fusion protein of any one of Embodiments 24-29, comprising a linker disposed between and connecting (1) the RBD polypeptide and (2) a one of the one or more stem-helix polypeptide.

Embodiment 31. The fusion protein of any one of Embodiments 24-30, comprising:

(i) a peptide tag fused or linked to the N-terminus of the RBD polypeptide; and

(ii) a stem-helix polypeptide fused or linked to the C-terminus of the RBD polypeptide.

Embodiment 32. The fusion protein of Embodiment 31, comprising, in N-terminal to C- terminal direction, an optional signal peptide, an optional linker, a SpyTag (optionally AHIVMVDAYKPTK (SEQ ID NO.:700)), a linker (optionally GSGGSGGSGGTG; SEQ ID NO.:702), an RBD, a linker (optionally GSGGSGGSGGTG; SEQ ID NO.:702), and a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 33. A fusion protein comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second RBD polypeptide, wherein, optionally, the coronavirus comprises a betacoronavirus. Embodiment 34. The fusion protein of Embodiment 33, comprising the first RBD polypeptide, the second RBD polypeptide, and a third RBD polypeptide, the first RBD polypeptide being linked to the second RBD polypeptide by a linker (1), and the second RBD polypeptide being linked to the third RBD polypeptide by a linker (2).

Embodiment 35. The fusion protein of Embodiment 34, wherein the linker (1) and the linker (2) comprise, consist essentially of, or consist of the same amino acid sequence.

Embodiment 36. The fusion protein of Embodiment 34, wherein the linker (1) and the linker (2) have different amino acid sequences from one another.

Embodiment 37. The fusion protein of Embodiment any one of Embodiments 33-36, wherein the linker comprises a stem-helix polypeptide.

Embodiment 38. The fusion protein of any one of Embodiments 34-36, wherein the linker (1) and the linker (2) each comprise a stem-helix polypeptide.

Embodiment 39. The fusion protein of any one of Embodiments 33-38, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2 Wuhan-Hu- 1; SARS- CoV-2 A.27; SARS-like coronavirus ZC45.

Embodiment 40. The fusion protein of any one of Embodiments 33-39, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2 Beta variant; SARS- CoV-2 A.2.7 + S494P; SARS-like coronavirus isolate Rs4231.

Embodiment 41. The fusion protein of any one of Embodiments 33-40, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2 Delta variant; GX- Pangolin; SARS-like coronavirus isolate Rs4231.

Embodiment 42. The fusion protein of any one of Embodiments 34-41, comprising three RBD polypeptides, wherein the three RBD polypeptides are from: (i) SARS-CoV-2 Wuhan-Hu- 1, SARS-CoV-2A.27, and SARS-like coronavirus ZC45, respectively; (ii) SARS-CoV-2 Beta variant, SARS-CoV-2 A.2.7 + S494P, and SARS-like coronavirus isolate Rs4231, respectively; or (iii) SARS-CoV-2 Delta variant, GX-Pangolin, and SARS-like coronavirus isolate Rs4231, respectively.

Embodiment 43. The fusion protein of any one of Embodiments 37-42, wherein the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 44. The fusion protein of Embodiment 33, further comprising a fourth RBD polypeptide and a fifth RBD polypeptide, wherein the fourth RBD polypeptide is linked to the third RBD polypeptide by a linker (3) and the fifth RBD polypeptide is linked to the fourth RBD polypeptide by a linker (4).

Embodiment 45. The fusion protein of Embodiment 44, wherein two, three, or all four of the linkers ( 1 )-(4) comprise, consist essentially of, or consist of the same amino acid sequence.

Embodiment 46. The fusion protein of Embodiment 44 or 45, wherein the two or more of the linkers have different amino acid sequences from one another.

Embodiment 47. The fusion protein of any one of Embodiments 44-46, wherein one or more of the linkers ( 1 )-(4) comprises or consists of a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 48. The fusion protein of Embodiment 47, wherein each of the peptide linkers (l)-(4) comprises or consists of a stem-helix polypeptide, wherein, optionally, the stemhelix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 49. The fusion protein of any one of Embodiments 44-48, comprising an RBD polypeptide from each of: (i) SARS-CoV-2 Wuhan-Hu-1, SARS-CoV-2 A.27, SARS- CoV-2 Alpha variant + E484K + S494P, SARS-like coronavirus ZC45, and SARS-CoV-1; or (ii) SARS-CoV-2 Delta variant, SARS-CoV-2 Beta variant, SARS-CoV-2 A.27 + S494P, GX- Pangolin, and SARS-like coronavirus isolate Rs4231.

Embodiment 50. The fusion protein of any one of Embodiments 33-49, further comprising a peptide tag, wherein, optionally, the peptide tag is disposed at a C-terminus of the fusion protein.

Embodiment 51. The fusion protein of Embodiment 50, wherein the peptide tag comprises a SpyTag and/or a His tag.

Embodiment 52. The fusion protein of any one of Embodiments 1-21, 24-38, 43-48, and 50-51, the polypeptide trimer of Embodiment 21 or 22, or the isolated RBD polypeptide of Embodiment 23, wherein the coronavirus comprises a betacoronavirus, wherein the betacoronavirus comprises a sarbecovirus.

Embodiment 53. The fusion protein of Embodiment 52, the polypeptide trimer of 52, or the isolated RBD polypeptide of Embodiment 52, wherein the sarbecovirus comprises a SARS- CoV-2, a SARS coronavirus, a SARS-like coronavirus, or an engineered variant thereof.

Embodiment 54. The fusion protein of Embodiment 53, the polypeptide trimer of Embodiment 53, or the isolated RBD polypeptide of Embodiment 53, wherein the sarbecovirus comprises a SARS-CoV-2, a Wuhan-Hu-1, an A.27 (Mayotte), an A.27 with a S494P substitution mutation, an AAV49723.1, an ATO98157.1, an AVP78031.1, a B.1.315, a B.167.2, a Wuhan-Hu-1 with the substitution mutations E484K, S494P, and N501Y, a QHD43416.1, an ADE34812, an AIA6227, a QIA48632.1, or any combination thereof.

Embodiment 55. The fusion protein of Embodiment 54, the protein trimer of 54, or the isolated RBD polypeptide of Embodiment 54, wherein the sarbecovirus comprises a SARS-CoV- 2.

Embodiment 56. A polypeptide comprising a variant of a SARS-CoV-2 Receptor Binding Domain (RBD), wherein the variant RBD comprises any one or more of the following changes (i)-(xiii) relative to an RBD comprising amino acids 328-531 of SEQ ID NO.: 1, wherein the numbering of amino acids is according to SEQ ID NO.: 1 : (i) amino acids 444-447 (K-V- G-G) replaced by a single P amino acid, by a single G amino acid, or by a single S amino acid; (ii) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, by the two amino acids G-G, or by the two amino acids G-S; (iii) a Y449G substitution; (iv) a Q498A substitution, a Q498G substitution, or a Q498N substitution, optionally further comprising a P499A substitution or a P499G substitution; (v) a P499A substitution or a P499G substitution; (vi) a T500A substitution; (vii) a N450G substitution; (viii) a L452A substitution; (ix) a T470N substitution and a I472T substitution; (x) a V483 A substitution; (xi) amino acids

481-483 (N-G-V) replaced by a single G amino acid; (xii) a E484A substitution; (xiii) a Q493A substitution.

Embodiment 57. An isolated polypeptide comprising a variant of a SARS-CoV-2 Receptor Binding Domain (RBD), wherein the variant RBD comprises any one or more of the following changes (i)-(vi) relative to an RBD comprising amino acids 328-531 of SEQ ID NO.: 1, wherein the numbering of amino acids is according to SEQ ID NO. : 1 : (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, by a single G amino acid, or by a single S amino acid; (ii) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, by the two amino acids G-G, or by the two amino acids G-S; (iii) a Y449G substitution; (iv) a Q498A substitution, a Q498G substitution, or a Q498N substitution, optionally further comprising a P499A substitution or a P499G substitution; (v) a P499A substitution or a P499G substitution; (vi) a T500A substitution.

Embodiment 58. An isolated polypeptide comprising a variant of a SARS-CoV-2 Receptor Binding Domain (RBD), wherein the variant RBD comprises any one or more of the following changes (i)-(viii) relative to an RBD comprising amino acids 328-531 of SEQ ID NO.:1, wherein the numbering of amino acids is according to SEQ ID NO.:1: (i) aN450G substitution; (ii) a L452A substitution; (iii) a T470N substitution; (iv) a I472T substitution, (v) a V483A substitution; (vi) amino acids 481-483 (N-G-V) replaced with a single G amino acid; (vii) a K484A substitution; (viii) a Q493 A substitution.

Embodiment 59. An isolated polypeptide comprising a variant of a SARS-CoV-2 Receptor Binding Domain (RBD), wherein the variant RBD comprises the following change(s) relative to an RBD comprising amino acids 328-531 of SEQ ID NO.: 1, wherein the numbering of amino acids is according to SEQ ID NO. : 1 : (1) a Y449G substitution; or (2) a Q498A substitution; or (3) a Q498G substitution; or (4) a T500A substitution; or (5) Y449G and Q498A substitutions; or (6) Y449G and Q498G substitutions; or (7) Y449G and T500A substitutions; or (8) Q498A and T500A substitutions; or (9) Q498G and T500A substitutions; or (10) Y449G, Q498A, and T500A substitutions; or (11) Y449G, Q498G, and T500A substitutions; or (12) a Q498N substitution; or (13) Q498N and P499A substitutions; or (14) Y449G, Q498N, and P499A substitutions; or (15) Q498N and P499G substitutions; or (16) Y449G, Q498N, and P499G substitutions; or (17) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid; or (18) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid; or (19) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid; or (20) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G; or (21) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G; or (22) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S; or (23) (i) amino acids 444- 447 (K-V-G-G) replaced by a single P amino acid, (ii) a Q498N substitution, and (iii) a P499A substitution; or (24) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or

(25) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a Q498N substitution, and (iii) a P499G substitution; or (26) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (27) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a Q498N substitution, and (iii) a P499A substitution; or (28) (i) amino acids 444-

447 (K-V-G-G) replaced by a single G amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (29) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a Q498N substitution, and (iii) a P499G substitution; or (30) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (31) (i) amino acids

444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Q498N substitution, and (iii) a P499A substitution; or (32) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (33) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Q498N substitution, and (iii) a P499G substitution; or (34) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (35) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a Q498N substitution, and (iii) a P499A substitution; or (36) (i) amino acids

444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (37) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a Q498N substitution, and (iii) a P499G substitution; or

(38) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or

(39) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Q498N substitution, and (iii) a P499A substitution; or (40) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (41) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Q498N substitution, and (iii) a P499G substitution; or (42)(i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (43) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Q498N substitution, and (iii) a P499A substitution; or (44) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499A substitution; or (45) (i) amino acids

444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Q498N substitution, and (iii) a P499G substitution; or (46) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Y449G substitution, (iii) a Q498N substitution, and (iv) a P499G substitution; or (47) a N450G substitution; or (48) a L452A substitution; or (49) a V483 A substitution; or (50) a K484A substitution; or (51) a Q493A substitution; or (52)N450G and Q493A substitutions; or (53) L452A and Q493 A substitutions; or (54) N450G, V483 A, and Q493 A substitutions; or (55) N450G, K484A, and Q493A substitutions; or (56) L452A, V483A, and Q493A substitutions; or (57) L452A, K484A, and Q493A substitutions; or (58) T470N and I472T substitutions; or (59) N450G, T470N, and I472T substitutions; or (60) L452A,

T470N, and I472T substitutions; or (61) T470N, I472T, and V483A substitutions; or (62)

N450G, T470N, I472T, and V483 A substitutions; or (63) L452A, T470N, I472T, and

V483 A substitutions; or (64) T470N, I472T, V483 A, and Q493 A substitutions; or (65) N450G, T470N, I472T, V483 A, and Q493 A substitutions; or (66) L452A, T470N,

I472T, V483A, and Q493A substitutions; or (67) amino acids 481-483 (N-G-V) replaced with a single G amino acid; or (68)(i) amino acids 481-483 (N-G-V) replaced with a single G amino acid, and (ii) a K484A substitution; or (69) (i) amino acids 481-483 (N-G-V) replaced with a single G amino acid, (ii) a K484A substitution, and (iii) a Q493 A substitution; or (70) (i) a

L452A substitution, (ii) amino acids 481-483 (N-G-V) replaced with a single G amino acid, and (iii) a K484A substitution; or (71) (i) a L452A substitution, (ii) amino acids 481-483 (N-G-V) replaced with a single G amino acid, (iii) a K484A substitution, and (iv) a Q493 A substitution; or (72) (i) a T470N substitution, (ii) a I472T substitution, and (iii) amino acids 481-483 (N-G-V) replaced with a single G amino acid; or (73) (i) a T470N substitution, (ii) a I472T substitution, (iii) amino acids 481-483 (N-G-V) replaced with a single G amino acid, and (iv) a K484A substitution; or (74) (i) a T470N substitution, (ii) a I472T substitution, (iii) amino acids 481- 483 (N-G-V) replaced with a single G amino acid, (iv) a K484A substitution, and (v) a Q493 A substitution; or (75) (i) a L452A substitution, (ii) a T470N substitution, (iii) a I472T substitution, and (iv) amino acids 481-483 (N-G-V) replaced with a single G amino acid; or (76) (i) a L452A substitution, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced with a single G amino acid, (v) a K484A substitution, and (vi) a Q493 A substitution; or (77) K484A, Q493 A, and Q498A substitutions; or (78) K484A, Q493 A, and Q498G substitutions; or (79) Y449G, K484A, Q493 A, Q498A, P499A, and T500A substitutions; or (80) Y449G, K484A, Q493 A, Q498G, P499A, and T500A substitutions; or (81) Y449G, L452A, V483A, K484A, Q493A, Q498A, P499A, and T500A substitutions; or (82) Y449G, L452A, V483A, K484A, Q493A, Q498G, P499A, and T500A substitutions; or (83) T470N, I472T, Q498N, and P499A substitutions; or (84) Y449G,

T470N, I472T, Q498N, and P499A substitutions; or (85) T470N, I472T, Q493A, Q498N, and P499A substitutions; or (86) T470N, I472T, K484A, Q498N, and P499A substitutions; or (87) L452A, T470N, I472T, Q498N, and P499A substitutions; or (88) Y449G, T470N, I472T, Q493 A, Q498N, and P499A substitutions; or (89) Y449G, T470N, I472T, K484A, Q498N, and P499A substitutions; or (90) Y449G, L452A, T470N, I472T, Q493 A, Q498N, and

P499A substitutions; or (91) Y449G, L452A, T470N, I472T, K484A, Q498N, and P499A substitutions; or (92) Y449G, L452A, T470N, I472T, K484A, Q493 A, Q498N, and P499A substitutions; or (93) T470N, I472T, Q498N, and P499G substitutions; or (94) Y449G, T470N, I472T, Q498N, and P499G substitutions; or (95) T470N, I472T, Q493 A, Q498N, and P499G substitutions; or (96) T470N, I472T, K484A, Q198N, and P499G substitutions; or (97) L452A, T470N, I472T, Q498N, and P499G substitutions; or (98) Y449G, T470N, I472T, Q493 A, Q498N, and P499G substitutions; or (99) Y449G, T470N, I472T, K484A, Q498N, and P499G substitutions; or (100) Y449G, L452A, T470N, I472T, Q493A, Q498N, and P499G substitutions; or (101) Y449G, L452A, T470N, I472T, K484A, Q498N, and

P499G substitutions; or (102) Y449G, L452A, T470N, I472T, K484A, Q493A, Q498N, and P499G substitutions; or (103) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (104) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (105) (i) amino acids

444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (106) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (107) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (108) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q498N substitution, and (vi) a P499A substitution; or (109) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (110) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (111) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a

T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (112) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (113) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (114) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a T470N substitution, (iii) a I472T substitution, (iv) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (v) a Q493 A substitution, (vi) a Q498N substitution, and (vii) a P499A substitution; or (115) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481- 483 (N-G-V) replaced by a single G amino acid, (vi) a Q493 A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (116) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a Q493 A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (117) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G- V) replaced by a single G amino acid, (vi) a Q493A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (118) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a Q493A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (119) (i) amino acids 444-

447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a Q493 A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (120) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a Q493A substitution, (vii) a Q498N substitution, and (viii) a P499A substitution; or (121) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (122) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481- 483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (123) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (124) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (125) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (126) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a L452A substitution, (iii) a T470N substitution, (iv) a I472T substitution, (v) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vi) a K484A substitution, (vii) a Q493 A substitution, (viii) a Q498N substitution, and (ix) a P499A substitution; or (127) (i) amino acids 444-447 (K-V-G-G) replaced by a single P amino acid, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (128) (i) amino acids 444-447 (K-V-G-G) replaced by a single G amino acid, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (129) (i) amino acids 444-447 (K-V-G-G) replaced by a single S amino acid, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (130) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids P-G, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (131) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-G, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution; or (132) (i) amino acids 444-447 (K-V-G-G) replaced by the two amino acids G-S, (ii) a Y449G substitution, (iii) a L452A substitution, (iv) a T470N substitution, (v) a I472T substitution, (vi) amino acids 481-483 (N-G-V) replaced by a single G amino acid, (vii) a K484A substitution, (viii) a Q493 A substitution, (ix) a Q498N substitution, and (x) a P499A substitution.

Embodiment 60. The polypeptide of any one of Embodiments 56-59, comprising no further changes relative to amino acids 444-500 of SEQ ID NO.: 1 and/or relative to amino acids 328-531 of SEQ ID NO : 1.

Embodiment 61. The polypeptide of any one of Embodiments 56-60, comprising at most 15, at most 14, at most 13, at most 12, at most 11, at most 10, at most 9, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2, or at most 1 further change(s) relative to amino acids 444-500 of SEQ ID NO.: 1 and/or relative to amino acids 328-531 of SEQ ID NO.: 1, wherein each further change independently comprises: (i) a deletion of one, two, or three amino acids; (ii) an insertion of one, two, or three amino acids; (iii) a conservative substitution; or (iv) a non-conservative substitution.

Embodiment 62. The polypeptide of any one of Embodiments 56-61, comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to amino acids 444-500 of SEQ ID NO : 1.

Embodiment 63. The polypeptide of any one of Embodiments 56-62, comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to amino acids 328-531 of SEQ ID NO : 1.

Embodiment 64. The polypeptide of any one of Embodiments 56-63, comprising the amino acid sequence of:

(i) amino acids 453-469 of SEQ ID NO. : 1, or a variant sequence thereof having one, two, or three amino acid substitutions; and/or

(ii) amino acids 473-480 of SEQ ID NO. : 1, or a variant sequence thereof having one, two, or three amino acid substitutions; and/or

(iii) amino acids 485-492 of SEQ ID NO. : 1, or a variant sequence thereof having one, two, or three amino acid substitutions; and/or

(iv) amino acids 501-531 of SEQ ID NO. : 1, or a variant sequence thereof having one, two, or three amino acid substitutions; and/or

(v) amino acids 328-443 of SEQ ID NO. : 1, or a variant sequence thereof having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acids 328-443 of SEQ ID NO.: 1.

Embodiment 65. The polypeptide of any one of Embodiments 56-64, comprising any one or more of the following amino acids, wherein the numbering of amino acids is according to SEQ ID NO.: 1 : S443; N448; Y451; E471; Y501.

Embodiment 66. The polypeptide of any one of Embodiments 56-65, wherein:

(i) amino acids 498-500 (numbering according to SEQ ID NO.: 1) comprise N-A-T, N-P-T, or N-G-T, respectively; and/or

(ii) amino acids 470-472 (numbering according to SEQ ID NO. : 1) comprise N-X-T, wherein X is any amino acid, and is preferably E.

Embodiment 67. The polypeptide of any one of Embodiments 56-66, wherein the polypeptide further comprises: a signal peptide; a SpyTag; a linker; a stem-helix polypeptide; or any combination thereof.

Embodiment 68. The polypeptide of any one of Embodiments 56-66, wherein the polypeptide consists essentially, or consists of, the variant RBD.

Embodiment 69. The polypeptide of any one of Embodiments 56-67, comprising an amino acid sequence having at least 80%, at least 85%, or at least 90% identity to the amino acid sequence set forth in SEQ ID NO. : 1.

Embodiment 70. The polypeptide of any one of Embodiments 36-67 or the isolated polypeptide of Embodiment 68 or 69, which is a variant SARS-CoV-2 spike polypeptide.

Embodiment 71. The polypeptide Embodiment 70, further comprising: a signal peptide; a SpyTag; a linker; a stem-helix polypeptide; or any combination thereof. Embodiment 72. The polypeptide of Embodiment 71, comprising: a SpyTag; a linker; a stem-helix polypeptide; or any combination thereof.

Embodiment 73. An isolated polypeptide having a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than 11 amino acids, and comprising an amino acid sequence according to SEQ ID NO.:4.

Embodiment 74. The polypeptide of Embodiment 73, comprising the amino acid sequence set forth in SEQ ID NO.:5.

Embodiment 75. An isolated polypeptide having a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than about 10 amino acids, or no more than 6 amino acids, and comprising the amino acid sequence set forth in any one of SEQ ID NOs.:4-12 and 14.

Embodiment 76. An isolated polypeptide comprising or consisting of any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 continuous amino acid residues of SEQ ID NO.: 13, provided that the isolated peptide comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 continuous amino acids of SEQ ID NO.:5.

Embodiment 77. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO.: 14 or 701.

Embodiment 78. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO : 15.

Embodiment 79. An isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 16-19.

Embodiment 80. An isolated polypeptide comprising:

(i) the amino acid sequence according to any one of SEQ ID NOs.:4-14; and

(ii) the amino acid sequence set forth in SEQ ID NO.: 15.

Embodiment 81. An isolated polypeptide comprising:

(i) a plurality of any one or more of SEQ ID NOs. :4-14, wherein the plurality is homogenous, homotypic, heterogeneous, or heterotypic; and, disposed between and connecting a two of the plurality;

(ii) a linker sequence.

Embodiment 82. An isolated polypeptide comprising:

(i) two, three, four, five, or more copies of SEQ ID NO.: 16;

(ii) two three, four, five, or more copies of SEQ ID NO. : 17; and/or

(iii) one or more copy of SEQ ID NO. : 16 and one or more copy of SEQ ID NO.: 17.

Embodiment 83. An isolated polypeptide comprising SEQ ID NO.: 18 or SEQ ID NO. : 19, wherein X is 2 or more, 3 or more, 4 or more, or 5 or more. Embodiment 84. A fusion protein comprising (i) a SARS-CoV-2 spike polypeptide or a portion thereof and (ii) the polypeptide of any one of any one of Embodiments 73-83, wherein, optionally, the SARS-CoV-2 spike polypeptide comprises (i) one or more modification that promotes an open conformation of a receptor binding domain (RBD) of the spike polypeptide (e.g., D614G, K986P with V987P) and/or (ii) one or more modification that promotes stabilization of a SARS-CoV-2 spike polypeptide trimer.

Embodiment 85. The fusion protein of Embodiment 84, comprising (ii) a plurality of polypeptides each independently selected from a polypeptide of any one of Embodiments 73-83.

Embodiment 86. The fusion protein of Embodiment 84 or 85, wherein the polypeptide or polypeptides of (ii) are disposed in a S2 subunit of the SARS-CoV-2 spike polypeptide.

Embodiment 87. The fusion protein of any one of Embodiments 84-86, comprising SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein X is 2 or more, 3 or more, 4 or more, or 5 or more.

Embodiment 88. A fusion protein comprising (i) a SARS-CoV-2 receptor binding domain (RBD) and (ii) the polypeptide of any one of any one of Embodiments 73-83.

Embodiment 89. The fusion protein of Embodiment 88, wherein the RBD is not comprised in a betacoronavirus spike polypeptide.

Embodiment 90. The fusion protein of Embodiment 88 or 89, comprising a plurality of RBDs of (i) and/or a plurality of polypeptides of (ii).

Embodiment 91. The fusion protein of Embodiment 90, further comprising a linker disposed between and linking a two of the plurality of RBDs.

Embodiment 92. The fusion protein of Embodiment 91, wherein the linker comprises or consists of the polypeptide of any one of Embodiments 73-83.

Embodiment 93. The fusion protein of any one of Embodiments 90-92, wherein the plurality of RBDs is homotypic.

Embodiment 94. The fusion protein of any one of Embodiments 90-92, wherein the plurality of RBDs is heterotypic.

Embodiment 95. The fusion protein of any one of Embodiments 84-94, comprising: ([RBD]-Px-[RBD])y, wherein P is a polypeptide of any one of Embodiments 73-83, x is 1 or more, and y is one or more.

Embodiment 96. The fusion protein of Embodiment 95, wherein P comprises or consists of the amino acid sequence set forth in SEQ ID NO.: 16 or SEQ ID NO.: 17 or SEQ ID NO.:701.

Embodiment 97. The fusion protein of Embodiment 95 or 96, wherein P comprises or consists of the amino acid sequence set forth in SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein, optionally, X is 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.

Embodiment 98. The fusion protein of any one of Embodiments 84-97, wherein the spike polypeptide or a portion thereof comprises an RBD having, or wherein the RBD has, or wherein an RBD of the plurality has, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 9%, or 100% identity to SEQ ID NO.:2. Embodiment 99. The fusion protein of any one of Embodiments 84-98, which does not comprise SEQ ID NO.:2 or a naturally occurring variant thereof.

Embodiment 100. The fusion protein of any one of Embodiments 84-99, wherein the spike polypeptide or a portion thereof comprises in an RBD, or the RBD comprises, or an RBD of the plurality comprise, any one or more of (i)-(iv) :

(i) one or more amino acid substitution relative to a native RBD;

(ii) one or more amino acid deletion relative to a native RBD;

(iii) one or more amino acid insertion relative to a native RBD;

(iv) one or more non-native carbohydrate attachment site relative to a native

RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof.

Embodiment 101. The fusion protein of any one of Embodiments 88-100, wherein the RBD comprises, or is comprised in, the polypeptide of any one of Embodiments 56-72.

Embodiment 102. A polypeptide comprising a variant of a SARS-CoV-2 receptor binding domain (RBD), comprising any one or more of (i)-(iv) :

(i) one or more amino acid substitution relative to a native RBD;

(ii) one or more amino acid deletion relative to a native RBD;

(iii) one or more amino acid insertion relative to a native RBD;

(iv) one or more non-native carbohydrate attachment site relative to a native

RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof.

Embodiment 103. A polypeptide comprising a variant of a SARS-CoV-2 receptor binding domain (RBD), comprising any one or more of (i)-(iv):

(i) one or more amino acid substitution relative to a native RBD;

(ii) one or more amino acid deletion relative to a native RBD;

(iii) one or more amino acid insertion relative to a native RBD;

(iv) one or more non-native carbohydrate attachment site relative to a native

RBD, which optionally comprises a glycosylation site, wherein, optionally, the glycosylation site comprises a C-linked glycosylation site, a N-linked glycosylation site, an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof, wherein, optionally, the engineered variant SARS-CoV-2 spike polypeptide comprises (i) one or more modification that promotes an open conformation of a receptor binding domain (RBD) of the spike polypeptide (e.g., D614G, K986P with V987P) and/or (ii) one or more modification that promotes stabilization of a SARS-CoV-2 spike polypeptide trimer.

Embodiment 104. The polypeptide of Embodiment 103, wherein the polypeptide comprises:

(i) a SARS-CoV-2 spike polypeptide; (ii) a linker, wherein, optionally, the linker comprises a stem-helix polypeptide;

(iii) a peptide tag, where, optionally, the peptide tag comprises a SpyTag;

(iv) a further RBD;

(v) a stem-helix polypeptide; or

(vi) any combination of (i)-(v).

Embodiment 105. The fusion protein of any one of Embodiments 1-20 and 24-55, the polypeptide trimer of of Embodiment 21 or 22, or the isolated RBD polypeptide of Embodiment 23, which is, or which comprises, the polypeptide of any one of Embodiments 56-72.

Embodiment 106. The fusion protein of any one of Embodiments 1-20, 24-55, and 105, or the polypeptide trimer of Embodiment 21, 22, or 105, comprising the polypeptide of any one of Embodiments 73-83.

Embodiment 107. An isolated polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699.

Embodiment 108. An isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699.

Embodiment 109. An isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699 with the signal peptide removed, wherein, optionally, a linker sequence adjacent the signal peptide is also removed.

Embodiment 110. An isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the variation consists of a His-tag being replaced with a different peptide tag.

Embodiment 111. An isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the variation consists of the His-tag not being HHHHHHHH (/.< ., is a His-tag of a longer or a shorter length than HHHHHHHH).

Embodiment 112. An isolated polypeptide, wherein the polypeptide is any one of: Cov0001-Cov0070, Cov0091-Cov0098, CovOlOl, Cov0102, Cov0121-Cov0128, Cov0130, Cov0132, Cov0151-Cov0514, Cov0556-Cov0629, Cov0631, Cov0633, Cov0662-Cov0690, Cov0693, Cov0722-Cov0739.

Embodiment 113. An isolated polypeptide, wherein the polypeptide is: CovOOOl,

Cov0002, Cov0003, Cov0004, Cov0005, Cov0006, Cov0007, Cov0008, Cov0009, CovOOlO, CovOOl l, Cov0012, Cov0013, Cov0014, Cov0015, Cov0016, Cov0017, Cov0018, Cov0019, Cov0020, Cov0021, Cov0022, Cov0023, Cov0024, Cov0025, Cov0026, Cov0027, Cov0028, Cov0029, Cov0030, Cov0031, Cov0032, Cov0033, Cov0034, Cov0035, Cov0036, Cov0037, Cov0038, Cov0039, Cov0040, Cov0041, Cov0042, Cov0043, Cov0044, Cov0045, Cov0046, Cov0047, Cov0048, Cov0049, Cov0050, Cov0051, Cov0052, Cov0053, Cov0054, Cov0055, Cov0056, Cov0057, Cov0058, Cov0059, Cov0060, Cov0061, Cov0062, Cov0063, Cov0064, Cov0065, Cov0066, Cov0067, Cov0068, Cov0069, Cov0070, Cov0091, Cov0092, Cov0093, Cov0094, Cov0095, Cov0096, Cov0097, Cov0098, CovOlOl, Cov0102, Cov0121, Cov0122,

Cov0123, Cov0124, Cov0125, Cov0126, Cov0127, Cov0128, Cov0130, Cov0132, Cov0151,

Cov0152, Cov0153, Cov0154, Cov0155, Cov0156, Cov0157, Cov0158, Cov0159, Cov0160,

Cov0161, Cov0162, Cov0163, Cov0164, Cov0165, Cov0166, Cov0167, Cov0168, Cov0169,

Cov0170, Cov0171, Cov0172, Cov0173, Cov0174, Cov0175, Cov0176, Cov0177, Cov0178,

Cov0179, Cov0180, Cov0181, Cov0182, Cov0183, Cov0184, Cov0185, Cov0186, Cov0187,

Cov0188, Cov0189, Cov0190, Cov0191, Cov0192, Cov0193, Cov0194, Cov0195, Cov0196,

Cov0197, Cov0198, Cov0199, Cov0200, Cov0201, Cov0202, Cov0203, Cov0204, Cov0205,

Cov0206, Cov0207, Cov0208, Cov0209, Cov0210, Cov0211, Cov0212, Cov0213, Cov0214,

Cov0215, Cov0216, Cov0217, Cov0218, Cov0219, Cov0220, Cov0221, Cov0222, Cov0223,

Cov0224, Cov0225, Cov0226, Cov0227, Cov0228, Cov0229, Cov0230, Cov0231, Cov0232,

Cov0233, Cov0239, Cov0240, Cov0241, Cov0242, Cov0243, Cov0244, Cov0245, Cov0246,

Cov0247, Cov0248, Cov0249, Cov0250, Cov0592, Cov0593, Cov0594, Cov0595, Cov0596,

Cov0597, Cov0598, Cov0599, Cov0600, Cov0601, Cov0602, Cov0603, Cov0604, Cov0605,

Cov0606, Cov0607, Cov0608, Cov0609, Cov0610, Cov0611, Cov0612, Cov0613, Cov0614,

Cov0615, Cov0616, Cov0617, Cov0618, Cov0619, Cov0620, Cov0621, Cov0622, Cov0623,

Cov0624, Cov0625, Cov0626, Cov0627, Cov0628, Cov0629, Cov0631, Cov0633, Cov0662,

Cov0663, Cov0664, Cov0665, Cov0666, Cov0667, Cov0668, Cov0669, Cov0670, Cov0671,

Cov0672, Cov0673, Cov0674, Cov0675, Cov0676, Cov0677, Cov0678, Cov0679, Cov0680,

Cov0681, Cov0682, Cov0683, Cov0684, Cov0685, Cov0686, Cov0687 Cov0688 Cov0689,

Cov0690, Cov0693, Cov0722, Cov0723, Cov0724, Cov0725, Cov0726 Cov0727 Cov0728,

Cov0729, Cov0730, Cov0731, Cov0732, Cov0733, Cov0734, Cov0735 Cov0736 Cov0737,

Cov0738, Cov0739, Cov0556, Cov0557, Cov0558, Cov0559, Cov0560 Cov056L Cov0562,

Cov0563, Cov0564, Cov0565, Cov0566, Cov0567, Cov0568, Cov0569 Cov0570 Cov0571,

Cov0572, Cov0573, Cov0574, Cov0575, Cov0576, Cov0577, Cov0578 Cov0579 Cov0580,

Cov0581, Cov0582, Cov0583, Cov0584, Cov0585, Cov0586, Cov0587 Cov0588, Cov0590,

Cov0591, Cov0592, Cov0251, Cov0252, Cov0253, Cov0254, Cov0255 Cov0256 Cov0257,

Cov0258, Cov0259, Cov0260, Cov0261, Cov0262, Cov0263, Cov0264 Cov0265 Cov0266,

Cov0267, Cov0268, Cov0269, Cov0270, Cov0271, Cov0272, Cov0273 Cov0274 Cov0275,

Cov0276, Cov0277, Cov0278, Cov0279, Cov0280, Cov0281, Cov0282 Cov0283 Cov0284,

Cov0285, Cov0286, Cov0287, Cov0288, Cov0289, Cov0290, Cov029L Cov0292 Cov0293,

Cov0294, Cov0295, Cov0296, Cov0297, Cov0298, Cov0299, Cov0300 Cov030L Cov0302,

Cov0303, Cov0304, Cov0305, Cov0306, Cov0307, Cov0308, Cov0309 Cov0310 Cov0311,

Cov0312, Cov0313, Cov0314, Cov0315, Cov0316, Cov0317, Cov0318 Cov0319 Cov0320,

Cov0321, Cov0322, Cov0323, Cov0324, Cov0325, Cov0326, Cov0327 Cov0328 Cov0329,

Cov0330, Cov0331, Cov0332, Cov0333, Cov0334, Cov0335, Cov0336 Cov0337 Cov0338,

Cov0339, Cov0340, Cov0341, Cov0342, Cov0343, Cov0344, Cov0345 Cov0346 Cov0347,

Cov0348, Cov0349, Cov0350, Cov0351, Cov0352, Cov0353, Cov0354 Cov0355 Cov0356,

Cov0357, Cov0358, Cov0359, Cov0360, Cov0361, Cov0362, Cov0363 Cov0364 Cov0365,

Cov0366, Cov0367, Cov0368, Cov0369, Cov0370, Cov0371, Cov0372 Cov0373 Cov0374, Cov0375, Cov0376, Cov0377, Cov0378, Cov0379, Cov0380, Cov0381, Cov0382, Cov0383, Cov0384, Cov0385, Cov0386, Cov0387, Cov0388, Cov0389, Cov0390, Cov0391, Cov0392, Cov0393, Cov0394, Cov0395, Cov0396, Cov0397, Cov0398, Cov0399, Cov0400, Cov0401, Cov0402, Cov0403, Cov0404, Cov0405, Cov0406, Cov0407, Cov0408, Cov0409, Cov0410, Cov0411, Cov0412, Cov0413, Cov0414, Cov0415, Cov0416, Cov0417, Cov0418, Cov0419, Cov0420, Cov0421, Cov0422, Cov0423, Cov0424, Cov0425, Cov0426, Cov0427, Cov0428, Cov0429, Cov0430, Cov0431, Cov0432, Cov0433, Cov0434, Cov0435, Cov0436, Cov0437, Cov0438, Cov0439, Cov0440, Cov0441, Cov0442, Cov0443, Cov0444, Cov0445, Cov0446, Cov0447, Cov0448, Cov0449, Cov0450, Cov0451, Cov0452, Cov0453, Cov0454, Cov0455, Cov0456, Cov0457, Cov0458, Cov0459, Cov0460, Cov0461, Cov0462, Cov0463, Cov0464, Cov0625, Cov0466, Cov0467, Cov0468, Cov0469, Cov0470, Cov0471, Cov0472, Cov0473, Cov0474, Cov0475, Cov0476, Cov0477, Cov0478, Cov0479, Cov0480, Cov0481, Cov0482, Cov0483, Cov0484, Cov0485, Cov0486, Cov0487, Cov0488, Cov0489, Cov0490, Cov0491, Cov0492, Cov0493, Cov0494, Cov0495, Cov0496, Cov0497, Cov0498, Cov0499, Cov0500, Cov0501, Cov0502, Cov0503, Cov0504, Cov0505, Cov0506, Cov0507, Cov0508, Cov0509, Cov0510, Cov0511, Cov0512, Cov0513, Cov0514, Cov0746, Cov0747, Cov0748, Cov0749, Cov0750, Cov0751, Cov0758, Cov0759, Cov0761, or Cov0762, or any of the foregoing with the signal peptide removed, with the peptide tag removed, with a different signal peptide, or with a different peptide tag.

Embodiment 114. A composition comprising:

(1) (i) the fusion protein of any one of Embodiments 1-20, 24-55, 84-101, and 105-106, (ii) the polypeptide trimer of Embodiment 21 or 22, (iii) the isolated RBD polypeptide of Embodiment 23, (iv) the polypeptide of any one of Embodiments 56-72, (v) the engineered variant RBD of Embodiment 102, (vi) the polypeptide of any one of Embodiments 73-83, (vii) the polypeptide of 103 or 104; and/or (viii) the polypeptide of any one of Embodiments 107-113; and

(2) a pharmaceutically acceptable carrier, excipient, or diluent.

Embodiment 115. A composition comprising:

(1) (i) a plurality of the fusion protein of any one of Embodiments 1-20, 24- 55, 84-101, and 105-106, (ii) a plurality of the polypeptide trimer of Embodiment 21 or 22, (iii) a plurality of the isolated RBD polypeptide of Embodiment 23, (iv) a plurality of the polypeptide of any one of Embodiments 56-72, (v) a plurality of the engineered variant RBD of Embodiment 102, (vi) a plurality of the polypeptide of any one of Embodiments 73-83, (vii) a plurality of the polypeptide of 103 or 104, and/or (viii) a plurality of the polypeptide of any one of Embodiments 107-113; and

(2) a pharmaceutically acceptable carrier, excipient, or diluent.

Embodiment 116. The composition of Embodiment 115, wherein the plurality of (i), the plurality of (ii), the plurality of (iii), the plurality of (iv), the plurality of (v), the plurality of (vi), and/or the plurality of (vii) is homotypic or heterotypic. Embodiment 117. A composition comprising a substrate and, disposed on an outer surface of the substrate: (i) a plurality of the fusion protein of any one of Embodiments 1-20, 24- 55, 84-101, and 105-106, (ii) a plurality of the polypeptide trimer of Embodiment 21 or 22, (iii) a plurality of the isolated RBD polypeptide of Embodiment 23, (iv) a plurality of the polypeptide of any one of Embodiments 56-72, (v) a plurality of the engineered variant RBD of Embodiment 102, (vi) a plurality of the polypeptide of any one of Embodiments 73-83, (vii) a plurality of the polypeptide of 103 or 104, and/or (viii) a plurality of the polypeptide of any one of Embodiments 107-113.

Embodiment 118. The composition of Embodiment 117, wherein the plurality of fusion proteins, the plurality of polypeptide trimers, the plurality of isolated RBD polypeptides, the plurality of engineered variant RBDs, and/or the plurality of polypeptides is homotypic or heterotypic.

Embodiment 119. A composition comprising a substrate and, disposed on an outer surface of the substrate: (i) the fusion protein of any one of Embodiments 1-20, 24-55, 84-101, and 105-106, (ii) the polypeptide trimer of Embodiment 21 or 22, (iii) the isolated RBD polypeptide of Embodiment 23, (iv) the polypeptide of any one of Embodiments 56-72; (v) the engineered variant RBD of Embodiment 102; (vi) the polypeptide of any one of Embodiments 73-83; (vii) the polypeptide of 103 or 104, and/or (viii) the polypeptide of any one of Embodiments 107-113.

Embodiment 120. The composition of any one of Embodiments 117-119, wherein the substrate comprises a nanoparticle or a virus-like particle.

Embodiment 121. The composition of any one of Embodiments 117-120, wherein the substrate further comprises a SpyCatcher polypeptide disposed on the outer surface of the substrate, wherein the fusion protein, polypeptide trimer, or polypeptide comprises a SpyTag coupled to the SpyCatcher polypeptide.

Embodiment 122. A cocktail comprising a plurality of composition of any one of Embodiments 114-121.

Embodiment 123. An isolated polynucleotide encoding: (i) the fusion protein of any one of Embodiments 1-20, 24-55, 84-101, and 105-106, (ii) the polypeptide trimer of Embodiment 21 or 22, (iii) the isolated RBD polypeptide of Embodiment 23, (iv) the polypeptide of any one of Embodiments 56-72, (v) the engineered variant RBD of Embodiment 102, (vi) the polypeptide of any one of Embodiments 73-83, (vii) the polypeptide of 103 or 104, and/or (viii) the polypeptide of any one of Embodiments 107-113.

Embodiment 124. An isolated polynucleotide encoding the polypeptide of any one of Embodiments 107-113.

Embodiment 125. The polynucleotide of Embodiment 124, which comprises ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA).

Embodiment 126. A vector comprising the polynucleotide of Embodiment 124 or 125.

Embodiment 127. The vector of Embodiment 126, which is a live vector. Embodiment 128. A host cell comprising the polynucleotide of any one of Embodiments 124-125 and/or the vector Embodiment 126 or 127.

Embodiment 129. A composition comprising:

(i) the polynucleotide of Embodiment 124 or 125; and/or

(ii) the vector of Embodiment 126 or 127; and/or

(iii) the host cell of Embodiment 128, and a pharmaceutically acceptable carrier, excipient, or diluent.

Embodiment la. A fusion protein comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second coronavirus RBD polypeptide, wherein, optionally, the first and/or the second RBD polypeptide is from a betacoronavirus, and wherein, further optionally, the first and the second RBD polypeptide are from different betacoronaviruses.

Embodiment 2a. The fusion protein of Embodiment la, comprising the first RBD polypeptide, the second RBD polypeptide, and a third coronavirus (e.g. betacoronavirus) RBD polypeptide, the first RBD polypeptide being linked to the second RBD polypeptide by a linker (1), and the second RBD polypeptide being linked to the third RBD polypeptide by a linker (2).

Embodiment 3 a. The fusion protein of Embodiment 2a, wherein the linker (1) and the linker (2) comprise, consist essentially of, or consist of the same amino acid sequence.

Embodiment 4a. The fusion protein of Embodiment 2a, wherein the linker (1) and the linker (2) have different amino acid sequences from one another.

Embodiment 5a. The fusion protein of Embodiment any one of Embodiments la-4a, wherein the linker, the linker (1), and/or the linker (2) comprises a stem-helix polypeptide.

Embodiment 6a. The fusion protein of any one of Embodiments 2a-5a, wherein the linker (1) and the linker (2) each comprise a stem-helix polypeptide.

Embodiment 7a. The fusion protein of any one of Embodiments la-6a, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2 Wuhan-Hu- 1; SARS- CoV-2 Beta variant (also called B.1.351); SARS-CoV-2 Delta variant (also called B.1.617.2); and SARS-CoV-2 Omicron variant (also called B.1.1.529).

Embodiment 8a. The fusion protein of any one of Embodiments la-7a, comprising an RBD polypeptide that comprises the amino acid sequence of any one of SEQ ID NOs.:2 and 722-729.

Embodiment 9a. The fusion protein of any one of Embodiments la-8a, comprising an RBD polypeptide that consists of the amino acid sequence of any one of SEQ ID NOs.:2 and 722-729.

Embodiment 10a. The fusion protein of any one of Embodiments la-9a, comprising an RBD polypeptide from any one or more of the following: PANG/GX; MP789; RaTG13; and RsSHC014.

Embodiment I la. The fusion protein of any one of Embodiments la- 10a, comprising an RBD polypeptide that comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:730-737. Embodiment 12a. The fusion protein of any one of Embodiments la-1 la, comprising three RBD polypeptides, wherein the three RBD polypeptides are from: MP789; RaTG13; and RsSHC014.

Embodiment 13 a. The fusion protein of any one of Embodiments la- 12a, comprising three RBD polypeptides, wherein the three RBD polypeptides comprise the amino acid sequence set forth in: (i) SEQ ID NO.:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731, respectively.

Embodiment 14a. The fusion protein of any one of Embodiments la- 13 a, comprising three RBD polypeptides, wherein the three RBD polypeptides consist of the amino acid sequence set forth in: (i) SEQ ID NO.:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731, respectively.

Embodiment 15a. The fusion protein of any one of Embodiments 5a-14a, wherein the stem-helix polypeptide comprises or consists of the amino acid sequence according to any one of SEQ ID NOs.:701, 4-19, 46, and 57-59.

Embodiment 16a. The fusion protein of any one of Embodiments 5a-15a, wherein the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 17a. The fusion protein of any one of Embodiments 2a-16a, further comprising a fourth coronavirus (e.g. betacoronavirus) RBD polypeptide and a fifth coronavirus (e.g. betacoronavirus) RBD polypeptide, wherein the fourth RBD polypeptide is linked to the third RBD polypeptide by a linker (3) and the fifth RBD polypeptide is linked to the fourth RBD polypeptide by a linker (4).

Embodiment 18a. The fusion protein of Embodiment 17a, wherein two, three, or all four of the linkers (l)-(4) comprise, consist essentially of, or consist of the same amino acid sequence.

Embodiment 19a. The fusion protein of Embodiment 17a or 18a, wherein the two or more of the linkers (l)-(4) have different amino acid sequences from one another.

Embodiment 20a. The fusion protein of any one of Embodiments 17a- 19a, wherein one or more of the linkers (l)-(4) comprises or consists of a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 21a. The fusion protein of Embodiment 20a, wherein each of the peptide linkers (l)-(4) comprises or consists of a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 22a. The fusion protein of any one of Embodiments 17a-21a, comprising an RBD polypeptide from each of: (i) SARS-CoV-2 Beta variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (ii) SARS-CoV-2 Beta variant; SARS-CoV-2 Omicron variant; MP789; RaTG13; and RsSHC014; or (iii) SARS-CoV-2 Omicron variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (iv) SARS-CoV-2 Delta variant; SARS-CoV-2 Omicron variant; MP789; RaTG13; and RsSHC014.

Embodiment 23a. The fusion protein of any one of Embodiments 17a-22a, comprising five RBD polypeptides, wherein the five RBD polypeptides comprise the amino acid sequence set forth in SEQ ID NO.: (i) 725, 731, 733, 735, and 737, respectively; or (ii) 725, 731, 729, 735, and 737, respectively; or (iii) 729, 731, 733, 735, and 737, respectively; or (iv) 727, 731, 729, 735, and 737, respectively.

Embodiment 24a. The fusion protein of Embodiment 23a, wherein: (1) the RBD polypeptide comprising SEQ ID NO.:725 comprises or consists of SEQ ID NO.:724; (2) the RBD polypeptide comprising SEQ ID NO.:727 comprises or consists of SEQ ID NO.:726; (3) the RBD polypeptide comprising SEQ ID NO.:729 comprises or consists of SEQ ID NO.:728; (4) the RBD polypeptide comprising SEQ ID NO.:731 comprises or consists of SEQ ID NO.:730; (5) the RBD polypeptide comprising SEQ ID NO.:733 comprises or consists of SEQ ID NO.:732; (6) the RBD polypeptide comprising SEQ ID NO.:735 comprises or consists of SEQ ID NO.:734; and/or (7) the RBD polypeptide comprising SEQ ID NO.:737 comprises or consists of SEQ ID NO. :736.

Embodiment 25a. The fusion protein of any one of Embodiments 17a-24a, comprising five RBD polypeptides, wherein the five RBD polypeptides comprise or consist of the amino acid sequence set forth in SEQ ID NO.: (i) 724, 732, 734, 736, and 730, respectively; or (ii) 724, 728, 734, 736, and 730, respectively; or (iii) 728, 732, 734, 736, and 730, respectively; or (iv) 726, 728, 735, 736, and 730, respectively.

Embodiment 26a. The fusion protein of any one of Embodiments 17a-25a, comprising, in N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide from SARS-CoV-2 Beta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (ii) an RBD polypeptide from SARS-CoV-2 Beta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from SARS-CoV-2 Omicron variant; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (iii) an RBD polypeptide from SARS- CoV-2 Omicron variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (iv) an RBD polypeptide from SARS-CoV-2 Delta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from SARS-CoV-2 Omicron variant; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13.

Embodiment 27a. The fusion protein of any one of Embodiments 17a-26a, comprising, in N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide comprising SEQ ID NO.:725; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:733; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or (ii) an RBD polypeptide comprising SEQ ID NO.:725; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or (iii) an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:733; an RBD polypeptide from comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or (iv) an RBD polypeptide comprising SEQ ID NO.:727; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737.

Embodiment 28a. The fusion protein of any one of Embodiments 17a-27a, comprising, in N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide comprising or consisting of SEQ ID NO.:724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (ii) an RBD polypeptide comprising or consisting of SEQ ID NO.:724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (iii) an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (iv) an RBD polypeptide comprising or consisting of SEQ ID NO.:726; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736.

Embodiment 29a. The fusion protein of any one of Embodiments 26a-28a, comprising the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) disposed between the first and second RBD polypeptides, between the second and third RBD polypeptides, between the third and fourth RBD polypeptides, and between the fourth and fifth RBD polypeptides, wherein the first RBD polypeptide is the N-terminal RBD polypeptide of the fusion protein and the fifth RBD polypeptide is the C-terminal RBD polypeptide of the fusion protein.

Embodiment 30a. The fusion protein of any one of Embodiments la-29a, further comprising a peptide tag, wherein, optionally, the peptide tag is disposed at a C-terminus of the fusion protein, preferably fused to a C-terminus of a C-terminal RBD polypeptide of the fusion protein.

Embodiment 31a. The fusion protein of Embodiment 30a, wherein the peptide tag is disposed at the C-terminus of the fusion protein.

Embodiment 32a. The fusion protein of Embodiment 30a or 3 la, wherein the peptide tag comprises a SpyTag and/or a His tag. Embodiment 33a. The fusion protein of any one of Embodiments la-32a, wherein the fusion protein does not comprise a peptide tag disposed at a C-terminus of the fusion protein, optionally at the C-terminus of the C-terminal RBD polypeptide.

Embodiment 34a. The fusion protein of any one of Embodiments la-33a, wherein the fusion protein does not comprise a His tag disposed at a C-terminus of the fusion protein.

Embodiment 35a. The fusion protein of any one of Embodiments la-34a, comprising a signal peptide, wherein, optionally, the signal peptide is disposed at a N-terminus of the fusion protein, and is preferably fused to the N-terminus of the N-terminal RBD polypeptide.

Embodiment 36a. The fusion protein of Embodiment 35a, wherein the signal peptide comprises or consists of the amino acid sequence MAPLLLLLPLL WAGALA (SEQ ID NO.:706), the amino acid sequence MNTQILVFALIAIIPTNADKI (SEQ ID NO.:705), the amino acid sequence MFVFLVLLPLVS (SEQ ID NO.:707) or the amino acid sequence MFVFLVLLPLVSS (SEQ ID NO.:708), and preferably consists of SEQ ID NO.:706.

Embodiment 37a. The fusion protein of any one of Embodiments la-36a, which, when administered to a mammal (e.g. a mouse, such as a female BALB/c mouse, optionally twice via intramuscular injection, wherein the two administrations are 20 or 21 days apart), elicits neutralizing antibodies against any one or more of, and optionally all of: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 B.1.351; SARS-CoV-2 B.1.617.2; SARS-CoV-2 B.1.1.529; and SARS-CoV-1, wherein, optionally, neutralizing antibodies are assessed using sera collected from the mammal 14 days post-second immunization, in a Vesicular Stomatitis Virus/Coronavirus Pseudovirus system, optionally using Vero-E6 TMPRSS cells.

Embodiment 38a. The fusion protein of any one of Embodiments la-37a, which, when administered to a mammal that had previously received a mRNA SARS-CoV-2 spike protein vaccine, elicits: (i) neutralizing antibodies against any one or more of, and optionally all of: SARS-CoV-2 Wuhan-Hu- 1; SARS-CoV-2 BAI; SARS-CoV-2 BA2; SARS-CoV-2 BA5; and SARS-CoV-1, optionally to a degree that is greater than is elicited by a third administration of the mRNA SARS-CoV-2 spike protein vaccine, wherein, optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered once via intramuscular injection and/or at Day 60 and the mammal had received the mRNA spike protein vaccine at Day 0 and again at Day 14; and/or neutralizing antibodies are assessed using sera collected from the mammal at Day 67 in a Vesicular Stomatitis Virus/Coronavirus Pseudovirus system; and/or (ii) antibodies that bind to an RBD from any one or more of: S ARS-Cov2 -Wuhan-Hu- 1 (Wu); - B.1.351 (Beta); SARS-Covl; Wiv-1; RatG13; PangGD; PANG/GX; Anlogl l2; YN2013; SX2001; SC2018; ZC45; BTK72; and BGR2008, optionally to a degree that is greater than is elicited by a third administration of the mRNA SARS-CoV-2 spike protein vaccine, wherein, optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered once via intramuscular injection and/or at Day 60 and the mammal had received the mRNA spike protein vaccine at Day 0 and again at Day 14; and/or binding antibodies are assessed by ELISA using sera collected from the mammal at Day 67. Embodiment 39a. The fusion protein of any one of Embodiments la-38a, which is capable of being bound by any one or more of the following antibodies: S2P6; S2E12; S2K146; S2X259; S309; and S2H97, or an antigen-binding fragment thereof, wherein, optionally, the antigen-binding fragment comprises a Fab that comprises the VH and VL of the antibody and further comprises an IgGl CHI and either an IgG kappa CL or an IgG lambda CL.

Embodiment 40a. An isolated polypeptide comprising: (i) SEQ ID NO.: 218;

(ii) SEQ ID NO.:218 without SEQ ID NO.:706; (iii) SEQ ID NO.:712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:715 without SEQ ID NO.:706; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) SEQ ID NO.:717 without SEQ ID NO.:706; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix)SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

Embodiment 41a. The polypeptide of Embodiment 40a, consisting of: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.:218 without SEQ ID NO.:706; (iii) SEQ ID NO.:712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:715 without SEQ ID NO.:706; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) SEQ ID NO.:717 without SEQ ID NO.:706; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

Embodiment 42a. A fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii): (i) one or more peptide tag; (ii) one or more stem-helix polypeptide, wherein, optionally, the one or more stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 43a. The fusion protein of Embodiment 42a, comprising: (a) a peptide tag linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises a N-terminus of the RBD polypeptide; (b) a peptide tag linked or fused to a second end of the RBD polypeptide, wherein the second end optionally comprises a C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide; (d) a stem-helix polypeptide linked or fused to a second end of the RBD polypeptide, wherein the first end optionally comprises the C-terminus of the RBD polypeptide; or (e) any combination of (a)-(d).

Embodiment 44a. The fusion protein of Embodiment 42a or 43 a, wherein the peptide tag comprises a His tag, wherein, optionally, the His tag comprises or consists of the amino acid sequence HHHHHHHH (SEQ ID NO.:704).

Embodiment 45a. The fusion protein of Embodiment 44a, wherein the peptide tag comprises a SpyTag. Embodiment 46a. The fusion protein of any one of Embodiments 42a-45a, comprising a linker disposed between and linking (1) the RBD polypeptide and (2) a peptide tag of the one or more peptide tag.

Embodiment 47a. The fusion protein of Embodiment 46a, comprising two or more linkers that comprise the same amino acid sequence as one another.

Embodiment 48a. The fusion protein of Embodiment 46a or 47a, wherein the linker, or one or more of the two or more linkers, comprises or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.:702).

Embodiment 49a. The fusion protein of any one of Embodiments 42a-48a, comprising a linker disposed between and connecting (1) the RBD polypeptide and (2) a one of the one or more stem-helix polypeptide.

Embodiment 50a. The fusion protein of any one of Embodiments 42a-49a, comprising a structure

PT1— LI— RBD— L2— SHP— PT2, wherein: PT1 and PT2 are each an optional peptide tag; LI and L2 are each an optional linker; RBD is an RBD polypeptide; and SHP is a stem-helix polypeptide.

Embodiment 51a. The fusion protein of Embodiment 50a, wherein: PT1, if present, has the amino acid sequence of SEQ ID NO.:700; LI, if present, has the amino acid sequence of SEQ ID NO.:702; L2 is absent or, if present, has the amino acid sequence GSG, GPP, GS, or PGP; SHP has the amino acid sequence of SEQ ID NO.:701; and PT2, if present, has the amino acid sequence of SEQ ID NO.: 704.

Embodiment 52a. The fusion protein of Embodiment 51a, wherein: (i) PT1, LI, SHP, L2, and PT2 are present; (ii) PT1, LI, SHP, and PT2 are present; (iii) L2, SHP, and PT2 are present; (iv) SHP and PT2 are present; (v) SHP and optionally L2 are present or (vi) L2, SHP, and and PT2 are present.

Embodiment 53a. The fusion protein of any one of Embodiments 42a-52a, comprising: (i) a signal peptide fused or linked to a N-terminus of the RBD polypeptide; and (ii) a stem-helix polypeptide fused or linked to a C-terminus of the RBD polypeptide.

Embodiment 54a. The fusion protein of Embodiment 53a, comprising, in N-terminal to C-terminal direction, a signal peptide (optionally MAPLLLLLPLLWAGALA (SEQ ID NO.:706)), an optional linker, an RBD, an optional linker, and a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 55a. The fusion protein of any one of Embodiments 42a-54a, wherein the RBD polypeptide is from any one of: SARS-CoV-2-Wuhan-Hu-l; SARS-CoV-2 Beta variant; SARS-CoV-2 Omicron variant; SARS-CoV-2 Delta variant; PANG_GX; MP789; RatG13; RsSCH014; RmYN02; BM48-31/BGR/2008; PC4-241; Rfl/2004; and Rp/Shaanxi 2011. Embodiment 56a. The fusion protein of any one of Embodiments 42a-55a, wherein the RBD polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:724-737.

Embodiment 57a. An isolated polypeptide comprising a structure:

RBD1 - LI - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 wherein RBD1, RBD2, RBD3, RBD4, and RBD5 are each a different RBD polypeptide selected from the group consisting of: SARS-CoV-2 Beta variant; SARS-CoV-2 Omicron variant; SARS-CoV-2 Delta variant; PANG/GX; MP789; RaTG13; and RsSHC014, wherein RBD1 is the N-terminal RBD polypeptide of the fusion protein and/or RBD5 is the C-terminal RBD polypeptide of the fusion protein, and wherein LI, L2, L3, and L4 are each a linker.

Embodiment 58a. The isolated polypeptide of Embodiment 57a, wherein one or more of LI, L2, L3, and L4 comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59, and wherein, optionally, LI, L2, L3, and L4 each independently comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59.

Embodiment 59a. The isolated polypeptide of Embodiment 57a or 58a, wherein LI, L2, L3, and L4 are identical, and LI, L2, L3, and L4 are preferably SEQ ID NO.:701.

Embodiment 60a. The isolated polypeptide of any one of Embodiments 57a-59a, wherein RBD1, RBD2, RBD3, RBD4, and RBD5 are independently selected from the group consisting of: (i) SEQ ID NO.: 724 or 725; (ii) SEQ ID NO.: 726 or 727; (iii) SEQ ID NO.: 728 or 729; (iv) SEQ ID NO.: 730 or 731; (v) SEQ ID NO.: 732 or 733; (vi) SEQ ID NO.: 734 or 735; and (vii) SEQ ID NO.: 736 or 737, preferably wherein five of (i)-(vii) are present.

Embodiment 61a. The isolated polypeptide of any one of Embodiments 57a-60a, wherein RBD1, RBD2, RBD3, RBD4, and RBD5 are from: (i) SARS-CoV-2 Beta variant; RsSHC014; PANG/GX; MP789; and RaTG13, respectively; or (ii) SARS-CoV-2 Beta variant; RsSHC014; SARS-CoV-2 Omicron variant; MP789; and RaTG13, respectively; or (iii) SARS- CoV-2 Omicron variant; RsSHC014; PANG/GX; MP789; and RaTG13, respectively; or (iv) SARS-CoV-2 Delta variant; RsSHC014; SARS-CoV-2 Omicron variant; MP789; RaTG13, respectively.

Embodiment 62a. The isolated polypeptide of any one of Embodiments 57a-61a, wherein RBD1, RBD2, RBD3, RBD4, and RBD5 comprise the amino acid sequence set forth in SEQ ID NO.: (i) 725, 731, 733, 735, and 737, respectively; or (ii) 725, 731, 729, 735, and 737, respectively; or (iii) 729, 731, 733, 735, and 737, respectively; or (iv) 727, 731, 729, 735, and 737, respectively, wherein, optionally, RBD1, RBD2, RBD3, RBD4, and RBD5 comprise or consists of the amino acid sequence set forth in SEQ ID NO.: (1) 724, 730, 732, 734, and 736, respectively; or (2) 724, 730, 728, 734, and 736, respectively; or (3) 728, 730, 732, 734, and 736, respectively; or (4) 726, 730, 728, 734, and 736, respectively.

Embodiment 63a. An isolated polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59. Embodiment 64a. An isolated polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO.:701, the amino acid sequence of SEQ ID NO.:14, the amino acid sequence of SEQ ID NO.: 15, the amino acid sequence of SEQ ID NO.: 16, or the amino acid sequence of SEQ ID NO.: 17.

Embodiment 65a. An isolated polynucleotide encoding the fusion protein of any one of Embodiments la-39a and 42a-56a, or the polypeptide of any one of Embodiments 40a, 41a, and 57a-64a.

Embodiment 66a. The polynucleotide of Embodiment 65a, comprising ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA).

Embodiment 67a. The polynucleotide of Embodiment 65a or 66a, comprising mRNA.

Embodiment 68a. A vector comprising the polynucleotide of any one of Embodiments 65a-67a, wherein, optionally, the vector is a live vector.

Embodiment 69a. A host cell comprising the polynucleotide of any one of Embodiments 65a-67a and/or the vector of Embodiment 68a.

Embodiment 70a. A composition comprising: (i) the fusion protein of any one of Embodiments la-39a and 42a-56a; and/or (ii) the polypeptide of any one of Embodiments 40a, 41a, and 57a-64a; and/or (i) the polynucleotide of any one of Embodiments 65a-67a; and/or (ii) the vector of Embodiment 68a; and/or (iii) the host cell of Embodiment 69a, and a pharmaceutically acceptable carrier, excipient, or diluent.

Embodiment 71a. The composition of Embodiment 70a, further comprising an adjuvant.

Embodiment 72a. A method for treating, or for inducing an immune response against, a coronavirus infection in a subject, the method comprising administering to the subject an effective amount of: the fusion protein of any one of Embodiments la-39a and 42a-56a; the polypeptide of any one of Embodiments 40a, 41a, and 57a-64a; the polynucleotide of any one of Embodiments 65a-67a; the vector of Embodiment 68a; the host cell of Embodiment 69a; or the composition of Embodiment 70a or 71a, wherein, optionally, the coronavirus infection comprises a sarbecovirus infection.

Embodiment 73 a. The fusion protein of any one of Embodiments la-39a and 42a- 56a; the polypeptide of any one of Embodiments 40a, 41a, and 57a-64a; the polynucleotide of any one of Embodiments 65a-67a; the vector of Embodiment 68a; the host cell of Embodiment 69a; or the composition of Embodiment 70a or 71a, for use in treating or inducing an immune response against a coronavirus infection in a subject, wherein, optionally, the coronavirus infection comprises a sarbecovirus infection.

Embodiment 74a. The fusion protein of any one of Embodiments la-39a and 42a- 56a; the polypeptide of any one of Embodiments 40a, 41a, and 57a-64a; the polynucleotide of any one of Embodiments 65a-67a; the vector of Embodiment 68a; the host cell of Embodiment 69a; or the composition of Embodiment 70a or 71a, for use in the manufacture of a medicament for treating or inducing an immune response against a coronavirus infection in a subject, wherein, optionally, the coronavirus infection comprises a sarbecovirus infection.

Embodiment 75a. The method of Embodiment 72a, or the fusion protein, polypeptide, polynucleotide, vector, host cell, or composition for use of Embodiment 73 a or 74a, wherein: (i) treating comprises pre-exposure prophylaxis; (ii) treating comprises post-exposure prophylaxis; (iii) the subject has previously received one or more, two or more, three or more, four or more, or five or more doses of a coronavirus vaccine composition, wherein, optionally: (1) the subject has received two or more different coronavirus vaccine compositions; (2) the coronavirus vaccine composition comprises: at least a portion of a SARS-CoV-2 spike protein (e.g., a RBD polypeptide or a full spike protein), a polynucleotide (e.g. mRNA) encoding at least a portion of a SARS-CoV-2 spike protein (e.g. encoding an RBD polypeptide, or encoding a full spike proteins), or a live, attenuated, or inactivated e.g. heat-killed or inactivated with P- propiolactone) virus; and/or (3) the coronavirus vaccine composition comprises Comirnaty (Pfizer-BioNTech), Spikevax (Modema), Janssen coronavirus vaccine (Johnson & Johnson), Nuvoxovid/Covavax (Novavax), Vaxzevria (Oxford-AstraZeneca), Coronavac aka BBIBP-CorV aka BBIBP (Sinovac), Covaxin aka BBV152 (Bharat Biotech), Convidecia aka AD5-nCOV (CanSino Biologies), Sputnik V aka Gam-COVID-Vac, Sinopharm WIBP aka WIBP-CorV (Sinovac), Abdala, Soberana 2, Soberana Plus, ZF2001 aka Anhui Zhifei Longcom ZifiVax ZF2001 aka ZF-UZ- VAC -2001 aka Zifivax (Anhui Zhifei Longcom Biopharmaceutical), Corbevax (Texas Children’s Hospital/Baylor College of Medicine/Dynavax), COVIran Barekat (Sifa Pharmed Industrial Group), VAT00002 or VAT00008 (Sanofi-GSK), SCB-2019 (Clover Biopharmaceuticals), VLA2001 (Valneva), HIPRA SARS-CoV-2 aka PHH-lV (HIPRA), mRNA-1273.214 (Moderna) and Sputnik V bivalent (L452R; Gamaleya National Research Center of Epidemiology and Microbiology), or any combination thereof; (iv) the fusion protein, polypeptide, polynucleotide, vector, host cell, or composition is administered once every twelve months, or once every six months; (v) the coronavirus infection is or comprises a SARS-CoV-2 infection.

Embodiment 76a. A method comprising introducing into a host cell the polynucleotide of any one of Embodiments 65a-67a or the vector of Embodiment 68a, and optionally culturing the host cell for a time and under conditions sufficient to express the encoded fusion protein or polypeptide, or to produce the polynucleotide (e.g. mRNA), and further optionally isolating the fusion protein, polypeptide, or produced polynucleotide.

Table la. Sequences

Table lb. Other Sequences

>Cov0001 (SEQ ID NO.: 107)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0002 (SEQ ID NO.: 108) MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSV KQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV NYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHH

>Cov0003 (SEQ ID NO.: 109)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVG YQPYRVVVLSFELLKAPATVCGPKQSTGSGHHHHHHHH

>Cov0004 (SEQ ID NO.: 110)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSK

HIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGV GHQPYRVVVLSFELLNAPATVCGPKKSTGSGHHHHHHHH

>Cov0005 (SEQ ID NO.:111)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFS

TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNT NSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGV GHQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0006 (SEQ ID NO.: 112)

MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSF

STFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWN TNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVG YQPYRVVVLSFELLNAPATVCGPKKSTGSGHHHHHHHH

>Cov0007 (SEQ ID NO.: 113)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTGSGHHHHHHHH

>Cov0008 (SEQ ID NO.: 114)

MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS

TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTGSGHHHHHHHH >Cov0009 (SEQ ID NO.: 115)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFS

TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT

RNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIG

YQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0010 (SEQ ID NO.: 116)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS

TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT

RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG

YQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0011 (SEQ ID NO.:117)

MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ

QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV

CGPKLSTGSGHHHHHHHH

>Cov0012 (SEQ ID NO.: 118)

MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFST

FKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQ

DVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVC

GPKLSTGSGHHHHHHHH

>Cov0013 (SEQ ID NO.: 119)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAN

QDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPAT

VCGPKLSTGSGHHHHHHHH

>Cov0014 (SEQ ID NO.: 120)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAK

QDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPA

TVCGPKLSTGSGHHHHHHHH

>Cov0015 (SEQ ID NO.: 121)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS

TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGSGHHHHHHHH

>Cov0016 (SEQ ID NO.: 122)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0017 (SEQ ID NO.:123)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSV KQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV NYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPT K

>Cov0018 (SEQ ID NO.: 124)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVG YQPYRVVVLSFELLKAPATVCGPKQSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0019 (SEQ ID NO.: 125)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSK HIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGV GHQPYRVVVLSFELLNAPATVCGPKKSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPT K

>Cov0020 (SEQ ID NO.: 126)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNT NSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGV GHQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPT K

>Cov0021 (SEQ ID NO.: 127)

MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSF

STFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWN TNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVG

YQPYRVVVLSFELLNAPATVCGPKKSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0022 (SEQ ID NO.: 128)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF

STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN

ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0023 (SEQ ID NO.: 129)

MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS

TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0024 (SEQ ID NO.: 130)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFS

TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIG

YQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0025 (SEQ ID NO.: 131)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS

TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG

YQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0026 (SEQ ID NO.: 132)

MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV CGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0027 (SEQ ID NO.: 133)

MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFST

FKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQ DVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVC GPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0028 (SEQ ID NO.: 134) MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAN

QDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPAT

VCGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0029 (SEQ ID NO.: 135)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAK

QDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPA

TVCGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0030 (SEQ ID NO.: 136)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS

TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK

QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV

CGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0031 (SEQ ID NO.: 137)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0032 (SEQ ID NO.: 138)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA

PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA

GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHH

HHH

>Cov0033 (SEQ ID NO.: 139)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIA

PGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQA

GSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSGHHHHH

HHH

>Cov0034 (SEQ ID NO.: 140) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGS KPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSGHHHHHH HH

>Cov0035 (SEQ ID NO.: 141)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHH HH

>Cov0036 (SEQ ID NO.: 142)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGQVFNASNF PSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQI APAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSA GGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGHHHHHH HH

>Cov0037 (SEQ ID NO.: 143)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITKLCPFDQVFNASSF PSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQI APSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTC STINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGHHHHHHHH

>Cov0038 (SEQ ID NO.: 144)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITQLCPFNEVFNITSFP SVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIA PAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTC SAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSGHHHHHHHH

>Cov0039 (SEQ ID NO.: 145)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSP DGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHH HH

>Cov0040 (SEQ ID NO.: 146) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKF

PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSP DGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHH HH

>Cov0041 (SEQ ID NO.: 147)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNFCPFDKVFNATRF

PNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGE TGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDF NPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0042 (SEQ ID NO.: 148)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDSIFNASRFP

SVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGE

TGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDF NPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0043 (SEQ ID NO.: 149)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDKVFNATRF

PSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPG ETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYD FYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0044 (SEQ ID NO.: 150)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDKVFNVTRF

PNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPG ETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTY DFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0045 (SEQ ID NO.: 151)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFDKVFNATRF

PSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPG QTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYD FNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0046 (SEQ ID NO.: 152)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELD KYFKNHTSDAASKAGPGHHHHHHHH

>Cov0047 (SEQ ID NO.: 153)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPGHHHHHHHH

>Cov0048 (SEQ ID NO.: 154)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIA PGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQA GSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELD KYFKNHTSDAASKAGPGHHHHHHHH

>Cov0049 (SEQ ID NO.: 155)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGS KPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPGHHHHHHHH

>Cov0050 (SEQ ID NO.: 156)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF

PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPGHHHHHHHH

>Cov0051 (SEQ ID NO.: 157)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGQVFNASNF

PSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQI APAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSA GGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPGHHHHHHHH

>Cov0052 (SEQ ID NO.: 158) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITKLCPFDQVFNASSF PSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQI APSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTC STINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNH TSDAASKAGPGHHHHHHHH

>Cov0053 (SEQ ID NO.: 159)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITQLCPFNEVFNITSFP SVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIA PAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTC SAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNH TSDAASKAGPGHHHHHHHH

>Cov0054 (SEQ ID NO.: 160)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSP DGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDK YFKNHTSDAASKAGPGHHHHHHHH

>Cov0055 (SEQ ID NO.: 161)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKF PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSP DGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDK YFKNHTSDAASKAGPGHHHHHHHH

>Cov0056 (SEQ ID NO.: 162)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNFCPFDKVFNATRF PNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGE TGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDF NPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHH HHHH

>Cov0057 (SEQ ID NO.: 163)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDSIFNASRFP SVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGE TGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDF NPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHH HHHH >Cov0058 (SEQ ID NO.: 164)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDKVFNATRF PSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPG ETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYD FYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHH HHHHH

>Cov0059 (SEQ ID NO.: 165)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDKVFNVTRF PNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPG ETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTY DFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHH HHHHHH

>Cov0060 (SEQ ID NO.: 166)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFDKVFNATRF PSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPG QTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYD FNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHH HHHHH

>Cov0151 (SEQ ID NO.: 167)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNT NSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGV GHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITKLCPFDQVFNASSFPSVYAWERVRIT DCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYN YKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPL KSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGEVFNATKFPS VYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPG QTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDG

KPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITN LCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYAD YFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKP YERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPK KSTGSGSGSRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVS PTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEF FYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELL NAPATVCGPKQSTGSHHHHHHHH >Cov0152 (SEQ ID NO.: 168)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFS

TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNT NSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGV GHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITKLCPFDQVFNASSFPSVYAWER VRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIA DYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCF APLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSGSGRFPNITNLCPFGEVFN ATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDV RQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNV PFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGS

GSGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLND LCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFR HGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPAT VCGPKQSTGSGSGSGSGRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFS TFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNT NSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGY QPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0153 (SEQ ID NO.: 169)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITKLCPFDQVFNASSFPSVYAWERVRIT DCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYN YKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPL KSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLCPFGEVFNATTFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP

GGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFP NITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSV YADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHG KIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTGPPSPPGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCY GVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSS NEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSF ELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0154 (SEQ ID NO.:170) MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSF STFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWN TNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVG YQPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG DDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERD ISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGS FKEELDKYFKNHTSDAASKAGPRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLY NSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVI AWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISF QPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV FNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGD DVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDL SNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGS

FKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYN SSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVI AWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIG FQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0155 (SEQ ID NO.:171)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITKLCPFDQVFNASSFPSVYAWERVRITD CVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNY KLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKS YGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGEVFNATTFPSVY AWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQT GVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQ SCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITQ LCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYAD YFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGR DLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTG

SGSGSRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKL NDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFY YRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELL NAPATVCGPKKSTGSHHHHHHHH

>Cov0156 (SEQ ID NO.:172) MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCV ADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLP DDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWP

LNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITKLCPFDQVFNA SSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVR QIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSG TCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSGSGRFPNI TNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYA DSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSK

LNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCG PKLSTGSGSGSGSGRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFK CYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSV DSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPY RVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0157 (SEQ ID NO.:173)

MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSF STFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWN TNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVG YQPYRVVVLSFELLNAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRIS NCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY KLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPN

CYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITKLCPFDQVF NASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDD VRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSP SGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNIT NLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYA DSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHG

KLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVC GPKLSTGPPSPPGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCY GVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSS NEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSF ELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0158 (SEQ ID NO.:174)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF

STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPD GKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKY FKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTF KCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNS VDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQP YRVVVLSFELLNAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFN ATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDV RQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSN DIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFK EELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSS ASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIA WNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGF

QPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0159 (SEQ ID NO.:175)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYS VLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFM GCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGY GFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITQLCPFNEVFNITSFPSVYA WERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQT GVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEG LNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGEV FNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGD DVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDL SNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSG

SGSRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLND LCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYR LFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNA PATVCGPKKSTGSHHHHHHHH

>Cov0160 (SEQ ID NO.:176)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVAD YSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDD FLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLR PYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGQVFNAS NFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVR QIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYN SAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSGS GRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLC FSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYR YLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNA PATVCGPKLSTGSGSGSGSGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSA SFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAW NTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQP YRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0161 (SEQ ID NO.:177)

MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADY SVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDF LGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRP YGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITKLCPFDQVFNASSFPS VYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAP SQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTI NNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLCPFG EVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVK GDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFER DISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGP PSPPGRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKL NDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFY YRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELL NAPATVCGPKKSTGSHHHHHHHH

>Cov0162 (SEQ ID NO.:178)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFST FQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNS LDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVV VLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFP

SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPD GKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKY FKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTF KCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNS VDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQP YRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0163 (SEQ ID NO.:179)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYS VLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFM GCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGY

GFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGQVFNASNFPSVY AWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQ TGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTC SSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSRFPNITQLC PFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYF VVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDL

SNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSG SGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDL CFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLY RWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELL NAPATVCGPKLSTGSHHHHHHHH

>Cov0164 (SEQ ID NO.: 180)

MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCV ADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLP DDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWP LNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGQVFNA SNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDV RQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLY NSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSG SGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDL CFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLY RWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELL NAPATVCGPKLSTGSGSGSGSGRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYN SSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIA WNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQ PYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0165 (SEQ ID NO.: 181)

MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATK FPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQI APGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFS PDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFS TFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFP SVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIA PAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAG GTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDKY FKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKC YGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKD SSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQP YRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0166 (SEQ ID NO.: 182)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDS KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIA DYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFT

GCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVV

LSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSV

LYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTG

CVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERY

GFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNRCPFDKVFNATRFPSVY

AWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGV IADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPS VPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0167 (SEQ ID NO.: 183)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS

TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK

QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTF KCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVK QDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVN

YQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRT

KISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNY KLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQ ATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFN

CYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNRCPFD KVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSS

EVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDEN GVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0168 (SEQ ID NO.: 184)

MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ

QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV

CGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC

YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDS

KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCV

ADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDD FTGCVIAWNTAKQDVGSYFYRSHRS SKLKPFERDLS SEENGVRTLSTYDFNQNVPLEYQATRVV VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYS VLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFT GCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLER YGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNRCPFDKVFNATRFPS VYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGET GVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDF YPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0169 (SEQ ID NO.: 185)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAN QDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPAT VCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRIS NCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNY KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFN CYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAA SKAGPRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLI DLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRA VKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKE ELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNST

SFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAW NSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTT GVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCP FDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIR FSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEE NGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0170 (SEQ ID NO.:186)

MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY GVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDA LTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPF RVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVA DYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDF TGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVV LSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSV LYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGC

VIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGF QPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNRCPFDKVFNATRFPSVYA WERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVI ADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPS

VPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0171 (SEQ ID NO.:187)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAN QDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPAT

VCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSV KQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV NYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQR TKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYN YKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDY QATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKR ISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYN

YKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGF NCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPF DKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRF SEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEEN GVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0172 (SEQ ID NO.:188)

MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ

QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV CGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDS

KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCV

ADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDD FTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVV VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYS VLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFT GCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLER YGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFDKVFNATRFPS VYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQT GVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFN

QNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0173 (SEQ ID NO.:189) MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV CGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISN CVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYK LPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNC

YYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASK AGPRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDL CFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKE KLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEE LDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFD KVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFS EVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRS SKLKPFERDLS SEENG VRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0174 (SEQ ID NO.:190)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAN QDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPAT VCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLD SKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCV ADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDD FTGCVIAWNTAKQDVGSYFYRSHRS SKLKPFERDLS SEENGVRTLSTYDFNQNVPLEYQATRVV VLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYS VLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFT

GCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLER YGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNFCPFDKVFNATRFPNV YAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGV IADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPN VPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0175 (SEQ ID NO.:191)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSV KQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV NYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQR TKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYN YKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDY QATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKR ISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYN

YKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGF NCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPF DKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRF SEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEEN GVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNRCPFD

KVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSS EVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDEN GVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0176 (SEQ ID NO.:192)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS

TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDS KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQP

YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCV ADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDD FTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVV VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYS VLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFT

GCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLER YGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNFCPFDKVFNATRFPN VYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETG VIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNP NVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0177 (SEQ ID NO.:193)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNFCPFDK VFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSE VRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGV

RTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKA GPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDL CFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLY

RLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLN GPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFNATRFPSVYAWER TKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADY NYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRS SKLKPFERDLS SEENGVRTLSTYDFNQNVPLE YQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDK VFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSE VRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENG VYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0178 (SEQ ID NO.:194)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSV KQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV NYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNFCPFDKVFNATRFPNVYAWQRTKI SDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKL PDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQAT RVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQ

SYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNRCPFDKVFNATRFP SVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGE TGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDF YPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFDKVFNATRFPSVYA WERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVI ADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNV PLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0179 (SEQ ID NO.:195)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN

NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRT KISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNY KLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQ ATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRI SNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYN YKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGL NCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNRCPF DKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS

SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDEN

GVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFDK

VFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSE

VRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGV

RTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0180 (SEQ ID NO.: 196)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAN

QDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPAT

VCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRIS

NCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNY

KLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLN

CYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAAS

KAGPRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLID

LCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSS

KLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEE

LDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS

FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNS

NNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV

GYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNFCPFD

KVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFS

EVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENG

VRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0181 (SEQ ID NO.: 197)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN

NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG

YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRIS

NCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNY

KLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLN

CYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFN

ATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVR

QIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIY

QAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHH

HHHHH

>Cov0182 (SEQ ID NO.: 198) MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSK HIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGV GHQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNR KRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIAD

YNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQV GLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF

ERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSHHHHHHHH

>Cov0183 (SEQ ID NO.: 199)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSK HIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGV GHQPYRVVVLSFELLNAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKR ISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYN

YKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGF NCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEV FNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGD EVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDIS

TEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSH HHHHHHH

>Cov0184 (SEQ ID N0.:200)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSV KQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV NYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRG DEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDI

STEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLY NSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIA WNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYP TDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0185 (SEQ ID NO.:201) MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFASVYAWNRKRIS NCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYK

LPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCY YPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNA SKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVR QIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIY QAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSHHHH

HHHH

>Cov0186 (SEQ ID NO.:202)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSV KQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV NYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATTFASVYAWNR KRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIAD

YNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQT GLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSGSGRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK

STGSHHHHHHHH

>Cov0187 (SEQ ID NO.:203)

MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSF STFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWN TNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVG YQPYRVVVLSFELLNAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRIS NCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY

KLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNC YWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITQLCPFNEVFN ITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDD VRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNP SGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHH

H

>Cov0188 (SEQ ID NO.:204) MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATK FPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQI APGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFS PDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFS TFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNT NSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGY QPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0189 (SEQ ID NO.:205)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGQVFNASNFPSVYAWERLRISD CVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNY KLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYE PLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSRFPNITQLCPFNEVFNITS FPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQ IAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGG TCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0190 (SEQ ID NO.:206)

MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTGSGSGSGSGRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVA DYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLP DDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLK SYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNAT KFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQ IAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPF SPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHH HHH

>Cov0191 (SEQ ID NO.:207)

MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSF

STFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWN TNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVG YQPYRVVVLSFELLNAPATVCGPKKSTGPPSPPGRFPNITQLCPFNEVFNITSFPSVYAWERMRIT NCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYN YKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPL ASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLCPFGEVFNATKFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPD GKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0192 (SEQ ID NO.:208)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNE VFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKG DDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLF NPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFS

TFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNT NSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGY QPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0193 (SEQ ID NO.:209)

MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCY GVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQ YYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKL STGSGSGSRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPS KLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRS

HRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSH HHHHHHH

>Cov0194 (SEQ ID NO.:210)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTF KCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDI GSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCG PKLSTGSGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKC YGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQG QYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPK LSTGSHHHHHHHH

>Cov0195 (SEQ ID NO.:211)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGPPSPPGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKC YGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQG QYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPK

LSTGPPSPPGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSP SKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRS HRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGS HHHHHHHH

>Cov0196 (SEQ ID NO.:212)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAN QDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPAT VCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNFCPFDKVFNATRFPNVYAWQRTKIS

DCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLP DDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATR VVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFNAT RFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVA PGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLST YDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0197 (SEQ ID NO.:213)

MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSGSGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTF

NCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQD VGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCG PKLSTGSGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKC YGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQG QYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPK

LSTGSHHHHHHHH

>Cov0198 (SEQ ID NO.:214)

MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS

TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAN

QDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPAT

VCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFNATRFPSVYAWERTKIS

DCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKL

PDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQAT

RVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNFCPFDKVFNA

TRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIA PGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLST YDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0061 (SEQ ID NO.:215)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSK

HIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGV

GHQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRIS

NCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY KLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPN

CYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFN

ATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEV

RQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEI YQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSG SRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLC

FTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYR

LFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLN GPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVG YQPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH

>Cov0062 (SEQ ID NO.:216)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN

NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERK RISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIAD YNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAV GPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLC PFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSF VITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPF ERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPK KSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY GVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDA LTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPF RVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATTFASVYAWNRKRISN CVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYK LPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCY FPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH

>Cov0063 (SEQ ID NO.:217)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRIS NCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY KLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPN CYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVF NATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDE VRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTE IYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGPPS PPGRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLND LCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYL YRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELL KAPATVCGPKQSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNST SFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAW NSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTT GVNYQPFRVVVLSFELLNGPATVCGPKLSTGSHHHHHHHH

>Cov0064 (SEQ ID NO.:218)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG DDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERD LSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVL

YNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGC VIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYG

FHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNI TNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVY

ADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATV

CGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISN CVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKL

PDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYY PLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0065 (SEQ ID NO.:219)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG

YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISN CVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYK LPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNC YNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFN ASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEV

RQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEI YQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSG SRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCF TNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLF

RKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAP ATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTF KCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNL DSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQ PYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH

>Cov0066 (SEQ ID NO.:220)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSK HIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGV

GHQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWER KRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIA

DYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSA VGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNL

CPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSF VVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKP

FERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPK

QSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY

GVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDA

LTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPF

RVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISN

CVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKL

PDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYF PLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0067 (SEQ ID NO.:221)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSN

NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVG

YQPYRVVVLSFELLKAPATVCGPKQSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRIS

NCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY

KLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPN

CYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVF

NATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDE

VRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTE

IYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGPPS

PPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLND

LCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYL

YRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELL

NGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSA

SFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWN

SNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYG VGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0068 (SEQ ID NO.:222)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS

TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSV

KQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV

NYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE

VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG

DDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERD

LSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPG

SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVL

YNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCV

IAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQ PTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITN LCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYAD SFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKP FERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPK KSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVAD YSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDF TGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQS YGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH

>Cov0069 (SEQ ID NO.:223)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSK HIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGV GHQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRIS

NCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY KLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPN CYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFN ASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEV RQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEI YQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSG SRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC FTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRL FRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHA PATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFST FKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNN

LDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGY QPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH

>Cov0070 (SEQ ID NO.:224)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVG YQPYRVVVLSFELLKAPATVCGPKQSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERK RISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIAD YNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAV GPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYG VSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALT GGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRV VVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCV ADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPD DFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPL YRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0091 (SEQ ID NO.:225)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIG YQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITKLCPFDQVFNASSFPSVYAWERVRITD CVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNY KLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKS YGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGEVFNATKFPSVY AWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQT GVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKP

CTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLC PFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYF VVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYE RDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKS TGSGSGSRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPT KLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFY RRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLN APATVCGPKQSTGSHHHHHHHH

>Cov0092 (SEQ ID NO.:226)

MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSF STFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWN TNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVG YQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERK RISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIAD YNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPA PNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITKLCPF DQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIV KGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSN

IPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSG SGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDL CFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKY RSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNA PATVCGPKLSTGSGSGSGSGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSA SFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAW NTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQP YRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0093 (SEQ ID NO.:227)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITKLCPFDQVFNASSFPSVYAWERVRIT DCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYN YKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPL KSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLCPFGEVFNATTFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPD

GKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNI TNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVY ADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKI KPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCG PKKSTGPPSPPGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYG VSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSN EFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFE LLNAPATVCGPKQSTGSHHHHHHHH

>Cov0094 (SEQ ID NO.:228)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITKLCPFDQ VFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKG DDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPY SPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTF KCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTR NIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGY

QPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVF NITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGD DVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFN PSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFST FKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTN

SVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQ

PYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0095 (SEQ ID NO.:229)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIG

YQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITKLCPFDQVFNASSFPSVYAWERVRITD CVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNY KLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKS YGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGEVFNATKFPSVY AWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQT GVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKP CTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITQLC PFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYF VVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDL SNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSG SGSRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLND LCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYR LFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNA PATVCGPKKSTGSHHHHHHHH

>Cov0096 (SEQ ID NO.:230)

MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVA DYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPD DFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPL NDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITKLCPFDQVFNAS SFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVR QIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSG TCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSGSGRFPNI TNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVY ADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRH GKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATV CGPKLSTGSGSGSGSGRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFST FKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTN SVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQ

PYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0097 (SEQ ID NO.:231)

MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSF STFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWN TNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVG YQPYRVVVLSFELLNAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRIS NCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY KLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNC YWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITKLCPFDQVFN ASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDV RQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPS GTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNIT NLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYA DSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHG KLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVC GPKLSTGPPSPPGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCY GVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSS NEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSF

ELLNAPATVCGPKQSTGSHHHHHHHH

>Cov0098 (SEQ ID NO.:232)

MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFS TFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTN SLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRV VVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATK FPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQI APGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFS PDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFS TFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPD GKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKY FKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTF KCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNS VDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQP

YRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0101 (SEQ ID NO.:233)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYS VLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFM GCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDY GFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITQLCPFNEVFNITSFPSVY AWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQ TGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAE

GLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLCPFGE VFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG DDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERD ISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPP SPPGRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLN DLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYY RLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLN APATVCGPKKSTGSHHHHHHHH

>Cov0102 (SEQ ID NO.:234)

MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSF STFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTN ALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVV VLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPD GKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKY FKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQ CYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLD SSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVL SFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSV YAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQ TGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGK PCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFK

NHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKC YGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVD SKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYR VVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0121 (SEQ ID NO.:235)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKC YGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIG NYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCG PKLSTGSGSGSRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGV SPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFY RSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTG SGSGSRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLI DLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSR KEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSG SRFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFT SVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLK PFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHH H

>Cov0122 (SEQ ID NO.:236)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSGSGRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTF KCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQD IGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTF KCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDI GSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCG PKLSTGSGSGSGSGRFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGS YFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKL STGSGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYG VSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQY YYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLS TGSHHHHHHHH

>Cov0123 (SEQ ID NO.:237) MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV CGPKLSTGPPSPPGRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKC YGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIG NYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCG PKLSTGPPSPPGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYG VSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSY

FYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLS TGPPSPPGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPS KLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYR SSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGP PSPPGRFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLID LCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRST KLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHH HHHH

>Cov0124 (SEQ ID NO.:238)

MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFST FKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQ DVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVC GPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDC VADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPD DFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQAT RVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNFCPFDKVFNA TRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIA PGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLST

YDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFP NITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVY ADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRS SRKEKLKPFE RDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGS YFYRSHRS SKLKPFERDLS SEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKL STGSHHHHHHHH

>Cov0125 (SEQ ID NO.:239)

MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFST FKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQ DVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVC GPKLSTGSGSGSRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCY GVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGN YYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGP KLSTGSGSGSRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVS PSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFY RSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTG SGSGSRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLI DLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSR KEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSG SRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFT SVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKP FERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0126 (SEQ ID NO.:240)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSGSGRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTF KCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQD IGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATV CGPKLSTGSGSGSGSGRFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFK CYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDV GSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGP KLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSY FYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLS TGSGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGV SPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYY YRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLST GSHHHHHHHH

>Cov0127 (SEQ ID NO.:241)

MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFST FKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQ DVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVC GPKLSTGPPSPPGRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCY GVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGN YYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGP KLSTGPPSPPGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGV SPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYF YRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLST GPPSPPGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSK LIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHR AVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSP PGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLC FTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEK LKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHH HH

>Cov0128 (SEQ ID NO.:242)

MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQ QDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATV CGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDKVFNVTRFPNVYAWERTKISD CVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLP DDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQA TRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFN ATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQ VAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTL

STYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGP RFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTS VYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKP FERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKY FKNHTSDAASKAGPRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFK CYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQ GQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGP KLSTGSHHHHHHHH

>Cov0130 (SEQ ID NO.:243)

MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFST FKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQ DVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVC GPKLSTGSGSGSGSGRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFK CYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDI GNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVC GPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFK CYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIG SYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGP

KLSTGSGSGSGSGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGS YFYRSHRS SKLKPFERDLS SEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKL STGSGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYG VSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQY YYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLS TGSHHHHHHHH

>Cov0132 (SEQ ID NO.:244)

MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFS TFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAK QDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATV CGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDKVFNVTRFPNVYAWERTKISD CVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLP DDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQA

TRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDSIFNA SRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQV APGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLS TYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPR FPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTS VYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKP

FERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKY FKNHTSDAASKAGPRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKC YGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGS YFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPK LSTGSHHHHHHHH

>Cov0234 (SEQ ID NO.:245)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0235 (SEQ ID NO.:246)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI

YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIIT TDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0236 (SEQ ID NO.:247)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA GICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLIT GRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVV FLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCD VVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNL NESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGS GGTGAHIVMVDAYKPTK

>Cov0237 (SEQ ID NO.:248)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL SSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE QGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAY KPTK

>Cov0238 (SEQ ID NO.:249)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSSTGQK SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG

WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRA AEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPEL DSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGS GYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPT K

>AAV49723 (SEQ ID NO.:250)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN

VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA GICASYHTVSSLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI

SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLI TGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGV VFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNC DVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKN LNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCCKFD EDDSEPVLKGVKLHYT

>ADE34812 (SEQ ID NO.:251)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL

TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL RSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS

FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE QYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCCKFDEDDSEPVLKGVKLH YT

>AIA62277 (SEQ ID NO.:252)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLRSTGQK

SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIR AAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTT APAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPE LDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI KWPWYVWLGFIAGLVGLFMAIILLCYFTSCCSCCKGMCSCGSCCRFDEDDSEPVLKGVKLHYT >QIA48632 (SEQ ID NO.:253)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFRSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHL MSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQI ITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQ KEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIIMVTIMLCCMTSCCSCLKG CCSCGSCCKFDEDDSEPVLKGVKLHYT

>SARS-Cov2_South_Africa_variant (SEQ ID NO.:254)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGY HLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYE PQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVV

NIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSC

LKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

>Cov0199 (SEQ ID NO.:255)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS

VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHH HHHHHH

>Cov0200 (SEQ ID NO.:256)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT

TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIIT TDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHH HHH

>Cov0201 (SEQ ID NO.:257)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA

GICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLIT GRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVV FLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCD VVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNL NESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH

>Cov0202 (SEQ ID NO.:258)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL SSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE QGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH

>Cov0203 (SEQ ID NO.:259)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSSTGQK SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL

YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRA AEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPEL DSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGS GYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH

>Cov0204 (SEQ ID NO.:260)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF KEELDKYFKNHTSDAASKAGPGSGSGHHHHHHHH

>Cov0205 (SEQ ID NO.:261)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI

QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF KEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGSGHHHHHHHH

>Cov0206 (SEQ ID NO.:262)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS

VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF

KEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKN HTSDAASKAGPGSGHHHHHHHH

>Cov0207 (SEQ ID NO.:263)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSF KEELDKYFKNHTSDAASKAGPGSGSGHHHHHHHH >Cov0208 (SEQ ID NO.:264)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSF KEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGSGHHHHHHHH

>Cov0209 (SEQ ID NO.:265)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSF KEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKN HTSDAASKAGPGSGHHHHHHHH

>Cov0210 (SEQ ID NO.:266)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI

YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIIT TDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEE LDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0211 (SEQ ID NO.:267)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIIT TDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEE LDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0212 (SEQ ID NO.:268)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIIT TDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEE LDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTS DAASKAGPGSGHHHHHHHH

>Cov0213 (SEQ ID NO.:269)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIIT TDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEE

LDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0214 (SEQ ID NO.:270)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI

YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIIT TDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEE LDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0215 (SEQ ID NO.:271)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIIT TDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEE LDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTS

DAASKAGPGSGHHHHHHHH

>Cov0216 (SEQ ID NO.:272)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA GICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD

MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLIT GRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVV FLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCD VVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNL NESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSD AASKAGPGSGHHHHHHHH >Cov0217 (SEQ ID NO.:273)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN

VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA GICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI

SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLIT GRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVV FLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCD VVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNL NESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSD AASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0218 (SEQ ID NO.:274)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN

VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA GICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI

SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLIT GRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVV FLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCD VVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNL NESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSD AASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSG HHHHHHHH

>Cov0219 (SEQ ID NO.:275)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN

ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA GICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLIT GRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVV

FLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCD VVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNL NESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSD AASKAGPGSGHHHHHHHH

>Cov0220 (SEQ ID NO.:276)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN

ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA GICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLIT GRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVV FLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCD VVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNL NESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSD AASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0221 (SEQ ID NO.:277)

MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNV TGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFEL CDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVY KGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFM LKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDD VRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISN VPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKN

QCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTN ASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGA GICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN MYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFS QILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDD MIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLIT GRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVV

FLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCD VVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNL NESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSD AASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSG HHHHHHHH

>Cov0222 (SEQ ID NO.:278)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL SSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Q

>Cov0223 (SEQ ID NO.:279)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL SSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE QGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSF KEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0224 (SEQ ID NO.:280)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL SSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE QGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSF KEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0225 (SEQ ID NO.:281)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL SSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE QGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSGHHH HHHHH >Cov0226 (SEQ ID NO.:282)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL SSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE QGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSF

KEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0227 (SEQ ID NO.:283)

MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNL TQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRV CNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDG FLSVYQTYTAVNLPRGLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLK YSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPF DKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRS SEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFERDLSSDD GNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKG TGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDV NCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTASVL SSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECS NLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRS FIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSG TATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKN FTTAPAICHEGKAYFPREGVFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPL QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE

QGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSF

KEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0228 (SEQ ID NO.:284)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSSTGQK SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRA AEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPEL DSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGS

GYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHH HH

>Cov0229 (SEQ ID NO.:285)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSSTGQK SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRA AEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPEL DSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGS GYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEEL DKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0230 (SEQ ID NO.:286)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSSTGQK SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG

WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRA AEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPEL DSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGS GYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEEL DKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0231 (SEQ ID NO.:287)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSSTGQK SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRA AEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPEL DSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGS GYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHH HHH

>Cov0232 (SEQ ID NO.:288)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSSTGQK SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG

WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRA AEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPEL DSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGS GYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEE LDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0233 (SEQ ID NO.:289)

MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFLRFNTTLT WYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQF CDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAY QPYDLAIGATAALPAQFLPLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMML SFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVF NATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVLT LSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDS SKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVP TTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSSTGQK SIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQY GSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLL YNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAG WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQ DVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRA AEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHEGKAYFPREGVFVSNGSSWFITQRNFYSPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPEL DSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGS

GYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEE LDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH

>Cov0239 (SEQ ID NO.:290)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGS GSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLY RLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGSHHHHHHHH >Cov0240 (SEQ ID NO.:291)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGS

GSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLY RLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY

NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVI AWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQ PTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0241 (SEQ ID NO.:292)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGS

GSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLY RLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY

NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVI AWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQ

PTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQ

TGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0242 (SEQ ID NO.:293)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGS GSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLY RLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGSHHHHHHHH

>Cov0243 (SEQ ID NO.:294)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGS

GSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLY RLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY

NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVI AWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQ

PTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGSHHHH HHHH

>Cov0244 (SEQ ID NO.:295)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS

VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGS

GSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLY RLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY

NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVI AWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQ

PTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQ

TGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYF KNHTSDAASKAGPGSHHHHHHHH

>Cov0245 (SEQ ID NO.:296)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT YGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0246 (SEQ ID NO.:297)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT YGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSHHHHHHHH >Cov0247 (SEQ ID NO.:298)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH

LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT YGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADY SVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFT GCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSY GFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0248 (SEQ ID NO.:299)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT YGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGSHHHHH HHH

>Cov0249 (SEQ ID N0.:300)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS

VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT YGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STPGSFKEELDKYFKNHTSDAASKAGPGSHHHHHHHH

>Cov0250 (SEQ ID NO.:301)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP

QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNI QKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT YGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADY SVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFT GCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSY GFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGSH HHHHHHH >Cov0251 (SEQ ID NO.:302)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0252 (SEQ ID NO.:303)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFAPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0253 (SEQ ID NO.:304)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFGPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0254 (SEQ ID NO.:305)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFQPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0255 (SEQ ID NO.:306)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFAPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0256 (SEQ ID NO.:307)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFGPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0257 (SEQ ID NO.:308)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFQPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0258 (SEQ ID NO.:309)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFAPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0259 (SEQ ID NO.:310)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFGPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0260 (SEQ ID NO.:311)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFAPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0261 (SEQ ID NO.:312)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFGPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0262 (SEQ ID NO.:313) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFNPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0263 (SEQ ID NO.:314)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH HHH

>Cov0264 (SEQ ID NO.:315)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH HHH

>Cov0265 (SEQ ID NO.:316)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH HHH

>Cov0266 (SEQ ID NO.:317)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH HHH

>Cov0267 (SEQ ID NO.:318)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0268 (SEQ ID NO.:319) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0269 (SEQ ID NO.:320)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0270 (SEQ ID NO.:321)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0271 (SEQ ID NO.:322)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0272 (SEQ ID NO.:323)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0273 (SEQ ID NO.:324)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0274 (SEQ ID NO.:325)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH >Cov0275 (SEQ ID NO.:326)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0276 (SEQ ID NO.:327)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0277 (SEQ ID NO.:328)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0278 (SEQ ID NO.:329)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0279 (SEQ ID NO.:330)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0280 (SEQ ID NO.:331)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0281 (SEQ ID NO.:332)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC

NGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0282 (SEQ ID NO.:333)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0283 (SEQ ID NO.:334)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0284 (SEQ ID NO.:335)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0285 (SEQ ID NO.:336)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP

CNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0286 (SEQ ID NO.:337)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTP

CNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0287 (SEQ ID NO.:338)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0288 (SEQ ID NO.:339) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0289 (SEQ ID NO.:340)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0290 (SEQ ID NO.:341)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0291 (SEQ ID NO.:342)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0292 (SEQ ID NO.:343)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0293 (SEQ ID NO.:344)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP CNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0294 (SEQ ID NO.:345)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTP

CNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH >Cov0295 (SEQ ID NO.:346)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTP

CNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0296 (SEQ ID NO.:347)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTP

CNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0297 (SEQ ID NO.:348)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0298 (SEQ ID NO.:349)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0299 (SEQ ID NO.:350)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0300 (SEQ ID NO.:351)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH >Cov0301 (SEQ ID NO.:352)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0302 (SEQ ID NO.:353)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0303 (SEQ ID NO.:354)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0304 (SEQ ID NO.:355)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0305 (SEQ ID NO.:356)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0306 (SEQ ID NO.:357)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAG STPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0307 (SEQ ID NO.:358)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAG STPCNGVAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0308 (SEQ ID NO.:359)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0309 (SEQ ID NO.:360)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0310 (SEQ ID NO.:361)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQA GSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0311 (SEQ ID NO.:362)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG STPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0312 (SEQ ID NO.:363) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAG STPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0313 (SEQ ID NO.:364)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQA GSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0314 (SEQ ID NO.:365)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG STPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0315 (SEQ ID NO.:366)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAG STPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0316 (SEQ ID NO.:367)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQA GSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0317 (SEQ ID NO.:368)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0318 (SEQ ID NO.:369) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0319 (SEQ ID NO.:370)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0320 (SEQ ID NO.:371)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAG

STPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0321 (SEQ ID NO.:372)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAG

STPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0322 (SEQ ID NO.:373)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0323 (SEQ ID NO.:374)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0324 (SEQ ID NO.:375)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH >Cov0325 (SEQ ID NO.:376)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQA

GSTPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHH

H

>Cov0326 (SEQ ID NO.:377)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQA

GSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHH

H

>Cov0327 (SEQ ID NO.:378)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVAGFNCYFPLASYGFAPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0328 (SEQ ID NO.:379)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVAGFNCYFPLASYGFGPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0329 (SEQ ID NO.:380)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVAGFNCYFPLASYGFAAAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0330 (SEQ ID NO.:381)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVAGFNCYFPLASYGFGAAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0331 (SEQ ID NO.:382)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISTEIYQAG

STPCNGAAGFNCYFPLASYGFAAAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0332 (SEQ ID NO.:383)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISTEIYQAG

STPCNGAAGFNCYFPLASYGFGAAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0333 (SEQ ID NO.:384)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0334 (SEQ ID NO.:385)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0335 (SEQ ID NO.:386)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0336 (SEQ ID NO.:387)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0337 (SEQ ID NO.:388)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQA

GSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH HHHH

>Cov0338 (SEQ ID NO.:389)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0339 (SEQ ID NO.:390)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0340 (SEQ ID NO.:391)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQA

GSTPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH HHHH

>Cov0341 (SEQ ID NO.:392)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQA

GSTPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH

HHHH

>Cov0342 (SEQ ID NO.:393) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQA

GSTPCNGVAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH HHHH

>Cov0343 (SEQ ID NO.:394)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0344 (SEQ ID NO.:395)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0345 (SEQ ID NO.:396)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0346 (SEQ ID NO.:397)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0347 (SEQ ID NO.:398)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQA

GSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH

HHHH >Cov0348 (SEQ ID NO.:399)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0349 (SEQ ID N0.:400)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAG

STPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH

HHH

>Cov0350 (SEQ ID NO.:401)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQA

GSTPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH HHHH

>Cov0351 (SEQ ID NO.:402)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQA

GSTPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH HHHH

>Cov0352 (SEQ ID NO.:403)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQA

GSTPCNGVAGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH HHHH

>Cov0353 (SEQ ID NO.:404)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISNETYQAGSTPC

GKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH >Cov0354 (SEQ ID NO.:405)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISNETYQAGSTP

CGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0355 (SEQ ID NO.:406)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPC

GKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0356 (SEQ ID NO.:407)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0357 (SEQ ID NO.:408)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0358 (SEQ ID NO.:409)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0359 (SEQ ID NO.:410)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISNETYQAGSTPC

GKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0360 (SEQ ID NO.:411)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISNETYQAGSTP

CGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0361 (SEQ ID NO.:412)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPC

GKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0362 (SEQ ID NO.:413)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0363 (SEQ ID NO.:414)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0364 (SEQ ID NO.:415)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0365 (SEQ ID NO.:416)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYAYRLFRKSNLKPFERDISNETYQAGSTP

CGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0366 (SEQ ID NO.:417)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYAYRLFRKSNLKPFERDISNETYQAGSTP

CGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0367 (SEQ ID NO.:418) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYAYRLFRKSNLKPFERDISNETYQAGSTP CGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0368 (SEQ ID NO.:419)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYAYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0369 (SEQ ID NO.:420)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYAYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0370 (SEQ ID NO.:421)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYAYRLFRKSNLKPFERDISNETYQAGST

PCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0371 (SEQ ID NO.:422)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYAYRLFRKSNLKPFERDISNETYQAGSTP CGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0372 (SEQ ID NO.:423)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYAYRLFRKSNLKPFERDISNETYQAGSTP CGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0373 (SEQ ID NO.:424)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYAYRLFRKSNLKPFERDISNETYQAGSTP

CGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH >Cov0374 (SEQ ID NO.:425)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYAYRLFRKSNLKPFERDISNETYQAGST PCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0375 (SEQ ID NO.:426)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYAYRLFRKSNLKPFERDISNETYQAGST

PCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0376 (SEQ ID NO.:427)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYAYRLFRKSNLKPFERDISNETYQAGST PCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0377 (SEQ ID NO.:428)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYAYRLFRKSNLKPFERDISNETYQAGSTP CGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0378 (SEQ ID NO.:429)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYAYRLFRKSNLKPFERDISNETYQAGSTP CGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0379 (SEQ ID NO.:430)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYAYRLFRKSNLKPFERDISNETYQAGSTP CGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0380 (SEQ ID NO.:431)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYAYRLFRKSNLKPFERDISNETYQAGST

PCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0381 (SEQ ID NO.:432)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYAYRLFRKSNLKPFERDISNETYQAGST

PCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0382 (SEQ ID NO.:433)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYAYRLFRKSNLKPFERDISNETYQAGST

PCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0383 (SEQ ID NO.:434)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0384 (SEQ ID NO.:435)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0385 (SEQ ID NO.:436)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK >Cov0386 (SEQ ID NO.:437)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPAYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0387 (SEQ ID NO.:438)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0388 (SEQ ID NO.:439)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0389 (SEQ ID NO.:440)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPAYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0390 (SEQ ID NO.:441)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPAYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0391 (SEQ ID NO.:442)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPAYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0392 (SEQ ID NO.:443)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPAYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0393 (SEQ ID NO.:444)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPAYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0394 (SEQ ID NO.:445)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0395 (SEQ ID NO.:446) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0396 (SEQ ID NO.:447)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0397 (SEQ ID NO.:448)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0398 (SEQ ID NO.:449)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0399 (SEQ ID NO.:450)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0400 (SEQ ID NO.:451)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0401 (SEQ ID NO.:452)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0402 (SEQ ID NO.:453)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0403 (SEQ ID NO.:454)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ

KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0404 (SEQ ID NO.:455)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD

PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0405 (SEQ ID NO.:456)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK

LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK >Cov0406 (SEQ ID NO.:457)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0407 (SEQ ID NO.:458)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0408 (SEQ ID NO.:459)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0409 (SEQ ID NO.:460)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0410 (SEQ ID NO.:461)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK

LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0411 (SEQ ID NO.:462)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0412 (SEQ ID NO.:463)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK

LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0413 (SEQ ID NO.:464)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0414 (SEQ ID NO.:465)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0415 (SEQ ID NO.:466) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0416 (SEQ ID NO.:467)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYLYRLFRKSNLK PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH

HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0417 (SEQ ID NO.:468)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP

QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0418 (SEQ ID NO.:469)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0419 (SEQ ID NO.:470)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP

QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0420 (SEQ ID NO.:471)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0421 (SEQ ID NO.:472)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD

PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0422 (SEQ ID NO.:473)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0423 (SEQ ID NO.:474)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD

PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0424 (SEQ ID NO.:475)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD

PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0425 (SEQ ID NO.:476)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD

PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK >Cov0426 (SEQ ID NO.:477)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP

QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0427 (SEQ ID NO.:478)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0428 (SEQ ID NO.:479)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP

QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0429 (SEQ ID NO.:480)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0430 (SEQ ID NO.:481)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0431 (SEQ ID NO.:482)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0432 (SEQ ID NO.:483)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0433 (SEQ ID NO.:484)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0434 (SEQ ID NO.:485)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0435 (SEQ ID NO.:486) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0436 (SEQ ID NO.:487)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0437 (SEQ ID NO.:488)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0438 (SEQ ID NO.:489)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS

NLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0439 (SEQ ID NO.:490)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0440 (SEQ ID NO.:491)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0441 (SEQ ID NO.:492)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKS

NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0442 (SEQ ID NO.:493)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS

NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0443 (SEQ ID NO.:494)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0444 (SEQ ID NO.:495)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKS

NLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0445 (SEQ ID NO.:496)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS

NLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK >Cov0446 (SEQ ID NO.:497)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0447 (SEQ ID NO.:498)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKS

NLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0448 (SEQ ID NO.:499)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS

NLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0449 (SEQ ID N0.:500)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG

PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF

GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV

NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT

EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0450 (SEQ ID NO.:501)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF

GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN

IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0451 (SEQ ID NO.:502)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP

QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0452 (SEQ ID NO.:503)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS NLKPFERDISTEIYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF

GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN

IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0453 (SEQ ID NO.:504)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS NLKPFERDISTEIYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP

QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0454 (SEQ ID NO.:505)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN

GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0455 (SEQ ID NO.:506) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD

PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0456 (SEQ ID NO.:507)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN

GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH

HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0457 (SEQ ID NO.:508)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS NLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN

GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0458 (SEQ ID NO.:509)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS NLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHV NNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTT EIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIY KTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFN

GLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD

PPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHL

MSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEP

QPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN

IQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHH

HHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0459 (SEQ ID NO.:510)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFAPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0460 (SEQ ID NO.:511)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFGPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0461 (SEQ ID NO.:512)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFAAAYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0462 (SEQ ID NO.:513)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFGAAYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0463 (SEQ ID NO.:514)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKS

NLKPFERDISTEIYQAGSTPCNGAAGFNCYFPLASYGFAAAYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH

HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0464 (SEQ ID NO.:515)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKS NLKPFERDISTEIYQAGSTPCNGAAGFNCYFPLASYGFGAAYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGH HHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0465 (SEQ ID NO.:516)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV

KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK >Cov0466 (SEQ ID NO.:517)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG

YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0467 (SEQ ID NO.:518)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV

KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0468 (SEQ ID NO.:519)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV

KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0469 (SEQ ID NO.:520)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0470 (SEQ ID NO.:521)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV

KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0471 (SEQ ID NO.:522)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0472 (SEQ ID NO.:523)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV

KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0473 (SEQ ID NO.:524)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKS NLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG

YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0474 (SEQ ID NO.:525)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKS NLKPFERDISNETYQAGSTPCNGVAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV

KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0475 (SEQ ID NO.:526) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG

YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0476 (SEQ ID NO.:527)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG

YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG

HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0477 (SEQ ID NO.:528)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV

KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0478 (SEQ ID NO.:529)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0479 (SEQ ID NO.:530)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG

YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0480 (SEQ ID NO.:531)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0481 (SEQ ID NO.:532)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKS NLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG

YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0482 (SEQ ID NO.:533)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKS NLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS

VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0483 (SEQ ID NO.:534)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKS NLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV

KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0484 (SEQ ID NO.:535)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKS NLKPFERDISNETYQAGSTPCNGVAGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDIT PCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTI SVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQV KQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICA

QKFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVL YENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKG YHLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNF YEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSG HHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0485 (SEQ ID NO.:536)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK >Cov0486 (SEQ ID NO.:537)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0487 (SEQ ID NO.:538)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0488 (SEQ ID NO.:539)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0489 (SEQ ID NO.:540)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0490 (SEQ ID NO.:541)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0491 (SEQ ID NO.:542)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH

HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0492 (SEQ ID NO.:543)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0493 (SEQ ID NO.:544)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE

AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0494 (SEQ ID NO.:545)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0495 (SEQ ID NO.:546) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0496 (SEQ ID NO.:547)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH

HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0497 (SEQ ID NO.:548)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYAYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0498 (SEQ ID NO.:549)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYAYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0499 (SEQ ID NO.:550)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYAYRLFRKSNLK PFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0500 (SEQ ID NO.:551)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYAYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0501 (SEQ ID NO.:552)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYAYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0502 (SEQ ID NO.:553)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYAYRLFRKSNL KPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0503 (SEQ ID NO.:554)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYAYRLFRKSNLK PFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0504 (SEQ ID NO.:555)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYAYRLFRKSNLK PFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT

VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0505 (SEQ ID NO.:556)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYAYRLFRKSNLK PFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK >Cov0506 (SEQ ID NO.:557)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYAYRLFRKSNL KPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0507 (SEQ ID NO.:558)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYAYRLFRKSNL KPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0508 (SEQ ID NO.:559)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYAYRLFRKSNL KPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI

IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0509 (SEQ ID NO.:560)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYAYRLFRKSNLK PFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0510 (SEQ ID NO.:561)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYAYRLFRKSNLK PFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP

VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0511 (SEQ ID NO.:562)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYAYRLFRKSNLK PFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGG VSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIP VSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTP PIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLT VLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLI ANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPE AEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSF PQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPIT TDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHH

HHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0512 (SEQ ID NO.:563)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYAYRLFRKSNL KPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI

IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0513 (SEQ ID NO.:564)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYAYRLFRKSNL KPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>Cov0514 (SEQ ID NO.:565)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYAYRLFRKSNL KPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN NSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEI IPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYK

TPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQK LIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPP EAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMS FPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPI TTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHH HHHGSGGSGGSGGTGAHIVMVDAYKPTK

>A.27_ [Mayotte] (SEQ ID NO.:566) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAG AAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESI VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRL FRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAP ATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILD ITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GVEYVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNF TISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQ VKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNV LYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKG

YHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNF YEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLVFIAGLIAIVMVTIMLCCMTSC CSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

>A.27+S494P [engineered] (SEQ ID NO.:567)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAG AAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESI VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRL FRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAP ATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILD ITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GVEYVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNF TISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQ VKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNV

LYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKG YHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNF YEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLVFIAGLIAIVMVTIMLCCMTSC CSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

>AAV49723.1_[SARS_coronavirus_PC4-241] (SEQ ID NO.:568)

MFIFLLFLTLTSGSDLDRCTTFDQAPNYTQSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFH TINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNP FFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGY QPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKY DENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNAT KFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQ IAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPF SPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCV NFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASS EVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGIC ASYHTVSSLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYI CGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILP DPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAA YTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQE SLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQ SLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVT YVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGII NNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLID LQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCCKFDEDDSEP VLKGVKLHYT

>AT098157.1_[Bat_SARS-like_coronavirus_Rs4231] (SEQ ID NO.:569)

MFIFLFFLTLTSGSDLESCTTVQAPPQHSSSRRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTI NHRFDNPVIPFKDGVYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPF FAVSKPTGTQTHTMIFDNAFNCTFEYISDSFSLDVAEKSGNFKHLREFVFKNKDGFLYVYKGYQP IDVVRDLPSGFNILKPIFKLPLGINITNFRAILTAFLPAQDTWGTSAAAYFVGYLKPATFMLKYDE NGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVAPSKEVVRFPNITNLCPFGEVFNATTFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNF NFNGLTGTGVLTSSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNTSSEV AVLYQDVNCTDVPVAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICAS YHTVSSLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICG DSTECANLLLQYGSFCTQLNRALSGIAVEQDRNTREVFAQVKQMYKTPALKDFGGFNFSQILPDP LKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVNARDLICAQKFNGLTVLPPLLTDDMIAAY TAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQES LTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQS LQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVT CVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRNFFSPQIITTDNTFVSGSCDVVIGIIN NTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDL QELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCCKFDEDDSEPV LKGVKLHYT

>AVP78031.1_[Bat_SARS-like_coronavirus_ZC45] (SEQ ID NO.:570)

LFFLFLQFALVNSQCVNLTGRTPLNPNYTNSSQRGVYYPDTIYRSDTLVLSQGYFLPFYSNVSWY YSLTTNNAATKRTDNPILDFKDGIYFAATEHSNIIRGWIFGTTLDNTSQSLLIVNNATNVIIKVCNF DFCYDPYLSGYYHNNKTWSIREFAVYSSYANCTFEYVSKSFMLNISGNGGLFNTLREFVFRNVD GHFKIYSKFTPVNLNRGLPTGLSVLQPLVELPVSINITKFRTLLTIHRGDPMPNNGWTAFSAAYFV GYLKPRTFMLKYNENGTITDAVDCALDPLSETKCTLKSLTVQKGIYQTSNFRVQPTQSVVRFPNI TNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYAD TFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERD LSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTQLVKNQCVNFNFNG LKGTGVLTDSSKRFQSFQQFGKDASDFIDSVRDPQTLEILDITPCSFGGVSVITPGTNTSLEVAVLY QDVNCTDVPTTIHADQLTPAWRIYATGTNVFQTQAGCLIGAEHVNASYECDIPIGAGICASYHTA SILRSTSQKAIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSIE CSNLLLQYGSFCTQLNRALSGIAIEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKR SFIEDLLFNKVTLADAGFIKQYGDCLGGISARDLICAQKFNGLTVLPPLLTDEMIAAYTAALISGT ATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLTSTASAL GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQ QLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYIPSQEKN FTTAPAICHEGKAHFPREGVFVSNGTHWFVTQRNFYEPKIITTDNTFVSGNCDVVIGIINNTVYDP LQPELDSFKEELDKYFKNHTSPDIDLGDISGINASVVNIQKEIDRLNEVARNLNESLIDLQELGKYE QYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLH YT

>B.1.315_[South_African] (SEQ ID NO.:571)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHRSYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTIS VTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSR LDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGY HLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYE PQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVV NIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSC LKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

>BA67 [Indian- VariantofConcern] (SEQ ID NO.:572)

MFVFLVLLPLVSSQCVNLRTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLDVYYHKNNKSWMESGVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKN IDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAA AYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRF PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTN VYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFR KSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPA TVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDI TPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIG AEHVNNSYECDIPIGAGICASYQTQTNSRRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFT ISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQ VKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNV LYENQKLIANQFNS AIGKIQDSLS STASALGKLQNVVNQNAQALNTLVKQLS SNFGAIS SVLNDIL SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKG YHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNF YEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS

VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSC CSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

>E484K+S494P+N501Y_[engineered] (SEQ ID NO.:573)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAG AAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESI VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRL FRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHA PATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEIL DITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCL IGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTN FTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFA QVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQN VLYENQKLIANQFNS AIGKIQDSLS STAS ALGKLQDVVNQNAQALNTLVKQLS SNFGAIS SVLND ILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCG KGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQR NFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGIN ASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMT SCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

>QHD43416.1 JSARS-CoV-2] (SEQ ID NO.:574)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAG AAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESI VRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRL FRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP ATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILD ITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNF TISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQ VKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNV LYENQKLIANQF S AIGKIQDSLS STASALGKLQDVVNQNAQALNTLVKQLS SNFGAIS SVLNDIL SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKG

YHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNF YEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSC CSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

>QIA48632.1_[Pangolin_coronavirus_PANG/GX] (SEQ ID NO.:575)

MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFN

TINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQ FCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVD GYFKIYSKHTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAA YYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWRVYSAGANVFQTRAGCLVG AEHVNNSYECDIPVGAGICASYHSMSSFRSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI YKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYEN QKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHL MSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQI ITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQ

KEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIIMVTIMLCCMTSCCSCLKG CCSCGSCCKFDEDDSEPVLKGVKLHYT

>Cov0592 (SEQ ID NO.:576)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0593 (SEQ ID NO.:577)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0594 (SEQ ID NO.:578)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH >Cov0595 (SEQ ID NO.:579)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0596 (SEQ ID NO.:580)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0597 (SEQ ID NO.:581)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH

HH

>Cov0598 (SEQ ID NO.:582)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHH

HHH

>Cov0599 (SEQ ID NO.:583)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKF

PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA

PGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSP DGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHH HH

>Cov0600 (SEQ ID NO.:584)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF

PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHH

HH

>Cov0601 (SEQ ID NO.:585)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNVCPFHKVFNATRF PSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQ TGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDF NPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0602 (SEQ ID NO.:586)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYA DTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFER

DLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSAT KLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGN YNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLS FELLNAP ATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVI

AWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQ PTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0603 (SEQ ID NO.:587)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS

NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRY LRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAP ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS

FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWER TKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYN YKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEY QATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKR ISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYN YKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGF

NCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0604 (SEQ ID NO.:588)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNV

YADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLR HGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPAT VCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK

CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD SKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCI ADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDD

FTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVV VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYS VLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG CVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYG FQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0605 (SEQ ID NO.:589)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK

YFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFK

CYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDV

GNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGP

KLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA

DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDD

FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQ

PYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPR

FPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRY LRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAP ATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEG FNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0606 (SEQ ID NO.:590)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYA DTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFER

DLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF

VIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSAT

KLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGN YNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLS FELLNAP ATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVI AWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQ PTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0607 (SEQ ID NO.:591)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRY LRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAP ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS

FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWER TKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYN YKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEY QATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKR ISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYN YKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGF NCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0608 (SEQ ID NO.:592)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNV

YADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLR HGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPAT VCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD

SKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCI ADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDD FTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVV VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYS

VLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG CVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYG FQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0609 (SEQ ID NO.:593)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELD

KYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTF

KCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQD

VGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCG

PKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCV

ADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPD

DFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPL

QSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGP

RFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS

NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRY

LRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAP ATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGF NCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0610 (SEQ ID NO.:594)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYA DTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFER DLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSAT KLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGN YNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLS FELLNAP ATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVI

AWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQP TNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0611 (SEQ ID NO.:595)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRY LRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAP ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWER TKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYN YKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEY QATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKR ISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYN YKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFN CYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0612 (SEQ ID NO.:596)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNV

YADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLR HGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPAT VCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK

CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD SKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQP YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCI ADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDD

FTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVV VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYS VLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG CVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYG FQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0613 (SEQ ID NO.:597)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFK CYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDV GNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGP

KLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQ SYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPR FPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRY LRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAP

ATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKG

FNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0614 (SEQ ID NO.:598)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVY ADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRH GKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATV CGPKLSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGN YFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKL STGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPT KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNY NYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLS FELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVI AWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQ PTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0615 (SEQ ID NO.:599)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTS VYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKP FERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRF PNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSN VYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYL RHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPA TVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASF STFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKG FNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH >Cov0616 (SEQ ID N0.:600)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVY ADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFE RDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITN LCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADS

FVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKL RPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVS PTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGG

NYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVV LSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSV LYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGC VIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGF QPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0617 (SEQ ID NO.:601)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTF

KCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTR NIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGY

QPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKV FNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVR

QVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVR TLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAG PRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC

FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRL FRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHA

PATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNR KRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIAD

YNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVE GFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH >Cov0618 (SEQ ID NO.:602)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSN LKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVC GPKKSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYG VSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDAT STGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRV VVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYT VFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGC VIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSF ELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPT YGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0619 (SEQ ID NO.:603)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLF RKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAP ATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSF STFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTA KQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPA TVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEG FNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0620 (SEQ ID NO.:604) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV

CGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCY

GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGN

YFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKL

STGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSA

TKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTG

NYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVV

LSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSV

LYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGC VIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGF QPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0621 (SEQ ID NO.:605)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELD

KYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFST

FKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNN

LDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY

QPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV

FNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGD

DVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDIS

NVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSF

KEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNS

TSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWN

TAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNA

PATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRK

RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY

NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEG FNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0622 (SEQ ID NO.:606) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSN LKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVC GPKKSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYG VSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDAT STGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRV VVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYT VFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGC VIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSF ELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPT NGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0623 (SEQ ID NO.:607)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLF RKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAP ATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSF STFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTA KQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPA TVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGF NCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0624 (SEQ ID NO.:608)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG

STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCY

GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGN

YFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKL

STGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSA

TKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTG

NYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVV

LSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSV

LYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGC VIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGF QPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0625 (SEQ ID NO.:609)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG

STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK

YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTF

KCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNL

DSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGY

QPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV

FNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGD

DVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDIS

NVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSF

KEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNS

TSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWN

TAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNA

PATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRK

RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGF NCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0626 (SEQ ID NO.:610)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVY ADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRH GKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATV CGPKLSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGN YFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKL STGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPT KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNY NYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLS FELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY NSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVI AWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQP TNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0627 (SEQ ID NO.:611)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTS VYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKP FERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRF PNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSN VYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYL RHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPA TVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASF STFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGF NCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0628 (SEQ ID NO.:612)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVY ADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFE RDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITN LCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADS FVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKL RPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVS PTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGG NYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVV LSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSV LYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGC VIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGF

QPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0629 (SEQ ID NO.:613)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTF KCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTR NIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGY QPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKV FNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVR QVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVR TLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAG

PRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRL FRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP ATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKG FNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0631 (SEQ ID NO.:614)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLF RKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP ATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSF STFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTA KQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPA TVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFS TFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRK RISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADY NYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKG FNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0633 (SEQ ID NO.:615)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFST FKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNT RNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIG YQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHK VFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEV RQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGV RTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKA

GPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDL CFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYR LFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHA PATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNR KRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIAD YNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVE GFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0662 (SEQ ID NO.:616)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVY ADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRS KLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVC GPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCY GVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSK VGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPY RVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVA DYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPD DFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYP LERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0663 (SEQ ID NO.:617)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCF TNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRL FRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGP ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWER KRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIA DYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAI GPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGHHHHHHHH

>Cov0664 (SEQ ID NO.:618)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNV YADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVR RSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPAT VCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK

CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLD

SKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQP

YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNC

VADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKL

PDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCY

YPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNA

TRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVR

QIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIY

QAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHH

HHHHH

>Cov0665 (SEQ ID NO.:619)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG

STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK

YFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTF

KCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVK

QDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVN YQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV FNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGD

EVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDIS

TEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGS

FKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYN

STSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVL

AWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFT TAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS

FVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKP

FERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHHH

>Cov0666 (SEQ ID NO.:620)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVY ADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKS KLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATV CGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS KVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPY RVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVA DYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPD DFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPL RPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFA SVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPG QTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGS KPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0667 (SEQ ID NO.:621)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCF TNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRL FRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGP ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWER KRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIA DYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAI GPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGHHHHHHHH

>Cov0668 (SEQ ID NO.:622)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNV YADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVR RSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPAT VCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD SKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNC VADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKL PDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCY YPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNA TRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVR QIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY

QAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHH HHHHH

>Cov0669 (SEQ ID NO.:623)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTF KCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNS KDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGH QPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVF NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDE

VRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDIST EIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYN STSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIA WNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHP TTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS FVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKP FERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHHH

>Cov0670 (SEQ ID NO.:624)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVY ADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKS KLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATV CGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS KVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPY RVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVA DYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPD DFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPL RPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFA SVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPG QTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGST PCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHH H

>Cov0671 (SEQ ID NO.:625)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRW VRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAP ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNR KRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIAD YNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQV GLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPF ERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGHHHHHHHH

>Cov0672 (SEQ ID NO.:626)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLD SKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCV ADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLP

DDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNP LRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATR FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIA PGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQA GSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHH HHH

>Cov0673 (SEQ ID NO.:627)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTF KCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNS KDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGH QPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVF NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDE

VRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDIST EIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYN STSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIA WNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHP TTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS FVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKP FERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPK

KSTGSGHHHHHHHH

>Cov0674 (SEQ ID NO.:628)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVY ADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRS KLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVC GPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCY GVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSK VGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVAD

YSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDF TGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQP YGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFAS VYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPG QTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGS TPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHH H

>Cov0675 (SEQ ID NO.:629)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGS GRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRL FRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHA PATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTS

FSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAW NTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAG VGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWN RKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIA DYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGV KGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS FVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKP

FERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHHH

>Cov0676 (SEQ ID NO.:630)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA

GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRF

PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTN

VYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFR

KSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPA

TVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTF

KCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNS

KDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGH

QPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISN

CVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKL

PDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYF

PLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNAT

RFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQI

APGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQ

AGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH

HHHH

>Cov0677 (SEQ ID NO.:631)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA

PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA

GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELD

KYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFST

FKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNN

LDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGY

QPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV

FNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGD

EVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDIS

TEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGS

FKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYN

STSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVL

AWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFT

TAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNL

CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS

FVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKP

FERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPK

KSTGSGHHHHHHHH

>Cov0678 (SEQ ID NO.:632) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY ADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSN LKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVC GPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYG VSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSS TSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYR VVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVAD YSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDF TGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQS YGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFAS VYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPG QTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGS TPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHH H

>Cov0679 (SEQ ID NO.:633)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLF RKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAP ATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSF STFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWN TNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGV GHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNR KRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIAD YNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVE GFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLC PFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSF VVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKP FERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPK LSTGSGHHHHHHHH

>Cov0680 (SEQ ID NO.:634) MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKS NLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV CGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKC YGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKD SSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPY RVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQ PYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNASKFA SVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAP GQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAG STPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHH HH

>Cov0681 (SEQ ID NO.:635)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFST FKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNN LDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV FNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGD DVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDL SNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQP TNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS FVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKP FERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHHH >Cov0682 (SEQ ID NO.:636)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKS NLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS KVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQP YRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCV ADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLP DDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNP LRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0683 (SEQ ID NO.:637)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRW VRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAP ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNR KRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIAD YNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVE GFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLC PFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSF VVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKP FERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPK LSTGSGHHHHHHHH >Cov0684 (SEQ ID NO.:638)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNV YADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVR RSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPAT VCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD

SKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQP YRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNC VADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFP LQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNASK FASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQI APGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQ AGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHH HHHH

>Cov0685 (SEQ ID NO.:639)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTF KCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNS KDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGH QPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVF NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDE

VRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDIST EIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT YGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLC PFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSF VVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKP FERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPK

LSTGSGHHHHHHHH >Cov0686 (SEQ ID NO.:640)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA

PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA

GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC

YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS

KVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPY

RVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVA

DYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPD

DFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPL

RPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFA

SVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPG

QTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGS

KPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0687 (SEQ ID NO.:641)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA

PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA

GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGS GRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC

FTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRL

FRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHA

PATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSA

SFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWN

SNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNG

VGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWE

RKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIA

DYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAI

GPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLC

PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF

VIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPF ERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGHHHHHHHH >Cov0688 (SEQ ID NO.:642)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP NITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNV YADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVR RSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPAT VCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFK CYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQ DALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNY QPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISN CVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKL

PDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYF PLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNAT RFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQI APGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQ AGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHH HHHH

>Cov0689 (SEQ ID NO.:643)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTF KCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVK QDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVN YQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV FNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGD DVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDL SNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN

SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQP TNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS FVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKP FERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK

KSTGSGHHHHHHHH

>Cov0690 (SEQ ID NO.:644)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSN

LKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVC GPKKSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY GVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDA LTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPF RVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVAD YSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDD

FLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLR PYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFAS VYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPG QTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGS KPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH

>Cov0693 (SEQ ID NO.:645)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFST FKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNN

LDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV FNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGD EVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDIS TEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGS FKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYN

STSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVL AWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFT TAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS FVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKP

FERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK

KSTGSGHHHHHHHH

>Cov0722 (SEQ ID NO.:646)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSN LKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVC GPKKSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYG VSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNY FYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLS TGSGHHHHHHHH

>Cov0723 (SEQ ID NO.:647)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNVCPFHKVFNATRF PSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQ TGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDF NPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQ TGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTP CNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV CGPKKSTGSGHHHHHHHH

>Cov0724 (SEQ ID NO.:648)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNVCPFHKVFNATRF PSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQ TGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDF NPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYA WNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTG KIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCN GVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADS FVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKP FERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK

KSTGSGHHHHHHHH

>Cov0725 (SEQ ID NO.:649)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTF KCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNL DSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQ PYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVF NATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQ

VAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTL STYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0726 (SEQ ID NO.:650)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYA DTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFER DLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPF

ERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STGSGHHHHHHHH

>Cov0727 (SEQ ID NO.:651)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG RFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTS VYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKP FERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRF PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTN VYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRK SNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPAT

VCGPKKSTGSGHHHHHHHH

>Cov0728 (SEQ ID NO.:652)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN

ITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVY

ADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRH

GKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATV

CGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC

YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS

KVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPY

RVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0729 (SEQ ID NO.:653)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG

STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG

RFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS

NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRY

LRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAP

ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSAS

FSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNS

NNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV

GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0730 (SEQ ID NO.:654)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKF

PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA

PGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSP

DGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC

YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS KVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPY

RVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0731 (SEQ ID NO.:655)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG

STPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDK

YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTF

KCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNL

DSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGY

QPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV

FNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGD

DVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDIS

NVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGH HHHHHHH

>Cov0732 (SEQ ID NO.:656)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKC

YGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNID

ATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPY

RVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0733 (SEQ ID NO.:657)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKF

PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA

PGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSP

DGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDK

YFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTF

KCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNL

DSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQ

PYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVF

NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDE VRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDIST

EIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSG

HHHHHHHH

>Cov0734 (SEQ ID NO.:658)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPN ITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVY ADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKS KLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATV CGPKLSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCY GVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDS

STSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPY RVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH

>Cov0735 (SEQ ID NO.:659)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGR FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFT NVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLF RKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP ATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTS FSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWN

SVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTG VNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHH

>Cov0736 (SEQ ID NO.:660)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTF PSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIA PGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPN ITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVY ADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKS KLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATV CGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS KVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQP

YRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH

>Cov0737 (SEQ ID NO.:661)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA

PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA

GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFST FKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNN LDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY

QPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEV FNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGD

DVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDL SNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSG HHHHHHHH

>Cov0738 (SEQ ID NO.:662)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRF

ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP

GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAG SKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSG

RFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS

NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRW

VRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAP ATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTS

FSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWN SVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTG VNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHH

>Cov0739 (SEQ ID NO.:663)

MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKF

ASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIA

PGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQA

GSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFST FKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTN SKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGH

QPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVF NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDE VRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDIST

EIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSG

HHHHHHHH

>Cov0556 (SEQ ID NO.:664)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFN

CYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0557 (SEQ ID NO.:665)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRI

SNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYN

YKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPN

CYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0558 (SEQ ID NO.:666)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC

YFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0559 (SEQ ID NO.:667) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC

YFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0560 (SEQ ID NO.:668)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC

YFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGE

VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRG

DEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDI

STEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGS

HHHHHHHH

>Cov0561 (SEQ ID NO.:669)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC

YFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGE

VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRG

DEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDI STEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGS

HHHHHHHH

>Cov0562 (SEQ ID NO.:670)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC

YFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGE

VFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG

DDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERD

ISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSH

HHHHHHH

>Cov0563 (SEQ ID NO.:671)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC YFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRG

DEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDI STEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGS HHHHHHHH

>Cov0564 (SEQ ID NO.:672)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNY KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFN

CYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFG EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFER DISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST

GSHHHHHHHH

>Cov0565 (SEQ ID NO.:673)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFN CYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFG EVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVK

GDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFER DISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGS HHHHHHHH

>Cov0566 (SEQ ID NO.:674) MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFN

CYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFG

EVFNATRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK

LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYN YRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSF ELLHAPATVCGPKKSTSTGSHHHHHHHH

>Cov0567 (SEQ ID NO.:675)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFN

CYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFG EVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVK

GDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFER DISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGS HHHHHHHH

>Cov0568 (SEQ ID NO.:676)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY KLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFN CYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFER

DISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKST

GSHHHHHHHH

>Cov0569 (SEQ ID NO.:677)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRI

SNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNY

KLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC

YFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGE

VFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG

DDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERD

ISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSH

HHHHHHH

>Cov0570 (SEQ ID NO.:678)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRI SNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYN

YKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPN

CYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFG EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD ISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTG

SHHHHHHHH

>Cov0571 (SEQ ID NO.:679)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRI

SNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYN

YKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPN

CYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD ISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTG SHHHHHHHH

>Cov0572 (SEQ ID NO.:680)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRI

SNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYN

YKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPN

CYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFG EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFER DISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST

GSHHHHHHHH

>Cov0573 (SEQ ID NO.:681)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRI SNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYN YKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPN CYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFG

EVFNATRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYN YRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSF ELLHAPATVCGPKKSTSTGSHHHHHHHH

>Cov0574 (SEQ ID NO.:682)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFER

DISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST

GSHHHHHHHH

>Cov0575 (SEQ ID NO.:683)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVK GDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFER

DISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGS

HHHHHHHH

>Cov0576 (SEQ ID NO.:684)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFER

DISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKST

GSHHHHHHHH

>Cov0577 (SEQ ID NO.:685)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD ISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTG SHHHHHHHH

>Cov0578 (SEQ ID NO.:686)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD ISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTG PPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADY

SVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFT GCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSY GFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0579 (SEQ ID NO.:687)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD

ISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTG PPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADY SVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFT GCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQS

YGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0580 (SEQ ID NO.:688)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD

ISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTG

PPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADY

SVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDF

MGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNG

YGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0581 (SEQ ID NO.:689)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD

ISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTG PPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADY SVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFT

GCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPY GFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0582 (SEQ ID NO.:690)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD ISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTG PPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADY SVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFT

GCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQS YGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH >Cov0583 (SEQ ID NO.:691)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD

ISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTG

PPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADY

SVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDF

MGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNG

YGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0584 (SEQ ID NO.:692)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERD

ISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTG

PPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADY

SVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFT GCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPY GFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTSTGSHHHHHHHH

>Cov0585 (SEQ ID NO.:693)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFER

DISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST

GPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVAD

YSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDD

FMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLN

GYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0586 (SEQ ID NO.:694)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFER

DISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST

GPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVAD

YSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDF

TGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQP

YGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0587 (SEQ ID NO.:695)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ

KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY

ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS

RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY

HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV

VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG

EVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR

GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFER

DISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKST

GPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVAD

YSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDD

FMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLN

GYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH

>Cov0588 (SEQ ID NO.:696)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF

HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC

EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF

KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA

YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV

CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP

CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA

EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK

QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY

IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG EVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVK GDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFER DISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGP PPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYS VLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG

CVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYG FQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0589 (SEQ ID NO.:697)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG EVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVK GDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFER DISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGP

PPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYS VLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTG

CVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYG

FQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0590 (SEQ ID NO.:698)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG EVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVK GDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFER DISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGP

PPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYS VLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG CVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSY GFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH

>Cov0591 (SEQ ID NO.:699)

MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVC EFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAA YYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP CSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTIS

VTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVK QIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLY ENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS RLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGY HLMSFPQAAPHGVVFLHVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFY

EPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASV VNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGY IPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFG EVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVK GDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFER DISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGP

PPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYS VLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG CVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYG FQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTSTGSHHHHHHHH

>SpyTag amino acid sequence (SEQ ID N0.:700)

AHIVMVDAYKPTK

>Engineered stem-helix polypeptide (SEQ ID NO.:701)

PGSFKEELDKYFKNHTSDAASKAGP

>Townsend linker (SEQ ID NO.:702)

GSGGSGGSGGTG

>RESERVED (SEQ ID NO.: 703)

>His Tag amino acid sequence (SEQ ID NO.:704)

HHHHHHHH

>Signal Peptide (SEQ ID NO.:705)

MNTQILVFALIAIIPTNADKI

>Signal Peptide (SEQ ID NO.:706) MAPLLLLLPLLWAGALA

>Signal Peptide (SEQ ID NO.:707)

MFVFLVLLPLVS

>Signal Peptide (SEQ ID NO.:708)

MFVFLVLLPLVSS

>Linker (SEQ ID NO.: 709)

GPPSPPG

>Linker (SEQ ID NO.:710)

GSGSGS

>Linker (SEQ ID NO.:711)

GSGSGSGSG

>Cov0746 (SEQ ID NO.:712)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN

NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG

YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE

VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG

DDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERD

LSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPG

SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVL

YNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCV

IAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFR

PTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITN

LCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYAD

SFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNL

KPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCG

PKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCV

ADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPD

DFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPL

YRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0747 (SEQ ID NO.:713)

MAPLLLLLPLLWAGALARFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPF

FTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN KLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVG

HQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE

VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG

DDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERD

LSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPG

SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVL

YNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGC

VIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYG

FHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNI

TNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVY

ADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATV

CGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISN

CVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKL

PDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYY

PLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0748 (SEQ ID NO.:714)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSN

NLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVG

YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE

VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG

DDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERD

LSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPG

SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVL

YNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCV

IAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFR

PTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITN

LCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYAD

SFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNL

KPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCG

PKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCV

ADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPD

DFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPL YRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH

>Cov0749 (SEQ ID NO.:715)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG

YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE

VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG

DDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERD

LSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPG

SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVL

YNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCV

IAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFR

PTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITN

LCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYAD

SFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNL

KPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCG

PKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCV

ADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPD

DFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPL

YRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKST

>Cov0750 (SEQ ID NO.:716)

MAPLLLLLPLLWAGALARFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPF

FTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN

KLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVG

HQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE

VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG

DDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERD

LSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPG

SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVL

YNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGC

VIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYG

FHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNI

TNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVY

ADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS

NLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATV

CGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISN

CVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKL

PDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYY

PLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKST

>Cov0751 (SEQ ID NO.:717)

MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS

TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSN NLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKG DDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERD LSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVL YNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCV IAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFR PTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITN LCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYAD SFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNL KPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCG PKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCV ADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPD DFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPL YRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKST

>Cov0758 (SEQ ID NO.:718)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQ FCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYF KIYSKHTPIIVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYY VGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYA DSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNL KPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYV NNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTT EILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIY KTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFK GLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDP PEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMS FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT TDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHH HHH

>Cov0759 (SEQ ID NO.:719) MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQ FCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYF KIYSKHTPIIVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYY VGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYA DSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNL KPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYV NNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTT EILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIY

KTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFK GLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQ KLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDP PEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMS FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT TDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLSPA

>Cov0761 (SEQ ID NO.:720)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQ FCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYF KIYSKHTPIIVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYY VGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYA DSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNL KPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYV NNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTT EILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIY

KTPPIKYFGGFNFSQILPDPSKPSKRSPIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFK GLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGPALQIPFPMQMAYRFNGIGVTQNVLYENQK LIANQFNSAIGKIQDSLSSTPSALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDPPE AEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFP QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD NTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEID RLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHH

HH

>Cov0762 (SEQ ID NO.:721)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWF HVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQ FCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYF KIYSKHTPIIVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYY VGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYA DSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNL KPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCG PKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSF GGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYV NNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTT EILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIY

KTPPIKYFGGFNFSQILPDPSKPSKRSPIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFK GLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGPALQIPFPMQMAYRFNGIGVTQNVLYENQK LIANQFNSAIGKIQDSLSSTPSALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDPPE AEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFP QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD NTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEID RLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLSPA

>SEQ ID No.:722 (Wuhan-Hu-1 RBD polypeptide) nitnlcpfgevfhatrfasvyawnrkrisncvadysvlynsasfstfkcygvsptklndlcftnvyadsfvirgdevrqiapgqtgkiadynyklpddf tgcviawnsnnldskvggnynylyrlfrksnlkpferdisteiyqagstpcngvegfhcyfplqsygfqptngvgyqpyrvvvlsfellhapatvcg pkkst

>SEQ ID No.:723 (Wuhan-Hu-1 RBD polypeptide) rfpnitnlcpfgevfhatrfasvyawnrkrisncvadysvlynsasfstfkcygvsptklndlcftnvyadsfvirgdevrqiapgqtgkiadynyklp ddftgcviawnsnnldskvggnynylyrlfrksnlkpferdisteiyqagstpcngvegfhcyfplqsygfqptngvgyqpyrvvvlsfellhapatv cgpkkst

>SEQ ID NO.:724 (SARS-CoV-2 Beta variant RBD polypeptide)

RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLF RKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAP ATVCGPKKST >SEQ ID NO.:725 (SARS-CoV-2 Beta variant RBD polypeptide)

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKS NLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKST

>SEQ ID NO.:726 (SARS-CoV-2 Delta variant RBD polypeptide)

RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLF RKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP ATVCGPKKST

>SEQ ID NO.:727 (SARS-CoV-2 Delta variant RBD polypeptide)

NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNV YADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKS NLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV CGPKKST

>SEQ ID NO.:728 (SARS-CoV-2 Omicron variant RBD polypeptide)

RFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLF RKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAP ATVCGPKKST

>SEQ ID NO.:729 (SARS-CoV-2 Omicron variant RBD polypeptide)

NITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNV

YADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKS NLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATV CGPKKST

>SEQ ID NO.:730 (RsSHC014 RBD polypeptide)

RFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFS NVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRW VRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAP ATVCGPKLST

>SEQ ID NO.:731 (RsSHC014 RBD polypeptide)

NITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNV

YADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVR RSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPAT

VCGPKLST

>SEQ ID NO.: 732 (PANG/GX RBD polypeptide)

RFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCF TNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRL FRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGP ATVCGPKLST

>SEQ ID NO.: 733 (PANG/GX RBD polypeptide)

NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRK SKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPAT VCGPKLST

>SEQ ID NO.:734 (PANG/GD RBD polypeptide)

RFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCF TNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRL FRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAP ATVCGPKQST

>SEQ ID NO.:735 (PANG/GD RBD polypeptide)

NITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRK SNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPAT VCGPKQST

>SEQ ID NO.:736 (RatG13 RBD polypeptide)

RFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCF TNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLF RKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAP ATVCGPKKST

>SEQ ID NO.:737 (RatG13 RBD polypeptide)

NITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNV YADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKA NLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATV CGPKKST

>SEQ ID NO.:738 (amino acid sequence from Cov0064)

RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLF RKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAP ATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKR

ISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADY

NYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVG

PNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDA

ASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTK

LNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNY

GYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLS

FELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVY

AWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQT

GRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC

NGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFK

NHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY

GVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKE

GGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYR

VVVLSFELLNAPATVCGPKKST

>SEQ ID NO.:739 (amino acid sequence from Cov0747)

RFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCF

TNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLF

RKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAP

ATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKR

ISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADY

NYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVG

PNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDA

ASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTK

LNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNY

GYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLS

FELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVY

AWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQT

GRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC

NGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFK

NHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY

GVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKE

GGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYR

VVVLSFELLNAPATVCGPKKST

>SEQ ID NO.:740 (amino acid sequence from Cov0748)

RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF

TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLF

RKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP ATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKR ISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADY NYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVG PNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDA ASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTK LNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYN YLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSF ELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVY AWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQT GRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY GVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKE GGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYR VVVLSFELLNAPATVCGPKKST

>SEQ ID NO.:741 (amino acid sequence from Cov0749)

RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLF RKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAP ATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKR ISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADY NYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVG PNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDA ASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTK LNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYN YLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSF ELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVY AWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQT GRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC NGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY GVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKE GGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYR VVVLSFELLNAPATVCGPKKST

>SEQ ID NO.:742 (amino acid sequence from Cov0750)

RFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCF TNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLF RKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAP ATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKR

ISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADY

NYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVG

PNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDA

ASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTK

LNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNY

GYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLS

FELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVY

AWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQT

GRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC

NGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFK

NHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY

GVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKE

GGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYR

VVVLSFELLNAPATVCGPKKST

>SEQ ID NO.:743 (amino acid sequence from Cov0751)

RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF

TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLF

RKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP

ATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKR

ISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADY

NYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVG

PNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDA

ASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTK

LNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYN

YLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSF

ELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVY

AWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQT

GRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPC

NGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFK

NHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCY

GVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKE

GGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYR

VVVLSFELLNAPATVCGPKKST

>SEQ ID NO.:744 (Wuhan-Hu-1 RBM)

NSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN

GVGYQPY >SEQ ID NO.: 745 (Linker)

GPPPGSFKEELDKYFKNHTSDAASKAGP

>SEQ ID NO.:746 (Ace2 Forward Primer)

CAAGAGCAAACGGTTGAACAC

>SEQ ID NO.:747 (Ace2 Reverse Primer)

CCAGAGCCTCTCATTGTAGTCT

>SEQ ID NO.: 748 (HPRT Forward Primer)

CCTGGCGTCGTGATTAGTG

>SEQ ID NO.:749 (HPRT Reverse Primer)

ACACCCTTTCCAAATCCTCAG

>SEQ ID NO.: 750 (TMPRSS2 Forward Primer)

CAAGTGCTCCRACTCTGGGAT

>SEQ ID NO.:751 (TMPRSS2 Reverse Primer)

AACACACCGRTTCTCGTCCTC

>SEQ ID NO.:752 (S Gene Forward Primer)

CGAGAAAAAGGCATCTGGAG

>SEQ ID NO.:753 (S Gene Reverse Primer)

CATTGAACTCGTCGGTCTC

>SEQ ID NO.:754 (S2E12 VH)

QVQLVQSGPEVKKPGTSVRVSCKASGFTFTSSAVQWVRQARGQRLEWVGWIVVGSGNTNYAQ

KFHERVTITRDMSTSTAYMELSSLRSEDTAVYYCASPYCSGGSCSDGFDIWGQGTMVTVSS

>SEQ ID NO.:755 (S2E12 VL)

DIVLTQTPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS

GSGTDFTLTISRLEPEDFAVYYCQQYVGLTGWTFGQGTKVEIK

>SEQ ID NO.: 756 (S2X259 VH)

QVQLVQSGAEVKKPGSSVKVSCKASGGIFNTYTISWVRQAPGQGLEWMGRIILMSGMANYAQK

IQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGNYYGWGDDDAFDISGQGTLVTVYS

>SEQ ID NO.: 757 (S2X259 VL) QTVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPGTAPKLLICGNSNRPSGVPDRFS

GSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPNWVFGGGTKLTVL

>SEQ ID NO.:758 (S2K146 VH)

QVQLVESGGVVVQPGGSLRLSCAASGFTFHDHTMHWVRQAPGKGLEWVSLITWNGGTIHYSDS

VKGRFTISRDNSKNSLYLQMNSLRTEDTALYYCAKDLGRGGWYLPSDAWGQGTLVTVSS

>SEQ ID NO.:759 (S2K146 VL)

QSVLTQPPSASGTPGQRVTISCSGSSANIGSNTVNWYQHLPGTAPKLLIYSNNQRPSGVPDRFSGS

KSGTSASLAISGLQSEDEADYYCAAWDDSLKGVFGGGTKLTVL

>SEQ ID NO.: 760 (S2L20 VH)

EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYAD

SVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVSS

>SEQ ID NO.:761 (S2L20 VL)

VIWMTQSPSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGS

GSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDFK

>SEQ ID NO.: 762 (S2H97 VH)

QVRLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSF

QGQVTISADKSISTVYLQWSSLKASDTAMYYCARQWSHYTYDYYYWGQGTLVTISS

>SEQ ID NO.: 763 (S2H97 VL)

QSVLTQPASVSGSPGQSITISCTGISSDVGGYNSVSWYQQHPGKAPKLMIYDVTNRPSGVSNRFSG

SKSGNTASLTISGLQAEDEADYYCSSYTSSSTPPYVFGTGTKVSVL

>SEQ ID NO.: 764 (S2X333 VH)

EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWYDGSNKFYAD

SVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYFCARAFPDSSSWSGFTIDYWGQGTLVTVSS

>SEQ ID NO.: 765 (S2X333 VL)

SYELTQPPSVSVAPGQTARITCGGNNIERKSVHWCQQKPGQAPALVVYDDSDRPSGIPERFSGSN

SGNTATLTISRVEAGDEADYYCQVWDSGSDQVIFGGGTKLTVL EXAMPLES

EXAMPLE 1

DESIGN AND TESTING OF SARS-COV-2 PROTEIN CONSTRUCTS

Protein constructs were generated using the spike (S) protein ectodomain or RBD from the SARS-CoV-2 South African variant. Spike ectodomain constructs, RBD monomer constructs (i.e., comprising a single RBD polypeptide), and hybrid spike:RBD constructs were prepared. As discussed herein, three spike ectodomain constructs preferably associate to form a trimer.

The spike ectodomain constructs included: (Figure 1 A) a wild-type spike protein ectodomain linked to a foldon; (Figure IB) a wild-type spike protein ectodomain linked to a foldon, a Townsend linker linking a foldon of the trimer to a SpyTag; and (Figure 1C) a wildtype Spike protein ectodomain linked to a a foldon (three of the Spike protein ectodomains associating to form a trimer), and, C-terminal to a foldon of the trimer, one, two, or three copies of: a linker (GSG or GPP) linked to a stem -helix polypeptide engineered from the epitope recognized by antibody S2P6 (see Example 9).

The RBD monomer constructs included: (Figure 2A) an RBD polypeptide; (Figure 2B) a wild-type RBD polypeptide linked at its N-terminal end or at its C-terminal end to a SpyTag via a Townsend linker; and (Figure 2C) an RBD polypeptide linked at its N-terminal end to a SpyTag via a Townsend linker and at its C-terminal end to a stem-helix polypeptide via a GSG or GPP linker.

The hybrid Spike/RBD constructs were: (Figure 3A) a wild-type spike ectodomain trimer fused at its C-terminal end to a foldon trimer; each foldon of the trimer being linked to a (first) RBD polypeptide. In some constructs, each first RBD polypeptide was linked to a second RBD polypeptide. In some constructs, each second RBD polypeptide was linked to a third RBD polypeptide; and (Figure 3B) constructs of the same design as summarized in Figure 3 A, except that each linker (between foldon and first RBD polypeptide, between successive RBD polypeptides) comprised a stem-helix polypeptide, with a further stem-helix polypeptide linked to the C-terminal RBD polypeptide (whether first, second, or third).

The constructs were tested for expression (yes or no), purification yield (high or low), biophysical properties (assessed using SDS-PAGE, SEC-HPLC, and DSF), and antigenic binding features (assessed using BLI).

For the spike ectodomain contracts, desired biophysical properties included formation of soluble trimers over aggregates and monomers. Desired antigenic binding features were equivalent or increased binding (versus comparator wild-type spike trimer) by a panel of SARS- CoV-2 -binding antibodies (among these was the antibody S2P6, for which increased binding was desired), and equivalent binding (versus wild-type spike trimer) to human ACE2. For SpyTag- containing constructs, conjugation to nanoparticles with surface SpyCatcher was investigated.

For the RBD monomer constructs, desired biophysical properties included formation of soluble monomers over aggregates. Desired antigenic binding features for the fusions (Figures 2B and 2C) included equivalent binding (versus comparator isolated RBD; Figure 2A) by a panel of SARS-CoV-2-binding antibodies (and, for stem-helix-containing constructs, binding by antibody S2P6). Binding to human ACE2 was also investigated. For Spy Tag-containing constructs, conjugation to nanoparticles with surface SpyCatcher was investigated.

For the hybrid spike:RBD constructs, desired biophysical properties included formation of soluble trimers over aggregates, monomers, and soluble oligomers. Desired antigenic binding features included increased binding (versus comparator wild-type spike trimer) by a panel of SARS-CoV-2-binding antibodies (including increased binding by antibody S2P6 for stem-helix- containing constructs). Binding to human ACE2 was also investigated.

EXAMPLE 2

DESIGN AND TESTING OF PROTEIN CONSTRUCTS BASED ON ZOONOTIC CORONAVIRUS STRAINS

Protein constructs were generated using spike protein ectodomains and RBD polypeptides from zoonotic coronavirus strains as backbones. Spike ectodomain constructs, RBD monomer constructs, and RBD concatamer constructs were prepared.

The spike ectodomain constructs were of the designs shown in Figures 1A, IB, and 1C (e.g., some embodiments including, C-terminal to a foldon of the foldon trimer, one, two, or three copies of: a linker (GSG or GPP) linked to a stem-helix polypeptide).

The RBD monomer constructs were of the designs shown in Figures 2A-2C.

The RBD concatemer constructs were: constructs of the design shown in Figure 4A, each comprising three heterotypic (i.e., each RBD being different from the others) RBD polypeptides selected from three groups of zoonotic strains, the RBD polypeptides linked to form a single chain wherein the linker was either (GlySer)n (e.g., SEQ ID NO.:710), GPPSPPG (SEQ ID NO.:709), or a stem-helix polypeptide; and constructs of the design shown in Figure 4B, some comprising five heterotypic RBD polypeptides selected from three groups of zoonotic strains, the RBD polypeptides linked to one other so as to form a single chain (wherein the linker was either: (GlySer)n (e.g., SEQ ID NO.:710), GPPSPPG (SEQ ID NO.:709), or a stem-helix polypeptide); and others comprising five heterotypic RBD polypeptides selected from two groups of zoonotic strains, the RBD polypeptides linked to one other so as to form a single chain; these thirty constructs comprised two groups of fifteen different constructs wherein the linker was either: (GlySer)n (e.g., SEQ ID NO.:710), GPPSPPG (SEQ ID NO.:709), or a stem-helix polypeptide.

The constructs were tested for expression (yes or no), purification yield (high or low; for RBD monomer constructs, high or low as compared to the zoonotic RBD standalone), biophysical properties (assessed using SDS-PAGE, SEC-HPLC, and DSF), and antigenic binding features (assessed using BLI).

For the spike ectodomain contracts, desired biophysical properties included formation of soluble trimers over aggregates and monomers. Desired antigenic binding features were equivalent binding (versus comparator wild-type spike trimer) by a panel of SARS-CoV-2- binding antibodies, and increased binding by the S2P6 antibody. Binding to human ACE2 was investigated. For Spy Tag-containing constructs, conjugation to nanoparticles with surface SpyCatcher was investigated.

For the RBD monomer constructs, desired biophysical properties included formation of soluble monomers over aggregates and soluble oligomers. Desired antigenic binding features included equivalent binding (versus WT zoonotic RBD standalone) by a panel of SARS-CoV-2 - binding antibodies (and for stem-helix-containing constructs, binding by antibody S2P6). Binding to human ACE2 was also investigated. For Spy Tag-containing constructs, conjugation to nanoparticles with surface SpyCatcher was investigated.

For the RBD concatemer constructs, desired biophysical properties included formation of soluble monomers over aggregates and soluble oligomers. Desired antigenic binding features included increased binding (versus WT zoonotic RBD standalone) by a panel of SARS-CoV-2- binding antibodies (and for stem-helix-containing constructs, binding by antibody S2P6). Binding to human ACE2 was also investigated. For Spy Tag-containing constructs, conjugation to nanoparticles with surface SpyCatcher was investigated.

EXAMPLE 3

DESIGN AND TESTING OF PROTEIN CONSTRUCTS BASED ON

ZOONOTIC CORONAVIRUS STRAINS

Selected constructs from Examples 1 and 2 that satisfied the respective quality criteria are tested in an animal model.

EXAMPLE 4

ENGINEERING IN SARS-CoV-2 RBD

A modified version of the SARS-CoV-2 South Africa variant spike ectodomain was selected as a backbone for engineering in the RBD. Constructs (RBD (monomer) fusions comprising a SpyTag (Figure 6, left), and spike ectodomain fusions comprising a SpyTag (Figure 6, right)) were generated that contained one or more amino acid substitution, deletion, and/or insertion relative to the backbone at selected RBD positions/regions. Engineering considered, inter alia, creation of one or more glycosylation site, deletions in loop regions, certain point mutations, and combinations of these. RBD mutations of selected constructs ("Cov0251"-"Cov0382") are summarized below in Tables 2A and 2B, and in Figures 5A-5G (as "251" - "382").

Table 2A. Summary of mutations in Constructs Cov0251-Cov0326

Table 2B. Summary of mutations in Constructs Cov0327-Cov0382

The constructs were tested for expression (yes or no), purification yield (high or low; for spike ectodomain fusion trimers, high or low as compared to wild-type spike trimer), biophysical properties (assessed using SDS-PAGE, SEC-HPLC, and DSF), and antigenic binding features (assessed using BLI).

For the RBD fusions, desired biophysical properties included formation of soluble monomers over aggregates. Desired antigenic binding features included equivalent binding (versus WT South African variant RBD monomer) by a panel of SARS-CoV-2-binding antibodies and decreased binding (versus the WT South African variant RBD monomer) to human ACE2. Conjugation to nanoparticles with surface SpyCatcher was also investigated.

For the spike ectodomain fusions, desired biophysical properties included formation of soluble trimers over aggregates and monomers. Desired antigenic binding features included equivalent or increased binding (versus WT South African spike trimer) by a panel of SARS- CoV-2-binding antibodies and decreased binding (versus WT South African variant spike trimer) to human ACE2. Conjugation to nanoparticles with surface SpyCatcher was also investigated.

EXAMPLE 5

DESIGN AND TESTING OF ADDITIONAL CORONAVIRUS FUSION PROTEINS

The SARS-CoV-2 South African variant S ectodomain was used as a backbone for engineering. Mutations were made to improve prefusion stability and to promote an "up" or "open" conformation of RBD. In preferred construct-containing trimers, two of the three RBDs were in an up or open conformation. Constructs were produced, all having a foldon added at the C -terminal end and a SpyTag linked to the foldon for nanoparticle conjugation (Figure 7). Control spike constructs were also made: SARS-CoV-2 Wuhan S-2P (S-2P = spike containing two proline substitutions in the S2 subunit; Wrapp et al. Science 367(6483): 1260-1263(2020)); SARS-CoV-2 Wuhan Hexapro (Hexapro = a variant of S-2P that contains six proline substitutions (F817P, A892P, A899P, A942P, plus S-2P); described in Hsieh et al. Science 369(6510): 1501-1505 (2020)); SARS-CoV-2 South African Hexapro; SARS-CoV-2 Indian variant S-2P; SARS-CoV-2 Indian variant HexaPro-like; and SARS-CoV-1.

The constructs were tested for expression (yes or no), purification yield (increased or decreased versus WT South African variant spike trimer containing S-2P), biophysical properties (assessed using SDS-PAGE, SEC-HPLC, and DSF), and antigenic binding features (assessed using BLI).

Desired biophysical properties included formation of soluble trimers over aggregates and monomers. Desired antigenic binding features included equivalent or increased binding (versus WT South African variant spike trimer) by a panel of SARS-CoV-2 -binding antibodies and equivalent binding (versus WT South African variant spike trimer) by antibody S2P6. Binding to human ACE2 was also investigated. Conjugation to nanoparticles with surface SpyCatcher was also investigated.

EXAMPLE 6

DESIGN AND TESTING OF ADDITIONAL SARS-COV-2 RBD CONCATEMERS

Heterotypic SARS-CoV-2 RBD concatemer constructs were constructed using selected strains. The constructs had the designs shown in Figures 4B (5 RBD polypeptides linked by stem-helix polypeptide or other linker) and 4A (3 RBD polypeptides linked by stem-helix polypeptide or other linker. Escape mutations and phylogenetically distinct strains from SARS- CoV-2 variants were distributed amongst five groups of constructs. In this regard, the constructs were as follows:

"2x5" concatemers

• Group 1 (30 constructs): Wuhan-Hu- 1 / A.27 / Alpha + E484K + S494P / ZC45 / SARS-CoV-1

• Group 2 (30 constructs): Delta / Beta / A.27 + S494P / GX-Pangolin / Rs4231. "3x3" concatemers

• Group 1 (6 constructs): Wuhan-Hu-1 / A.27 / ZC45

• Group 2 (6 constructs): Beta / A.27 + S494P / Rs4231

• Group 3 (6 constructs): Delta / GX-Pangolin / Rs4231

All constructs were designed with a SpyTag for nanoparticle conjugation.

The constructs were tested for expression (yes or no), purification yield (high or low), biophysical properties (assessed using SDS-PAGE, SEC-HPLC, and DSF), and antigenic binding features (assessed using BLI).

Desired biophysical properties included formation of soluble monomers over soluble oligomers and aggregates. Desired antigenic binding features included increased binding (versus RBD standalone) by a panel of SARS-CoV-2 -binding antibodies (and for stem-helix-containing constructs, binding by antibody S2P6). Binding to human ACE2 was also investigated. For Spy Tag-containing constructs, conjugation to nanoparticles with surface SpyCatcher was investigated.

EXAMPLE 7

DESIGN AND TESTING OF ADDITIONAL CORONAVIRUS SPIKE: RBD FUSIONS

Heterotypic spike ectodomain:RBD hybrid constructs were constructed using an engineered version of the SARS-CoV-2 South African variant spike ectodomain as a backbone. RBDs were selected from Wuhan-Hu-1, Beta, Delta, A.27 + S494P, and SARS-CoV-1 :

Single-RBD fusions (Figure 8A; 8 constructs)

• Foldon-RBD linker = (GS)n

• Foldon-RBD linker = stem -helix polypeptide Two-RBD fusions (Figure 8B; 28 constructs) • Foldon-RBD linker = (GS)n

• Foldon-RBD linker = stem -helix polypeptide

The tested two-RBD fusions included a combination of all five RBD types.

The constructs were tested for expression (yes or no), purification yield (high or low), biophysical properties (assessed using SDS-PAGE, SEC-HPLC, and DSF), and antigenic binding features (assessed using BLI).

Desired biophysical properties included formation of soluble trimers over soluble oligomers, aggregates, and monomers. Desired antigenic binding features included increased binding (versus WT South African variant spike trimer) by a panel of SARS-CoV-2 -binding antibodies (and for stem-helix-containing constructs, binding by antibody S2P6). Binding to human ACE2 was also investigated.

EXAMPLE 8

FURTHER DESCRIPTION OF CERTAIN CONSTRUCTS

The following provides additional information regarding certain constructs as described in Examples 1, 2, and 4-7. Constructs are "Cov0001"-"Cov0060", "Cov0061"-"Cov0070", "Cov0091"-"Cov0098", "Cov0101"-"Cov0102", "Cov0121"-"Cov0128", "Cov0130", "Cov0132", "Cov0199"-"Cov0514", "Cov0556"-"Cov0629", "Cov0631", "Cov0633", "Cov0662"-"Cov0690", "Cov0693", and "Cov0722"-"Cov0739".

Table 3. Summary of RBD Monomer Constructs "Cov0001"-"Cov0060"

"Standalone" constructs Cov0001-Cov0015 were of the scheme shown in Figure 9 A, taking CovOOl as an example. "C-ter SpyTag" constructs Cov00016-Cov0030 were of the scheme shown in Figure 9B, taking Cov0016 as an example. "N-ter SpyTag" constructs Cov00031-Cov0045 were of the scheme shown in Figure 9C, taking Cov0031 as an example. "N-ter + S2P6 C-ter" constructs Cov00046-Cov0060 were of the scheme shown in Figure 9D, taking Cov0046 as an example.

Table 4. Strains Selected for RBD 3x5 Constructs "Cov0061"-"Cov0070"

The strain numbers in Table 4 are represented in the 5 RBDs of the constructs in Table 5. Table 5. Summary of RBD 3x5 Constructs "Cov0061"-"Cov0070"

Table 6. Strains Selected for RBD 3x5 Constructs "Cov0091"-"Cov0098" and "Cov0101"-"Cov0102"

The strain numbers in Table 6 are represented in the 5 RBDs of the constructs in Table 7. Table 7. Summary of RBD 3x5 Constructs "Cov0091"-"Cov0098" and "Cov0101"-"Cov0102"

Table 8. Strains Selected for RBD 3x5 Constructs "Cov0121"-"Cov0132"

The strain numbers in Table 8 are represented in the 5 RBDs of the constructs in Table 9.

Table 9. Summary of RBD 3x5 Constructs "Cov0121"-"Cov0132"

The constructs summarized in Tables 5, 7, and 9 included a N-terminal modified signal peptide based on the CD33 signal peptide and a C-terminal linker-His-tag sequence GSHHHHHHHH.

Table 10. Strains Selected for RBD 2x5 Constructs "Cov0151"-"Cov0165"

The strain numbers in Table 10 are represented in the 5 RBDs of the constructs in Table

Table 11. Summary of RBD 2x5 Constructs "Cov0151"-"Cov0165"

Table 12. Strains Selected for RBD 2x5 Constructs "Cov0166"-"Cov0180"

The strain numbers in Table 12 are represented in the 5 RBDs of the constructs in Table 13. Table 13. Summary of RBD 2x5 Constructs "Cov0166"-"Cov0180"

The constructs summarized in Tables 11 and 13 included a modified signal peptide based on the CD33 signal peptide and a C-terminal linker-His-tag sequence GSHHHHHHHH. Table 14. Strains Selected for RBD 3x3 Constructs "Cov0181"-"Cov0186"

The strain numbers in Table 14 are represented in the 3 RBDs of the constructs in Table

15.

Table 15. Summary of RBD 3x3 Constructs "Cov0181"-"Cov0186"

Table 16. Strains Selected for RBD 3x3 Constructs "Cov0187"-"Cov0192"

The strain numbers in Table 16 are represented in the 3 RBDs of the constructs in Table 17.

Table 17. Summary of RBD 3x3 Constructs "Cov0187"-"Cov0192"

Table 18. Strains Selected for RBD 3x3 Constructs "Cov0193"-"Cov0198"

The strain numbers in Table 18 are represented in the 3 RBDs of the constructs in Table Table 19. Summary of RBD 3x3 Constructs "Cov0193"-"Cov0198"

The constructs summarized in Tables 15, 17, and 19 included a modified signal peptide based on the CD33 signal peptide and a C-terminal linker-His-tag sequence GSHHHHHHHH.

Table 20. Summary of Constructs "Cov0204"-"Cov0233", comprising a Spike Ectodomain portion and One or More Copies of an Engineered Sequence based on S2P6 Antibody

Epitope

All four zoonotic Spike sequences contained a substitution mutation to proline at an equivalent position for prefusion (see rectangle in the partial sequence alignment in Figure 50A) and, in the S1/S2 cleavage site, Arg replaced by a Ser (see rectangle in the partial sequence alignment in Figure 5 OB).

The engineered sequence based on S2P6 epitope is: PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) ("S2P6" in Table 20). The linker separating the different SEQ ID NO.:701 copies is -GS-. The Cov0222 sequence was incomplete, due to a mistake resulting in lack of a C-terminal foldon followed by one copy of re- engineered S2P6. Certain constructs (e.g. Cov0204, Cov0205, Cov0207, Cov0208) contained an additional, un-intended -GS- between the last S2P6 sequence copy and the GSG-His-tag sequence i.e., GSGSGHHHHHHHH.

Table 21. Summary of Spike-RBD Fusion Constructs "Cov0239"-"Cov0250"

For constructs "Cov0239"-"Cov0250", the Spike ectodomain and RBDs were from a

SARS-CoV-2 South Africa variant backbone. The engineered sequence based on S2P6 epitope (PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)) was used in constructs Cov0245- Cov0250 as part of a linker between a foldon and the first RBD and as the linker between two

RBDs, and as a C-terminal element in Cov0242-0244 and Cov0248-Cov0250.

Constructs Cov0251-Cov0382 are discussed in Example 4; see also the partial sequences/mutations summarized in Table 2 and Figures 5A-5G. These constructs were of the scheme shown in Figure 10, taking Cov0251 as an example. Table 22. Summary of SpyTag-RBD Fusion Constructs "Cov0592"-"Cov0601"

Constructs Cov0592-Cov0601 comprised the general organization shown in Figure 11 (the numbering of amino acids in Figure 11 is not germane to all of these constructs, and for purposes of illustrating the general organization of the constructs can be ignored).

Table 23. Strains Selected for RBD 2x5 Concatemer Constructs

"Cov0602"-"Cov0631" and "Cov0633"

The strain numbers in Table 23 are represented in the 5 RBDs of the constructs in Table

24. Table 24. Summary of RBD 2x5 Concatemer Constructs

"Cov0602"-"Cov0631" and "Cov0633"

Table 25. Strains Selected for RBD 2x5 Concatemer Constructs "Cov0662"-"Cov0690" and "Cov0693"

The strain numbers in Table 25 are represented in the 5 RBDs of the constructs in Table 26.

Table 26. Summary of RBD 2x5 Concatemer Constructs "Cov0662"-"Cov0690" and "Cov0693"

Constructs "Cov0662"-"Cov0690" and "Cov0693" contained a signal peptide from H7

HA (A/HongKong/125/2017), followed by a GSG linker, followed by a SpyTag, then a Townsend linker (GSGGSGGSGGTG), followed by the concatenated RBDs. A C-terminal GS- His-tag (GSHHHHHHHH) was included for purification purposes.

Table 27. Strains Selected for RBD 3x3 Concatemer Constructs "Cov0722"-"Cov0727"

The strain numbers in Table 27 are represented in the 3 RBDs of the constructs in Table 28. Table 28. Summary of RBD 3x3 Concatemer Constructs "Cov0722"-"Cov0727"

Table 29. Strains Selected for RBD 3x3 Concatemer Constructs "Cov0728"-"Cov0733"

The strain numbers in Table 29 are represented in the 3 RBDs of the constructs in Table 30. Table 30. Summary of RBD 3x3 Concatemer Constructs "Cov0728"-"Cov0733"

Table 31. Strains Selected for RBD 3x3 Concatemer Constructs "Cov0734"-"Cov0739"

The strain numbers in Table 31 are represented in the 3 RBDs of the constructs in Table 32. Table 32. Summary of RBD 3x3 Concatemer Constructs "Cov0734"-"Cov0739"

Constructs "Cov0722"-"Cov0739" contained a signal peptide from H7 HA (A/HongKong/125/2017), followed by a GSG linker, followed by a SpyTag, then a Townsend linker (GSGGSGGSGGTG), followed by the concatenated RBDs. A C-terminal GS-His-tag (GSHHHHHHHH) was included for purification purposes. Table 33. Summary of Spike-RBD-Hybrid Constructs "Cov0556"-"Cov0592"

EXAMPLE 9

NEUTRALIZING ANTIBODIES AGAINST A CONSERVED ANTIGENIC REGION IN BETACORONAVIRUS S PROTEIN STEM HELIX

To identify mAbs targeting highly conserved regions of the S glycoprotein, human IgG⁺ memory B cells from COVID-19 convalescent donors were interrogated. mAbs were identified that bound to the prefusion-stabilized S ectodomain trimers of viruses belonging to all three- human infecting P-coronavirus subgenera, i.e., sarbecovirus (SARS-CoV and SARS-CoV-2), merbecovirus (MERS-CoV) and embecovirus (OC43 and HKU1), but not to the human a- coronaviruses (229E and NL63). Monoclonal antibody S2P6 was tested for binding to the spike protein of different human beta-coronaviruses by enzyme-linked immunoabsorbant assay (ELISA; Figure 12). S2P6 comprises a VH comprising the sequence provided in SEQ ID NO:26 and a VL comprising the sequence provided in SEQ ID NO:30. Pre-fusion stabilized spike proteins from SARS-CoV (Urbani strain, GenBank: AAP 13441; ncbi.nlm.nih.gov/protein/30027620), SEQ ID NO:22, SARS-CoV-2 (B etaCo V/Wuhan-Hu- 1/2019, GenBank: MN908947), SEQ ID NO:3, MERS (Londonl/2012; GenBank: KC164505), SEQ ID NO:24, OC43 (GenBank AAT84362.1), SEQ ID NO:23, and HKU1 (GenBank YP 173238.1), SEQ ID NO:25 were coated at 1 pg/ml and PBS-only was used as a negative control. Half maximal effective concentration (EC50) was determined and reported as ng/ml. Binding of antibody to alpha-coronaviruses was also measured by ELISA; no binding was observed (data not shown).

Additional monoclonal antibodies S2S40, S2S41, S2S42, S2S43, and S2X529 were tested for binding to spike protein of different human beta-coronaviruses and to the spike protein subunit S2 for SARS-CoV-2, as described above. Results are shown in Table 34.

Table 34.

Binding by S2P6 (expressed as recombinant IgGl bearing M428L/N434S Fc mutations; "MLNS") to the spike proteins of different human beta-coronaviruses expressed on the surface of mammalian cells was measured by flow cytometry. Briefly, Expi-CHO cells were transiently transfected with phCMVl expression plasmids encoding full-length spike proteins from human beta-coronaviruses. Binding to spike proteins from SARS-CoV-2 (BetaCoV/Wuhan-Hu-1/2019, SARS-CoV (Urbani strain, AAP13441;), OC43, and MERS-CoV (London 1/2012) was measured.

Additionally, binding by S2P6 to SI, S2, and Receptor Binding Domain (RBD) from SARS-CoV-2 (BetaCoV/Wuhan-Hu-1/2019) S protein was measured by ELISA. Proteins were coated at 1 pg/ml. The results indicated that S2P6 binds in S2.

Neutralizing activity of S2P6 against infection by SARS-CoV-2 virus was evaluated using a luciferase reporter assay. VeroE6 cells were infected with a SARS-CoV-2-luciferase reporter virus for 24 hours at a multiplicity of infection (MOI) of 0.01. A curve showing percent neutralization at increasing antibody concentration, along with calculatd IC50 values (ng/ml), was generated. Neutralization by comparator antibody “S309” (See Pinto et al., Cross- neutralizaiton of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature 583 :290-295 (July 2020)), was also tested; S2P6 was a less potent neutralizer than S309 in this assay.

Neutralization of pseudotyped virus by S2P6 was evaluated by a luciferase reporter assay. S2P6 neutralization of MERS-CoV in Huh7 cells, and of SARS-CoV-2 in Vero E6 cells, was examined. . Neutralization by comparator antibodies, LCA60 (anti-MERS; Corti et al., PNAS 722(33): 10473-10478 (2015)) and S309, was also measured. Neutralization IC50 values (reported in pg/ml) were: for MERS PVs, LCA60 = 0.01246, S2P6 = 6.328; for SARS-CoV-2 PVs, S309 = 0.2649, S2P6 = 4.679.

Further studies were performed. Another antibody, S2S8, but not S2P6, is cross-reactive against alpha-coronaviruses. S2P6 can activate human FcyRIIa (H131 allele) and FcyRIIIa (VI 58 allele), elicits effector function, and protects against SARS-CoV-2 infection in a Syrian hamster model (Figures 18, 26, and 27). S2P6 binding did not block SARS-CoV-2 RBD from binding to human ACE2. S2P6 inhibited cell-cell fusion using Vero-E6 cells transfected with SARS-CoV-2 S.

Peptide mapping studies were performed to identify epitope regions. See Figures 17, 27, and 22. From these studies, S2P6 binds a conserved epitope in the P-coronavirus stem helix region (Figure 22; e.g. SARS-CoV-2 motif FiusKEELDKYFnse located in the stem helix within the S2 subunit, which is highly conserved among human beta-coronaviruses).

S2P6 was shown to bind to all full-length SARS-CoV-2 S variants tested and to 24 S glycoproteins representative of all sarbecovirus clades transiently expressed on the surface of ExpiCHO cells (Figures 20, 29A-29C, and 30). S2P6 binds comparably to the stem helix peptides of the five beta-coronaviruses that infect humans (albeit with a faster off-rate for HKU1) as well as of the MERS-CoV-related bat viruses (HKU4 and HKU5) and murine hepatitis virus (MHV) (data not shown). S2P6 also exhibited binding to postfusion SARS-CoV- 2 spike protein even though its epitope appears to be buried at the interface of the targeted protomer with the other two protomers of the rod-shaped trimer of the spike protein and, therefore, may not be expected to be fully accessible (data not shown).

Further Discussion

S2P6 activates immune cell-dependent effector functions in vitro and protects hamsters challenged with SARS-CoV-2 Wuhan- 1 and B.1.351 strains. Serological and B cell repertoire analysis, as well as germline reversion of the cross-reactive mAbs herein identified demonstrate that the generation of pan-P-coronavirus mAbs are rare events that require somatic mutations. S2P6 and S2S43 mAbs are derived from two donors and use VH1-46*O1 and D5-12*01 genes. Overall, the level of somatic mutations in these mAbs in variable regions was limited. The mAbs bound to both prefusion and post-fusion SARS-CoV-2 S with comparable apparent avidities, indicating that their cognate epitope is accessible in both conformational states of the S glycoprotein.

S2P6 was selected for further characterization and shown to bind to all full-length SARS- CoV-2 S variants tested to 24 S glycoproteins representative of all sarbecovirus clades transiently expressed on the surface of ExpiCHO cells. Using surface plasmon resonance (SPR), the S2P6 Fab fragment was found to have had the highest affinity for SARS-CoV-2 S and SARS-CoV S followed by MERS-CoV S and OC43 S with equilibrium dissociation constants (KD) of 7, 7, 12 and 16 nM, respectively. S2P6 also bound to HKU1 S albeit with reduced affinity (KD -120 nM). The recognition of prefusion SARS-CoV-2 S by this mAb is pH dependent with higher binding affinity at pH 7, relative to pH 5, in both IgG and Fab formats. These data demonstrate unique and efficient cross-reactivity of S2P6 towards all humaninfecting P-coronaviruses.

To evaluate neutralization potency and breadth of S2P6, its ability to inhibit entry of authentic SARS-CoV-2 into Vero-E6 cells in the presence or absence of the S-activating protease TMPRSS2 was investigated. S2P6 completely neutralized infection of TMPRSS2- positive Vero-E6 cells but was much less effective in neutralizing infection of Vero-E6 cells. Previous studies established that the main route of SARS-CoV-2 entry into cultured lung cells occurs through TMPRSS2-activated fusion with the cytoplasmic membrane (Hoffmann, Mdsbauer, et al. 2020; Hoffmann, Kleine-Weber, et al. 2020; Hoffmann, Kleine-Weber, and Pbhlmann 2020). The more efficient S2P6-mediated neutralization of SARS-CoV-2 entry into Vero-E6 cells expressing TMPRSS2, relative to cells lacking this protease, is consistent with dampened binding at endosomal pH and suggests that S2P6 is maximally efficient towards the viral entry pathway associated with lung cell infection. S2P6-mediated neutralization of vesicular stomatitis virus (VSV) (Kaname et al. 2010) pseudotyped with SARS-CoV-2 S with several variants of concern (VOC), including B. l.1.7, B.1.351 and P. l, was assessed. Similar potency was observed to that found against the parental SARS-CoV-2 D614G S. Moreover, S2P6 inhibited SARS-CoV S, Pangolin Guangdong 2019 (P-GD) S, MERS-CoV S and OC43 S VSV pseudotypes with IC50 values ranging from 0.02 to 17 pg/ml. S2P6 therefore features an unprecedented broad P-coronavirus neutralizing activity, including SARS-CoV-2 and circulating voc.

To define the epitopes recognized by the identified mAbs, peptide mapping experiments were performed using 15-mer linear overlapping peptides. All mAbs were found to bind to peptides containing the SARS-CoV-2 motif F sKEELDKYF use located in the stem helix within the S2 subunit. This region is highly conserved among P-coronaviruses, and overlaps with the epitopes of B6 and 28D9, two mAbs which were previously identified following mouse immunization (Sauer et al. 2020; Wang et al. 2021). S2P6 bound with comparable magnitudes to the stem helix peptides of the five P-coronaviruses that infect humans (albeit with a faster off- rate for HKU1) as well as of the MERS-CoV-related bat viruses (HKU4 and HKU5) and murine hepatitis virus (MHV). S2S43 exhibited similar overall binding to S2P6 with markedly weaker reactivity towards the HKU1, HKU4 and HKU5 peptides.

Viral escape mutant selection was carried out in vitro in the presence of S2P6 using a replication-competent VSV-SARS-CoV-2 S chimeric virus (Case et al. 2020). After two passages, virus neutralization by S2P6 was completely abrogated and deep sequencing analysis revealed the emergence of five distinct resistance mutations: LI 152F, DI 153N/G/A and Fl 156L. These mutations are consistent with reduced binding by S2P6 in the substitution scan analysis. The cumulative frequency of these mutations was greater than 90% after the second passage and they occurred as quasi-species (i.e., they were not seen within the same sequencing reads). The isolation of neutralization escape mutants at key interface residues highlights the key role of the interactions identified for S2P6 mAb binding. These mutations, however, have been detected with very low prevalence in circulating SARS-CoV-2 isolates (0.01%, 146 out of 1,217,814 sequences as of April 30, 2021).

To validate the inferred mechanism of S2P6-mediated broad coronavirus neutralization, it was first shown that S2P6 binding did not block engagement of SARS-CoV-2 S by ACE2 using ELISA. S2P6, however, blocked cell-cell fusion between Vero-E6 cells transfected with full- length SARS-CoV-2 S as effectively as the S2M11 mAb which locks SARS-CoV-2 S in the closed state (M. A. Tortorici et al. 2020). mAbs have been described that target RBD antigenic site la (e.g. S2E12) and Ila (e.g. S2X259 or S2X35) which can mimic receptor attachment and prematurely trigger fusogenic S conformational changes (A. C. Walls et al. 2019; Lempp et al. 2021; Piccoli et al. 2020). Accordingly, S2P6 abrogated the formation of syncytia mediated by S2E12 at concentrations as low as 1 ng/ml. Collectively, these results suggest that the main mechanism of S2P6 neutralization is to prevent viral entry via inhibition of membrane fusion resulting from impeding S fusogenic rearrangements. S2P6-mediated protection against SARS-CoV-2 challenge is enhanced by Fc-mediated effector functions in hamsters

Fc-mediated effector functions can contribute to in vivo protection by promoting viral clearance and anti-viral immune responses (Schafer et al. 2021; Bournazos, Wang, and Ravetch 2016; Bournazos et al. 2020; Winkler et al. 2020). The potential of S2P6 to trigger activation of FcyRIIa and FcyRIIIa, as well as to exert Fc effector functions in vitro, was analyzed. S2P6 promoted moderate dose-dependent FcyRIIa and FcyRIIIa mediated signaling using a luciferase reporter assay. S2P6 promoted robust activation of Ab-dependent cell cytotoxicity (ADCC), to levels comparable to those observed with the S309 mAb (Pinto et al. 2020), following incubation of SARS-CoV-2 S expressing ExpiCHO target cells (CHO-S) with human NK cells. S2P6 also showed Ab-dependent cellular phagocytosis (ADCP) activity using Cell-Trace- Violet-labelled peripheral blood mononuclear cells (PBMCs) as phagocytic cells, and CHO-S cells. Finally, S2P6 did not promote complement-dependent cytotoxicity (CDC) indicating that S2P6 Fc- mediated effector functions, but not complement activation, might participate in viral control in vivo.

Prophylactic activity of S2P6 (harboring either fully human IgGl or hamster IgG2a constant regions) against challenge with the prototypic (Wuhan-1 related) SARS-CoV-2 in a Syrian hamster model (Boudewijns et al. 2020) was evaluated. Previous findings showed that human IgGl mAbs are not able to recognize hamster FcgRs (Lempp et al. 2021); S2P6 was therefore also produced in the hamster IgG2 format to provide optimal interaction with hamster FcgRs. Two different doses of human IgGl (Hu-S2P6) or hamster IgG2 (Hm-S2P6) were administered 24h prior to intranasal SARS-CoV-2 challenge and the lungs of the animals were assessed 4 days post infection for viral RNA load and replicating virus. Hm-S2P6 administered at 20 mg/kg reduced viral RNA copies and replicating viral titers in the lungs of hamsters by two orders of magnitude relative to a control (irrelevant) mAb. Moreover, Hm-S2P6 at 20 mg/kg reduced viral RNA copies detected in the lungs to levels significantly lower than those observed with Hu-S2P6, suggesting a beneficial effect of S2P6 effector functions in vivo. Based on the comparable S2P6 neutralization potencies towards SARS-CoV-2 VOC observed in vitro, protective efficacy of S2P6 in hamsters challenged with SARS-CoV-2 B.1.351 was assessed. Prophylactic administration of Hu-S2P6 at 20 mg/kg reduced replicating viral titers in the lungs (but not RNA copy numbers) by ~1.5 order of magnitude relative to the control group, in line with the strict conservation of the stem helix epitope in all VOC identified to date.

Collectively, these findings indicate that Abs targeting a highly conserved epitope in the S fusion machinery can trigger Fc-mediated ADCC and ADCP in vitro and protect against SARS-CoV-2 challenge via both neutralization and effector functions in vivo.

Natural infection or vaccination predominantly elicit stem helix-directed Abs of narrow specificities

To understand how frequently stem helix-specific Abs are elicited, serological analysis using plasma samples from pre-pandemic, convalescent, and vaccinated individuals was performed. The titers of plasma IgG binding to stem helix peptides of SARS-CoV-2/SARS-CoV (SARS-CoV/-2), OC43, MERS-CoV, HKU1, HKU4 and HKU5 were determined. Overall, plasma Abs binding to stem helix peptides were not found in pre-pandemic samples, except for HKU1, probably reflecting prior infection with this virus in this cohort. Conversely, stem helixspecific Abs were found at low frequency in individuals previously infected with SARS-CoV-2 or receiving two doses of mRNA vaccines. Overall, these data show that plasma Ab responses to the stem helix are elicited upon SARS-CoV-2 infection or vaccination although they are relatively rare.

The frequency of stem helix specific Abs in the memory B cell repertoire of 21 convalescent and 17 vaccinated individuals was investigated using a clonal analysis based on in vitro polyclonal stimulation (Pinna et al. 2009), here referred as antigen-specific B-cell memory repertoire analysis (AMBRA). In both cohorts frequencies of stem helix specific IgGs ranging from 0.1-2.5% were observed, except for one individual (infected and vaccinated with a single dose of mRNA vaccine) for whom a 97% frequency of SARS-CoV/-2-specific Abs was measured. Most SARS-CoV-2 stem helix specific Abs were found to be cross-reactive with OC43, consistent with the high sequence identity of the stem helices of these two viruses. Abs specific for the HKU1 S stem helix were found in some individuals but they were not cross- reactive with other b-coronaviruses. This analysis revealed a single example of cross-reactivity to all stem helix b-coronaviruses peptides tested.

These findings indicate that stem helix Abs are rarely induced upon SARS-CoV-2 infection or vaccination and appear to have limited cross-reactivity among b-coronaviruses.

Broadly reactive b-coronavirus Abs acquire affinity and breadth through somatic mutations

To define the ontogeny of S2P6, a panel of germline variants was generated. Two out of 7 S2P6 heavy chain residues that are mutated relative to germline contribute to epitope recognition (Q32 and H57) whereas none of the 5 light chain mutated residues participate in S binding. To address the role of VH and VK somatic mutations a panel of S2P6 germline variants for the heavy or the light chain, or both variable regions (VH and VK) was generated. The fully germline S2P6 (UCA) bound to OC43 and MERS-CoV stem helix peptides (with approximately 1 order of magnitude higher EC50 compared to the mutated mAb) but not to SARS-CoV/-2 or HKU1 peptides. Somatic mutations in VH were sufficient for high avidity binding to SARSCoV/-2, whereas both VH and VK mutations were required for optimal binding to HKU1. The presence of residue G103 in CDRH3 was found to be essential for binding to all b- coronaviruses. Collectively, these findings indicate that the S2P6 mAb likely arose in response to OC43 infection, and its specificity was broadened towards SARS-CoV-2 and HKU1 through somatic mutations selected upon natural infection with one or both of these P-coronaviruses. Together with the serological and B cell repertoire analysis, these findings demonstrate that pan- P-coronavirus antibodies may result from priming of virus-specific B cells gaining affinity and breadth through somatic mutations in response to heterotypic coronavirus exposures. The coronavirus S2 subunit (so-called fusion machinery) contains several important antigenic sites, including the fusion peptide and the heptad-repeat 2 regions, and is more conserved than the Si subunit (Daniel et al. 1993; Zhang et al. 2004; Poh et al. 2020; Elshabrawy et al. 2012; Zheng et al. 2020). As a result, it is an attractive target for broad coronavirus detection and neutralization (A. C. Walls et al. 2016). The recent identification of 3 cross- reactive mAbs targeting the stem helix unveiled this previously unknown S2 subunit epitope, which is conserved among P-coronavirus S glycoproteins (Sauer et al. 2020; C. Wang et al. 2021; Song et al. 2020), although none of them inhibit members of all three P-coronavirus subgenera (lineages). Here, mAbs targeting overlapping epitopes in the S stem helix and crossreacting with human and animal b-coronaviruses are identified. S2P6 broadly neutralizes all sarbecoviruses, merbecoviruses and embecoviruses evaluated through inhibition of membrane fusion and provide evidence that an S2 subunit-directed mAb protects hamsters from SARS- CoV-2 challenge, including with the SARS-CoV-2 B.1.351 VOC, with a beneficial effect of Fc- mediated effector functions. These data extend previous studies describing the participation of effector functions to in vivo efficacy of SARS-CoV-2 RBD-specific mAbs (Schafer et al. 2021; Winkler et al. 2020) as well as influenza A hemagglutinin stem-specific broadly neutralizing mAbs (Corti et al. 2011; DiLillo et al. 2014). This observation is reminiscent of similar findings for mAbs to a highly conserved epitope on the stem of the influenza hemagglutinin, and indicate that the combination of cross reactivity plus effector functions may provide particular potency for antibodies against these infections (refs).

The exceptionally broad cross-reactivity and neutralization breadth of S2P6 may be explained by the conserved nature of the stem helix among b-coronaviruses. Within SARS-CoV- 2 fewer than 0.01% sequences have been reported to be mutated between S residues 1146 and 1159 out of more than 1.3 million genomes deposited in GISAID (date) and no SARS-CoV-2 VOC harbor residue substitutions within this region.

The stem helix is thought to form a 3-helix bundle in prefusion SARS-CoV-2 S and dynamic conformational changes are likely required to expose the otherwise buried hydrophobic epitope, which is surrounded by conserved glycans potentially further shielding this conserved site. The results shown here provide evidence that stem helix-targeted Abs are elicited upon natural infection by endemic (OC43 or HKU1) or pandemic (SARS-CoV-2) coronaviruses as well as by COVID-19 mRNA vaccines. However, stem helix-specific Abs are present at low titers in convalescent or vaccinated individuals in plasma samples and at low frequency in their memory B cell repertoire possibly as a result of limited epitope exposure.

Stem helix-targeted Abs are predominantly of narrow specificities and only few of them mediate broad P-coronavirus neutralization and protection through accumulation of somatic mutations. EXAMPLE 10

ANALYSIS OF HUMAN BETA-CORONAVIRUS SPIKE PROTEINS

Partial S2 segments from human beta-coronavirus spike proteins are shown in Figure 13. A region in the C-terminal portion of the prefusion ectodomain (Figure 14A) was determined to have some conservation. A model showing helical structure of the surface-exposed linker region at the tail of the pre-fusion ectodomain is provided in Figure 14B. Figure 14C shows a closer view of the surface-exposed linker region and indicates certain amino acid residues. Structural analysis provided the following:

Table 35. Structural characterization of amino acids in Betacoronavirus Linker Helix feature (amino acid numbering as in prefusion conformation)

Structure of the post-fusion spike protein was also examined (Figure 15 A). A detailed view (Figures 15B and 15C (pre-fusion conformation shown at bottom of 15C for comparison)) of the linker region shows partial rearrangement and exposure of residues 1148-1158. Numbering of the residues in post-fusion Figures 15A-15C does not account for the signal peptide, which adds an additional 18 residue positions.

EXAMPLE 11

MATERIALS AND METHODS FOR EXAMPLES 9 AND 10

For the experiments described in Examples 9 and 10, the following Materials and Methods were used: Generation of stable overexpression cell lines

Lentiviruses were generated by co-transfection of Lenti-X 293T cells (Takara) with lentiviral expression plasmids encoding DC-SIGN (CD209), L-SIGN (CLEC4M), SIGLEC1, TMPRSS2 or ACE2 (all obtained from Genecopoeia) and the respective lentiviral helper plasmids. Forty-eight hours post transfection, lentivirus in the supernatant was harvested and concentrated by ultracentrifugation for 2 h at 20,000 rpm. Lenti-X 293T (Takara), Vero E6 (ATCC), MRC5 (Sigma-Aldrich), A549 (ATCC) were transduced in the presence of 6 ug/mL polybrene (Millipore) for 24 h. Cell lines overexpressing two transgenes were transduced subsequently. Selection with puromycin and/or blasticidin (Gibco) was started two days after transduction and selection reagent was kept in the growth medium for all subsequent culturing. Single cell clones were derived from the A549-ACE2-TMPRSS2 cell line, all other cell lines represent cell pools.

S A RS- Col -2 neutralization

Vero E6 or Vero E6-TMPRSS2 cells cultured in DMEM supplemented with 10% FBS (VWR) and lx Penicillin/Streptomycin (Thermo Fisher Scientific) were seeded in black 96-well plates at 20,000 cells/well. Serial 1 :4 dilutions of the monoclonal antibodies were incubated with 200 pfu of SARS-CoV-2 (isolate USA-WA1/2020, passage 3, passaged in Vero E6 cells) for 30 min at 37°C in a BSL-3 facility. Cell supernatant was removed and the virus-antibody mixture was added to the cells. 24 h post infection, cells were fixed with 4% paraformaldehyde for 30 min, followed by two PBS (pH 7.4) washes and permeabilization with 0.25% Triton X-100 in PBS for 30 min. After blocking in 5% milk powder/PBS for 30 min, cells were incubated with a primary antibody targeting SARS-CoV-2 nucleocapsid protein (Sino Biological, cat. 40143- R001) at a 1 :2000 dilution for Ih. After washing and incubation with a secondary Alexa647- labeled antibody mixed with 1 ug/ml Hoechst33342 for 1 hour, plates were imaged on an automated cell-imaging reader (Cytation 5, Biotek) and nucleocapsid-positive cells were counted using the manufacturer’s supplied software.

SARS-CoV-2-Nluc neutralization

Neutralization was determined using SARS-CoV-2-Nluc, an infectious clone of SARS- CoV-2 (based on strain 2019-nCoV/USA_WAl/2020) encoding nanoluciferase in place of the viral ORF7, which demonstrates comparable growth kinetics to wild type virus (Xie et al., Nat Comm, 2020, https://doi.org/10.1038/s41467-020-19055-7). Cells were seeded into blackwalled, clear-bottom 96-well plates at 20,000 cells/well (293T cells were seeded into poly-L- lysine-coated wells at 35,000 cells/well) and cultured overnight at 37°C. The next day, 9-point 4- fold serial dilutions of antibodies were prepared in infection media (DMEM + 10% FBS). SARS- CoV-2-Nluc was diluted in infection media at the indicated MOI, added to the antibody dilutions and incubated for 30 min at 37°C. Media was removed from the cells, mAb-virus complexes were added, and cells were incubated at 37°C for 24 h. Media was removed from the cells, Nano- Glo luciferase substrate (Promega) was added according to the manufacturer’s recommendations, incubated for 10 min at RT and luciferase signal was quantified on a VICTOR Nivo plate reader (Perkin Elmer).

SA RS- CoV-2 pseudotyped VSV production and neutralization

To generate SARS-CoV-2 pseudotyped vesicular stomatitis virus, Lenti-X 293T cells (Takara) were seeded in 10-cm dishes for 80% next day confluency. The next day, cells were transfected with a plasmid encoding for SARS-CoV-2 S-glycoprotein (YP_009724390.1) harboring a C-terminal 19 aa truncation using TransIT-Lenti (Minis Bio) according to the manufacturer’s instructions. One day post-transfection, cells were infected with VSV(G*AG- luciferase) (Kerafast) at an MOI of 3 infectious units/cell. Viral inoculum was washed off after one hour and cells were incubated for another day at 37°C. The cell supernatant containing SARS-CoV-2 pseudotyped VSV was collected at day 2 post-transfection, centrifuged at 1000 x g for 5 minutes to remove cellular debris, aliquoted, and frozen at -80°C.

For viral neutralization, Cells were seeded into black-walled, clear-bottom 96-well plates at 20,000 cells/well (293T cells were seeded into poly-L-lysine-coated wells at 35,000 cells/well) and cultured overnight at 37°C. The next day, 9-point 4-fold serial dilutions of antibodies were prepared in media. SARS-CoV-2 pseudotyped VSV was diluted 1 :30 in media in the presence of 100 ng/mL anti-VSV-G antibody (clone 8G5F11, Absolute Antibody) and added 1 :1 to each antibody dilution. Virus:antibody mixtures were incubated for 1 hour at 37°C. Media was removed from the cells and 50 pL of virus:antibody mixtures were added to the cells. One hour post-infection, 100 pL of media was added to all wells and incubated for 17-20 hours at 37°C. Media was removed and 50 pL of Bio-Gio reagent (Promega) was added to each well. The plate was shaken on a plate shaker at 300 RPM at room temperature for 15 minutes and RLUs were read on an EnSight plate reader (Perkin-Elmer).

Transfection-based attachment receptor screen

Lenti-X 293T cells (Takara) were transfected with plasmids encoding the following receptor candidates (all purchased from Genecopoeia): ACE2 (NM_021804), DC-SIGN (NM_021155), L-SIGN (BC110614), LGALS3 (NM_002306), SIGLEC1 (NM_023068), SIGLEC3 (XM 057602), SIGLEC9 (BC035365), SIGLEC10 (NM 033130), MGL (NM_182906), MINCLE (NM_014358), CD147 (NMJ98589), ASGR1 (NM_001671.4), ASGR2 (NM_080913), NRP1 (NM_003873). One day post transfection, cells were infected with SARS-CoV-2 pseudotyped VSV at 1 :20 dilution in the presence of 100 ng/mL anti-VSV-G antibody (clone 8G5F11, Absolute Antibody) at 37°C. One hour post-infection, 100 pL of media was added to all wells and incubated for 17-20 hours at 37°C. Media was removed and 50 pL of Bio-Gio reagent (Promega) was added to each well. The plate was shaken on a plate shaker at 300 RPM at room temperature for 15 minutes and RLUs were read on an EnSight plate reader (Perkin-Elmer). Trans-infection

Parental HeLa cells or HeLa cells stably expressing DC-SIGN, L-SIGN or SIGLEC1 were seeded at 5,000 cells per well in black-walled clear-bottom 96-well plates. One day later, cells reached about 50% confluency and were inoculated with SARS-CoV-2 pseudotyped VSV at 1 : 10 dilution in the presence of 100 ng/mL anti-VSV-G antibody (clone 8G5F11, Absolute Antibody) at 37°C for 2 h. For antibody-mediated inhibition of trans-infection, cells were preincubated with 10 ug/mL anti-SIGLECl antibody (Biolegend, clone 7-239) for 30 min. After 2 h inoculation, cells were washed four times with complete medium and 10,000 VeroE6-TMPRSS2 cells per well were added and incubated 17-20 h at 37°C for trans-infection. Media was removed and 50 pL of Bio-Gio reagent (Promega) was added to each well. The plate was shaken on a plate shaker at 300 RPM at room temperature for 15 minutes and RLUs were read on an EnSight plate reader (Perkin-Elmer).

Cell-cell fusion of CHO-S cells

CHO cells stably expressing SARS-CoV-2 S-glycoprotein were seeded in 96 well plates for microscopy (Thermo Fisher Scientific) at 12’500 cells/well and the following day, different concentrations of mAbs and nuclei marker Hoechst (final dilution 1 : 1000) were added to the cells and incubated for additional 24h hours. Fusion degree was established using the Cytation 5 Imager (BioTek) and an object detection protocol was used to detect nuclei as objects and measure their size. The nuclei of fused cells (i.e., syncytia) are found aggregated at the center of the syncitia and are recognized as a unique large object that is gated according to its size. The area of the objects in fused cells divided by the total area of all the object multiplied by 100 provides the percentage of fused cells

Immunofluorescence analysis

HEK 293T cells were seeded onto poly-D-Lysine-coated 96-well plates (Sigma-Aldrich) and fixed 24 h after seeding with 4% paraformaldehyde for 30 min, followed by two PBS (pH 7.4) washes and permeabilization with 0.25% Triton X-100 in PBS for 30 min. Cells were incubated with primary antibodies anti-DC-SIGN/L-SIGN (Biolegend, cat. 845002, 1 :500 dilution), anti-DC-SIGN (Cell Signaling, cat. 13193S, 1 :500 dilution), anti-SIGLECl (Biolegend, cat. 346002, 1 :500 dilution) or anti-ACE2 (R&D Systems, cat. AF933, 1 :200 dilution) diluted in 3% milk powder/PBS for 2 h at room temperature. After washing and incubation with a secondary Alexa647-labeled antibody mixed with 1 ug/ml Hoechst33342 for 1 hour, plates were imaged on an inverted fluorescence microscope (Echo Revolve).

ACE2/TMPRSS2 RT-qPCR

RNA was extracted from the cells using the NucleoSpin RNA Plus kit (Macherey-Nagel) according to the manufacturer’s protocol. RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) according to the manufacturer’s instructions. Intracellular levels of ACE2 (Forward Primer: CAAGAGCAAACGGTTGAACAC, Reverse Primer: CCAGAGCCTCTCATTGTAGTCT), HPRT (Forward Primer: CCTGGCGTCGTGATTAGTG, Reverse Primer: ACACCCTTTCCAAATCCTCAG), and TMPRSS2 (Forward Primer: CAAGTGCTCCRACTCTGGGAT, Reverse Primer: AACACACCGRTTCTCGTCCTC) were quantified using the Luna Universal qPCR Master Mix (New England Biolabs) according to the manufacturer’s protocol. Levels of ACE2 and TMPRSS2 were normalized to HPRT. Hela cells were used as the reference sample. All qPCRs were run on a QuantStudio 3 Real-Time PCR System (Applied Biosystems).

SA RS 2 D614G Spike Production and biotinylation

Prefusion-stabilized SARS2 D614G spike (comprising amino acid sequence Q14 to K1211) with a C-terminal TEV cleavage site, T4 bacteriophage fibritin foldon, 8x His-, Avi- and EPEA-tag was transfected into HEK293 Freestyle cells, using 293fectin as a transfection reagent. Cells were left to produce protein for three days at 37°C. Afterwards, supernatant was harvested by centrifuging cells for 30 minutes at 500 xg, followed by another spin for 30 minutes at 4000 xg. Cell culture supernatant was filtered through a 0.2 um filter and loaded onto a 5 mL C-tag affinity matrix column, pre-equilibrated with 50 mM Tris pH 8 and 200 mM NaCl. SARS2 D614G spike was eluted, using 10 column volumes of 100 mM Tris, 200 mM NaCl and 3.8 mM SEPEA peptide. Elution peak was concentrated and injected on a Superose 6 increase 10/300 GL gel filtration column, using 50 mM Tris pH 8 and 200 mM NaCl as a running buffer. SEC fractions corresponding to monodisperse SARS2 D614G spike were collected and flash frozen in liquid nitrogen for storage at -80°C. Purified SARS2 D614G spike protein was biotinylated using BirA500 biotinylation kit from Avidity. To 50 ug of spike protein, 5 ug of BirA, and 11 uL of BiomixA and BiomixB was added. Final spike protein concentration during the biotinylation reaction was ~1 uM. The reaction was left to proceed for 16 hours at 4°C. Then, protein was desalted using two Zeba spin columns pre-equilibrated with lx PBS pH 7.4.

Flow cytometry analysis for DC-SIGN, L-SIGN, SIGLEC1 and ACE-2

HEK 293T cells expressing DC-SIGN, L-SIGN, SIGLEC1 or ACE2 were resuspended at 4xl0⁶ cells/mL and 100 pL per well were seeded onto V-bottom 96-well plates (Corning, 3894). The plate was centrifuged at 2,000 rpm for 5 minutes and washed with PBS (pH 7.4). The cells were resuspended in 200 pL of PBS containing Ghost violet 510 viability dye (Cell Signaling, cat. 13-0870-T100, 1 : 1,000 dilution), incubated for 15 minutes on ice and then washed. The cells were resuspended in 100 pL of FACS buffer prepared with 0.5% BSA (Sigma-Aldrich) in PBS containing the primary antibodies at a 1 : 100 dilution: mouse anti-DC/L-SIGN (Biolegend, cat. 845002), rabbit anti-DC-SIGN (Cell Signaling, cat. 13193), mouse anti-SIGLECl (Biologend, cat. 346002) or goat anti-ACE2 (R&D Systems, cat. AF933). After 1 h incubation on ice, the cells were washed two times and resuspended in FACS buffer containing the Alexa Fluor-488- labeled secondary antibodies at a 1 :200 dilution: goat anti-mouse (Invitrogen cat. Al 1001), goat anti-rabbit (Invitrogen cat. Al 1008) or donkey anti-goat (Invitrogen cat. Al 1055). After incubation for 45 min on ice, the cells were washed three times with 200pL of FACS buffer and fixed with 200pL of 4% PFA (Alfa Aesar) for 15 mins at room temperature. Cells were washed three times, resuspended in 200pL of FACS buffer and analyzed by flow cytometry using the CytoFLEX flow cytometer (Beckman Coulter).

Flow cytometry of SARS-CoV-2 Spike and RBD binding to cells

Biotinylated SARS-CoV-2 Spike D614G protein (Spikebiotin, in-house generated) or the biotinylated SARS-CoV-2 Spike receptor-binding domain (RBDbiotin, Sino Biological, 40592- V08B) were incubated with Alexa Fluor® 647 streptavidin (AF647-strep, Invitrogen, S21374) at a 1 :20 ratio by volume for 20 min at room temperature. The labeled proteins were then stored at 4°C until further use. Cells were dissociated with TrpLE Express (Gibco, 12605-010) and 10⁵ cells were transferred to each well of a 96-well V bottom plate (Corning, 3894). Cells were washed twice in flow cytometry buffer (2% FBS in PBS (w/o Ca/Mg)) and stained with Spikebiotin-AF647-strep at a final concentration of 20 pg/ml or RBDbiotin-AF647-strep at a final concentration of 7.5 pg/ml for Ih on ice. Stained cells were washed twice with flow cytometry buffer, resuspended in 1% PFA (Electron Microscopy Sciences, 15714-S) and analyzed with the Cytoflex LX (Beckman Coulter).

Recombinant expression of SARS-CoV-2-specific mAbs.

Human mAbs were isolated from plasma cells or memory B cells of SARS-CoV-2 immune donors, as previously described. Recombinant antibodies were expressed in ExpiCHO cells at 37°C and 8% CO2. Cells were transfected using ExpiFectamine. Transfected cells were supplemented 1 day after transfection with ExpiCHO Feed and ExpiFectamine CHO Enhancer. Cell culture supernatant was collected eight days after transfection and filtered through a 0.2 pm filter. Recombinant antibodies were affinity purified on an AKTA xpress FPLC device using 5 mL HiTrap™ MabSelect™ PrismA columns followed by buffer exchange to Histidine buffer (20 mM Histidine, 8% sucrose, pH 6) using HiPrep 26/10 desalting columns

SARS-CoV-2 infection model in hamster

Virus preparation

The SARS-CoV-2 strain used in this study, BetaCov/Belgium/GHB-03021/2020 (EPI ISL 109 407976|2020-02-03), was recovered from a nasopharyngeal swab taken from an RT- qPCR confirmed asymptomatic patient who returned from Wuhan, China in February 2020. A close relation with the prototypic Wuhan-Hu- 1 2019-nCoV (GenBank accession 112 number MN908947.3) strain was confirmed by phylogenetic analysis. Infectious virus was isolated by serial passaging on HuH7 and Vero E6 cells; passage 6 virus was used for the study described here. The titer of the virus stock was determined by end-point dilution on Vero E6 cells by the Reed and Muench method. Cells

Vero E6 cells (African green monkey kidney, ATCC CRL-1586) were cultured in minimal essential medium (Gibco) supplemented with 10% fetal bovine serum (Integra), 1% L- glutamine (Gibco) and 1% bicarbonate (Gibco). End-point titrations were performed with medium containing 2% fetal bovine serum instead of 10%.

SARS-CoV-2 infection model in hamsters

The hamster infection model of SARS-CoV-2 has been described before. The specific study design is shown in the schematic below. In brief, wild-type Syrian Golden hamsters (Mesocricetus auratus) were purchased from Janvier Laboratories and were housed per two in ventilated isolator cages (IsoCage N Biocontainment System, Tecniplast) with ad libitum access to food and water and cage enrichment (wood block). The animals were acclimated for 4 days prior to study start. Housing conditions and experimental procedures were approved by the ethics committee of animal experimentation of KU Leuven (license P065- 2020). Female 6-8 week old hamsters were anesthetized with ketamine/xylazine/atropine and inoculated intranasally with 50 pL containing 2 10⁶ TCID50 SARS-CoV-2 (day 0).

Treatment regimen

Animals were prophylactically treated 48h before infection by intraperitoneal administration (i.p.) and monitored for appearance, behavior, and weight. At day 4 post infection (p.i.), hamsters were euthanized by i.p. injection of 500 pL Dolethal (200 mg/mL sodium pentobarbital, Vetoquinol SA). Lungs were collected and viral RNA and infectious virus were quantified by RT-qPCR and end-point virus titration, respectively. Blood samples were collected before infection for PK analysis.

SARS-CoV-2 RT-qPCR

Collected lung tissues were homogenized using bead disruption (Precellys) in 350pL RLT buffer (RNeasyMinikit, Qiagen) and centrifuged (10.000 rpm, 5 min) to pellet the cell debris. RNA was extracted according to the manufacturer’s instructions. Of 50 pL eluate, 4 pL was used as a template in RT-qPCR reactions. RT-qPCR was performed on a LightCycler96 platform (Roche) using the iTaq Universal Probes One-Step RT-qPCR kit (BioRad) with N2 primers and probes targeting the nucleocapsid. Standards of SARS-CoV-2 cDNA (IDT) were used to express viral genome copies per mg tissue or per mL serum.

End-point virus titrations

Lung tissues were homogenized using bead disruption (Precellys) in 350 pL minimal essential medium and centrifuged (10,000 rpm, 5min, 4°C) to pellet the cell debris. To quantify infectious SARS-CoV-2 particles, endpoint titrations were performed on confluent Vero E6 cells in 96- well plates. Viral titers were calculated by the Reed and Muench method using the Lindenbach calculator and were expressed as 50% tissue culture infectious dose (TCID50) per mg tissue.

Histology

For histological examination, the lungs were fixed overnight in 4% formaldehyde and embedded in paraffin. Tissue sections (5 pm) were analyzed after staining with hematoxylin and eosin and scored blindly for lung damage by an expert pathologist. The scored parameters, to which a cumulative score of 1 to 3 was attributed, were the following: congestion, intra-alveolar hemorrhagic, apoptotic bodies in bronchus wall, necrotizing bronchiolitis, perivascular edema, bronchopneumonia, perivascular inflammation, peribronchial inflammation and vasculitis.

Binding of immunocomplexes to hamster monocytes

Immunocomplexes (IC) were generated by complexing S309 mAb (hamster IgG, either wt or N297A) with a biotinylated anti-idiotype fab fragment and Alexa-488-streptavidin, using a precise molar ratio (4:8: 1, respectively). Pre-generated fluorescent IC were serially diluted incubated at 4°C for 3 hrs with freshly revitalized hamster splenocytes, obtained from a naive animal. Cellular binding was then evaluated by cytometry upon exclusion of dead cells and physical gating on monocyte population. Results are expressed as Alexa-488 mean florescent intensity of the entire monocyte population.

Bioinformatic analyses

Processed Human Lung Cell Atlas (HLCA) data and cell-type annotations were downloaded from Github (github.com/krasnowlab/HLCA). Processed single-cell transcriptome data and annotation of lung epithelial and immune cells from SARS-CoV-2 infected individuals were downloaded from NCBI GEO database (ID: GSE158055) and Github (github.com/zhangzlab/covid_balf). Available sequence data from the second single-cell transcriptomics study by Liao et al. were downloaded from NCBI SRA (ID: PRJNA608742) for inspection of reads corresponding to viral RNA. The proportion of sgRNA relative to genomic RNA was estimated by counting TRS-containing reads supporting a leader-TRS junction. Criteria and methods for detection of leader-TRS junction reads were adapted from Alexandersen et al. The viral genome reference and TRS annotation was based on Wuhan-Hu- 1 NC_045512.2/MN908947⁴⁹. Only 2 samples from individuals with severe COVID-19 had detectable leader-TRS junction reads (SRR11181958, SRR11181959).

Cell lines

Cell lines used in this study were obtained from ATCC (HEK293T and Vero-E6) or ThermoFisher Scientific (Expi CHO cells, FreeStyle™ 293-F cells and Expi293F™ cells). Sample donors

Samples were obtained from cohorts of individuals enrolled before June 2019 (prepandemic), of SARS-CoV-2 infected individuals or of vaccinated individuals immunized with Modema or Pfizer/BioNTech BNT162b2 vaccines under study protocols approved by the local Institutional Review Boards (Canton Ticino Ethics Committee, Switzerland, the Ethical committee of Luigi Sacco Hospital, Milan, Italy and WCG North America, Princeton, NJ, US). All donors provided written informed consent for the use of blood and blood components (such as PBMCs, sera or plasma) and were recruited at hospitals or as outpatients. PBMCs were isolated from blood by Ficoll density gradient centrifugation and either used freshly or stored in liquid nitrogen for later use. Sera were obtained from blood collected using tubes containing clot activator, followed by centrifugation and stored at -80 °C.

AMBRA (antigen-specific memory B cell repertoire analysis) of IgG antibodies

Replicate cultures of PBMC were seeded in 96 U-bottom plates (Corning) and stimulated with 2.5 pg/ml R848 (3 M) and 1000 U/ ml human recombinant IL-2 for 10 days at 37 °C 5% CO2. The cells culture supernatants were collected for further analysis.

Antibody discovery and expression

Antigen specific IgG+ memory B cells were isolated and cloned from total PBMCs of convalescent individuals. Antibody VH and VL sequences were obtained by reverse transcription PCR (RT-PCR) and mAbs were expressed as recombinant human IgGl, carrying the half-life extending M428L/N434S (LS) mutation in the Fc region or Fab fragment. ExpiCHO cells were transiently transfected with heavy and light chain expression vectors as previously described (Pinto et al. 2020). For in vivo experiments in Syrian hamsters, S2P6 was produced with a Syrian hamster IgG2 Fc. UCA sequences were constructed using IMGT/V-QUEST and VH and VL with somatic mutation recumbently produced. MAbs affinity purification was performed on AKTA Xpress FPLC (Cytiva) operated by UNICORN software version 5.11 (Build 407) using HiTrap Protein A columns (Cytiva) for full length human and hamster mAbs and CaptureSelect CH1-XL MiniChrom columns (ThermoFisher Scientific) for Fab fragments, using PBS as mobile phase. Buffer exchange to the appropriate formulation buffer was performed with a HiTrap Fast desalting column (Cytiva). The final products were sterilized by filtration through 0.22 pm filters and stored at 4 °C.

Flow cytometry of Antibody on Spike Protein expressing ExpiCHO-S Cells

For Expi-CHO cells transient transfection, S plasmids (Pinto et al. 2020; M. Alejandra Tortorici et al. 2021) were diluted in cold OptiPRO SFM, mixed with ExpiFectamine CHO Reagent (Life Technologies, A29130) and added to the cells seeded at 6 x 106 cells/ml in a volume of 5 ml in a 50 ml bioreactor. Transfected cells were incubated at 37°C, 8% CO2 with an orbital shaking speed of 209 rpm (orbital diameter of 25 mm) for 42 hours. To test mAb binding, transfected ExpiCHO cells were collected, washed twice in wash buffer (1% w/v solution of Bovine Serum Albumin (BSA; Sigma) in PBS, 2 mM EDTA) and distributed at 60,000 cells/well into 96 U-bottom plates (Coming). mAb serial dilutions from 10 pg/ml were added onto cells for 30 minutes on ice and, after two washes, Alexa Fluot647-labelled Goat Anti-Human IgG secondary Ab (Jackson Immunoresearch, 109-606-098) was used for detection. After 15 minutes of incubation on ice, cells were washed twice and mAb binding analyzed by flow cytometry using a ZE5 Cell Analyzer (Biorard).

Enzyme-linked immunosorbent assay (ELISA)

Spectraplate-384 with high protein binding treatment (Perkin Elmer) or 96-well plates (Corning) were coated overnight at 4°C with recombinant stabilized prefusion spike trimers or S2 subunit at 1 pg/ml or coronaviruses stem helix peptides at 8 pg/ml, all diluted in phosphate- buffered saline (PBS). Plates were blocked with a 1% w/v solution of Bovine Serum Albumin (BSA; Sigma) in PBS or, for ELISA with plasma, with Blocker Casein (1% w/v) in PBS (Thermo Fisher Scientific) supplemented with 0.05% Tween 20. Serial dilutions of mAbs or plasma were added for 1 hour at room temperature. After further wash, mAbs bound were revealed using an anti-human IgG coupled to alkaline phosphatase (Jackson Immunoresearch) incubated for 1 hour. Substrate (p-NPP, Sigma) was used for color development and plates read at 405 nm by a microplate reader (Biotek). The data have been plotted with Graph Prism software.

Blockade of SARS-CoV-2 spike to ACE 2

SARS-CoV-2 S prefusion (final concentration 300 ng/ml) was incubated with 1 pg/ml of S309 mouse Fc-tagged mAb (S309-mFc) 30 minutes at 37°C before the addition of serially diluted S2P6 (from 20 pg/ml) and incubated for additional 30 minutes at 37°C. The complex spike:S309:S2P6 was then added to a pre-coated hACE2 (2 pg/ml in PBS) 96-well plate MaxiSorp (Nunc) and incubated 1 hour at room temperature. Subsequently, the plates were washed and secondary Ab goat anti-mouse IgG (Southern Biotech) added to detect SARS-CoV-2 spike: S309-mFc binding. After further washing, the substrate (p-NPP, Sigma) was added, and plates were read at 405 nm using a microplate reader (Biotek). The percentage of inhibition was calculated as follow: (1-((OD sample-OD neg ctr)/(OD pos. ctr-OD neg. ctr))*100.

Epitope identification and Substitution scan

PEPperMAP Epitope Mapping (PEPperPRINT GmbH, Heidelberg, Germany) was performed to determine mAbs epitope through a Pan-corona Spike Protein Microarray covering the spike proteins of all beta-coronaviruses. Briefly, microarray containing 15-mer peptides (overlapping of 13-mer) was incubated with 10 pg/ml mAb for 16 hours at 4°C shaking at 140 rpm followed by staining with secondary and control Abs for 45 minutes at room temperature. Microarray read-out was performed with a LLCOR Odyssey Imaging System at scanning intensities of 7/7 (red/green). Epitope substitution scan was performed on the identified epitope based on a stepwise single amino acid exchange on all amino acid positions. The mAbs binding to the generated microarray was performed as above.

SPR binding measurements

SPR binding measurements were performed using a Biacore T200 instrument using anti- AviTag pAb covalently immobilized on CM5 chips to capture S ECDs except the Cytiva Biotin CAPture kit was used to capture biotinylated OC43 S ECD. Running buffer was Cytiva HBS- EP+ (pH 7.4) or 20 mM phosphate pH 5.4, 150 mM NaCl, 0.05% P-20, for neutral or acidic pH experiments, respectively. All measurements were performed at 25 °C. S2P6 Fab or IgG concentrations were 11, 33, 100, and 300 nM run as single-cycle kinetics. Double reference- subtracted data were fit to a binding model using Biacore Evaluation software. All data for SARS-CoV-2 S, SARS-CoV S, and OC43 S were fit to a 1 : 1 binding model. Data for MERS S were fit to a Heterogeneous Ligand binding model, due to a kinetic phase with very slow dissociation presumed to be an artifact; the lower affinity of the two KDs returned by the fit is reported as the KD of the S2P6:MERS S interaction and is indicated to be approximate (the Rmax associated with the higher affinity kinetic phase is proportional to the magnitude of the final signal above baseline). Data for HKU1 S were fit to a steady-state binding model, because of the low signal and fast approach to equilibrium within each association phase; the reported KD is indicated to be approximate. IgG binding data yield an “apparent KD” due to avidity.

Neutralization of authentic SARS-CoV-2 virus

For SARS-CoV-2 neutralization experiments, cells were cultured in DMEM (Gibco 11995-040) supplemented with 10% FBS (VWR 97068-085 lot#345K19) and 100 U/ml Penicillin-Streptomycin (Gibco 15140-122). Cells were seeded in black, 96-well glass bottom plates (Cellvis P96-1.5H-N) at a density of 20,000 cells/well. In a BSL3 facility, serial dilutions of mAbs (1 :4) were incubated with 200 PFU (plaque forming units, corresponding to a multiplicity of infection of 0.01) of authentic SARS-CoV-2 (isolate USA-WA1/2020, passage 3, passaged in Vero-E6 cells) for 30 minutes at 37°C. After removal of cell culture supernatants, cells were infected with the virus: antibody mixtures and incubated for 20 hours at 37°C. Cells were then fixed with 4% paraformaldehyde (Electron Microscopy Sciences, 15714-S) in PBS (Gibco 10010-031) for 30 minutes, permeabilized with 0.1% Triton X-100 (Sigma, X100- 500ML) for 30 minutes, and stained with Human SARS Coronavirus Nucleoprotein/NP Antibody, Rabbit Mab (Sino Biological, 40143-R001) at a dilution of 1 :2000 dilution in 2% milk (RPI, M17200-500.0) for 1 hour. Subsequently, cells were stained with Goat anti-Rabbit IgG (H+L) AF647 (Invitrogen, Cat. A21245 Lot. 223 2862) at a dilution of 1 : 1000 and 2 ug/ml Hoechst 33342 in 2% milk for 1 hour. Plates were imaged with an automated microscope (Cytation5, Biotek), and nuclei and cells positive for the SARS-CoV-2 Nucleoprotein were quantified using the supplied Gen5 software. Neutralization of SARS-CoV-2 Nluc virus

Cells were cultured in DMEM (Gibco 11995-040) supplemented with 10% FBS (VWR 97068-085 lot#345K19) and 100 U/ml Penicillin-Streptomycin (Gibco 15140-122). For neutralization experiments, cells were seeded in black, 96-well glass bottom plates (Coming, 3904) at 20,000 cells/well and transferred to a BSL3 facility. Serial 1 :4 dilution series of mAbs were incubated with 200 PFU of SARS-CoV-2 Nluc, an infectious clone of SARS-CoV-2 (strain 2019-nCoV/USA_WAl/2020) in which the viral ORF7 gene was replaced with a nanoluciferase reporter (Xie et al. 2020). After 30 minutes incubation at 37°C, the virus: antibody mixtures were used to infect the target cells at a multiplicity of infection of 0.01. At 20 hours post infection, cells were allowed to equilibrate to room temperature and cell culture supernatants were aspirated. A 1 : 1 mixture ofNano-Glo® Live Cell Assay System (Promega N2012) reagent and DPBS (with Ca/Mg) (Gibco 14040-133) was added to the cells. After 10 minutes incubation at room temperature, the luciferase signal was read out with a luminescent plate reader (PerkinElmer VICTOR Nivo™).

VSV pseudotype virus production and neutralization

Sarbecovirus spike cassettes with a C-terminal deletion of 19 amino acids (DI 9) were synthesized and cloned into Mammalian expression constructs (pcDNA3.1(+) or pTwist-CMV) for the following Sarbecoviruses: SARS-CoV-2 (Accession QOU99296.1), SARS-CoV-1 (Accession AAP13441.1), hCoV-19/pangolin/Guangdong/l/2019 (GD19, Accession QLR06867.1), and Middle East respiratory syndrome-related coronavirus (MERS, Accession YP_009047204). To generate pseudotyped VSV, 293T Lenti-X packaging cells (Takara, 632180) were seeded in 15 cm dishes such that the cells would be 80% confluent the following day. Cultures were then transfected with various spike expression plasmids using TransIT-Lenti transfection reagent (Minis, 6600) according to the manufacturer’s instructions. 24 hours after transfection, the packaging cells were infected with VSV-G*AG-luciferase (Kerafast, EH1020- PM). 48 hours after infection the supernatant containing Sarbecovirus pseudotyped VSV-luc was collected, centrifuged at 1000 * g for 5 min, aliquoted and frozen at -80°C.To perform pseudovirus neutralization assays, the following cells supporting robust pseudovirus were employed: VeroE6-TMPRSS2 cells were used for VSV-SARS-CoV-2, VSV-SARS-CoV-1, and VSV-GD19and Huh7 cells were used for VSV-MERS. Cells were seeded into clear bottom white-walled 96-well plates at 20,000 cells/well. The following day, 1 :3 serial dilutions of Ab were prepared in basal DMEM in triplicate. Pseudotyped VS Vs were diluted in basal DMEM and added to each Ab dilution such that the final dilution of pseudovirus was 1 :20. Pseudovirus:antibody mixtures were incubated for 1 hour at 37°C. Media was removed from the cells seeded the previous day and replaced with 50 pl of pseudovirus: Ab mixtures and incubated at 37°C. One hour post-infection, 50 pl of complete culture media was added to each well and cells incubated overnight at 37°C. The media from infected cells was then removed and 100 pl of 1 : 1 diluted PBS:Bio-Glo (Promega, G7940) luciferase substrate was added to each well. The plates were shaken at 300 rpm at room temperature for 10 min and relative light units (RLUs) were then read on an EnSight microplate reader (Perkin Elmer). Percent neutralization was determined by subtracting the mean background (uninfected cells with luciferase substrate alone) values of 6 wells per plate from all data points. Percent neutralization for each antibody concentration was calculated relative to control wells receiving no antibody for each plate. Percent neutralization data were analyzed using Prism (GraphPad, v9.0.1). Absolute EC50 values were calculated by fitting a curve using a variable slope 4 parameter non-linear regression model and values were interpolated from the curve at y=50.

Selection of VSV-SARS-CoV-2 mAh escape mutants

Resistant virus selection:

Cells were cultured in DMEM (Gibco 11995-040) supplemented with 10% FBS (VWR 97068-085 lot#345K19) and 100 U/ml Penicillin-Streptomycin (Gibco 15140-122). The day before infection, 250,000 VeroE6-TMPRSS2 cells were seeded in 12-well plates in 2 ml of DMEM (Gibco 11995-040) supplemented with 10% FBS (VWR 97068-085 lot#345K19) and 100 U/ml Penicillin-Streptomycin (Gibco 15140-122) and incubated overnight at 37C. The next day, S2P6 was serially diluted 1 :4 starting at 80 ug/ml in infection media (DMEM (supplemented with 2% FBS and 20mM HEPES (Gibco, 15630-080)) and incubated with replication-competent VSV-SARS-CoV-2 (Case et al. 2020) at MOI 2 for 1 hour at 37°C. A no Ab control was included to account for any tissue culture adaptations and quasispecies variability that may occur during virus replication. The mAb-virus complexes were adsorbed on the cells for Ihour at 37°C, with manual rocking every 15 minutes. After adsorption, cells were washed with PBS and overlaid with infection media containing an equivalent amount of S2P6 as was used for the initial infection. Infection was monitored visually by microscopy for GFP expression and cytopathic effect (CPE) of the cells at day 1 and day 3 post infection. At day 3 post infection, when the no mAb control well reached >50% CPE, the well with the highest Ab concentration showing >20% CPE (in this case the 80 ug/ml well) was selected for passaging. The cell supernatant was centrifuged to remove cell debris, diluted 1 : 10 in infection medium and added to fresh VeroE6-TMPRRS2 cells with the same S2P6 concentration range and treatment as for the initial passage. Selection was stopped after two passages, after no virus neutralization was observed at the highest concentration tested.

Sequencing of S gene:

Viral RNA was extracted from the supernatant of viral passages using the QIAamp Viral RNA Mini Kit (Qiagen, 52904) according to the manufacturer’s instructions, without the addition of carrier RNA. Reverse transcription reactions were performed with 6 pl of purified RNA and random primers using the NEB ProtoScript II First Strand cDNA Synthesis Kit (NEB, E6560S), according to manufacturer’s instructions. The resulting cDNA was used as a template for PCR amplification of the spike gene using the KapaBiosystems polymerase (KAPA HiFi HotStart Ready PCR Kit KK2601) with primers 5’- CGAGAAAAAGGCATCTGGAG -3’ and 5’ - CATTGAACTCGTCGGTCTC -3’. Amplification conditions included an initial 3 minutes at 95°C, followed by 28 cycles with 20 seconds at 98°C, 15 seconds at 59°C and 72°C for 2 minutes, with a final 4 minutes at 72°C. PCR products were purified using AMPure XP beads (Beckman Coulter, A63881) following manufacturer’s instructions. The size of the amplicon was confirmed by analyzing 2 pl of PCR products using the Agilent D5000 ScreenTape System (Agilent D5000 ScreenTape, 5067-5588, Agilent D5000, Reagents 5067-5589). Products were quantified by analyzing 2 pl with the Quant-iT dsDNA High-Sensitivity Assay Kit (Thermo Fisher, Q331120). Twenty ng of purified PCR product was used as input for library construction using the NEBNext Ultra II FS DNA Library Prep Kit (NEB, E6177S) following manufacturer’s instructions. DNA fragmentation was performed for 13 minutes. NEBNext Multiplex Oligos for Illumina Dual Index Primer Set 1 (NEB, E7600S) was used for library construction, with a total of 6 PCR cycles. Libraries size was determined using the Agilent D1000 ScreenTape System (Agilent D1000 ScreenTape, 5067-5582, Agilent D5000 Reagents, 5067-5583) and quantified with the Quant-iT dsDNA High-Sensitivity Assay Kit. Equal amounts of each library were pooled together for multiplexing and ‘Protocol A: Standard Normalization Method’ of the Illumina library preparation guide was used to prepare 8 pM final multiplexed library with 1% PhiX spike-in for sequencing. The Illumina MiSeq Reagent Kit v3 (600-cycle) (Illumina, MS- 102-300) was used for sequencing the libraries on the Illumina MiSeq platform, with 300 cycles for Read 1, 300 cycles for Read 2, 8 cycles for Index 1, and 8 cycles for Index 2.

Bioinformatic analysis:

The average read length after running Illumina’s Bcl2fastq command was ranging from 149 to 188bp on average per sample. For consistency across samples, paired-end reads were initially trimmed to 2X150bp and further cleaned to remove Illumina’s adapter and low quality bases using Trimmomatic (Bolger, Lohse, and Usadel 2014). Read alignment was performed with Burrows- Wheeler Aligner (BWA (Li 2013)) using a custom reference sequence. Variants were called with LoFreq upon indel realignment and base quality recalibration (Wilm et al. 2012), using a frequency threshold of 1%. Two consecutive rounds of alignments and variant calling were perfomed, where the variants called during the first round at allelic frequency >50% were integrated in the reference for the second round in order to alignment rate and variant calling accuracy. Variants were annotated with SnpEff (Cingolani et al. 2012). The reference sequence coordinates were mapped back to the SARS-CoV-2 Wuhan-Hu- 1 sequence (NCBI: NC_045512.2) in order to match the reference sequence nomenclature. Extensive QCs were performed at read, alignment and variant level using FastQC , samtools, picard, mosdepth (Pedersen and Quinlan 2018), bcftools(Danecek et al. 2021), MultiQC (Ewels et al. 2016) and inhouse scripts, notably to remove variants that were consistently called at a static position in reads (such as the beginning or end of reads that were carrying it, rather than being randomly distributed throughout those reads.). An end-to-end workflow was automated using NextFlow (Di Tommaso et al. 2017). All programs are available through the Bioconda Initiative (Griming et al. 2018)(bioconda.github.io). MAb-dependent activation of human FcyRIIIa and FcyRIIa

Determination of m Ab-dependent activation of human FcyRIIIa and FcyRIIa was performed using ExpiCHO cells stably expressing full-length wild-type SARS-CoV-2 spike (S) (target cells). Cells were incubated with different amounts of mAbs for 10 minutes before incubation with Jurkat cells stably expressing FcyRIIIa receptor (VI 58 variant) or FcyRIIa receptor (H131 variant) and NFAT-driven luciferase gene (effector cells) at an effector to target ratio of 6: 1 for FcyRIIIa and 5: 1 for FcyRIIa. Activation of human FcyRs was quantified by the luciferase signal produced as a result of NF AT pathway activation. Luminescence was measured after 21 hours of incubation at 37°C with 5% CO2 with a luminometer using the Bio-Glo-TM Luciferase Assay Reagent according to the manufacturer’s instructions (Promega, Cat. Nr.: G7018 and G9995).

Antibody-dependent cell cytotoxicity (ADCC)

ADCC assays were performed using SARS-CoV2 CHO-K1 cells (genetically engineered to stably express a HaloTag-HiBit-tagged) as target cells and PBMC as effector cells at a E:T ratio of 33: 1. HiBit-cells were seeded at 3,000 cells/well and incubated for 16 hours at 37°C, while PBMC isolated from fresh blood (VV donor) were cultivated overnight in an incubator at 37°C in the presence of 5 ng/ml of IL-2. The day after, media was removed and titrated concentrations of mAbs were added before the addition of PBMCs at 100,000 cells/well. As 100% specific lysis, Digitonin at 100 ug/ml was used. After 4 hours of incubation at 37°C, ADCC was measured with Nano-Gio HiBiT Extracellular Detection System (Promega; Cat. Nr. : N2421) using a luminometer (Integration Time 00:30).

Antibody-dependent cellular phagocytosis (ADCP)

ADCP was performed using CHO cells stably expressing full-length wild-type SARS- CoV-2 S glycoprotein (target cells) fluorescently labelled with PKH67 Fluorescent Cell Linker Kits (Sigma Aldrich; Cat. Nr.: MINI67). Target cells were incubated with titrated concentrations of mAbs for 10 minutes, followed by incubation with PBMCs fluorescently labelled with Cell Trace Violet (Invitrogen, cat. no. C34557) after an overnight incubation in 5 ng/ml IL-2 (Recombinant Human Interleukin-2; ImmunoTools GmbH; Cat. Nr.: 11340027). An effectortarget ratio of 20:1 was used. After an overnight incubation at 37 °C, cells were stained with anti-human CD14-APC antibody (BD Pharmingen, cat. no. 561708, Clone M5E2) to stain monocytes. ADCP was determined by flow cytometry, gating on CD 14+ cells that were doublepositive for cell trace violet and PKH67.

Complement-dependent cytotoxicity (CDC)

CDC was performed on CHO cells stably expressing SARS-CoV-2 S glycoprotein (target cells) incubated with serial dilutions of mAbs for 10 minutes, followed by incubation with preadsorbed Low-Tox M Rabbit Complement (Cederlane Laboratories Limited; Cat. Nr.: CL3051) at a final dilution of 1 : 12. CDC was measured after incubation for 3 hours at 37 °C 5% CO2 with a luminometer using the CytoTox-Glo Cytotoxicity Assay (Promega; Cat. Nr.: G9291) according to the manufacturer’s instructions.

S2P6 binding and S2P6/B6 competition experiments to different synthetic coronavirus S stem peptides

All biotinylated coronavirus S stem helix peptides binding experiments were performed in PBS supplemented with 0.005 % Tween20 (PBST) at 30 °C and 1,000 rpm. shaking on an Octet Red instrument (Fortebio). For S2P6 binding to different stem helix peptides, 1 pg/mlL biotinylated stem peptide (15- or 16-residue long stem peptide-PEG6-Lys-Biotin synthesized fom Genscript) was loaded on SA biosensors to a threshold of 0.5 nm. Then, the system was equilibrated in PBST for 300 seconds prior to immersing the sensors in 0.1 pM S2P6 mAb, respectively, for 300 seconds prior to dissociation in buffer for 300 seconds. For S2P6-B6 competition, 1 pg/ml biotinylated to SARS CoV-2 peptide was loaded on SA biosensors to a threshold of 0.5 nm. The system was equilibrated in PBST for 180 seconds and each subsequent step was monitored for 900 seconds. The first sample biosensor was immersed in 0.1 pM mAb S2P6 prior to immersing the sample biosensor in a solution of 0.1 pM mAb S2P6 and B6, respectively. The second sample biosensor was immersed in PBST and subsequently in 0.1 pM mAb B6. To monitor unspecific binding, identical experiments were performed without loading stem peptides to the biosensors.

Fusion inhibition assay

For testing inhibition of spike-mediated cell-cell fusion VeroE6 cells were seeded in 96 well plates at 20,000 cells/ well in 70 pl DMEM with high glucose and 2.4% FBS (Hyclone). After 16 hours, cells were transfected with SARS-CoV-2-S-D19_pcDNA3.1 as follows: for 10 wells, 0.57 pg plasmid SARS-CoV-2- S-D19_pcDNA3.1 were mixed with 1.68 pl X- tremeGENE HP in 30 pl OPTIMEM. After 15 minutes incubation, the mixture was diluted 1 : 10 in DMEM medium and 30 pl was added per well. A 4-fold serial dilution mAb was prepared and added to the cells, with a starting concentration of 20 pg/ml. The following day, 30 pl 5X concentrated DRAQ5 in DMEM was added per well and incubated for 2 hours at 37°C. Nine images of each well were acquired with a Cytation 5 equipment for analysis.

In vivo mAb testing using a Syrian hamster model

KU LEUVEN R&D has developed and validated a SARS-CoV-2 Syrian Golden hamster infection model (Boudewijns et al. 2020).

SARS-CoV-2 virus production

The wt SARS-CoV-2 strain used in this study, BetaCov/Belgium/GHB-03021/2020 (EPI ISL 109 407976|2020-02-03), was recovered from a nasopharyngeal swab taken from an RT- qPCR confirmed asymptomatic patient who returned from Wuhan, China in the beginning of February 2020. A close relation with the prototypic Wuhan-Hu-1 2019-nCoV (GenBank accession 112 number MN908947.3) strain was confirmed by phylogenetic analysis. Infectious virus was isolated by serial passaging on HuH7 and VeroE6 cells (Boudewijns et al. 2020); passage 6 virus was used for the study described here. The titer of the virus stock was determined by end-point dilution on Vero-E6 cells by the Reed and Muench method (Reed and Muench 1938). The variant strain B.1.351 (hCoV-19/Belgium/rega- 1920/2021; EPI_ISL_896474, 2021- 01-11) was isolated from nasopharyngeal swabs taken from a traveler returning to Belgium and developing respiratory symptoms. The patients’ nasopharyngeal swabs were directly subjected to sequencing on a MinlON platform (Oxford Nanopore) (Abdelnabi et al https://www.biorxiv.Org/content/10. l 101/2021.02.26.433062vl).

Live virus-related work was conducted in the high-containment A3 and BSL3+ facilities of the KU Leuven Rega Institute (3CAPS), under licenses AMV 30112018 SBB 219 2018 0892 and AMV 23102017 SBB 219 20170589 according to institutional guidelines.

SARS-CoV-2 infection model in hamsters

Wildtype Syrian hamsters (Mesocricetus auratus) were purchased from Janvier Laboratories and were housed per two in ventilated isolator cages (IsoCage N Biocontainment System, Tecniplast) with ad libitum access to food and water and cage enrichment (wood block). Housing conditions and experimental procedures were approved by the ethical committee of animal experimentation of KU Leuven (license P065-2020). Female hamsters of 6-10 weeks old were anesthetized with ketamine/xylazine/atropine and inoculated intranasally with 50 pl containing 2^ 106 or 1x104 TCID50 for wt or B.1.351 variants respectively. Monoclonal antibody treatment (human or hamster S2P6 (2-20 mg/kg) was initiated either 24) or 48 hours before infection by intraperitoneal injection. Hamsters were monitored for appearance, behavior and body weight. At day 4 post infection, hamsters were euthanized by intraperitoneal injection of 500 pl Dolethal (200 mg/mL sodium pentobarbital, Vetoquinol SA). Lungs were collected, and viral RNA and infectious virus were quantified by RT-qPCR and end-point virus titration, respectively. Blood samples were collected before infection for pharmacokinetics analysis.

SARS-CoV-2 RT-qPCR:

Hamster tissues were collected after sacrifice and were homogenized using bead disruption (Precellys) in 350 pll RLT buffer (RNeasy Mini kit, Qiagen) and centrifuged (10,000 rpm, 5 minutes) to pellet the cell debris. RNA was extracted according to the manufacturer’s instructions. To extract RNA from serum, a NucleoSpin kit (Macherey -Nagel) was used. 4 pl out of 50 pl eluate were used as a template in RT-qPCR reactions. RT-qPCR was performed on a LightCycler96 platform (Roche) using the iTaq Universal Probes One-Step RTqPCR kit (BioRad) with N2 primers and probes targeting the nucleocapsid (Boudewijns et al. 2020). Standards of SARS-CoV-2 cDNA (IDT) were used to express viral genome copies per mg tissue or per ml serum. End-point virus titrations

Lung tissues were homogenized using bead disruption (Precellys) in 350 pl minimal essential medium and centrifuged (10,000 rpm, 5 minutes, 4°C) to pellet the cell debris. To quantify infectious SARS-CoV-2 particles, endpoint titrations were performed on confluent Vero-E6 cells in 96-well plates. Viral titers were calculated by the Reed and Muench method (Reed and Muench 1938) using the Lindenbach calculator and were expressed as 50% tissue culture infectious dose (TCID50) per mg tissue.

REFERENCES

Anderson, Elizabeth M., Eileen C. Goodwin, Anurag Verma, Claudia P. Arevalo, Marcus J. Bolton, Madison E. Weirick, Sigrid Gouma, et al. 2021. “Seasonal Human Coronavirus Antibodies Are Boosted upon SARS-CoV-2 Infection but Not Associated with Protection.” Cell 184 (7): 1858-1864. elO.

Azoitei, M. L., B. E. Correia, Y. E. Ban, C. Carrico, O. Kalyuzhniy, L. Chen, A. Schroeter, et al. 2011. “Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold.” Science 334 (6054): 373-76.

Bolger, Anthony M., Marc Lohse, and Bjoern Usadel. 2014. “Trimmomatic: A Flexible Trimmer for Illumina Sequence Data.” Bioinformatics (Oxford, England) 30 (15): 2114-20.

Boudewijns, R., H. J. Thibaut, S. J. F. Kaptein, R. Li, V. Vergote, L. Seldeslachts, J. Van Weyenbergh, et al. 2020. “STAT2 Signaling Restricts Viral Dissemination but Drives Severe Pneumonia in SARS-CoV-2 Infected Hamsters.” Nature Communications 11 (1): 5838.

Bournazos, S., D. Corti, H. W. Virgin, and J. V. Ravetch. 2020. “Fc-Optimized Antibodies Elicit CD8 Immunity to Viral Respiratory Infection.” Nature 588 (7838): 485-90.

Bournazos, S., T. T. Wang, and J. V. Ravetch. 2016. “The Role and Function of Fey Receptors on Myeloid Cells.” Microbiol Spectr 4 (6). https://doi.Org/10.l 128/microbiolspec.MCHD-0045-2016.

Boyoglu-Bamum, Seyhan, Daniel Ellis, Rebecca A. Gillespie, Geoffrey B. Hutchinson, Young- Jun Park, Syed M. Moin, Oliver J. Acton, et al. 2021. “Quadrivalent Influenza Nanoparticle Vaccines Induce Broad Protection.” Nature, March. https://doi.org/10.1038/s41586-021-03365-x.

Cai, Y., J. Zhang, T. Xiao, H. Peng, S. M. Sterling, R. M. Walsh, S. Rawson, S. Rits- Volloch, and B. Chen. 2020. “Distinct Conformational States of SARS-CoV-2 Spike Protein.” Science 369 (6511): 1586-92.

Case, J. B., P. W. Rothlauf, R. E. Chen, Z. Liu, H. Zhao, A. S. Kim, L. M. Bloyet, et al. 2020. “Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV- SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.” Cell Host & Microbe 28 (3): 475-485. e5.

Chen, S., G. McMullan, A. R. Faruqi, G. N. Murshudov, J. M. Short, S. H. Scheres, and R. Henderson. 2013. “High-Resolution Noise Substitution to Measure Overfitting and Validate Resolution in 3D Structure Determination by Single Particle Electron Cryomicroscopy.” Ultramicroscopy 135 (December): 24-35. Cingolani, Pablo, Adrian Platts, Le Lily Wang, Melissa Coon, Tung Nguyen, Luan Wang, Susan J. Land, Xiangyi Lu, and Douglas M. Ruden. 2012. “A Program for Annotating and Predicting the Effects of Single Nucleotide Polymorphisms, SnpEff: SNPs in the Genome of Drosophila Melanogaster Strain W1118; Iso-2; Iso-3.” Fly 6 (2): 80-92.

Correia, B. E., J. T. Bates, R. J. Loomis, G. Baneyx, C. Carrico, J. G. Jardine, P. Rupert, et al. 2014. “Proof of Principle for Epitope-Focused Vaccine Design.” Nature 507 (7491): 201- 6.

Corti, D., J. Voss, S. J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S. G. Vachieri, et al. 2011. “A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins.” Science 333 (6044): 850-56.

Danecek, Petr, James K. Bonfield, Jennifer Liddle, John Marshall, Valeriu Ohan, Martin O. Pollard, Andrew Whitwham, et al. 2021. “Twelve Years of SAMtools and BCFtools.” GigaScience 10 (2). https://doi.org/10.1093/gigascience/giab008.

Daniel, C., R. Anderson, M. J. Buchmeier, J. O. Fleming, W. J. Spaan, H. Wege, and P. J. Talbot. 1993. “Identification of an Immunodominant Linear Neutralization Domain on the S2 Portion of the Murine Coronavirus Spike Glycoprotein and Evidence That It Forms Part of Complex Tridimensional Structure.” Journal of Virology 67 (3): 1185-94.

Di Tommaso, Paolo, Maria Chatzou, Evan W. Floden, Pablo Prieto Barja, Emilio Palumbo, and Cedric Notredame. 2017. “Nextflow Enables Reproducible Computational Workflows.” Nature Biotechnology 35 (4): 316-19.

DiLillo, D. J., G. S. Tan, P. Palese, and J. V. Ravetch. 2014. “Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Require FcyR Interactions for Protection against Influenza Virus in Vivo.” Nature Medicine 20 (2): 143-51.

Elshabrawy, H. A., M. M. Coughlin, S. C. Baker, and B. S. Prabhakar. 2012. “Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing.” PloS One 7 (11): e50366.

Ewels, Philip, Mans Magnusson, Sverker Lundin, and Max Kaller. 2016. “MultiQC: Summarize Analysis Results for Multiple Tools and Samples in a Single Report.” Bioinformatics 32 (19): 3047-48.

Fan, X., D. Cao, L. Kong, and X. Zhang. 2020. “Cryo-EM Analysis of the Post-Fusion Structure of the SARS-CoV Spike Glycoprotein.” Nature Communications 11 (1): 3618.

Griming, Bjorn, Ryan Dale, Andreas Sjbdin, Brad A. Chapman, Jillian Rowe, Christopher H. Tomkins-Tinch, Renan Valieris, Johannes Koster, and Bioconda Team. 2018. “Bioconda: Sustainable and Comprehensive Software Distribution for the Life Sciences.” Nature Methods 15 (7): 475-76.

Gui, M., W. Song, H. Zhou, J. Xu, S. Chen, Y. Xiang, and X. Wang. 2017. “CryoElectron Microscopy Structures of the SARS-CoV Spike Glycoprotein Reveal a Prerequisite Conformational State for Receptor Binding.” Cell Research 27 (1): 119-29. Hoffmann, M., H. Kleine-Weber, and S. Pbhlmann. 2020. “A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.” Molecular Cell i (4): 779-784. e5.

Hoffmann, M., H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, T. S. Schiergens, et al. 2020. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.” Cell 181 (2): 271-280. e8.

Hoffmann, M., K. Mdsbauer, H. Hofmann-Winkler, A. Kaul, H. Kleine-Weber, N. Kruger, N. C. Gassen, M. A. Muller, C. Drosten, and S. Pbhlmann. 2020. “Chloroquine Does Not Inhibit Infection of Human Lung Cells with SARS-CoV-2.” Nature 585 (7826): 588-90.

Kallewaard, N. L., D. Corti, P. J. Collins, U. Neu, J. M. McAuliffe, E. Benjamin, L. Wachter-Rosati, et al. 2016. “Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.” Cell 166 (3): 596-608.

Kaname, Y., H. Tani, C. Kataoka, M. Shiokawa, S. Taguwa, T. Abe, K. Moriishi, T. Kinoshita, and Y. Matsuura. 2010. “Acquisition of Complement Resistance through Incorporation of CD55/Decay- Accel erating Factor into Viral Particles Bearing Baculovirus GP64.” Journal of Virology 84 (7): 3210-19.

Kanekiyo, M., M. G. Joyce, R. A. Gillespie, J. R. Gallagher, S. F. Andrews, H. M. Yassine, A. K. Wheatley, et al. 2019. “Mosaic Nanoparticle Display of Diverse Influenza Virus Hemagglutinins Elicits Broad B Cell Responses.” Nature Immunology 20 (3): 362-72.

Kanekiyo, M., C. J. Wei, H. M. Yassine, P. M. McTamney, J. C. Boyington, J. R. Whittle, S. S. Rao, W. P. Kong, L. Wang, and G. J. Nabel. 2013. “Self- Assembling Influenza Nanoparticle Vaccines Elicit Broadly Neutralizing H1N1 Antibodies.” Nature 499 (7456): 102- 6.

Kirchdoerfer, R. N., N. Wang, J. Pallesen, D. Wrapp, H. L. Turner, C. A. Cottrell, K. S. Corbett, B. S. Graham, J. S. McLellan, and A. B. Ward. 2018. “Stabilized Coronavirus Spikes Are Resistant to Conformational Changes Induced by Receptor Recognition or Proteolysis.” Scientific Reports 8 (1): 15701.

Lempp, Florian A., Leah Soriaga, Martin Monti el -Ruiz, Fabio Benigni, Julia Noack, Young- Jun Park, Siro Bianchi, et al. 2021. “Membrane Lectins Enhance SARS-CoV-2 Infection and Influence the Neutralizing Activity of Different Classes of Antibodies.” BioRxiv. bioRxiv. https://doi.org/10.1101/2021.04.03.438258.

Li, Heng. 2013. “Aligning Sequence Reads, Clone Sequences and Assembly Contigs with BWA-MEM.” ArXiv [q-Bio.GN] . arXiv. http://arxiv.org/abs/1303.3997.

Marcandalli, J., B. Fiala, S. Ols, M. Perotti, W. de van der Schueren, J. Snijder, E. Hodge, et al. 2019. “Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus.” Cell 176 (6): 1420-1431 el7.

Pedersen, Brent S., and Aaron R. Quinlan. 2018. “Mosdepth: Quick Coverage Calculation for Genomes and Exomes.” Bioinformatics 34 (5): 867-68.

Piccoli, L., Y. J. Park, M. A. Tortorici, N. Czudnochowski, A. C. Walls, M. Beltramello, C. Silacci-Fregni, et al. 2020. “Mapping Neutralizing and Immunodominant Sites on the SARS- CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.” Cell 183 (4): 1024-1042. e21.

Pinna, Debora, Davide Corti, David Jarrossay, Federica Sallusto, and Antonio Lanzavecchia. 2009. “Clonal Dissection of the Human Memory B-Cell Repertoire Following Infection and Vaccination.” European Journal of Immunology 39 (5): 1260-70.

Pinto, D., Y. J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, et al. 2020. “Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody.” Nature 583 (7815): 290-95.

Poh, C. M., G. Carissimo, B. Wang, S. N. Amrun, C. Y. Lee, R. S. Chee, S. W. Fong, et al. 2020. “Two Linear Epitopes on the SARS-CoV-2 Spike Protein That Elicit Neutralising Antibodies in COVID-19 Patients.” Nature Communications 11 (1): 2806.

Punjani, A., J. L. Rubinstein, D. J. Fleet, and M. A. Brubaker. 2017. “CryoSPARC: Algorithms for Rapid Unsupervised Cryo-EM Structure Determination.” Nature Methods 14 (3): 290-96.

Reed, L. L, and H. Muench. 1938. “A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12.” American Journal of Epidemiology 27 (3): 493-97.

Sauer, Maximilian M., M. Alexandra Tortorici, Young- Jun Park, Alexandra C. Walls, Leah Homad, Oliver Acton, John Bowen, et al. 2020. “Structural Basis for Broad Coronavirus Neutralization.” BioRxiv : The Preprint Server for Biology, December. https://doi.org/10.1101/2020.12.29.424482.

Schafer, A., F. Muecksch, J. C. C. Lorenzi, S. R. Leist, M. Cipolla, S. Bournazos, F. Schmidt, et al. 2021. “Antibody Potency, Effector Function, and Combinations in Protection and Therapy for SARS-CoV-2 Infection in Vivo.” The Journal of Experimental Medicine 218 (3). https://doi.org/10.1084/jem.20201993.

Sesterhenn, F., C. Yang, J. Bonet, J. T. Cramer, X. Wen, Y. Wang, C. I. Chiang, et al. 2020. “De Novo Protein Design Enables the Precise Induction of RSV-Neutralizing Antibodies.” Science 368 (6492). https://doi.org/10.1126/science.aay5051.

Song, Ge, Wan-Ting He, Sean Callaghan, Fabio Anzanello, Deli Huang, James Ricketts, Jonathan L. Torres, et al. 2020. “Cross-Reactive Serum and Memory B Cell Responses to Spike Protein in SARS-CoV-2 and Endemic Coronavirus Infection.” BioRxiv, 2020.09.22.308965.

Tegunov, D., and P. Cramer. 2019. “Real-Time Cryo-Electron Microscopy Data Preprocessing with Warp.” Nature Methods 16 (11): 1146-52.

Tortorici, M. A., M. Beltramello, F. A. Lempp, D. Pinto, H. V. Dang, L. E. Rosen, M. McCallum, et al. 2020. “Ultrapotent Human Antibodies Protect against SARS-CoV-2 Challenge via Multiple Mechanisms.” Science 370 (6519): 950-57.

Tortorici, M. A., and D. Veesler. 2019. “Structural Insights into Coronavirus Entry.” Advances in Virus Research 105: 93-116.

Tortorici, M. Alejandra, Nadine Czudnochowski, Tyler N. Starr, Roberta Marzi, Alexandra C. Walls, Fabrizia Zatta, John E. Bowen, et al. 2021. “Structural Basis for Broad Sarbecovirus Neutralization by a Human Monoclonal Antibody.” BioRxiv.Org: The Preprint Server for Biology, April, https://doi.org/10.1101/2021.04.07.438818.

Walls, A. C., B. Fiala, A. Schafer, S. Wrenn, M. N. Pham, M. Murphy, L. V. Tse, et al. 2020. “Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.” Cell 183 (5): 1367-1382.el7.

Walls, A. C., Y. J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Veesler. 2020. “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.” Cell 181 (2): 281-292. e6.

Walls, A. C., M. A. Tortorici, B. J. Bosch, B. Frenz, P. J. M. Rottier, F. DiMaio, F. A. Rey, and D. Veesler. 2016. “Cryo-Electron Microscopy Structure of a Coronavirus Spike Glycoprotein Trimer.” Nature 531 (7592): 114-17.

Walls, A. C., M. A. Tortorici, J. Snijder, X. Xiong, B. J. Bosch, F. A. Rey, and D. Veesler. 2017. “Tectonic Conformational Changes of a Coronavirus Spike Glycoprotein Promote Membrane Fusion.” Proceedings of the National Academy of Sciences of the United States of America 114 (42): 11157-62.

Walls, A. C., X. Xiong, Y. J. Park, M. A. Tortorici, J. Snijder, J. Quispe, E. Cameroni, et al. 2019. “Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion.” Cell 176 (5): 1026-1039.el5.

Walls, Alexandra C., Marcos C. Miranda, Minh N. Pham, Alexandra Schafer, Allison Greaney, Prabhu S. Arunachalam, Mary-Jane Navarro, et al. 2021. “Elicitation of Broadly Protective Sarbecovirus Immunity by Receptor-Binding Domain Nanoparticle Vaccines.” BioRxiv.Org: The Preprint Server for Biology, March. https://doi.org/10.1101/2021.03.15.435528.

Wang, Chunyan, Rien van Haperen, Javier Gutierrez -Alvarez, Wentao Li, Nisreen M. A. Okba, Irina Albulescu, Ivy Widjaja, et al. 2021. “A Conserved Immunogenic and Vulnerable Site on the Coronavirus Spike Protein Delineated by Cross-Reactive Monoclonal Antibodies.” Nature Communications 12 (1): 1715.

Wilm, Andreas, Pauline Poh Kim Aw, Denis Bertrand, Grace Hui Ting Yeo, Swee Hoe Ong, Chang Hua Wong, Chiea Chuen Khor, Rosemary Petrie, Martin Lloyd Hibberd, and Niranjan Nagarajan. 2012. “LoFreq: A Sequence-Quality Aware, Ultra-Sensitive Variant Caller for Uncovering Cell-Population Heterogeneity from High-Throughput Sequencing Datasets.” Nucleic Acids Research 40 (22) : 11189-201.

Winkler, Emma S., Pavlo Gilchuk, Jinsheng Yu, Adam L. Bailey, Rita E. Chen, Seth J. Zost, Hyesun Jang, et al. 2020. “Human Neutralizing Antibodies against SARS-CoV-2 Require Intact Fc Effector Functions and Monocytes for Optimal Therapeutic Protection.” BioRxiv, 2020.12.28.424554.

Wrapp, D., N. Wang, K. S. Corbett, J. A. Goldsmith, C. L. Hsieh, O. Abiona, B. S. Graham, and J. S. McLellan. 2020. “Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation.” Science 367 (6483): 1260-63. Xie, Xuping, Antonio E. Muruato, Xianwen Zhang, Kumari G. Lokugamage, Camila R. Fontes-Garfias, Jing Zou, Jianying Liu, et al. 2020. “A Nanoluciferase SARS-CoV-2 for Rapid Neutralization Testing and Screening of Anti-Infective Drugs for COVID-19.” Nature Communications 11 (1): 5214.

Yuan, Y., D. Cao, Y. Zhang, J. Ma, J. Qi, Q. Wang, G. Lu, et al. 2017. “Cryo-EM Structures of MERS-CoV and SARS-CoV Spike Glycoproteins Reveal the Dynamic Receptor Binding Domains.” Nature Communications 8: 15092.

Zhang, H., G. Wang, J. Li, Y. Nie, X. Shi, G. Lian, W. Wang, et al. 2004. “Identification of an Antigenic Determinant on the S2 Domain of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Capable of Inducing Neutralizing Antibodies.” Journal of Virology 78 (13): 6938-45.

Zheng, Z., V. M. Monteil, S. Maurer-Stroh, C. W. Yew, C. Leong, N. K. Mohd-Ismail, S. Cheyyatraivendran Arularasu, et al. 2020. “Monoclonal Antibodies for the S2 Subunit of Spike of SARS-CoV- 1 Cross-React with the Newly-Emerged SARS-CoV-2.” Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 25 (28). https://doi.org/10.2807/1560-7917.ES.2020.25.28.2000291.

Zhou, P., X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, et al. 2020. “A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin.” Nature, February, https://doi.org/10.1038/s41586-020-2012-7.

EXAMPLE 12

STEM-HELIX POLYPEPTIDES COMPRISING AMINO ACIDS FROM THE EPITOPE RECOGNIZED BY ANTIBODY S2P6

Recombinant polypeptides were produced that comprise amino acid sequences according to any one of SEQ ID NOs.:4-19. The polypeptides comprise and/or were engineered from a portion of the SARS-CoV-2 spike polypeptide stem region. The below table shows the amino acid sequence of the SARS-CoV-2 subunit, as well as fragments thereof comprising the S2P6 epitope region or a portion thereof, and an engineered polypeptide comprising the S2P6 epitope region with stabilizing mutations in the S2 flanking sequence C-terminal to the S2P6 epitope region.

Table 36.

Further engineered polypeptides can be made by, for example: including more or less flanking sequence on either side of the S2P6 epitope region from SARS-CoV-2 or another coronavirus that comprises an S2P6 epitope region (in the case of SARS-CoV-2, SEQ ID NO.:5) (and optionally introducing mutations into the flanking sequence(s), e.g. stabilizing mutations); including a portion, but not all, of the S2P6 epitope region, preferably provided that one or more, two or more, three or more, or four or more of the key residues for S2P6 binding are retained and the polypeptide maintains an overall structure that is capable of being recognized by S2P6; mutating one or more amino acids within the S2P6 epitope region, preferably provided that one or more, two or more, three or more, or four or more of the key residues for S2P6 binding are retained and the polypeptide maintains an overall structure that is capable of being recognized by S2P6; mutating one or more amino acids within the S2P6 epitope region, or the like. In some embodiments, an engineered polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Fusion proteins containing two or more of the polypeptides were produced; certain of the fusion proteins further comprise a SARS-CoV-2 spike protein, or a receptor binding domain (RBD) thereof. In some embodiments, the polypeptides link together two or more RBDs, which comprise variant (i.e. engineered) RBDs and/or RBDs that comprise a naturally occurring RBD amino acid sequence.

Certain embodiments of constructs comprising engineered stem-helix polypeptides are illustrated in, for example, Figures 1C, 2C, 3 A, 3B, 4A (lower construct), 4B (lower construct), 8A (lower construct), 8B (lower construct), and 9D, and described in the Examples herein.

EXAMPLE 13

IN VIVO MOUSE STUDY 1 USING CORONAVIRUS CONSTRUCTS

Eight- to ten-week old female BALB/c mice were IM (gastrocnemius muscle) immunized twice, 21 days apart, with one of five constructs: Cov0064, Cov0199, Cov0200, Cov0208, and Cov0211. The design of these constructs is illustrated in Figure 36.

Constructs were administered at 0.1 pg, 0.3 pg, 0.9 pg, 2.7 pg, and 8.1 pg and formulated with AS03 adjuvant (a-tocopherol and squalene as an oil in water emulsion). Each dose of each construct was administered to six animals. An additional control group of six animals received injections of NaCl without a construct. Blood samples were collected for further serum preparation at 14 days post-first and -second immunization, and, for animals administered 0.1 pg, 0.9 pg, or 8.1 pg of construct, spleens were collected at 14 days post-second immunization. Mice were eventually euthanized by intra-peritoneal injection of pentobarbital.

Pseudovirus-based neutralization assays

Mouse sera collected at 14 days post-second immunization were tested, as a primary study endpoint, in Vesicular Stomatis Virus/Coronavirus Pseudovirus (VSV/CoV PV)-based neutralization assays, for their in vitro neutralizing activity against SARS-Cov2-Wuhan-Hu-1, - B.1.351 (Beta), -B.1.617.2 (Delta), SARSCovl, MERS-CoV, and, only for Cov0064 and Cov0199, against SARS-Cov2-B.1.1.529 (Omicron).

Vero-E6 TMPRSS2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)-high glucose supplemented with penicillin 50 U/mL, streptomycin 50 pg/mL, puromycin 8 pg/mL, and 10% fetal bovine serum. The VSV/CoV PVs were further tested for their infectious titer by Tissue Culture Infectious Dose 50 (TCID50) assay. Vero-E6 TMPRSS2 cells were seeded into 96-well plates, at the density of 20000 cells/well. Twenty-four hours later, approximately 11000 VSV/CoV PV TCID50/well were mixed with equal volumes of heat- inactivated, and 3-fold serially diluted, sera to reach final serum dilutions ranking from 1 :30 to 1 :65610. The virus/serum mixtures were then incubated for 1 h at 37°C-5% CO2 under gentle shaking prior to being transferred onto the previously seeded Vero-E6 TMPRSS2 cells, and further incubated for 1 h at 37°C-5% CO2 under gentle shaking. The virus/serum mixtures were then removed, replaced by fresh cell culture medium, and the cells were further incubated 24 h at 37°C-5% CO2. After washing with PBS, the Steadylite Substrate (PerkinElmer cat. 0RT0569) was added prior to reading the Luc signal using a Synergy reader. Neutralization curves were next generated and analysed using GraphPad Prism 9.2. Nonlinear regression fitting with sigmoidal dose-response (variable slope) was used to determine the Effective Dilution 50 (ED50) corresponding to the reciprocal serum dilution associated with 50% reduction in Luc activity, when compared to VSV/CoV PV alone. In the absence of detection of neutralizing activity, the corresponding sample was assigned an arbitrary titer corresponding to one third of the initial dilution, namely 10.

The measured coronavirus neutralizing antibody (nAb) titers are shown in Figure 37 and in Tables 37A-37E.

Table 37a. Geometric Mean Neutralizing Antibody Titers (ED50) in

Response to Cov0199 at specified dose

Table 37b. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to

Cov0064 at specified dose

Table 37c. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to Cov0200 at specified dose

Table 37d. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to CovOlll at specified dose

Table 37e. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to Cov0208 at Specified Dose

No MERS-CoV-neutralizing activity was detected with any of the five tested constructs.

No or very low SARS-CoVl -neutralizing activity was detected with all assessed CoV S- based constructs, i.e. Cov0199, Cov0208, Cov0200 and Cov0211, while SARS-CoVl-nAb responses were detected, although at titers lower than against SARS-CoV2 variants, with the multiple RBD-based construct Cov0064.

Radar representations of the measured ED50 GMTs of the CoV-nAb profiles associated with Cov0199 versus Cov0064, are shown in Figure 38. As observed in Figure 38, Cov0199 and Cov0064 elicited similar nAb responses against SARS-Cov2-Wuhan-Hu-1 and -B.1.617.2 (Delta variant). In contrast, Cov0199 induced higher neutralizing antibodies (nAbs) responses, when compared with Cov0064, against SARS-Cov2-B.1.351 (Beta variant) and -B.1.1.529 (Omicron variant).

Out of the five tested constructs, three elicited low SARS-Cov-nAb responses (Cov0200 & Cov0211) or were not associated with increased/broader SARS-Cov-nAb responses when compared to the parental construct (Cov0208 versus Cov0199). In contrast, both the SARS- Cov2-B.1.351-based S construct Cov0199 and the multiple RBD-based construct Cov0064, elicited high SARS-Cov2-nAb responses against all tested variants. While Cov0199 elicited broad SARS-Cov2-nAb responses, Cov0064 elicited SARS-Covl-nAb responses which were not detected following immunization with Cov0199.

CoV-binding antibody responses

Mouse sera collected at 14 days post-second immunization were further tested for their Cov-binding Ab titers, expressed as ECL units, using two commercially available kits covering a wide panel of SARS-Cov2 variants, as well as SARS-Covl, SARS-MERS and the 4 human endemic CoVs.

Two commercial kits from MesoScale Discovery (MSD) were used to assess CoV- binding Ab responses, namely one kit covering all human CoVs, including SARS-Covl, SARS- MERS, and the four endemic human CoVs (“V-plex Covidl9 Panel 3”, cat. 5397A-1), and one kit specific for different SARS-Cov2 variants (“V-plex SARS-Cov2 Panel 23”, cat. KI 5567). Importantly, the kits were initially developed to measure, in human sera, CoV-binding Ab titers. The kits were then modified, by the provider, to allow detection of mouse Abs (replacement of the secondary Ab). However, the standard and positive controls that were human-specific could not be modified. As a consequence, the measured Ab titers were expressed here as electrochemiluminescence (ECL) units, and not as pg/mL with respect to the standard. The assays were performed following the provider’s instructions. Briefly, after an initial blocking step performed, with the kit blocking buffer, for 30 min, at room temperature and under shaking, the plates were extensively washed and serum samples, diluted 1 : 125000 (CoVs assay) or 1 : 500000 (SARS-Cov2 assay) in the kit diluent buffer, were added, in duplicate, and incubated for 2h, at room temperature and under shaking. The plates were then washed, and the detection Ab (Sulfo-TagTM), diluted in the kit diluent buffer, was added and incubated for Ih, at room temperature and under shaking. The plates were then washed, and the Read Buffer was added prior to measuring the luminescence using a MSD Reader.

Radar representations of CoV-binding Ab responses elicited by Cov0199 and Cov0064 are illustrated in Figures 39A-39B. Shown are the ECL geometric means determined for each construct dose and against each tested construct. Figure 39A shows the results obtained for SARS-Cov2-B.1.351 Spike (Beta); S ARS-Cov2 -Wuhan-Hu- 1 Spike (Wuhan); SARS-Cov2- B.1.1.7. Spike (Alpha); SARS-Cov2-Pl Spike (Gamma); SARS-Cov2-B.1.1.529 Spike (Omicron,); and SARS-Cov2-B.1.617.2 Seql (Delta-Seql), AY.4 (Delta-AY4) and AY.4.2 (Delta-AY42) Spikes. Figure 39B shows the results obtained for S ARS-Cov2 -Wuhan-Hu- 1 Spike (Cov2-S); S ARS-Cov2 -Wuhan-Hu- 1 recombinant RBD (Cov2-sRBD); SARS-Cov2- Wuhan-Hu-1 Nucleocapsid (Cov2-N); SARS-Covl Spike (Covl-S); MERS-CoV Spike (MERS,); NL63-CoV Spike (NL63); 229E-CoV Spike (229E); OC43-CoV Spike (OC43); and HKUl-CoV Spike (HKU1). SARS-Cov2 -binding Ab responses were detected with all tested constructs and against all tested SARS-Cov2 variants. The levels of binding Ab responses against a given SARS-Cov2 variant were similar when comparing the different constructs except for very slightly higher SARS-Cov2 (Omicron)- (at the two highest construct doses) and SARS-Cov2 (Beta)-binding Ab responses detected with Cov0199 versus Cov0064.

When further looking at the global CoV-binding Ab responses, Cov0199, Cov0208, Cov0200 and Cov0211 elicited binding Ab responses against all tested CoVs, including SARS- Covl and MERS-CoV. In contrast, the RBD-based construct, Cov0064, did not elicit binding Ab responses against any of the four endemic human CoVs (NL63, 229E, OC43, HKU1), nor against SARS-MERS (detected signals lower than the non-specific ones measured in the assay against the negative control BSA protein). However, Cov0064 elicited high binding Ab responses against both SARS-Covl and SARS-Cov2 (Wuhan), which tended to be higher, at all tested construct doses, when compared to Cov0199.

CoV-specific B and T cell responses

The construct-elicited immunity was then further assessed by characterizing, in spleen- derived cells collected at 14 days post-second immunization from groups immunized with the lowest (0.1 pg), middle (0.9 pg), and the highest (8.1 pg) construct doses as well as from the NaCl control group, the SARS-Cov2-B.1.351 (Beta) S- and SARS-Covl S-specific B cell responses, as well as, following re-stimulation with CoV-specific peptide pools, type 1 and type 2 T helper (Thl and Th2) CD4+ and CD8+ T cell responses. All cell responses were measured by flow cytometry.

Assessment of vaccine-elicited B and T cell responses was performed on spleen-derived cells. Spleens were collected and placed in RPMI1640 medium (Gibco cat. 31870-025) supplemented with glutamine 2 mM, penicillin 50 U/mL, streptomycin 50 pg/mL, sodium pyruvate 1 mM, 1 : 100 non-essential amino acids (Life Technologies cat.11140-035), and 2- mercaptoethanol 0.05 mM (further referred to as complete medium). Cell suspensions were prepared from each spleen using a tissue grinder. The spleen cell suspensions were filtered (Cell strainer 100pm BD cat. 352360) and washed with 35 mL cold PBS-EDTA 2 mM. After centrifugation (335g for 10 min at 4°C), cells were resuspended in cold PBS-EDTA 2 mM, and re-filtered. The cells were then further centrifuged (335 g for 10 min at 4°C) prior to being resuspended in 2 mL of complete medium-5% heat inactivated fetal bovine serum (Serana cat. S- FBS-SA-021). Cells were then counted using MACSQUANT.

The T cell stimulation was then performed as follows. Freshly collected cells were transferred to round bottom 96-well plates at the density of 1 million cells/well. Splenocytes were then stimulated for 6 h (37°C, 5% CO2) with Ipg/mL anti-CD28 (clone 37.51, BD cat. 553294), 1 pg/mL anti-CD49d (clone 9C10 MFR4.B, BD cat. 553313), 1 :500 anti-CD107a (clone 1D4B, Biolegend cat. 121606), with or without Ipg/mL peptide pools (MERS-CoV, SARS-CoV, SARS-CoV-2 Spike B.1.351, SARS-CoV-2 Spike, SARS-CoV-2 Spike B.1.429, SARS-CoV-2 Spike B.1.1.7, SARS-CoV-2 S-RBD, SARSCoV-2 S-RBD B.1.429, SARS-CoV-2 S-RBD B.1.351 or SARS-CoV-2 S-RBD B. l.1.7, all from JPT). After 2 h, Brefeldin A (BD cat. 555029) diluted 1 : 1000 and Monensin (BD cat. 51-2092KZ) diluted 1 :500 in complete medium were added for 4 additional hours. Plates were then stored overnight at 4°C. The intra-cellular straining was then performed as follows. Cells were transferred to V-bottom 96-well plates, centrifuged at 189 g for 5 min at 4°C, and resuspended in 50 pL Brillant Stain Buffer (BD cat. 563794) containing 1 :50 anti-CD16/32 (clone 2.4G2, BD cat. 553142) for 10 min at 4°C. Then, 50 pL Brillant Stain Buffer containing 1 : 100 anti-CD4-Alexa700 (clone RM4-5, BD cat. 557956), 1 :50 anti-CD8-BUV805 (clone 53-6.7, BD cat. 564920), 1 :50 anti-CD44-BUV563 (clone IM7, BD cat. 741227), 1 : 100 anti-ICOS-BUV 737 (clone 7E17G9, BD cat. 624286), 1 :50 anti-CD127-BV421 (clone A7R34, BD cat. 566377), 1 :800 anti-CD62L-BV786 (clone MEL-14, BD cat. 564109), and 1 :500 Live/dead-near-IR (Invitrogen cat. L10119) were added for 30 min at 4°C. Cells were then centrifuged (189 g for 5 min at 4°C) and washed with 200 pL FACS Buffer (PBS-1% heat inactivated FBS). Cells were next fixed and permeabilized by adding 200 pL of Cytofix/Cytoperm solution (BD cat. 554722) for 15 min at 4°C. Cells were then centrifuged (500 g for 5 min at 4°C) and washed with 200 pL Perm/Wash buffer (BD cat. 554723). After an additional centrifugation step, cells were stained using 50 pL Perm/Wash buffer containing 1 :200 anti-IL2-PE-CF594 (clone JES6-5H4, BD cat. 562483), 1 : 100 anti- IFNy-BV480 (clone XMG1.2, BD cat. 566097), 1 :700 anti-TNFa-PE (clone MP6-XT22, BD cat. 554419), 1 :50 anti-IL5-APC (clone TRFK5, BD cat. 554396), 1 :50 anti-IL13-PE-Cy7 (clone eBiol3A, eBiosciences cat. 25-7/33-80), and 1 : 100 anti-IL17-BV605 (clone TC11-18H10, BD cat. 564169) antibodies, for 1 h at 4°C. One hundred pL of FACS buffer were then added, and the cells were washed twice with the Perm/Wash buffer prior to being finally re-suspended in 220 pL of PBS. The percentages of stained cells were then determined by flow cytometry using a BD FACSymphony and the FlowJo software.

The B cell staining was performed as follows. Fresh splenocytes were added, in duplicate, to V-bottom 96-well plates at 2 million cells per well. Cells were centrifuged at 189 g for 5 min at 4°C, and resuspended in 50 pL PBS-1% FBS containing 1 :50 anti-CD16/32 (clone 2.4G2, BD cat. 553142), and incubated for 10 min at 4°C. Then, 50 pL of PBS-1% FBS containing 2 pg/mL biotynilated-S (SARS-Covl S or SARS-Cov2 Bl.351 S) were added for 30 min at 4°C. One hundred pL of PBS-1% FBS were added prior to centrifugating the cells at 189 g for 5 min at 4°C, and then washing them with 200 pL of FACS buffer. Then, 50 pL of Brillant Stain Buffer (BD cat. 563794) containing 1 : 100 anti-CD38 BB700/Percp Cy5.5 (clone 90/CD38, BD cat. 742132), 1 : 100 anti-CD45R B220 BUV661 (clone RA3-6B2, BD cat. 565077), 1 :50 anti- CD138 PE (clone 281-2, BD cat. 553714), 1 :25 anti-IgM BV421(clone R6-60.2, BD cat. 562595), 1 :200 anti-IgD BV786 (clone l l-26c2a, BD cat. 563618), 1 :25 anti-CD95 PECy7 (clone JO2, BD cat. 557653), 1 :400 anti-CD19 BV650 (clone 1D3, BD cat. 563235), 1 : 100 anti- F4/80 APCCy7 (clone BM8, Biolegend cat. 123118), 1 :200 anti-TER-119 APC-Cy7 (clone TER-119, BD cat. 560509), 1 : 100 anti-NKl. l APC-Cy7 (clone PK136, BD cat. 560618), 1 : 100 anti-CD3e APC-Cy7 (clone 1452cl l, BD cat. 557596), 1 :25 anti-GL7 FITC (clone GL7, BD cat. 553666), 1 :50 anti-CD27 BUV395 (clone LG.3A10, BD cat. 740247), and 1 :500 Live & dead Far red (APC, Molecular Probes cat. L10120) were added for 30 min at 4°C. One hundred pL of FACS buffer were added, cells were centrifuged at 189 g for 5 min at 4°C, and resuspended in 50 pL of PBS-1% FBS containing 1 :250 streptavidin PE-CF594 (BD cat. 562284) for 20 min at room temperature. One hundred pL of FACS buffer were added, cells were centrifuged at 189g for 5 min at 4°C, and resuspended in 200 pL of Cytofix/Cytoperm solution (BD cat. 554722) for 15 min at room temperature. Cells were then again centrifuged at 189 g for 5 min at 4°C prior to being washed with 200 pL of FACS buiffer. After an additional centrifugation step, cells were finally re-suspended in 200 pL PBS. Stained cells were then analyzed by flow cytometry using a BD FACSymphony and the FlowJo software.

Tables 38a-38b present the Cov S-specific germinal center (GC) B cell responses as percentages of SARS-Cov2-B.1.351 (Beta) S- and SARS-Covl S-specific GC B cells, among the total GC B cell population.

Table 38a. Geometric Mean Percentages of SARS-Cov2-B.1.351 (Beta) S-Specific GC B Cells, Among the Total GC B Cell Population in Response to Specified Construct at

Specified Dose

Table 38b. Geometric Mean Percentages of SARS-Covl S-Specific GC B Cells, Among the Total GC B Cell Population in Response to Specified Construct at Specified Dose

GC B cells specific for both SARSCovl and SARS-Covl -B.1.351 (Beta) were detected with all tested constructs at frequencies higher than in the NaCl control group. While the frequency in SARS-Covl -specific GC B cells was quite similar across all tested constructs, that in SARS-Cov2-B.1.351 (Beta)-specific GC B cells tended to be numerically higher with Cov0199 when compared to the other tested constructs, including Cov0064.

The Thl and Th2 CD4+ and CD8+ T cell responses were characterized following restimulation of spleen-derived cells with peptide pools specific for different SARS-Cov2 variants, as well as for SARS-Covl and MERSCoV.

Figures 51A-51B show percentages of Thl CD4+ T cells (51 A) and Th2 CD4+ T cells, (5 IB). Figures 52A-52B show percentages of Thl CD8+ T cells (52A) and Th2 CD8+ T cells, (52B). As shown in Figures 51A-52A, for constructs other than Cov0064, stimulation with Cov- 2 full-spike peptides produced higher frequencies of Thl CD4+ T cells, Th2 CD4+ T cells, and Thl CD8+ T cells, stimulation with RBD peptides lower frequencies, and stimulation with CoV- 1 full-spike peptides produced frequencies in between. For Cov0064, stimulation with Cov-2 full-spike peptides produced comparable results to stimulation with Cov-2 RBD peptides.

Broad CD4+ and CD8+ T cell responses were detected with all tested constructs against all tested SARS-Cov2 variants, as well as, although at lower levels, against SARS-Covl. Both Thl and Th2 CD4+ and CD8+ T cell responses were detected with a Thl -biased profile (particularly strong for CD8+ T cell responses). No MERS-Cov-specific CD4+ or CD8+ T cell responses were detected.

When further comparing Cov0199 with Cov0064, both constructs elicited similar levels of CD4+ T cell responses, though slightly higher frequencies in RBD-specific CD4+ T cell responses were detected with the RBD-based Cov0064 when compared to Cov0199. Numerically higher frequencies in SARS-Cov2-specific CD8+ T cell responses were detected with Cov0199 versus Cov0064 while both constructs elicited similar levels of SARS-Covl- specific CD8+ T cell responses.

All tested constructs elicited broad Cov-binding antibody, and specific CD4+/CD8+ T cell responses. Cov0200, Cov0208, and Cov0211 elicited low SARS-Cov2-nAbs responses when compared to the parental construct Cov0199. Both Cov0064 and Cov0199 elicited broad and high SARS-Cov2-nAb responses. Cov0199 elicited broader CoV-binding Ab and CD8+ T cell responses, as well as higher nAb responses against SARS-Cov2-B.1.351 (beta) and - B.1.1.529 (Omicron), when compared to Cov0064. Cov0064 also elicited SARS-Covl- nAb responses.

EXAMPLE 14

IN VIVO MOUSE STUDY 2 USING CORONAVIRUS CONSTRUCTS

Eight- to ten-week old female BALB/c mice were IM (gastrocnemius muscle) immunized twice, 21 days apart, with one of six constructs or combinations of two or more constructs (Cov0242; Cov0184; combination of Cov0184+Cov0192; combination of Cov0184+Cov0196; combination of Cov0184+Cov0192+Cov0196; and Cov0177) or with Covl99 as a control. These constructs and combinations are illustrated in Figure 40.

Constructs were administered at 0.1 pg, 0.3 pg, 0.9 pg, 2.7 pg, and 8.1 pg and formulated with AS03 adjuvant (a-tocopherol and squalene as an oil in water emulsion). Each dose of each construct was administered to six animals. An additional control group of six animals received injections of NaCl without a construct. Blood samples were collected for further serum preparation at 14 days post-first and -second immunization, and, for animals administered 0.1 pg, 0.9 pg, or 8.1 pg of construct, spleens were collected at 14 days post-second immunization. Mice were eventually euthanized by intra-peritoneal injection of pentobarbital. Pseudovirus-based neutralization assays

Mouse sera collected at 14 days post-second immunization were tested, as a primary study endpoint, in Vesicular Stomatis Virus/Coronavirus Pseudovirus (VSV/CoV PV)-based neutralization assays, for their in vitro neutralizing activity against SARS-Cov2-Wuhan-Hu-1, - B.1.351 (Beta), -B.1.617.2 (Delta), -B.1.1.529 (Omicron), SARS-Covl, and MERS-CoV.

Pseudovirus-based neutralization assays were performed as described in Example 13.

The measured CoV-nAb titers are shown in Figures 41A-41B and in Tables 39a-39g.

Table 39a. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to

Cov0199 at Specified Dose

Table 39b. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to Cov0242 at Specified Dose

Table 39c. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to Cov0177 at Specified Dose

Table 39d. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to Cov0184 at Specified Dose

Table 39e. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to Cov0184+Cov0192 at Specified Dose

Table 39f. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to Cov0184+Cov0196 at Specified Dose

Table 39g. Geometric Mean Neutralizing Antibody Titers (ED50) in Response to Cov0184+Cov0192+Cov0196 at Specified Dose

Radar representations of CoV-nAb responses elicited by Cov0199 vs Cov0242 are shown in Figure 42A; Cov0199 vs Cov0184 vs Cov0177 in Figure 42B; and Cov0184 vs Cov0184+Cov0192 vs Cov0184+Cov0196 vs Cov0184+CoV0192+Cov0196 in Figure 42C.

No MERS-CoV-neutralizing activity was detected with any of the six tested constructs, nor with the control construct Cov0199 (as already observed in Example 13). Cov0199 and Cov0242 induced similar SARS-Cov2-B.1.351 (Beta)-nAb responses. When compared to Cov0199, Cov0242 induced slightly higher nAb responses against the 3 other tested SARS-Cov2 variants (observed only at the lowest tested construct dose, i.e. 0.1 pg/mouse for SARS-Cov2-B.1.1.529 (Omicron)) as well as around twice higher SARS-Covl-nAb titers, when compared to Cov0199.

When compared to Cov0199, Cov0177 and Cov0184 elicited much lower nAb titers against all tested SARS-Cov2 variants but much higher SARS-Covl-nAb titers. Cov0184 elicited slightly higher nAb responses against all tested viruses, when compared to Cov0184+Cov0196, indicating no added value of combining Cov0196 with Cov0184. Cov0184 elicited higher SARS-Cov2- and lower SARS-Covl-nAb responses compared to Cov0184+Cov0192 and Cov0184+Cov0192+Cov0196. Although not formally compared, SARS-Covl-nAb titers measured with Cov0184+Cov0192 and with Cov0184+Cov0192+Cov0196 reached, at the highest tested construct doses, the same ranges of SARS-CoV-2-nAb titers detected with either Cov0199 or Cov0242 against all variants but SARS-Cov2-B.1.351 (Beta).

CoV-binding antibody responses

Mouse sera collected at 14 days post-second immunization were further tested for their Cov-binding Ab titers, expressed as ECL units, using two commercially available kits covering a wide panel of SARS-Cov2 variants, as well as SARS-Covl, SARS-MERS and the 4 human endemic CoVs.

Multiplex electrochemiluminescence assays were performed as in Example 13. Figures 53 A and 53B show comparative radar representations of measured SARS-Cov2- (53 A) and CoV-binding (53B) antibody responses from sera of mice immunized with Cov0242 or Cov0199. Figures 54A and 54B show comparative radar representations of measured SARS- Cov2- (54A) and CoV-binding (54B) antibody responses from sera of mice immunized with Cov0199, Cov0184, or Cov0177. Figures 55A and 55B show comparative radar representations of measured SARS-Cov2- (55A) and CoV-binding (55B) antibody responses from sera of mice immunized with Cov0184+Cov0196, Cov0184+Cov0192, Cov0184+Cov0192+Cov0196, or Cov0184. Figures 53A, 54A, 55A show results of binding to SARS-Cov2-B.1.351 Spike (Beta); S ARS-Cov2 -Wuhan-Hu- 1 Spike (Wuhan); SARS-Cov2-B.1.1.7. Spike (Alpha); SARS-Cov2-Pl Spike (Gamma); SARS-Cov2-B.1.1.529 Spike (Omicron,); and SARS-Cov2-B.1.617.2 Seql (Delta-Seql), AY.4 (Delta-AY4) and AY.4.2 (Delta-AY42) Spikes. Figures 53B, 54B, 55B show results of binding to S ARS-Cov2 -Wuhan-Hu- 1 Spike (Cov2-S); S ARS-Cov2 -Wuhan-Hu- 1 recombinant RBD (Cov2-sRBD); S ARS-Cov2 -Wuhan-Hu- 1 Nucleocapsid (Cov2-N); SARS- Covl Spike (Covl-S); MERS-CoV Spike (MERS,); NL63-CoV Spike (NL63); 229E-CoV Spike (229E); OC43-CoV Spike (OC43); and HKUl-CoV Spike (HKU1).

All constructs produced similar SARS-Cov2- and SARS-Covl -binding antibody responses. Only Cov0199 and Cov0242 elicited binding Ab responses against non-SARS-CoVs, namely against MERS-CoV and the human endemic CoVs. Non-SARS-CoV-binding Ab responses were higher with Cov0199 than with Cov0242.

CoV-specific B and T cell responses

The vaccine candidates-elicited immunity was then further assessed by characterizing, in spleen-derived cells collected at 14 days post-second immunization from the sub-study 1, and from groups immunized with the middle (0.9 pg) and highest (8.1 pg) construct doses for B cell responses, or with the lowest (0.1 pg), middle (0.9 pg), and highest (8.1 pg) construct doses for T cell responses (as well as from the NaCl control group), the SARSCov2- B.1.351 (Beta) S- and SARS-Covl S-specific B cell responses, and, following restimulation with CoV-specific peptide pools, type 1 and type 2 T helper (Thl and Th2) CD4+ and CD8+ T cell responses. All cell responses were measured by flow cytometry as in Example 13.

Tables 40a-40b present the Cov S-specific germinal center (GC) B cell responses as percentages of SARS-Cov2-B.1.351 (Beta) S- and SARS-Covl S-specific GC B cells, among the total GC B cell population.

Table 40a. Geometric Mean Percentages of SARS-Cov2-B.1.351 (Beta) S-Specific GC B Cells, Among the Total GC B Cell Population in Response to Specified

Construct/Combination at Specified Dose

Table 40b. Geometric Mean Percentages of SARS-Covl S-Specific GC B Cells, Among the Total GC B Cell Population in Response to Specified Construct/Combination at Specified Dose

Compared to othe other tested constructs, Cov0177 produced higher frequencies in SARS-Cov2- and SARS-Covl -specific GC B cells. Otherwise, the constructs produced similar frequencies in antigen-specific GC B cells, among all detected GC B cells. The Thl and Th2 CD4+ and CD8+ T cell responses were characterized following restimulation of spleen-derived cells with peptide pools specific for different SARS-Cov2 variants, as well as for SARS-Covl and MERSCoV. Figure 56 shows comparative radar representations of measured percentages of Thl CD4+ T cells (top) and Th2 CD4+ T cells (bottom) responses from sera of mice immunized with NaCl, Cov0242, or Cov0199. Figure 57 shows comparative radar representations of measured percentages of Thl CD4+ T cells (top) and Th2 CD4+ T cells (bottom) responses from sera of mice immunized with NaCl, Cov0199, Cov0184, or Cov0177. Figure 58 shows comparative radar representations of measured percentages of Thl CD4+ T cells (top) and Th2 CD4+ T cells (bottom) responses from sera of mice immunized with NaCl, Cov0184+Cov0196, Cov0184+Cov0192, Cov0184+Cov0192+Cov0196, or Cov0184. Figure 59 shows comparative radar representations of measured percentages of Thl CD8+ T cells (top) and Th2 CD8+ T cells (bottom) responses from sera of mice immunized with NaCl, Cov0242, or Cov0199. Figure 60 shows comparative radar representations of measured percentages of Thl CD8+ T cells (top) and Th2 CD8+ T cells (bottom) responses from sera of mice immunized with NaCl, Cov0199, Cov0184, or Cov0177. Figure 61 shows comparative radar representations of measured percentages of Thl CD8+ T cells (top) and Th2 CD8+ T cells (bottom) responses from sera of mice immunized with NaCl, Cov0184+Cov0196, Cov0184+Cov0192, Cov0184+Cov0192+Cov0196, or Cov0184.

Broad CD4+ and CD8+ T cell responses were detected against all tested SARS-Cov2 variants, as well as, although at lower levels, against SARS-Covl, without clear between- construct difference. Both Thl and Th2 CD4+ and CD8+ T cell responses were detected with a Thl-biased profile (particularly strong for CD8+ T cell responses). For each tested construct candidate, no or low MERS-Cov-specific CD4+ or CD8+ T cell responses were detected.

The results reported here support, for Cov0242, an improved immunogenicity profile when compared with the control Ag Cov0199, and for Cov0192, its capacity at eliciting high SARS-Covl -cross-nAb titers.

EXAMPLE 15

BLI VALIDATION OF CONSTRUCTS

Biolayer interferometry (BLI) was used to assess binding between coronavirus constructs and anti-SARS-Cov2 monoclonal antibodies. The tested antibodies include S2P6 as well as five mAbs that bind the RBD: S2E12 (which binds to site la); S2K146; S2X259 (which binds to site II); S309 (which binds to site IV); and S2H97 (which binds to site V) as well as two mAbs that bind to the spike N-terminal domain (NTD): S2L20 (which binds to site iv) and S2X333 (which binds to site i).

Biolayer interferometry was performed using an Octet Red96 (ForteBio). All reagents were prepared in kinetics buffer (PBS 0.01% BSA) at the indicated concentrations. S2P6-rIgG was prepared at 3 pg/ml and loaded on prehydrated Protein A biosensors (Sartorius) for at least 10 minutes. Biosensors were then moved into a solution containing the subject antigen and association recorded for 7 minutes for the full spike based antigens or 2 minutes for the RBD based antigens, prepared at 5 pg/ml. A second association step was subsequently performed into a solution of an unrelated mAb (as control), or one of the assayed mAbs at 20 pg/ml and recorded for 5 minutes for the full spike based antigens or 2 minutes for the RBD based antigens. Response values were exported and plotted using GraphPad Prism 9.1.0.

Figure 43 A shows BLI data for the full spike-based constructs Cov0211; Cov0208; Cov0200; and Cov0199 assayed against S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; S2L20-rFab; S2X333-rFab; S2H97-rFab; and an unrelated mAb. The S2X333-rFab served as a negative control. As shown by Figure 43A and summarized in Figure 43B, each construct demonstrated binding to S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; S2L20-rFab; and S2H97-rFab but did not show binding to the S2X333-rFab or unrelated mAb controls. All constructs showed binding to S2P6-rIgG.

Figure 44A shows BLI data for the RBD concatemer-based constructs Cov0064; Cov0196; Cov0184; and Cov0192 assayed against S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; S2L20-rFab; S2H97-rFab; and an unrelated mAb. The S2L20-rFab served as a negative control. As shown by Figure 44A and summarized in Figure 44B, Cov0064 and Cov0184 demonstrated binding to S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; and S2H97-rFab; Cov0192 demonstrated binding to S2K146-rFab; S2X259-rFab; S309-Fab; and S2H97-rFab; and Cov0196 demonstrated binding to S2E12-rFab; S2K146-rFab; S309-Fab; and S2H97-rFab. No construct showed binding to the S2L20-rFab or unrelated mAb controls. All constructs showed binding to S2P6-rIgG.

Figure 45A shows BLI data for the RBD monomer-based constructs Cov0046; Cov0047; and Cov0049 assayed against S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; S2L20-rFab; S2H97-rFab; and an unrelated mAb. The S2L20-rFab served as a negative control. As shown by Figure 45A and summarized in Figure 45B, each construct demonstrated binding to S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; and S2H97-rFab. No construct showed binding to the S2L20-rFab or unrelated mAb controls. All constructs showed binding to S2P6-rIgG.

EXAMPLE 16

BOOSTING COV2 SPIKE MRNA- VACCINATED MICE WITH RBD CONCATEMER

Eight- to ten-week old female BALB/c mice were IM (gastrocnemius muscle) immunized twice with an mRNA SARS-CoV2 spike vaccine at day 0 and day 15 At day 60, mice were given a booster immunization with one of 1) PBS (negative control), 2) the mRNA SARS-CoV2 spike vaccine, or 3) Cov0064 plus AddaS03 adjuvant. Serum was taken at days 15, 21, and 67 for analysis of neutralizing and binding Ab responses.

Mouse sera collected at day 67 post-second immunization were tested using a VSV-based pseudovirus neutralization assay for their in vitro neutralizing activity against SARS-Cov2- Wuhan-Hu-1 (Wu), -B.1.351 (BAI), -B.1.617.2 (BA2), -B.1.1.529 (BA5), and SARSCovl. Figures 46 and 48 present the results of these assays. Each point represents an individual mouse, the bars represent the geometric mean, and the error bars represent the geometric standard deviation. Statistical significant was determined using the Kruskal-Wallis test and noted using the following indicators: ns = non-significant; * = p<0.05; ** = p<0.01, *** = p<0.001; and **** = p<0.0001. The assay results indicate that boosting with Cov0064 boosts CoV2 Omicron neutralizing antibodies (nAbs) similarly to boosting with the mRNA spike vaccine, but produces higher Covl nAbs than boosting with mRNA spike vaccine. Pre-existing anti-spike protein antibodies from prior immunization with the mRNA vaccine did not disrupt induction of anti- SARS-CoV-1 nAbs by CoV0064. Boosting with CoV0064 increased nAb responses against SARS-CoV-2, SARS-CoV-2 Omicron, and SARS-CoV-1.

The collected sera were also tested using an ELISA assay for antibody binding to the engineered S2P6 linker peptide, as well as RBDs from the following viruses: SARS-Cov2- Wuhan-Hu-1 (Wu), -B.1.351 (Beta), SARS-Covl, Wiv-1, RatG13, PangGD, PangGx, Anlogl l2, YN2013, SX2001, SC2018, ZC45, BTK72, and BGR2008. As illustrated in Figure 30, these represent viruses from each of the sarbecovirus clades. Figures 47 and 49A-49D present the results of these assays. Each point represents an individual mouse, the bars represent the geometric mean, and the error bars represent the geometric standard deviation. Statistical significant was determined using the Kruskal-Wallis test and noted using the following indicators: ns = non-significant; * = p<0.05; ** = p<0.01, *** = p<0.001; and **** = p<0.0001.

The assay results indicate that Cov0064 boosts binding antibodies against multiple sarbecoviruses from Clades 1, 2, and 3 higher than does a mRNA spike protein vaccine. Notably, Cov0064 boosts binding to RBDs beyond the five viruses represented in the concatemer.

EXAMPLE 17

EXPRESSION OF CERTAIN PROTEIN CONSTRUCTS

For concatemer constructs comprising various linkers, protein expression and the ability of selected anti-SARS-CoV-2 antibodies to bind the expressed constructs was assessed. Results are summarized in Tables 41 and 42; higher numbers under the “Adj Cone (mg/ml”) column header are associated with higher protein expression, and higher numbers under the “CORRECT BLI response to protein” column header are associated with the presence of epitopes detected by the selected antibodies.

Table 41. Analysis of Protein Expression and Epitope Presence in Certain Concatamerized Constructs

Table 42. Analysis of Protein Expression and Epitope Presence in Certain Other Concatamerized Constructs

Across all tested concatemerized constructs, constructs bearing the engineered S2P6 epitope linker (PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)) performed best.

In further characterization studies, constructs including Cov0061-Cov0070 (see Table 5) were expressed in host cells and assessed for, inter alia, protein concentration; adjusted concentration (mg/mL); and response of selected anti-SARS-CoV-2 antibodies (binding as measured by BLI) to the protein. Results for Cov0061-Cov0070 are summarized in Table 43.

Table 43. Expression, and Recognition by SARS-CoV-2 Antibodies, of Constructs Cov0061-Cov0070

EXAMPLE 18

DESIGN OF ADDITIONAL PROTEIN CONSTRUCTS

Additional protein constructs were designed, as summarized in Table 44. Constructs Cov0746-Cov0751 were designed using Cov0064 (also shown in Table 44 for reference) as a starting point. Constructs Cov0758, Cov0759, Cov0761, and Cov0762 are spike ectodomainbased constructs. Table 44. Summary of constructs Cov0064, Cov0746-Cov0751, Cov0758, Cov0759, Cov0761, and Cov0762

In Table 44, "Beta" is SARS-CoV-2 B.1.351, "Omicron" is SARS-CoV-2 Bl.1.529, and "Delta" is SARS-CoV-2 B.1.617.2. "S2P6" sis the engineered linker sequence SEQ ID NO.:701. This linker is disposed between each two successive RBDs, i.e., connecting RBD1 with RBD2, RBD2 with RBD3, RBD3 with RBD4, and RBD4 with RBD5. "His" = C-terminal His tag (either following RBD5 or at the C-terminus of the spike construct), and " — " = no His tag is present.

Constructs Cov0064 and Cov0746-Cov0751 comprise the N-terminal signal peptide MAPLLLLLPLL WAGALA (SEQ ID NO.:706). Constructs Cov0758, Cov0759, Cov0761, and Cov0762 comprise the N-terminal signal peptide MFVFLVLLPLVSS.

The amino acid sequences of the constructs in Table 44 are as follows: Cov0064 = SEQ ID NO.:218; Cov0746 = SEQ ID NO.:712; Cov0747 = SEQ ID NO.:713; Cov0748 = SEQ ID NO.:714; Cov0749= SEQ ID NO.:715; Cov0750= SEQ ID NO.:716; Cov0751 = SEQ ID NO.:717; Cov0758 = SEQ ID NO.:718; Cov0759 = SEQ ID NO.:719; Cov0761 = SEQ ID NO.:720; Cov0762 = SEQ ID NO.:721.

The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification, including U.S. Provisional Application No. 63/238,078 filed on August 27, 2021, are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments. These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

Claims

1. A fusion protein comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second coronavirus RBD polypeptide, wherein, optionally, the first and/or the second RBD polypeptide is from a betacoronavirus, and wherein, further optionally, the first and the second RBD polypeptide are from different betacoronaviruses.

2. The fusion protein of claim 1, comprising the first RBD polypeptide, the second RBD polypeptide, and a third coronavirus (e.g. betacoronavirus) RBD polypeptide, the first RBD polypeptide being linked to the second RBD polypeptide by a linker (1), and the second RBD polypeptide being linked to the third RBD polypeptide by a linker (2).

3. The fusion protein of claim 2, wherein the linker (1) and the linker (2) comprise, consist essentially of, or consist of the same amino acid sequence.

4. The fusion protein of claim 2, wherein the linker (1) and the linker (2) have different amino acid sequences from one another.

5. The fusion protein of claim any one of claims 1-4, wherein the linker, the linker

(1), and/or the linker (2) comprises a stem-helix polypeptide.

6. The fusion protein of any one of claims 2-5, wherein the linker (1) and the linker

(2) each comprise a stem-helix polypeptide.

7. The fusion protein of any one of claims 1-6, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2 Wuhan-Hu- 1; SARS-CoV-2 Beta variant (also called B.1.351); SARS-CoV-2 Delta variant (also called B.1.617.2); and SARS-CoV-2 Omicron variant (also called B.1.1.529).

8. The fusion protein of any one of claims 1-7, comprising an RBD polypeptide that comprises the amino acid sequence of any one of SEQ ID NOs.:2 and 722-729.

9. The fusion protein of any one of claims 1-8, comprising an RBD polypeptide that consists of the amino acid sequence of any one of SEQ ID NOs.:2 and 722-729.

10. The fusion protein of any one of claims 1-9, comprising an RBD polypeptide from any one or more of the following: PANG/GX; MP789; RaTG13; and RsSHC014.

11. The fusion protein of any one of claims 1-10, comprising an RBD polypeptide that comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:730-737.

12. The fusion protein of any one of claims 1-11, comprising three RBD polypeptides, wherein the three RBD polypeptides are from: MP789; RaTG13; and RsSHC014.

13. The fusion protein of any one of claims 1-12, comprising three RBD polypeptides, wherein the three RBD polypeptides comprise the amino acid sequence set forth in: (i) SEQ ID NO.:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731, respectively.

14. The fusion protein of any one of claims 1-13, comprising three RBD polypeptides, wherein the three RBD polypeptides consist of the amino acid sequence set forth in: (i) SEQ ID NO.:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731, respectively.

15. The fusion protein of any one of claims 5-14, wherein the stem-helix polypeptide comprises or consists of the amino acid sequence according to any one of SEQ ID NOs.:701, 4- 19, 46, and 57-59.

16. The fusion protein of any one of claims 5-15, wherein the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

17. The fusion protein of any one of claims 2-16, further comprising a fourth coronavirus (e.g. betacoronavirus) RBD polypeptide and a fifth coronavirus (e.g. betacoronavirus) RBD polypeptide, wherein the fourth RBD polypeptide is linked to the third RBD polypeptide by a linker (3) and the fifth RBD polypeptide is linked to the fourth RBD polypeptide by a linker (4).

18. The fusion protein of claim 17, wherein two, three, or all four of the linkers (1)- (4) comprise, consist essentially of, or consist of the same amino acid sequence.

19. The fusion protein of claim 17 or 18, wherein the two or more of the linkers (1)- (4) have different amino acid sequences from one another.

20. The fusion protein of any one of claims 17-19, wherein one or more of the linkers (l)-(4) comprises or consists of a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

21. The fusion protein of claim 20, wherein each of the peptide linkers ( 1 )-(4) comprises or consists of a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

22. The fusion protein of any one of claims 17-21, comprising an RBD polypeptide from each of: (i) SARS-CoV-2 Beta variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (ii) SARS-CoV-2 Beta variant; SARS-CoV-2 Omicron variant; MP789; RaTG13; and RsSHC014; or (iii) SARS-CoV-2 Omicron variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (iv) SARS-CoV-2 Delta variant; SARS-CoV-2 Omicron variant; MP789; RaTG13; and RsSHC014.

23. The fusion protein of any one of claims 17-22, comprising five RBD polypeptides, wherein the five RBD polypeptides comprise the amino acid sequence set forth in SEQ ID NO.: (i) 725, 731, 733, 735, and 737, respectively; or (ii) 725, 731, 729, 735, and 737, respectively; or (iii) 729, 731, 733, 735, and 737, respectively; or (iv) 727, 731, 729, 735, and 737, respectively.

24. The fusion protein of claim 23, wherein: (1) the RBD polypeptide comprising SEQ ID NO.:725 comprises or consists of SEQ ID NO.:724; (2) the RBD polypeptide comprising SEQ ID NO.:727 comprises or consists of SEQ ID NO.:726; (3) the RBD polypeptide comprising SEQ ID NO.:729 comprises or consists of SEQ ID NO.:728; (4) the RBD polypeptide comprising SEQ ID NO.:731 comprises or consists of SEQ ID NO.:730; (5) the RBD polypeptide comprising SEQ ID NO.:733 comprises or consists of SEQ ID NO.:732; (6) the RBD polypeptide comprising SEQ ID NO.:735 comprises or consists of SEQ ID NO.:734; and/or (7) the RBD polypeptide comprising SEQ ID NO.:737 comprises or consists of SEQ ID NO.:736.

25. The fusion protein of any one of claims 17-24, comprising five RBD polypeptides, wherein the five RBD polypeptides comprise or consist of the amino acid sequence set forth in SEQ ID NO.: (i) 724, 732, 734, 736, and 730, respectively; or (ii) 724, 728, 734, 736, and 730, respectively; or (iii) 728, 732, 734, 736, and 730, respectively; or (iv) 726, 728, 735, 736, and 730, respectively.

26. The fusion protein of any one of claims 17-25, comprising, in N-terminal to C- terminal direction of the fusion protein:

(i) an RBD polypeptide from SARS-CoV-2 Beta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or

(ii) an RBD polypeptide from SARS-CoV-2 Beta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from SARS-CoV-2 Omicron variant; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or

(iii) an RBD polypeptide from SARS-CoV-2 Omicron variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or

(iv) an RBD polypeptide from SARS-CoV-2 Delta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from SARS-CoV-2 Omicron variant; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13.

27. The fusion protein of any one of claims 17-26, comprising, in N-terminal to C- terminal direction of the fusion protein:

(i) an RBD polypeptide comprising SEQ ID NO. :725; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:733; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or (ii) an RBD polypeptide comprising SEQ ID NO.:725; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or

(iii) an RBD polypeptide comprising SEQ ID NO. :729; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:733; an RBD polypeptide from comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737; or

(iv) an RBD polypeptide comprising SEQ ID NO. :727; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:735; and an RBD polypeptide comprising SEQ ID NO.:737.

28. The fusion protein of any one of claims 17-27, comprising, in N-terminal to C- terminal direction of the fusion protein:

(i) an RBD polypeptide comprising or consisting of SEQ ID NO.:724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or

(ii) an RBD polypeptide comprising or consisting of SEQ ID NO. :724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or

(iii) an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or

(iv) an RBD polypeptide comprising or consisting of SEQ ID NO.:726; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736.

29. The fusion protein of any one of claims 26-28, comprising the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) disposed between the first and second RBD polypeptides, between the second and third RBD polypeptides, between the third and fourth RBD polypeptides, and between the fourth and fifth RBD polypeptides, wherein the first RBD polypeptide is the N-terminal RBD polypeptide of the fusion protein and the fifth RBD polypeptide is the C-terminal RBD polypeptide of the fusion protein.

30. The fusion protein of any one of claims 1-29, further comprising a peptide tag, wherein, optionally, the peptide tag is disposed at a C-terminus of the fusion protein, preferably fused to a C-terminus of a C-terminal RBD polypeptide of the fusion protein.

31. The fusion protein of claim 30, wherein the peptide tag is disposed at the C- terminus of the fusion protein.

32. The fusion protein of claim 30 or 31, wherein the peptide tag comprises a SpyTag and/or a His tag.

33. The fusion protein of any one of claims 1-32, wherein the fusion protein does not comprise a peptide tag disposed at a C-terminus of the fusion protein, optionally at the C- terminus of the C-terminal RBD polypeptide.

34. The fusion protein of any one of claims 1-33, wherein the fusion protein does not comprise a His tag disposed at a C-terminus of the fusion protein.

35. The fusion protein of any one of claims 1-34, comprising a signal peptide, wherein, optionally, the signal peptide is disposed at a N-terminus of the fusion protein, and is preferably fused to the N-terminus of the N-terminal RBD polypeptide.

36. The fusion protein of claim 35, wherein the signal peptide comprises or consists of the amino acid sequence MAPLLLLLPLL WAGALA (SEQ ID NO.:706), the amino acid sequence MNTQILVFALIAIIPTNADKI (SEQ ID NO.:705), the amino acid sequence MFVFLVLLPLVS (SEQ ID NO.:707) or the amino acid sequence MFVFLVLLPLVSS (SEQ ID NO.:708), and preferably consists of SEQ ID NO.:706.

37. The fusion protein of any one of claims 1-36, which, when administered to a mammal (e.g. a mouse, such as a female BALB/c mouse, optionally twice via intramuscular injection, wherein the two administrations are 20 or 21 days apart), elicits neutralizing antibodies against any one or more of, and optionally all of: SARS-CoV-2 Wuhan-Hu- 1; SARS-CoV-2 B.1.351; SARS-CoV-2 B.1.617.2; SARS-CoV-2 B.1.1.529; and SARS-CoV-1, wherein, optionally, neutralizing antibodies are assessed using sera collected from the mammal 14 days post-second immunization, in a Vesicular Stomatitis Virus/Coronavirus Pseudovirus system, optionally using Vero-E6 TMPRSS cells.

38. The fusion protein of any one of claims 1-37, which, when administered to a mammal that had previously received a mRNA SARS-CoV-2 spike protein vaccine, elicits:

(i) neutralizing antibodies against any one or more of, and optionally all of: SARS- CoV-2 Wuhan-Hu-1; SARS-CoV-2 BAI; SARS-CoV-2 BA2; SARS-CoV-2 BA5; and SARS- CoV-1, optionally to a degree that is greater than is elicited by a third administration of the mRNA SARS-CoV-2 spike protein vaccine, wherein, optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered once via intramuscular injection and/or at Day 60 and the mammal had received the mRNA spike protein vaccine at Day 0 and again at Day 14; and/or neutralizing antibodies are assessed using sera collected from the mammal at Day 67 in a Vesicular Stomatitis Virus/Coronavirus Pseudovirus system; and/or

(ii) antibodies that bind to an RBD from any one or more of: SARS-Cov2 -Wuhan- Hu-1 (Wu); -B.1.351 (Beta); SARS-Covl; Wiv-1; RatG13; PangGD; PANG/GX; Anlogl l2; YN2013; SX2001; SC2018; ZC45; BTK72; and BGR2008, optionally to a degree that is greater than is elicited by a third administration of the mRNA SARS-CoV-2 spike protein vaccine, wherein, optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered once via intramuscular injection and/or at Day 60 and the mammal had received the mRNA spike protein vaccine at Day 0 and again at Day 14; and/or binding antibodies are assessed by ELISA using sera collected from the mammal at Day 67.

39. The fusion protein of any one of claims 1-38, which is capable of being bound by any one or more of the following antibodies: S2P6; S2E12; S2K146; S2X259; S309; and S2H97, or an antigen-binding fragment thereof, wherein, optionally, the antigen-binding fragment comprises a Fab that comprises the VH and VL of the antibody and further comprises an IgGl CHI and either an IgG kappa CL or an IgG lambda CL.

40. An isolated polypeptide comprising: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.:218 without SEQ ID NO.:706; (iii) SEQ ID NO.:712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:715 without SEQ ID NO.:706; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) SEQ ID NO.:717 without SEQ ID NO.:706; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

41. The polypeptide of claim 40, consisting of: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.:218 without SEQ ID NO.:706; (iii) SEQ ID NO.:712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:715 without SEQ ID NO.:706; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) SEQ ID NO.:717 without SEQ ID NO.:706; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

42. A fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii):

(i) one or more peptide tag;

(ii) one or more stem-helix polypeptide, wherein, optionally, the one or more stemhelix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

43. The fusion protein of claim 42, comprising:

(a) a peptide tag linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises a N-terminus of the RBD polypeptide;

(b) a peptide tag linked or fused to a second end of the RBD polypeptide, wherein the second end optionally comprises a C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked or fused to a first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide;

(d) a stem-helix polypeptide linked or fused to a second end of the RBD polypeptide, wherein the first end optionally comprises the C-terminus of the RBD polypeptide; or

(e) any combination of (a)-(d).

44. The fusion protein of claim 42 or 43, wherein the peptide tag comprises a His tag, wherein, optionally, the His tag comprises or consists of the amino acid sequence HHHHHHHH (SEQ ID NO.:704).

45. The fusion protein of claim 44, wherein the peptide tag comprises a SpyTag.

46. The fusion protein of any one of claims 42-45, comprising a linker disposed between and linking (1) the RBD polypeptide and (2) a peptide tag of the one or more peptide tag.

47. The fusion protein of claim 46, comprising two or more linkers that comprise the same amino acid sequence as one another.

48. The fusion protein of claim 46 or 47, wherein the linker, or one or more of the two or more linkers, comprises or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.:702).

49. The fusion protein of any one of claims 42-48, comprising a linker disposed between and connecting (1) the RBD polypeptide and (2) a one of the one or more stem-helix polypeptide.

50. The fusion protein of any one of claims 42-49, comprising a structure

PT1— LI— RBD— L2— SHP— PT2, wherein: PT1 and PT2 are each an optional peptide tag; LI and L2 are each an optional linker; RBD is an RBD polypeptide; and SHP is a stem-helix polypeptide.

51. The fusion protein of claim 50, wherein: PT1, if present, has the amino acid sequence of SEQ ID NO.:700; LI, if present, has the amino acid sequence of SEQ ID NO.:702; L2 is absent or, if present, has the amino acid sequence GSG, GPP, GS, or PGP; SHP has the amino acid sequence of SEQ ID NO.:701; and PT2, if present, has the amino acid sequence of SEQ ID NO.:704.

52. The fusion protein of claim 51, wherein: (i) PT1, LI, SHP, L2, and PT2 are present; (ii) PT1, LI, SHP, and PT2 are present; (iii) L2, SHP, and PT2 are present; (iv) SHP and PT2 are present; (v) SHP and optionally L2 are present or (vi) L2, SHP, and and PT2 are present.

53. The fusion protein of any one of claims 42-52, comprising:

(i) a signal peptide fused or linked to a N-terminus of the RBD polypeptide; and

(ii) a stem-helix polypeptide fused or linked to a C-terminus of the RBD polypeptide.

54. The fusion protein of claim 53, comprising, in N-terminal to C-terminal direction, a signal peptide (optionally MAPLLLLLPLLWAGALA (SEQ ID NO.:706)), an optional linker, an RBD, an optional linker, and a stem-helix polypeptide, wherein, optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

55. The fusion protein of any one of claims 42-54, wherein the RBD polypeptide is from any one of: SARS-CoV-2-Wuhan-Hu-l; SARS-CoV-2 Beta variant; SARS-CoV-2 Omicron variant; SARS-CoV-2 Delta variant; PANG GX; MP789; RatG13; RsSCH014; RmYN02; BM48-31/BGR/2008; PC4-241; Rf 1/2004; and Rp/Shaanxi 2011.

56. The fusion protein of any one of claims 42-55, wherein the RBD polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:724-737.

57. An isolated polypeptide comprising a structure:

RBD1 - LI - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5

440 wherein RBD1, RBD2, RBD3, RBD4, and RBD5 are each a different RBD polypeptide selected from the group consisting of: SARS-CoV-2 Beta variant; SARS-CoV-2 Omicron variant; SARS-CoV-2 Delta variant; PANG/GX; MP789; RaTG13; and RsSHC014, wherein RBD1 is the N-terminal RBD polypeptide of the fusion protein and/or RBD5 is the C-terminal RBD polypeptide of the fusion protein, and wherein LI, L2, L3, and L4 are each a linker.

58. The isolated polypeptide of claim 57, wherein one or more of LI, L2, L3, and L4 comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59, and wherein, optionally, LI, L2, L3, and L4 each independently comprises or consists of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59.

59. The isolated polypeptide of claim 57 or 58, wherein LI, L2, L3, and L4 are identical, and LI, L2, L3, and L4 are preferably SEQ ID NO.:701.

60. The isolated polypeptide of any one of claims 57-59, wherein RBD1, RBD2, RBD3, RBD4, and RBD5 are independently selected from the group consisting of: (i) SEQ ID NO.: 724 or 725; (ii) SEQ ID NO.: 726 or 727; (iii) SEQ ID NO.: 728 or 729;

(iv) SEQ ID NO.: 730 or 731; (v) SEQ ID NO.: 732 or 733; (vi) SEQ ID NO.: 734 or 735; and (vii) SEQ ID NO.: 736 or 737, preferably wherein five of (i)-(vii) are present.

61. The isolated polypeptide of any one of claims 57-60, wherein RBD1, RBD2, RBD3, RBD4, and RBD5 are from:

(i) SARS-CoV-2 Beta variant; RsSHC014; PANG/GX; MP789; and RaTG13, respectively; or

(ii) SARS-CoV-2 Beta variant; RsSHC014; SARS-CoV-2 Omicron variant; MP789; and RaTG13, respectively; or

(iii) SARS-CoV-2 Omicron variant; RsSHC014; PANG/GX; MP789; and RaTG13, respectively; or

(iv) SARS-CoV-2 Delta variant; RsSHC014; SARS-CoV-2 Omicron variant; MP789; RaTG13, respectively.

441

62. The isolated polypeptide of any one of claims 57-61, wherein RBD1, RBD2,

RBD3, RBD4, and RBD5 comprise the amino acid sequence set forth in SEQ ID NO.:

(i) 725, 731, 733, 735, and 737, respectively; or

(ii) 725, 731, 729, 735, and 737, respectively; or

(iii) 729, 731, 733, 735, and 737, respectively; or

(iv) 727, 731, 729, 735, and 737, respectively, wherein, optionally, RBD1, RBD2, RBD3, RBD4, and RBD5 comprise or consists of the amino acid sequence set forth in SEQ ID NO.:

(1) 724, 730, 732, 734, and 736, respectively; or

(2) 724, 730, 728, 734, and 736, respectively; or

(3) 728, 730, 732, 734, and 736, respectively; or

(4) 726, 730, 728, 734, and 736, respectively.

63. An isolated polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46, and 57-59.

64. An isolated polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO.:701, the amino acid sequence of SEQ ID NO.: 14, the amino acid sequence of SEQ ID NO.: 15, the amino acid sequence of SEQ ID NO.: 16, or the amino acid sequence of SEQ ID NO.: 17.

65. An isolated polynucleotide encoding the fusion protein of any one of claims 1-39 and 42-56, or the polypeptide of any one of claims 40, 41, and 57-64.

66. The polynucleotide of claim 65, comprising ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA).

67. The polynucleotide of claim 65 or 66, comprising mRNA.

68. A vector comprising the polynucleotide of any one of claims 65-67, wherein, optionally, the vector is a live vector.

442

69. A host cell comprising the polynucleotide of any one of claims 65-67 and/or the vector of claim 68.

70. A composition comprising: (i) the fusion protein of any one of claims 1-39 and 42-56; and/or (ii) the polypeptide of any one of claims 40, 41, and 57-64; and/or (i) the polynucleotide of any one of claims 65-67; and/or (ii) the vector of claim 68; and/or

(iii) the host cell of claim 69, and a pharmaceutically acceptable carrier, excipient, or diluent.

71. The composition of claim 70, further comprising an adjuvant.

72. A method for treating, or for inducing an immune response against, a coronavirus infection in a subject, the method comprising administering to the subject an effective amount of: the fusion protein of any one of claims 1-39 and 42-56; the polypeptide of any one of claims 40, 41, and 57-64; the polynucleotide of any one of claims 65-67; the vector of claim 68; the host cell of claim 69; or the composition of claim 70 or 71, wherein, optionally, the coronavirus infection comprises a sarbecovirus infection.

73. The fusion protein of any one of claims 1-39 and 42-56; the polypeptide of any one of claims 40, 41, and 57-64; the polynucleotide of any one of claims 65-67; the vector of claim 68; the host cell of claim 69; or the composition of claim 70 or 71, for use in treating or inducing an immune response against a coronavirus infection in a subject, wherein, optionally, the coronavirus infection comprises a sarbecovirus infection.

74. The fusion protein of any one of claims 1-39 and 42-56; the polypeptide of any one of claims 40, 41, and 57-64; the polynucleotide of any one of claims 65-67; the vector of claim 68; the host cell of claim 69; or the composition of claim 70 or 71, for use in the manufacture of a medicament for treating or inducing an immune response against a coronavirus infection in a subject, wherein, optionally, the coronavirus infection comprises a sarbecovirus infection.

75. The method of claim 72, or the fusion protein, polypeptide, polynucleotide, vector, host cell, or composition for use of claim 73 or 74, wherein:

(i) treating comprises pre-exposure prophylaxis;

443 (ii) treating comprises post-exposure prophylaxis;

(iii) the subject has previously received one or more, two or more, three or more, four or more, or five or more doses of a coronavirus vaccine composition, wherein, optionally: (1) the subject has received two or more different coronavirus vaccine compositions; (2) the coronavirus vaccine composition comprises: at least a portion of a SARS-CoV-2 spike protein (e.g., a RBD polypeptide or a full spike protein), a polynucleotide (e.g. mRNA) encoding at least a portion of a SARS-CoV-2 spike protein e.g. encoding an RBD polypeptide, or encoding a full spike proteins), or a live, attenuated, or inactivated e.g. heat-killed or inactivated with P- propiolactone) virus; and/or (3) the coronavirus vaccine composition comprises Comirnaty (Pfizer-BioNTech), Spikevax (Modema), Janssen coronavirus vaccine (Johnson & Johnson), Nuvoxovid/Covavax (Novavax), Vaxzevria (Oxford-AstraZeneca), Coronavac aka BBIBP-CorV aka BBIBP (Sinovac), Covaxin aka BBV152 (Bharat Biotech), Convidecia aka AD5-nCOV (CanSino Biologies), Sputnik V aka Gam-COVID-Vac, Sinopharm WIBP aka WIBP-CorV (Sinovac), Abdala, Soberana 2, Soberana Plus, ZF2001 aka Anhui Zhifei Longcom ZifiVax ZF2001 aka ZF-UZ- VAC -2001 aka Zifivax (Anhui Zhifei Longcom Biopharmaceutical), Corbevax (Texas Children’s Hospital/Baylor College of Medicine/Dynavax), COVIran Barekat (Sifa Pharmed Industrial Group), VAT00002 or VAT00008 (Sanofi-GSK), SCB-2019 (Clover Biopharmaceuticals), VLA2001 (Valneva), HIPRA SARS-CoV-2 aka PHH-lV (HIPRA), mRNA-1273.214 (Moderna) and Sputnik V bivalent (L452R; Gamaleya National Research Center of Epidemiology and Microbiology), or any combination thereof;

(iv) the fusion protein, polypeptide, polynucleotide, vector, host cell, or composition is administered once every twelve months, or once every six months;

(v) the coronavirus infection is or comprises a SARS-CoV-2 infection

76. A method comprising introducing into a host cell the polynucleotide of any one of claims 65-67 or the vector of claim 68, and optionally culturing the host cell for a time and under conditions sufficient to express the encoded fusion protein or polypeptide, or to produce the polynucleotide (e.g. mRNA), and further optionally isolating the fusion protein, polypeptide, or produced polynucleotide.

444